Note: Descriptions are shown in the official language in which they were submitted.
CA 02421372 2003-03-25
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVETS
COMPREND PLUS D'UN TOM
CECI EST LE TOME ~ DE
NOTE: Pour les tomes additionels, veillez contacter 1e Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME ~ OF
NOTE: Eor additional volumes please contact the Canadian Patent Office.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
FIELD OF THE INVENTION
The present invention relates generally to the identification and isolation of
novel DNA and to the
recombinant production of novel polypeptides encoded by that DNA.
S
BACKGROUND OF THE INVEN~ON
Extracellular proteins play an important role in the formation,
differentiation and maintenance of
multicellular organisms. The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or
interaction with other cells, is typically governed by information received
from other cells and/or the immediate
environment. This information is often transmitted by secreted polypeptides
(for instance, mitogertic factors, survival
factors, cytotoxic factors, differentiation factors, neuropeptides, and
hormones) which are, in turn, received and
interpreted by diverse cell receptors or membrane-bound proteins. These
secreted polypeptides or signaling
molecules normally pass through the cellular secretory pathway to reach their
site of action in the extracellular
environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents. Efforts are being undertaken
by both industry and academia to identify new, native secreted proteins. Many
efforts are focused on the screening
of mammalian recombinant DNA libraries to identify the coding sequences for
novel secreted proteins. Examples
of screening methods and techniques are described in the literature [see, for
example, Klein et al., Proc. Natl. Acad.
~, X3:7108-7113 (1996); U.S. Patent No. 5,536,b37)].
Membrane-bound proteins and receptors can play an important role in the
formation, differentiation and
maintenance of multicellular organisms. The fate of many individual cells,
e.g., proliferation, migration,
differentiation, or interaction with other cells, is typically governed by
information received from other cells and/or
the immediate environment. This information is often transmitted by secreted
polypeptides (for instance, mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides, and hormones) which are, in turn,
received and interpreted by diverse cell receptors or membrane-bound proteins.
Such membrane-bound proteins and
cell receptors include, but are not limited to, cytokine receptors, receptor
kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and cellular adhesin molecules like
selectins and integrins. For instance,
transduction of signals that regulate cell growth and differentiation is
regulated in pan by phosphorylation of various
_ cellular proteins. Protein tyrosine kinases, enzymes that catalyze that
process, can also act as growth factor
receptors. Examples include fibroblast growth factor receptor and nerve growth
factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
1
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction. Efforts are being undertaken by both
industry and academia to identify new, native receptor proteins. Many efforts
are focused on the screening of
mamma3ian recombinant DNA libraries to identify the coding sequences for novel
receptor proteins.
We herein describe the identification and characterization of novel secreted
and transmembrane polypeptides
and novel nucleic acids encoding those polypeptides.
1. PR0213
Human growth arrest-specific gene 6 (gash) encodes a protein that is expressed
in a variety of different
tissues and which has been reported to be highly expressed during periods of
serum starvation and negatively
regulated during growth induction. See Manfioletti et al., Mol. Cell. Biol.
13(8}:4976-4985 (1993) and Stitt et al.,
Cell 80:661-670 (1995). Manfioletti et al. (1993), supra, have suggested that
the gash protein is member of tire
vitamin K-dependent family of proteins, wherein the members of the latter
family of proteins (which include, for
example, Protein S, Protein C and Factor X) all play regulatory roles in the
blood coagulation pathway. Thus, it has
been suggested that gash may play a role in the regulation of a protease
cascade relevant in growth regulation or in
the blood coagulation cascade.
Given the physiological importance of the gash protein, efforts are currently
being undertaken by both
industry and academia to identify new, native proteins which are homologous to
gash. Many of these efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
secreted and membrane-botirtd receptor proteins, specifically those having
homology to gash. Examples of such
screening methods and techniques are described in the literature [see, for
example, Klein et al., Proc. Natl. Acad.
ci , x:7108-7113 (1996); U.S. Patent No. 5,536,637)]. We herein describe the
identification of a novel polypeptide
which has homology to the gash polypeptide.
2. PR0274 .
The 7-transmembrane ("7TM") proteins or receptors, also referred to in the
literature as G-protein coupled
receptors, are specialized proteins designed for recognition of ligands and
the subsequent signal transduction of
information contained within those ligands to the machinery of the cell. The
primary purpose of cell surface receptors
is to discriminate appropriate ligands from the various extracellular stimuli
which each cell encounters, then to
activate an effector system that produces an intracellular signal, thereby
controlling cellular processes. [Dohhnan,
H.,Ann. Rev. Biochem., øx:653 (1991)]. The ability of 7TM receptors to bind
ligand to a recognition domain and
allosterically transmit the information to an intracellular domain is a
specialized feature of 7TM proteins [Kenakin,
T., Phatmacol. Rev., 4_$:413 (1996)]. The gene family which encodes the 7TM
receptors or G-protein linked
receptors encode receptors which recognize a large number of ligands,
including but not limited to, CSa, interleukin
8 and related chemokines. Research in this area suggests that distinct signals
at the cell surface feed into common
pathways of cell activation. [Getard, C. and Gerard, N.,Curr. Op. Immunol.,
_6:140 (1994), Gerard, C. and Gerard,
N.,Ann. Rev. Irnmunol., j~:775 (1994)]. The superfarnily of 7TM or G-protein
coupled receptors contains several
hundred members able to recognize various messages such as photons, ions and
amino acids among others (Schwartz,
T.W., et al., H.,Trends in Pharmacol. Sci., 17 :213 (1996)].
(Dohlinan, H.,Ann. Rev. $iochem., øQ:653 (1991)]. [Schwartz. T.W., et al.,
H.,Eur. J. Phatmt. Sci., 2_:85 (1994)].
2
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
We describe herein the identification of a novel polypeptide (designated
herein as PR0274) which has homology to
the 7 uansmembrane segment receptor proteins and the Fn54 protein.
3. PR0300
The Diff 33 protein is over-expressed in mouse testicular tumors. At present
its role is unclear, however,
it may play a role in cancer. Given the medical importance of understanding
the physiology of cancer, efforts are
currently being under taken to identify new, native proteins which are
involved in cancer. We describe herein the
identification of a novel polypeptide which has homology to Diff 33,
designated herein as PR0300.
4. PR0284
Efforts arre currently being undertaken to identify and characterize novel
trartsmembrane proteins. We
herein describe the identification and characterization of a novel
transmembrane polypeptide, designated herein as
PR0284.
5. PR0296
Cancerous cells often express numerous proteins that are not expressed in the
corresponding normal cell
type or are expressed at different levels than in the corresponding normal
cell type. Many of these proteins are
involved in inducing the transformation from a normal cell to a cancerous cell
or in maintaining the cancer phenotype.
As such, there is significant interest in identifying and characterizing
proteins that are expressed in cancerous cells.
We herein describe the identification and characterization of a novel
polypeptide having homology to the sarcoma-
amplified protein SAS, designated herein as PR0296.
6. PR0329
Immunoglobulin molecules play roles in many important mammalian physiological
processes. The structure
of immunoglobulin molecules has been extensively studied and it has been well
documented that intact
immunoglobulins possess distinct domains, one of which is the constant domain
or F~ region of the immunoglobulin
molecule. The F~ domain of an immunoglobulin, while not being directly
involved in antigen recognition and binding,
does mediate the ability of the immunoglobulin molecule, either uncomplexed or
complexed with its respective
antigen, to bind to F~ receptors either circulating in the serum or on the
surface of cells. The ability of an F~ domain
of an immunoglobulin to bind to an F~ receptor molecule results in a variety
of important activities, including for
example, in mounting an immune response against unwanted foreign particles. As
such, there is substantial interest
in identifying novel F~ receptor proteins and subunits thereof. We herein
describe the identification and
characterization of a novel polypeptide having homology to a high affinity
immunoglobulin F~ receptor protein,
designated herein as PR0329.
7. PR0362
Colorectal carcinoma is a malignant neoplastic disease which has a high
incidence in the Western world,
particularly in the United States. Tumors of this type often metastasize
through lymphatic and vascular channels and
result in the death of some 62,000 persons in the United States annually.
3
CA 02421372 2003-03-25
v
WO 99/46281 PCT/US99/05028
Monoclonal antibody A33 (mAbA33) is a murine immunoglobulin that has undergone
extensive preclinical
analysis and localization studies in patients inflicted with colorectal
carcinoma (Welt et al., J. Clln. Oncol. 8:1894-
1906 (1990) and Welt et al., J. Clin. Oncof. 12:1561-1571 (1994)). mAbA33 has
been shown to bind to an antigen
found in and on the surface of nom~al colon cells and colon cancer cells. In
carcinomas originating from the colonic
mucosa, the A33 antigen is expressed homogeneously in more than 95 % of the
cases. The A33 antigen, however,
has not been detecting in a wide range of other normal tissues, i.e., its
expression appears to be rather organ specific.
Therefore, the A33 antigen appears to play an important role in the induction
of colorectal cancer.
Given the obvious importance of the A33 antigen in tumor cell formation and/or
proliferation, there is
substantial interest in identifying homologs of the A33 antigen. In this
regard, we herein describe the identification
and characterization of a novel polypeptide having homology to the A33 antigen
protein, designated herein as
PR0362.
8. PR0363
The cell surface protein HCAR is a membrane-bound protein that acts as a
receptor for subgroup C of the
adenoviruses and subgroup B of the coxsackieviruses. Thus, HCAR may provide a
means for mediating viral
infection of cells in that the presence of the HCAR receptor on the cellular
surface provides a binding site for viral
particles, thereby facilitating viral infection.
In light of the physiological itnportartce of membrane-bound proteins and
spcficially those which serve a cell
surface receptor for viruses, efforts are currently being undertaken by both
industry and academia to identify new,
native membrane-bound reeptor proteins. Many of these efforts are focused on
the screening of mammalian
recombinant DNA libraries to identify the coding sequences for novel receptor
proteins. We herein describe a novel
membrane-bound polypeptide having homology to the cell surface protein HCAR
and to various tumor antigens
including A33 and carcinoembryonic antigen, designated herein as PR0363,
wherein this polypeptide may be a novel
cell surface virus receptor or tumor antigen.
9. PR0868
Control of cell numbers in mammals is believed to be determined, in part, by a
balance between cell
proliferation and cell death. One fotlrt of cell death, sometimes referred to
as necrotic cell death, is typically
characterized as a pathologic form of cell death resulting from some trauma or
cellular injury. In contrast, there is
another, "physiologic" form of cell death which usually proceeds in an orderly
or controlled manner. This orderly
or controlled form of cell death is often referred to as "apoptosis" (see,
e.g., Barr et al., Bio/Tec~trtology, x_2:487-493
(1994); Steller et al., ' nce, 267:1445-1449 (1995)]. Apoptotic cell death
naturally occurs in many physiological
processes, including embryonic development and clonal selection in the immune
system [ltoh et al., Cell, 66:233-243
(1991)]. Decreased levels of apoptotic cell death have been associated with a
variety of pathological conditions,
including cancer, lupus, and herpes virus infection [Thompson, ci , 267:1456-
1462 (1995)]. Increased levels
of apoptotic cell death may be associated with a variety of other pathological
conditions, including AIDS, Alzheimer's
disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple
sclerosis, retinitis pigmentosa, cerebellar
degeneration, aplastic anemia, myocardial infarction, suoke, reperfusion
injury, and toxin-induced liver disease (see,
Thompson, ra .
4
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Apoptotic cell death is typically accompanied by one or more characteristic
morphological and biochemical
changes in cells, such as condensation of cytoplasm, loss of plasma membrane
rnicrovilli, segmentation of the
nucleus, degradation of chromosomal DNA or loss of mitochondria) function. A
varien~ of extrinsic and intrinsic
signals are believed to trigger or induce such morphological and biochemical
cellular changes [Raft, ature, X56:397-
400 (1992); Steller, supra; Sachs et al., Blood, 82:15 (1993)]. For instance,
they can be triggered by hormonal
stimuli, such as glucocorticoid hormones for immature thymocytes, as well as
withdrawal of certain growth factors
[Watanabe-Fukunaga et al., Na r , X56:314-317 (1992)]. Also, some identified
oncogenes such as myc, re), and
EIA, and tumor suppressors, like p53, have been reported to have a role in
inducing apoptosis. Certain
chemotherapy drugs and some forms of radiation have likewise been observed to
have apoptosis-inducing activity
['Thompson, a ra .
Various molecules, such as tumor necrosis factor-a ("TNF-a"), tumor necrosis
factor-~i ("TNF-Vii" or
"lymphotoxin-a"), lymphotoxin-~i ("LT-(3"), CD30 ligand, CD27 ligand, CD40
ligand, OX-40 ligand, 4-1BB ligand,
Apo-l ligand (also referred to as Fas ligand or CD95 ligand), and Apo-2 ligand
(also referred to as TRAIL) have been
identified as members of the tumor necrosis factor ("TNF") family of cytokines
[See, e.g., Gruss and Dower, Blood,
$5:3378-3404 (1995); Pitti et a).,1. Biol. Chem., 271:12687-12690 (1996);
Wiley et al., uni , x:673-682 (1995);
Browning et al., Cgll, x:847-856 (1993); Arntitage et al. Nature, 37:80-82
(1992), WO 97/01633 published January
16, 1997; WO 97/25428 published July 17, 1997]. Among these molecules, TNF-a,
TNF-p, CD30 ligand, 4-1BB
ligand, Apo-1 ligand, and Apo-2 ligand (TRAIL) have been reported to be
involved in apoptotic cell death. Both
TNF-a and TNF-p have been reported to induce apoptotic death in susceptible
tumor cells [Schmid et al., roc. Nat).
ad. S i , 83:1881 (1986); Dealtry et al., ~w. J. Immune" X7:589 (1987)]. Zheng
et al. have reported that TNF-a
is involved in post-stimulation apoptosis of CD8-positive T cells [Zheng et
al., N_ arure, 377:348-351 (1995)]. Other
investigators have reported that CD30 ligand may be involved in deletion of
self-reactive T cells in the thymus
[Amakawa et al., Cold Spring Harbor Laboratory Symposium on Programmed Cell
Death, Abstr. No. 10, (1995)].
Mutations in the mouse Fas/Apo-1 receptor or ligand genes (called )pr and gld,
respectively) have been
associated with some autoimmune disorders, indicating that Apo-1 ligand may
play a role in regulating the clonal
deletion of self-reactive lymphocytes in the periphery [Kratnmer et al., Curr.
Op. Immunol., ø:279-289 (1994);
Nagata et al., ien , x:1449-1456 (1995)]. Apo-1 ligand is also reported to
induce post-stimulation apoptosis
in CD4-positive T lymphocytes and in B lymphocytes, and may be involved in the
elimination of activated
lymphocytes when their function is no longer needed [Krammer et al., supra;
Nagata et al., su . Agonist mouse
monoclonal antibodies specifically binding to the Apo-1 receptor have been
reported to exhibit cell killing activity
that is comparable to or similar to that of TNF-a [Yonehara et a).,1. Exp.
Med., ~Q:1747-1756 (1989)].
Induction of various cellular responses mediated by such TNF family cytokines
is believed to be initiated
by their binding to specific cell receptors. Two distinct TNF receptors of
approximately 55-kDa (TNFR1) and 75-
kDa (TNFR2) have been identified [Hohtnan et al., j. Biol. Chem., x:14927-
14934 (1989); Brockhaus et al., Proc.
Nat). Acad. Sci., $2:3127-3131 (1990); EP 417,563, published March 20, 1991]
and human and mouse cDNAs
corresponding to both receptor types have been isolated and characterized
[Loetscher et al., C~,[~, ø,2:351 (1990);
Schall et al., ~g]1, øx:361 (1990); Smith et al., Science, x$:1019-1023
(1990); Lewis et al., PrQc. Nat). Acad. Sci.,
$$:2830-2834 (1991); Goodwin et al., Mol. Cell. Biol., x,_1:3020-3026 (1991)].
Extensive polymorphisms have been
associated with both TNF receptor genes (see, e.g., Takao et al.,
r~,JtmunoEenetics, x:199-203 (1993)]. Both TNFRs
share the typical structwe of cell swface receptors including extracellular,
transmembrane and intracellular regions.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99I05028
The extracellular portions of both receptors are found naturally also as
soluble TNF-binding proteins (Nophar, Y.
et al., ME BO J., x:3269 (1990): and Kohno, T. et al., Proc. Natl. Acad. Sci.
U.S.A., 87:8331 (1990)]. More
recently, the cloning of recombinant soluble TNF receptors was reported by
Hale et al. [J. Cell. Biochem.
Supplement 15F, 1991, p. 113 (P424)].
The extracellular portion of type 1 and type 2 TNFRs (TNFRI and TNFR2)
contains a repetitive amino acid
sequence pattern of four cysteine-rich domains (CRDs) designated 1 through 4,
staving from the NH:-terminus. Each
CRD is about 40 amino acids long and contains 4 to 6 cysteine residues at
positions which are well conserved (Schall
et al., supra; Loetscher et al., sub; Smith et al., supra; Nophar et al.,
supra; Kohno et al., su ra . In TNFR1, the
approximate boundaries of the four CRDs are as follows: CRDI- amino acids 14
to about S3; CRD2- amino acids
from about 54 to about 97; CRD3- amino acids from about 98 to about 138; CRD4-
amino acids from about 139 to
about 167. In TNFR2, CRD1 includes amino acids 17 to about 54; CRD2- amino
acids from about SS to about 9?;
CRD3- amino acids from about 98 to about 140; and CRD4- amino acids from about
141 to about 179 [Banner et al. ,
Cell, 73:431-435 (1993)]. The potential role of the CRDs in ligand binding is
also described by Banner et al., ssunra.
A similar repetitive pattern of CRDs exists in several other cell-surface
proteins, including the p75 nerve
growth factor receptor (NGFR) (Johnson et al., Cell, 47:545 (1986); Radeke et
al., Nature, 325:593 (1987)], the B
cell antigen CD40 [Stamenkovic et al., EM O ., $:1403 (1989)], the T cell
antigen OX40 [Mallet et al., EMBO J.,
9:1063 (1990)] and the Fas antigen (Yonehara et al., supra and ltoh et al.,
Cell, 66:233-243 (1991)]. CRDs are also
found in the soluble TNFR (sTNFR)-like T2 proteins of the Shope and myxoma
poxviruses [Upton et al., Virolotrv,
x:20-29 (1987); Smith et al., ]3iochem. Biophvs.. Res. Commun., 176:335
(1991); Upton et al., V'ro o , x:370
(1991)]. Optimal alignment of these sequences indicates that the positions of
the cysteine residues are well conserved.
These receptors are sometimes collectively referred to as members of the
TNF/NGF receptor superfamily. Recent
studies on p75NGFR showed that the deletion of CRDI [Welcher, A.A. et al.,
Proc. Natl. Acad. S~. USA, 8~:159-
163 (1991)] or a 5-amino acid insertion in this domain [Yap, H. and Chao,
M.V., J. Biol. Chem., 66:12099-12104
(1991)] had liNe or no effect on NGF binding [Yap, H. and Chao, M.V., su a .
p7S NGFR contains a proline-rich
stretch of about 60 amino acids, between its CRD4 and transmembrane region,
which is not involved in NGF binding
[Peetre, C. et al., Eur. 1. Hematol., 4,x.:414-419 (1988}; Seckinger, P. et
al., J. Biol. Chem., x:11966-11973
(1989); Yan, H. and Chao, M.V., su . A similar proline-rich region is found in
TNFR2 but not in TNFRI.
The TNF family ligands identified to date, with the exception of lymphotoxin-
a, are type II transmembrane
proteins, whose C-terminus is extracelhtlat. In cottaast, most receptors in
the TNF receptor (TNFR) family identified
to date are type I transmembrane proteins. In both the TNF ligand and receptor
families, however, homology
identified between family members has been found mainly in the extracellular
domain ("ECD"). Several of the TNF
family cytokines, including TNF-a, Apo-I ligand and CD40 ligand, are cleaved
proteolytically at the cell swface;
the resulting protein in each case typically forms a homotrimeric molecule
that functions as a soluble cytokine. TNF
receptor family proteins are also usually cleaved proteolytically to release
soluble receptor ECDs that can function
as inhibitors of the cognate cytokines.
Recently, other members of the TNFR family have been identified. Such newly
identified members of the
TNFR family include CARL, HVEM and osteoprotegerin (OPG) [Brojatsch et al.,
ell, 87:845-8SS (1996);
Montgomery et al., ~, x:427-436 (1996); Marsters et al., J. Biol. Chem.,
x:14029-14032 (1997); Simonet et
al., ~, $Q:309-319 (1997)]. Unlike other known TNFR-like molecules, Simonet et
al., supra, report that OPG
contains no hydrophobic transmembrane-spanning sequence.
6
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Moreover, a new member of the TNF/NGF receptor family has been identified in
mouse, a receptor referred
to as "GTTR" for "glucocorticoid-induced tumor necrosis factor receptor family-
related gene" [Nocentini et al., Proc.
Natl. Acad. Sci. USA 94:6216-6221 (1997)]. The mouse GITR receptor is a 228
amino acid type I transmembranc
protein that is expressed in normal mouse T lymphocytes from thymus, spleen
and lymph nodes. Expression of the
mouse GITR receptor was induced in T lymphocytes upon activation with anti-CD3
antibodies, Con A or phorbol
12-myristate 13-acetate. It was speculated by the authors that the mouse GITR
receptor was involved in the
regulation of T cell receptor-mediated cell death.
In Marsters et al., Curr. Biol., ø:750 (1996), investigators describe a full
length native sequence human
polypeptide, called Apo-3, which exhibits similarity to the TNFR family in its
extracellular cysteine-rich repeats and
resembles TNFRI and CD95 in that it contains a cytoplasmic death domain
sequence see also Marsters et al., Curr.
Biol., 6_:1669 (1996)]. Apo-3 has also been referred to by other investigators
as DR3, wsl-1 and TRAMP
[Chinnaiyan et al., Science, 274:990 (1996); Kitson et al., Nature, x:372
(1996); Bodmer et al., Immunity, ø:79
(1997)].
Pan et al. have disclosed another TNF receptor family member refened to as
"DR4" [Pan et al., Science,
~:11I-113 (1997)]. The DR4 was reported to contain a cytoplasmic death domain
capable of engaging the cell
suicide apparatus. Pan et al. disclose that DR4 is believed to be a receptor
for the ligand known as Apo-2 ligand or
TRAIL.
In Sheridan et al., cie , x:818-821 (1997) and Pan et al., Scie , 77:815-818
(1997), another
molecule believed to be a receptor for the Apo-2 ligand (TRAIL) is described.
That molecule is referred to as DRS
(it has also been alternatively referred to as Apo-2). Like DR4, DRS is
reported to contain a cytoplasatic death
domain and be capable of signaling apoptosis.
In Sheridan et al., supra, a receptor called DcRl (or alternatively, Apo-2DcR)
is disclosed as being a
potential decoy receptor for Apo-2 ligand (TRAIL). Sheridan et al. report that
DcRl can inhibit Apo-2 ligand
function in vitro. See also, Pan et al., supra, for disclosure on the decoy
receptor referred to as TRID.
For a review of the TNF family of cytokines and their receptors, see Gruss and
Dower, supra.
As presently understood, the cell death program contains at lcast three
important elements - activators,
inhibitors, and effectors; in C. elegans, these elements are encoded
respectively by three genes, Ced-4, Ced-9 and
Ced 3 [Steller, Sci. ence, x:1445 (1995); Chinnaiyan et al., cie , X5:1122-
1126 (1997); Wang et al., ~1, Q~:1-
20 (1997)]. Two of the TNFR family members, TNFR1 and Fas/Apol (CD95), can
activate apoptotic cell death
[Chinnaiyan and Dixit, current Biology, ø:555-562 (1996); Fraser and Evan,
~e,~; $5:781-784 (1996)]. TNFRl is
also known to mediate activation of the transcription factor, NF-xB [Tartaglia
et al., ('gel , 74:845-853 (1993); Hsu
et al., Cg)~, ,$4:299-308 (1996)]. In addition to some ECD homology, these two
receptors share homology in their
itt>racelhilar domain (ICD) in an oligomerization interface known as the death
domain (Tanaglia et al., suQra; Nagata,
fig,[[, x:355 (1997)]. Death domains are also found in several metazoan
proteins that regulate apoptosis, namely,
the Drosophila protein, Reaper, and the mat<unalian proteins referred to as
FADD/MORTI, TRADD, and RIP
[Cleaveland and Ihle, ~, ,$~:479~82 (1995)].
Upon ligand binding and receptor clustering, TNFR1 and CD95 are believed to
recruit FADD into a death-
inducing signalling complex. CD95 purportedly binds FADD directly, while TNFR1
binds FADD indirectly via
TRADD [Chinnaiyan et al., ~, $1:505-512 (1995); Boldin et al., L, Biol. Chem.,
x,70:387-391 (1995); Hsu et al.,
supra; Chinnaiyan et al., 1. Biol. Chem., x:4961-4965 (1996)]. It has been
reported that FADD serves as an
7
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
adaptor protein which recruits the Ced-3-related protease, MACHa/FLICE
(caspase 8), into the death signalling
complex [Boldin et al., Cell, ,5:803-815 (1996); Muzio et al., ell, x:817-827
(1996)]. MACHaIFLICE appears
to be the trigger that sets off a cascade of apoptotic proteases, including
the interleukin-1 [i convening enzyme (ICE)
and CPP32/Yama, which may execute some critical aspects of the cell death
programme [Eraser and Evan, su ra .
It was recently disclosed that programmed cell death involves the activity of
members of a family of cysteine
proteases related to the C. elegans cell death gene, ced-3, and to the
mammalian IL-1-converting enzyme, ICE. The
activity of the ICE and CPP32/Yama proteases can be inhibited by the product
of the cowpox virus gene, crmA [Ray
et al., Cell, 69:597-604 (1992); Tewari et al., Cetl, > 1:801-809 (1995)].
Recent studies show that CrmA can inhibit
TNFR1- and CD95-induced cell death [Enari et al., Nature, 75:78-81 (1995);
Tewari et al., J. Biol. Chem.,
X0:3255-3260 (1995)].
l0 As reviewed recently by Tewari et al., TNFR1, TNFR2 and CD40 modulate the
expression of
proinflammatory and costimulatory cytoltines, cytokine receptors, and cell
adhesion molecules through activation of
the transcription factor, NF-xB [Tewari et al., Curr. Op. Genet. Develop.,
_6:394 (1996)]. NF-xB is the prototype
of a family of dimeric transcription factors whose subunits contain conserved
Rel regions [Verma et al., Genes
evelo ., Q:2723-2735 (1996); Baldwin, Ann. Rev. Immunol., 14:649-681 (1996)].
In its latent form, NF-xB is
IS complexed with members of the ItcB inhibitor family; upon inactivation of
the IxB in response to certain stimuli,
released NF-tcB translocates to the nucleus where it binds to specific DNA
sequences and activates gene transcription.
10. PR0382
Proteases are enzymatic proteins which are involved in a large number of very
important biological
20 processes in mammalian and non-mammalian organisms. Numerous different
protease enzymes from a variety of
different matnmalian and non-mammalian organisms have been both identified and
characterized, including the serine
proteases which exhibit specific activity toward various serine-containing
proteins. The mammalian protease enzymes
play important roles in biological processes such as, for example, protein
digestion, activation, inactivation, or
modulation of peptide hormone activity, and alteration of the physical
properties of proteins and enzymes.
25 In light of the imponant physiological roles played by protease enzymes,
efforts are currently being
undertaken by both industry and academia to identify new, native protease
homologs. Many of these efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
membrane-bound receptor proteins. Examples of screening methods and techniques
are described in the literature
[see, for example, Klein et al., Proc. Natl. Acad. Sci., 23:7108-7113 (1996);
U.S. Patent No. 5.536,637)]. We
30 herein describe the identification of novel polypeptides having homology to
serine protease enzymes, designated
herein as PR0382 polypeptides_
11. P~,0545
The ADAM (A Disintegrin And Metalloprotease) family of proteins of which
meltrin is a member may have
35 an important role in cell interactions and in modulating cellular
responses. [see, for example, Gilpin et al., 7. Biol.
Chem., 273(11:157-166 (1998)]. The ADAM proteins have been implicated in
carcinogenesis. Meitrin-a (ADAM 12)
is a myoblast gene product reported to be required for cell fusion. (Harris et
al., J. Cell. Biochem., 67(I1:136-142
(1997), Yagami-Hiromasa et al., Nature, X77:652-656 (1995)]. The mehrins
contain disintegrin and metalloprotease
domains and are implicated in cell adhesive events involved in development,
through the integrin-binding disintegrin
8
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
domain, but also have an anti-adhesive function through a zinc-dependent
metalloprotease domain. [Alfandari et al.,
Devel. Biol., 18212):314-330 (1997)]. Given the medical importance of cell
fusion and modulation of cellular
responses in carcinogenesis and other disease mechanisms, efforts are
currently being under taken to identify new,
native proteins which are involved in cell fusion and modulation of cellular
responses. We describe herein the
identification of a novel polypeptide which has homology to meltrin,
designated herein as PR0545.
12. PR0617
CD24 is a protein that is associated with the cell surface of a variety of
different cells of the mammalian
immune system, including for example, neutrophils, monocytes and some
lymphocytes, for example, B lymphocytes.
CD24 has been shown to be a ligand for the platelet-associated surface
glycoprotein P-selectin (also known as granule
membrane protein-140 or GMP-140), a glycoprotein that is constitutively
synthesized in both platelets and endothelial
cells and becomes exposed on the surface of platelets when those cells become
activated. In this way, P-selectin
mediates the calcium-dependent adhesion of activated platelets and endothelial
cells to the various cells of the immune
system that express one or more Iigands for the P-selectin molecule,
particularly CD24. This mechanism allows for
recruitment of immune system cells to locations where they are most needed,
for example, sites of injury. Thus,
IS there is substantial interest in identifying novel polypeptides that
exhibit homology to the cell surface antigens of the
immune system cells. We herein describe the identification and
characterization of a novel polypeptide having
homology to the CD24 protein, wherein that novel polypeptide is herein
designated PR0617.
13. PR0700
Protein-disulfide isomerase (PDn is a catalyst of disulfide formation and
isomerization during protein
folding. It has two catalytic sites housed in two domains homologous to
thioredoxin, one near the N terminus and
the other near the C terminus. [See for example, Gilbert HF, l.Biol.Chem.,
47:29399-29402 (1997), Mayfield KJ,
Science, 278:1954-1957 (1997) and Puig et al., l.BioI.Chem., 52:32988-32994
(1997)]. PDI is useful for formation
of natural type disulfide bonds in a protein which is produced in aprokaryotic
cell. (See also, U.S. Patent Nos.
5,700,659 and 5,700,678).
Thus, PDI and molecules related thereto are of interest, particularly for
ability to catalyze the formation of
disulfide bonds. Moreover, these molecules are generally of interest in the
study of redox reactions and related
processes. PD/ and related molecules are further described in Darby, et al.,
Biochemistry 34, 11725-11735 (1995).
We herein describe the identification and characterization of novel
polypeptides having homology to protein disulfide
isomerase, designated herein as PR0700 polypeptides.
14. PR0702
Conglutinin is a bovine serum protein that was originally described as a
vertebrate lectin protein and which
belongs to the family of C-type lectins that have four characteristic domains,
(I) an N-terminal cysteine-rich domain,
(2) a collagen-like domain, (3) a neck domain and (4) a carbohydrate
recognition domain (CRD). Recent reports have
demonstrated that bovine conglutinin can inhibit hemagglutination by influenza
A viruses as a result of their lectin
properties (F.da et al., Biochem. 1. 316:43-48 (1996)). It has also bcen
suggested that lectins such as conglutinin can
function as immunoglobulin-independent defense molecules due to complement-
mediated mechanisms. Thus,
conglutittin has been shown to be useful for purifying immune complexes in
vitro and for removing circulating
9
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
immune complexes from patients plasma in vivo (Lim et al., Biochem. Bio~hvs.
Res. Cotnmun. 218:260-266 (1996)).
We herein describe the identification and characterization of a novel
polypeptide having homology to the conglutinin
protein, designated herein as PR0702.
15. R~ 0703
Very-long-chain acyl-CoA synthetase ("VLCAS") is a long-chain fatty acid
transport protein which is active
in the cellular transport of long and very long chain fatty acids. [see for
example, Uchida et al., J Biochem (Tokyo)
119(3):565-571 (1996) and Uchiyama et al., 1 Biol Chem 271(48):30360-30365
(I996). Given the biological
importance of fatty acid transport mechanisms, efforts are currently being
under taken to identify new, native proteins
which are involved in fatty acid transport. We describe herein the
identification of a novel polypeptide which has
homology to VLCAS, designated herein as PR0703.
16. RP 0705
The glypicans are a family of glycosylphosphatidylinositol (GPI)-anchored
proteoglycans that, by virtue of
their cell surface localization and possession of heparin sulfate chains, may
regulate the responses of cells to
numerous heparin-binding growth factors, cell adhesion molecules and
extracellular matrix components. Mutations
in one glypican protein cause of syndrome of human birth defects, suggesting
that the glypicans may play an
important role in development (Litwack et al., ev. 211:72-87 (1998)). Also,
since the glypicans may interact
with the various extracellular matrices, they may also play important roles in
wound healing (McGrath et al., Pa o
183:251-252 (1997)). Furthermore, since glypicans are expressed in neurons and
glioma cells, they may also play
an itztportarri role in the regulation of cell division and survival of cells
of the nervous system (Lung et al., ~ Cell.
io . 139:851-864 (1997)). It is evident, therefore, that the glypicans are an
extremely important family of
proteoglycans. There is, therefore, substantial interest in identifying novel
polypeptides having homology to members
of the glypican family. We herein describe the identification and
characterization of a novel polypeptide having
homology to K-glypican, designated herein as PR0705.
17. ~R0708
Aryl sulfatases are enzymes that exist in a number of different isofotms,
including aryl sulfatase A (ASA),
aryl sulfatase B (ASB) and aryl sulfatase C (ASC), and that function to
hydrolyze a variety of different aromatic
sulfates. Aryl sttlfarases have been isolated from a variety of different
animal tissues and microbial sources and their
structures and functions have been extensively studied (see, e.g., Nichol and
Roy, J. Biochem. 55:643-651 (1964)).
ASA deficiency has been reported to be associated with metachromatic
leukodystrophy (MLD) (tiles et al., Pre
is n. 7(4):245-252 (1987) and Herska et al., A~~.. J. Med. Gg~tet. 26(3):629-
635 (1987)). Additionally, other
groups have reported that aryl sulfatases have been found in high levels in
natural killer cells of the immune system
and have hypothesized a possible role for these enzymes in NK cell-mediated
cellular lysis (see, e.g., Zucker-Franklin
et al., Proc. Nat],. Acad. Sci. USA 80(22):6977-6981 (1983)). Given the
obvious physiological importance of the
aryl sulfatase enzymes, there is a substantial interest in identifying novel
aryl sulfatase homolog polypeptides. We
herein describe the identification and characterization of novel polypeptides
having homology to the aryl sulfatases,
wherein these novel polypeptides are herein designated PR0708 polypeptides.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
18. PR 32
Fibulin-I is a cysteine-rich, calcium-binding extracellular matrix (ECM)
component of basement membranes
and connective tissue elastic fibers and plasma protein, which has four
isoforms, A-D, derived from alternative
splicing. Fibulin-1 is a modular glycoprotein with amino-terminal anaphlatoxin-
like modules followed by nine
epidermal growth factor (EGF)-like modules and, depending on alternative
splicing, four possible carboxyl termini.
Fibulin-2 is a novel extracellular matrix protein frequently found in close
association with microfibrils containing
either fibronectin or fibrillin. There are multiple forms of fibulin-1 that
differ in their C-terminal regions that are
produced through the process of altet-native splicing of their precursor RNA.
(see for example Tran et al., a rix
~jol 15(7):479-493 (1997).]
Northern and Western blotting analysis of 16 ccll lines established from
tumors formed in athymic mice and
malignant cell lines derived from patients indicate that low expression of
fibulin-1D plays a role in tumor formation
and invasion. [Qing et al., Oncoeene, 18:2159-2168 (1997)]. Ovarian-cancer
cells are characterized by their ability
to invade freely the peritoneal cavity. It has been demonstrated that
estradiol stimulates the proliferation of estrogen-
receptor (ER)-positive ovarian-cancer cells, as well as expression of fibulin-
1. Studies on the effect of fibulin-1 on
motility of the MDA-MB231 breast-cancer cell line, indicated inhibition of
haptotactic migration of MDA-MB231
cells, and the authors concluded that fibulin-1 can inhibit cancer cell
motility in vitro and therefore has the potential
to inhibit tumor invasion. [Hayashido et al., lnt ) Cancer , 75(4):654-658
(1998)]
Thus, fibulin, and molecules related thereto are of interest, particularly for
the use of preventing cancer.
Moreover, these molecules are generally of interest in the study of connective
tissue and attachment molecules and
related mechanisms. Fibulin and related molecules are further described in
Adams, et al., J. Mol. Biol.,
272(2):226-36 (1997); Kielry and Shuttleworth, Microsc. Res. Tech., 38(4):413-
27 (1997); and Child. J. Card. Surg,.
12(2Supp.):131-5 (1997).
We herein describe the identification and characterization of novel
polypeptides having homology to fibulin;
designated herein as PR0320 polypepddes.
19. PR0324
Oxidoreductases are enzymes that catalyze a reaction in which two molecules of
a compound interact so that
one molecule is oxidized and the other is reduced, with a molecule of water
entering the reaction. There are many
different types of oxidoreductase enzymes that play very important
physiological roles in the mammalian organism.
Some of the most important oxidoreductases include, for example, lyases,
lactases, cholesterol oxidases, and the like.
These enzymes play roles in such essential processes as digestion, signal
transduction, maintenance of ionic
homeostasis, and the like. As such, given that oxidoreductase enzymes find
various essential uses in the mammalian
organism, there is a substantial interest in identifying novel oxidoreductase
enzyme homologs. We herein describe
the identi5cation and characterization of a novel polypeptide having homology
to oxidoreductases, designated herein
as PR0324.
20. PR0351
Prostasin is a novel human serine proteinase purified from human seminal
fluid. Immunohistochemical
localization reveals that prostasin is present in epithelial cells and ducts
of the prostate gland. The cDNA for
prostasin has been cloned and characterized. Southern blot analysis, following
a reverse transcription polymerase
11
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
chain reaction. indicates that prostasin mRNA is expressed in prostate, liver,
salivary gland, kidney, lung, pancreas,
colon, bronchus, renal proximal tubular cells, and prostate carcinoma LNCaP
cells. Cellular locaiization of prostasin
mRNA was identified within epithelial cells of the human prostate gland by in
situ hybridization histochemistry. [See
for example, Yu et al., J Biol Chem. (1994) 269(29):I8843-18848, and Yu et
al., J Biol Chem. (1994) 270(22):13483-
13489] .
Thus, prostasin, and molecules related thereto are of interest, particularly
for the study, diagnosis and
treaanent of medical conditions involving the prostate. Prostasin and related
molecules are further described in Yu
et al., Genomics (1996) 32(3):334-340. We herein describe the identification
and characterization of novel
polypeptides having homology to prostasin, designated herein as PR0351
polypeptides.
21. PRA
Butyrophilin is a milk glycoprotein that constitutes more than 40% of the
total protein associated with the
fat globule membrane in mammalian milk. Expression of buryrophilin mRNA has
been shown to correlate with the
onset of milk fat production toward the end pregnancy and is maintained
throughout lactation. Buryrophilin has been
identified in bovine, murine and human (see Taylor et al., Biochim. Bionhys.
Acta 1306:1-4 (1996), Ishii et al.,
Biochim. Bio~hvs. Acta 1245:285-292 (1995), Mather et al., ~. Daity Sci.
76:3832-3850 (1993) and Banghart et al.,
J. Biol. Chem. 273:4171-4179 (1998)) and is a type I transmembrane protein
that is incorporated into the fat globulin
membrane. It has been suggested that buryrophilin may play a role as the
principle scaffold for the assembly of a
complex with xanthitte dehydrogenaseloxidase and other proteins that function
in the budding and release of milk-fat
globules from the apical surface during lactation (Banghart et al., s a .
Given that buryrophilin plays an obviously important role in mammalian milk
production, there is substantial
interest in identifying novel buryrophilin homologs. We herein describe the
identification and characterization of a
novel polypeptide having homology to buryrophilin, designated herein as
PR0352.
22. PR0381
The immunophilins are a family of proteins that function as receptors for
immunosuppressant drugs, such
as cyclosporin A, FIC506, and rapamycin. The immunophilins occur in two
separate classes, (1) the FK506-binding
proteins (FKBPs), which bind to FK506 and rapamycin, and (2) the cyclophilins,
which bind to cyclosporin A. With
regard to the FIC506-binding proteins, it has been reported that the
FK506/F1CBP complex functions to inhibit the
activity of the serine/threonine protein phosphatase 2B (calcineurin), thereby
providing immtmosuppressant activity
(Gold, Mol. Neurobiol. 15:285-306 (1997)). It has also been reported that the
FICBP immtmophilins are found in
the mammalian nervous system and may be involved in axonai regeneration in the
central nervous system through
a mechanism that is independent of the process by which immunosuppression is
achieved (Gold, supra). Thus, there
is substantial interest in identifying novel polypeptides having homology to
the FKBP immunophilins. We herein
describe the identification and characterization of a novel polypeptide having
homology to an FKBP immunophilin
protein, designated herein as PR0381.
23. PR0386
Martttttalian cell membranes perform very important functions relating to the
structural integrity and activity
of various cells and tissues. Of particular interest in membrane physiology is
the study of transtnembrane ion
12
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
channels which act to directly control a variety of physiological,
pharmacological and cellular processes. Numerous
ion channels have been identified including calcium (Ca), sodium (Na) and
potassium (K) channels, each of which
have been analyzed in detail to determine their roles in physiological
processes in vertebrate and insect cells.
One type of cell membrane-associated ion channel, the sodium channel, plays an
extremely important role
in a cell's ability to maintain ionic homeostasis as well as transmit
intracellular and extracellular signals. Voltage-
gated sodium channels in brain neurons have been shown to be complexes of a
pore-forming alpha unit with smaller
beta-1 and beta-2 subunits (lsom et al., Cell 83:433-442 (1995)). Given the
obvious importance of sodium channels
in cellular homeostasis and other important physiological functions, there is
a significant interest in identifying novel
polypeptides having homology to sodium channel subttnits. We herein describe
the identification and characterization
of a novel polypeptide having homology to the beta-2 subunit of the rat sodium
channel, designated herein as
PR0386.
24. R~ ,0540
Lecithin-cholesterol acyltransferase ("LCAT"), also known as
phosphatidylcholine-sterol acyltransferase is
a key enzyme in the intravascular metabolism of high density lipoproteins,
specifically in the process of cholesterol
metabolism. (see, for example, Brousseau et al., J. Lipid Res., 38(12):2537-
2547 (1997), Hill et al., Biochem. J.,
294:879-884 (1993), and Drayna et al., Nature 327 (6123):632-634 (1987)].
Given the medical importance of lipid
metabolism, efforts are currently being under taken to identify new, native
proteins which are involved in lipid
transport. We describe herein the identification of a novel polypeptide which
has homology to LCAT, designated
herein as PR0540.
25. PR0615
Synaptogyrin is a synaptic vesicle protein that is uniformly distributed in
the nervous system. The cDNA
encoding synaptogyrin has been cloned and sequenced and the sequence predicts
a protein with a molecular mass of
25,900 D with four membrane-spanning domains. Synaptogyrin has been implicated
in membrane traffic to and from
the plasma membrane. Stenius et al., J. Cell. Biol. 131(6-2):1801-1809 (1995).
In addition, a novel isoform of
synaptogyrin called cellugyrin exhibits sequence identity with synaptogyrin.
In rat tissues, cellugyrin and
syttaptogyrins are expressed in mirror image patterns. Cellugyrin is
ubiquitously present in all tissues tested with the
lowest levels in brain tissue, whereas synaptogyrin protein is only detectable
in brain. In rat tissues, cellugyrin and
synaptogyrins are expressed in mirror image patterns. The synaptic vesicle
protein synaptogyrin tray be a specialized
version of a ubiquitous protein, cellugyrin, with the two proteins sharing
structural sittlilariry but differing in
localization. This finding supports the emerging concept of synaptic vesicles
as the simplified and specialized form
of a generic trafficking organelle. [Janz et al., ,~ Biol. Chem. 273(5):2851-
2857 (1998)] . The sequence for
cellugyrin derived from the Norway rat, Rattus norvegicus has been deposited
in the Genbank database on 23
December 1997, designated accession number AF039085. See also, Janz et al., J.
Biol. Chem. 273 (1998), in press.
Given the medical importance of synaptic transmission, efforts are currently
being under taken to identify
new, native proteins that may be pan of a simplified and specialized generic
trafficking organelle in the form of
synaptic vesicles. We describe herein the identification of a novel
polypeptide which has homology to synaptogyrin,
designated herein as PR0615.
13
CA 02421372 2003-03-25
WO 99146281 PC?/US99105028
26. PR 18
Enteropeptidase is a key enzyme in the intestinal digestion cascade
specifically cleaves the acidic propeptide
from trypsinogen to yield active trypsin. This cleavage initiates a cascade of
proteolytic reactions leading to the
activation of many pancreatic zymogens.
See, for example, Matsushima et a1.,1. Biol. Chem. 269(31):19976-19982 (1994),
Kitamoto et al., Proc. Nat. Acad.
ci., 91(16):7588-7592 (1994). Enterokinase (enteropeptidase) is a related to
mammalian serine proteases involved
in digestion, coagulation, and fibrinolysis. LaVallie et al., J Biol Chem.,
268(31):23311-23317 (1993).
Given the medical importance of digestive processes, efforts are currently
being under taken to identify new,
native proteins that may be involved in digestion, coagulation, and
fibrinolysis. We describe herein the identification
of a novel polypeptide which has homology to enteropeptidasc, designated
herein as PR0618.
27. PR0719
Lipoprotein lipase is a key enzyme that mediates the hydrolysis of
triglycerides and phospholipids present
in circulating plasma lipoproteins (Dugi et al., J. Biol. Chem.. 270:25396-
25401 (1995)). Moreover, lipoprotein
lipase has been shown to mediate the uptake of lipoproteins into cells,
wherein cellular uptake of lipoproteins is
initiated by binding of lipoprotein lipase to cell surface proteoglycans and
to the low density lipoprotein (LDL)
receptor-related protein (Krapp et al., J. LiQid Res. 36:2362-2373 (1995)).
Thus, it is clear that lipoprotein lipase
plays an extremely important role in lipoprotein and cholesterol metabolism.
There is, therefore, substantial interest
in identifying novel polypeptides that share sequence homology andlor
biological activity with lipoprotein lipase. We
herein describe the identification and characterization of a novel polypeptide
having sequence homology to lipoprotein
lipase H, designated heein as PR0719.
28. PR0724
The low density lipoprotein (LDL) receptor is a membrane-bound protein that
plays a key role in cholesterol
homeostasis, mediating cellular uptake of lipoprotein panicles by high
affinity binding to its ligands, apolipoprotein
(apo) B-100 and apoE. The ligand-binding domain of the LDL receptor contains 7
cysteine-rich repeats of
approximately 40 amino acids, wherein each repeat contains 6 cysteines, which
form 3 infra-repeat disulfide bonds.
These unique stivctural features provide the LDL receptor with its ability to
specifically interact with apo B-100 and
apoE, thereby allowing for transport of these lipoprotein panicles across
cellular membranes and metabolism of their
components. Soluble fragments containing the extracellular domain of the LDL
receptor have been shown to retain
the ability to interact with its specific lipoprotein ligands (Simmons et al.,
J. Biol. Chem. 272:25531-25536 (1997)).
Thus, it is clear that the LDL receptor is intimately involved in important
physiological activities related to cholesterol
metabolism. As such, there is substantial interest in identifying novel LDL
receptor homolog proteins. We herein
describe the identification and characterization of a novel polypeptide having
homology to the human LDL receptor
protein, designated herein as PR0724..
29. PR 772
Expression of the human gene A4 is enriched in the colonic epithelium and is
uanscriptionally activated on
differentiation of colottic epithelial cells in vitro (Oliva et al., Arch.
Biocher~ Bioohvs. 302:183-192 (1993) and Oliva
et al., Am. J. Phvsiol. 272:C957-C965 (1997)). A4 cDNA contains an open
reading frame that predicts a polypeptide
14
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
of approximately 17 kilodaltons in size. Hydropathy analysis of the A4 protein
revealed four putative membrane-
spanning alpha-helices. Immunocytochemical studies of cells expressing A4
protein indicated that expression is
localized to the endoplasmic reticulum. The four membrane-spanning domains and
the biophysical characteristics
of the A4 protein suggest that it belongs to a family of integral membrane
proteins called proteolipids, some of which
multimerize to form ion channels. In fact, preliminary evidence has suggested
that A4 may itself multimerize and
take on the properties of an ion channel (Oliva et al., Am. J. Physiol.
272:C957-C965 (1997)). Given the importance
of ion channels in maintaining cellular homeostasis, there is a significant
interest in identifying novel polypeptides
having homology to known and putative ion channels. We herein describe the
identification and characterization of
a novel polypeptide having homology to the putative ion channel protein, A4,
designated herein as PR0772.
30. RP 0852
Proteases are enzymatic proteins which are involved in a large number of very
important biological
processes in mammalian and non-mammalian organisms. Numerous different
protease enzymes from a variety of
different mammalian and non-mammalian organisms have been both identified and
characterized. The mammalian
protease enzymes play important roles in many different biological processes
including, for example, protein
digestion, activation, inactivation, or modulation of peptide hormone
activity, and alteration of the physical properties
of proteins and enzymes.
In light of the important physiological roles played by protease enzymes,
efforts are currently being
undertaken by both industry and academia to identify new, native protease
homologs. Many of these efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
secreted and membrane-bound receptor proteins. Examples of screening methods
and techniques are described in
the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci.,
23:7108-7113 (1996); U.S. Patent No.
5,536,637)]. We herein describe the identification of novel polypeptides
having homology to various protease
enzymes, designated herein as PR0852 polypeptides.
31. PR 53
Studies have reported that the redox state of the cell is an important
determinant of the fate of the cell.
Furthermore, reactive oxygen species have been reported to be cytotoxic,
causing inflammatory disease, including
tissue necrosis, organ failure, atherosclerosis, infertility, birth defects,
premature aging, mutations and malignancy.
Thus, the control of oxidation and reduction is important for a number of
reasons, including the control and
prevention of strokes, heap attacks, oxidative stress, hypertension and may be
associated with the development of
malignancies. The levels of antioxidant enzymes, such as reductases, which
catalyze the conversion of reactive
oxygen species to water have been shown to be low in cancer cells. In
particular, malignant prostate epithelium may
have lowered expression of such antioxidant enzymes [Baker et ., to 32(4):229-
233 (1997)]. In this regard,
reductases, are of interest. In addition, the transcription factors, NF-kappa
B and AP-1, are known to be regulated
by redox state and to affect the expression of a large variety of genes
thought to be involved in the pathogenesis of
AIDS, cancer, atherosclerosis and diabetic complications. Publications further
describing this subject matter include
Engman et al., Elnticancer Res. (Greecel, I7:4599~1605 (1997), Kelsey, et al.,
Br. J. Cancer, 76(7):852-4 (1997);
Friedrich and Weiss,1. Theor. Biol., 187(4):529-40 (1997) and Pieulle, et al.,
J. Bacteriol., 179(18):5684-92 (1997).
Given the physiological importance of redox reactions in tdvo, efforts are
currently being under taken to identify new,
1S
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
native proteins which are involved in redox reactions. We describe herein the
identification of a novel prostate
specific polypeptide which has sequence similarity to reductase, designated
herein as PR0853.
32. PR0860
Newofascin is a member of the LI subgroup of the cellular adhesion molecule
("CAM") family of nervous
system adhesion molecules and is involved in cellular aggregation. Cell-cell
recognition and patterning of cell
contacts have a critical role in mediating reversible assembly of a wide
variety or transcellular complexes in the
nervous system. Cell interactions may be regulated through modulation of
ankyrin binding to neurofascin. See, for
example, Tuvia et al., Proc. Nat Acad. 5ci., 94(24) 12957-12962 (1997).
Neurofascin has been described as a
member of the Ll subgroup of the immunoglobulin superfamily implicated in
neurite extension during embryonic
development for which numerous isoforms have been detected at various stages
of development. See also Hassel et
al., J. Biol. Chem., 272(45) 28742-28749 (1997), Grumet., Cell. Tissue Res.
290(2) 423-428 (1997), Garver et al.,
J. Cell. Biol., 137:703-714 (1997), and Lambent et al., J. Neurosci., 17:7025-
7-36 (1997),.
Given the physiological importance of cellular adhesion molecules and
development of the nervous system
in vivo, efforts are currently being under taken to identify new, native
proteins which are involved in regulation of
cellular interactions in the nervous system. We describe herein the
identification and characterization of a novel
polypeptide which has sequence similarity to neurofascin, designated herein as
PR0860.
33. PR0846
The CMRF35 monoclonal antibody was used to identify a cell membrane antigen,
designated CMRF35,
which is present on the surface of monocytes, neutrophils, a proportion of
peripheral blood T and B lymphocytes and
lymphocytic cell lines. The CMRF35 cDNA encodes a novel integral membrane
glycoprotein member of the
immunoglobulin (Ig) gene superfamily. The molecule comprises (a) a single
extracellular Ig variable domain
remarkably similar to the Fc receptor for polymeric 1gA and lgM, (b) a
membrane-proximal domain containing a high
proportion of proline, serine and threonine residues that was predicted to be
heavily O-glycosylated, (c) an unusual
transmembrane anchor that contained a glutamic acid and a proline residue and
(d) a short cytoplasmic tail.
Transcripts encoding the CMRF35 protein have been detected in early monocytic
cell lines, in peripheral blood T
cells and in some B lytnphoblastoid cell lines, confirming the results of
immunocytological staining. Jackson et al.,
Eur. J. Immunol. 22(5):1157-1163 (1992). CMRF-35 molecules are differentially
expressed in hematopoietic cells,
and the expression of the antigen was shown to be markedly influenced by
stimulation with mitogens and cytokines.
See, for example, Clark et al., Exp, Hematol. 25(8):759 (1997), Daish et al.,
Immu . 79(1):55-63 (1993), and
Clark et al., Tissue Antigens 48:461 (1996).
Given the physiological importance of the immune system and antigens
associated with various immune
system cells, efforts are currently being under taken to identify new, native
proteins which are expressed on various
cclls of the immune system. We describe herein the identification of a novel
polypeptide which has sequence
similarity to CMRF35, designated herein as PR0846.
34. PR0862
Lysozyme is a protein which is widely distributed in several human tissues and
secretions including milk,
tears and saliva. It has been demonstrated to hydrolyze linkages between N-
acerylglucosamines. It has been
16
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
demonstrated to be an inhibitor of chemotaxis and of the production of toxic
oxygen free radicals and may also have
some role in the calcification process. As such, there is substantial interest
in identifying novel polypeptides having
homology to lysozyme. We describe herein the identification of a novel
polypeptide which has sequence similarity
to lysozyme.
35. PR0864
Wnt-4 is a secreted glycoprotein which correlates with, and is required for,
kidney tubulogenesis. Mice
lacking Wnt-4 activity fail to form pretubular cell aggregates; however, other
aspects of mesenchymal and ureteric
development are unaffected. Thus, Wntsl appears to act as an autoinducer of
the mesenchyme to epithelial transition
that underlies nephron development. Stark et al., Nature ;372(6507):679-683
(1994). In addition, members of the
Wnt gene family code for cysteine-rich, secreted proteins, which are
differentially expressed in the developing brain
and possibly act as intercellular signaling molecules. A Wnt gene, e.g., Wnt-1
is known to be essential for
specification of the midbrain cell fate. Yoshioka et al., Biochem. Biophvs.
Res. Commun. 203(3):1581-1588 (1994).
Several member of the Wnt family of secreted factors are strongly implicated
as regulators of mammary cellular
growth and differentiation. Shimizu et al., Cell Growth Differ. 8(12) 1349-
1358. Wnt-4 is normally expressed in
early pregnancy. Wnt-4 may therefore be a local signal driving epithelial
branching in pregnancy. Edwards PA,
Biochem Soc Sym~.63:21-34 11998). See also, Lipschutz JH, Vim. J. Kidnev Dis.
31(3):383-397, (1998). We
describe herein the identification and characterizaton of a novel polypeptide
which has sequence similarity to Wnt-4,
designated herein as PR0864.
36. PR0792
At least two cell-derived signals have been shown to be necessary for the
induction of immunoglobulin
isotype switching in Bells. The first signal is given by either of the soluble
lymphokines, interleukin (IL)-4 or IL-
13, which induce germline epsilon transcript expression, but this alone is
insufficient to trigger secretion of
immuttoglobulin E (IgE). The second signal is provided by a physical
interaction between B-cells and activated T-
cells, basophils and mast cells, and it has been shown that the CD40/CD40
ligand pairing is crucial for mediating
IgE synthesis. Additionally, amongst the numerous pairs of surface adhesion
molecules that are involved in IgE
synthesis, the CD23/CD21 pair appears to play a key role in the generation of
IgE. CD23 is a protein that is
positively and negatively regulated by factors which increase or decrease 1gE
production, respectively. Antibodies
to CD23 have been shown to inhibit IL-4-induced human IgE production in vitro
and to inhibit antigen-specific IgE
responses in a rat model, in an isotype selective manner (Bonnefoy et al.,
Eur. Respir. J. Suvnl. 22:63S-66S (1996)).
CD23 interacts with CD21 on B-cells, preferentially driving IgE production.
Given that the CD23 protein plays an
extremely important role in the induction of a mammalian IgE response, there
is significant interest in identifying
novel polypeptides having homology to CD23. We herein describe the
identification and characterization of a novel
polypeptide having homology to CD23, designated herein as PR0792.
37. PROSø~
Mindin and spondin proteins are secreted proteins that are structurally
related to one another and which have
been identified in a variety of organisms. For example, Higashijima et al.,
Dev iol. 192:211-227 (1997) have
reported the identification of spondin and mindin expression in floor plate
cells in the zebrafish embryonic axis,
17
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
thereby suggesting that mindin and spondin prtoteins play important roles in
embryonic development. This same
group has reported that mindin and spondin proteins function as extracellular
matrix proteins that have a high affmiry
for the basal lamina. (Id.). It has been reported that F-spondin is a secreted
protein that promotes neural adhesion
and neurite extension (Klan et al., Cell 69:95-110 (1992) and that M-spondin
is an extracellular matrix protein that
localizes to muscle attachment sites in Drosophila (Umemiya et al., Dev. Biol.
186:165-176 (1997)). Thus, there
S is significant inteest in identifying novel polypeptides having homology to
the mindin and spondin proteins. We herein
describe the identification and characterization of a novel polypeptide having
homology to mindin2 and mindinl ,
designated herein as PR0866.
38. PR0871
Cyclophiiins are a family of proteins that bind to cyclosporin A and possess
peptidyl-prolyl cis-traps
isomerase activity (Sherry et al., Proc. Natl. Acad. Sci. USA 95:1758-1763
(1998)). In addition, cyclophilins are
secreted by activated cells and act in a cytokine-like manner, presumably via
signaling through a cell surface
tyc1ophlllp receptor. Host cell-derived cyclophilin A has been shown to be
incorporated into HIV-1 virions and its
incorporation has been shown to be essential for viral infectiviry. Thus, one
or more the cyclophilins may be directly
associated with HIV-I infectiviry. Given the obvious importance of the
tyc1ophlllp proteins, there is substantial
interest in identifying novel polypeptides which have sequence homology to one
or more of the tyc1ophlllp proteins.
We herein describe the identification and characterization of a novel
polypeptide having homology to tyc1ophlllp-like
protein CyP-60, designated herein as PR0871.
39. PR0873
Enzymatic proteins play important roles in the chemical reactions involved in
the digestion of foods, the
biosynthesis of macromolecules, the controlled release and utilization of
chemical energy, and other processes
necessary to sustain life. Enzymes have also been shown to play important
roles in combating various diseases and
disorders. For example, liver carboxylesterases have been reported to assist
in sensitizing human tumor cells to the
cancer prodrugs. Danks et al., report that stable expression of the cDNA
encoding a carboxylesterase in Rh30 human
rhabdomyosarcoma cells increased the sensitivity of the cells to the CPT-11
cancer prodrug 8.1-fold. Cancer Res.
(1998) 58(1):20-22. The authors propose that this prodrug/enzyme combination
could be exploited therapeutically
in a manner analogous to approaches currently under investigation with the
combinations of ganciclovirlherpes
simplex virus thymidine kinase and 5-fluorocytosine/cytosine deaminase. van
Pelt er al. demonstrated that a 55 kD
human liver carboxylesterase inhibits the invasion of Plasmodium falcipatum
malaria sporozoites into primary human
hepatocytes in culture. a of (1997) 27(4):688-698.
Carboxylesterases have also been found to be of importance in the
detoxification of drugs, pesticides and
other xenobiotics. Purified human liver carboxylesterases have been shown to
be involved in the metabolism of
various drugs including cocaine and heroin. Prindel et al. describe the
purification and cloning of a broad substrate
specificity human liver carboxyiesterase which catalyzes the hydrolysis of
cocaine and heroin and which may play
an important role in the degradation of these drugs in human tissues. J. Biol.
Chem. (1997) 6:272(23):14769-14775.
Brienzinski et al. describe a spectrophotometric competitive inhibition assay
used to identify drug or environmental
esters that are metabolized by carboxylesterases. j~~, Metab Disoos (1997)
25(9):1089-1096.
18
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In light of the important physiological roles played by carboxylesterases,
efforts are being undertaken by
both industry and academia to identify new, native carboxylesterase homologs.
We herein describe the identification
and characterization of a novel polypeptide having homology to
carboxylesterase, designated herein as PR0873.
40. PR0940
CD33 is a cell-surface protein that is a member of the sialoadhesin family of
proteins that are capable of
mediating sialic-acid dependent binding with distinct specificities for both
the type of sialic acid and its linkage to
subterminal sugars. CD33 is specifically expressed in early myeloid and some
monocyte cell lineages and has been
shown to be strongly associated with various myeloid tumors including, for
example, acute non-lymphocytic leukemia
(ANLL). As such, CD33 has been suggested as a potential target for the
treatment of cancers associated with high
level expression of the protein. There is, therefore, significant interest in
the identification of novel polypeptides
having homology to CD33. In fact, one CD33 homolog (designated CD33L) has
already been identified and
described (see Takei et al., C~openet. Cell Genet. 78:295-300 (1997)). We
herein describe the identification of
another novel polypeptide having homology to CD33, designated herein as
PR0940. The novel polypeptide described
herein also exhibits significant homology to the human OB binding proteins
designated HSU71382 1 and
HSU71383_1 in the Dayhoff database (version 35.45 SwissProt 35).
41. PR 0941
Cadherins are a large family of transmembrane proteins. Cadherins comprise a
family of calcium-dependent
glycoproteins that function in mediating cell-cell adhesion in virtually all
solid tissues of multicellular organisms.
At least cadherins I-13 as well as types B, E, EP, M, N, P and R have been
identified and characterized. Among
the functions cadherins are known for, with some exceptions, are that
cadherins participate in cell aggregation and
are associated with cell-cell adhesion sites. Recently, it has been reported
that while all cadherins share multiple
repeats of a cadherin specific motif believed to correspond to folding of
extracellular domains, members of the
cadherin superfamily have divergent structures and, possibly, functions. In
particular it has been reported that
members of the cadherin superfamily are involved in signal transduction. See,
Suzuki, J. Cell Biochem., 61(4):531-
542 (1996). Cadherins are further described in Tanihara et al., 1. Cell Sci.,
107(6):1697-1704 (1994), Aberle et al.,
J. CeU Biochem., 61(4):514-523 (1996) and Tanihara et al., Cell Adhes.
Commun., 2(1):15-26 (1994). We herein
describe the identification and characterization of a novel polypeptide having
homology to a cadherin protein,
designated herein as PR0941.
42. PR0944
Clostridiwrt petfringens enterotoxin (CPE) is considered to be the virulence
factor responsible for causing
the symptoms of C. perfringens type A food poisoning and may also be involved
in other hutnatt and veterinary
illnesses (McClane, Toxicon. 34:1335-1343 (1996)). CPE carries out its adverse
cellular functions by binding to an
approximately 50 kD cell surface receptor protein designated the Clostridium
perfringens enterotoxin receptor (CPE-
R) to form an approximately 90,000 kD complex on the surface of the cell.
cDNAs encoding the CPE-R protein have
been identified characterized in both human and mouse (Katahira et al., J.
Cell Biol. 136:1239-1247 (1997) and
Katahira et al., J. Biol. Chem. 272:26652-26658 (1997)). Since the CPE toxin
has been reported to cause a variety
of illnesses in matrurtalian hosts and those illnesses are initiated by
binding of the CPE toxin to the CPE-R, there is
19
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
significant interest in identifying novel CPE-R homologs. We herein describe
the identification and characterization
of a novel polypeptide having homology to the CPE-R, designated herein as
PR0944.
43. PR0983
Membrane-bound proteins include not only cell-surface membrane-bound proteins,
but also proteins that are
found on the surface of intracellular vesicles. These vesicles are involved in
exocytosis, which is the fusion of
secretory vesicles with the cellular plasma membrane, and have two main
functions. One is the discharge of the
vesicle contents into the extracellular space, and the second is the
incorporation of new proteins and lipids into the
plasma membrane itself. Exocytosis can be either constitutive or regulated.
All eukaryotic cells exhibit constitutive
exocytosis, which is marked by the immediate fusion of the secretory vesicle
after formation. In contrast, regulated
exocytosis results in the accumulation of the secretory vesicles that fuse
with the plasma membrane upon receipt of
an appropriate signal by vesicle-associated membrane proteins. Usually, this
signal is an increase in the cytosolic
free Ca2' concentration. However, regulated exocytosis that is independent of
Ca+ has been reported (see, e.g.
Fujita-Yoshigaki et al. J. Biol. Chem. (1996) 31:271(22):13130-13134).
Regulated exocytosis is crucial to many
specialized cells, including neurons (neurotransmitter release from synaptic
vesicles), adrenal chromaffm cells
(adrenaline secretion), pancreatic acinar cells (digestive enzyme secretion),
pancreatic p-cells (insulin secretion), mast
cells (histamine secretion), mammary cells (milk protein secretion), sperm
(enzyme secretion), egg cells (creation
of fertilization envelope) and adipocytes (insertion of glucose transporters
into the plasma membrane).
Disorders involving exocytosis are known. For example, inflammatory mediator
release from mast cells
leads to a variety of disorders, including asthma. Similarly, Chediak-Higashi
Syndrome (CHS) is a rare autosomal
recessive disease in which neutrophils, monocytes and lymphocytes contain
giant cytoplasmic granules. Accordingly,
the proteins involved in exocytosis are of paramount interest and efforts are
being undertaken by both industry and
academia to identify new, vesicle-associated proteins. For example, Skehel et
al. identified a 33-kilodalton membrane
protein in Aplysia, termed VAP-33, which is required for the exocytosis of
neurotransmitter. Science (1995)
15:269(5230):1580-1583, and Neurophatmacoloev (1995) 34(11):1379-1385. Many
efforts are focused on the
screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel vesicle- associated
membrane proteins. It is an object of the invention to provide proteins having
homology to the vesicle associated
protein, VAP-33, designated herein as PR0983.
44. R 7
Proteases are enzymatic proteins which are involved in a large number of very
important biological
processes in mammalian and non-mammalian organisms. Numerous different
protease enzymes from a variety of
different mammalian and non-mammalian organisms have been both identified and
characterized. The mammalian
protease enzymes play important roles in many different biological processes
including, for example, protein
digestion, activation, inactivation, or modulation of peptide hormone
activity, and alteration of the physical properties
of proteins and enzymes.
In light of the important physiological roles played by protease enzymes,
efforts are currently being
undertaken by both industry and academia to identify new, native protease
homologs. Many of these efforts are
focused on the screening of marrunalian recombinant DNA libraries to identify
the coding sequences for novel
secreted proteins. Examples of screening methods and techniques are described
in the literature [see, for example,
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Klein et al., Proc. Nat(. Acad. Sci" x:7108-7113 (1996); U.S. Patent No.
5,536,637)]. We herein describe the
identification of novel polypeptides having homology to various protease
enrymes, designated herein as PR01057
polypeptides.
45. P 01071
Thrombospondin-1 is a trimeric high molecular weight glycoprotein that is
released from platelet alpha-
granules in response to thrombin stimulation and that is also a transient
component of the extracellular matrix in
developing and repairing tissues (Adams, )nt. J. Biochem. Cell Biol. 29:861-
865 (1997) and Qian et al., P~oc. SQc.
F~cp. Biol. Med. 212:199-207 (1996)). A variety of factors regulate
thrombospondin expression and the protein is
degraded by both extracellular and intracellular routes. Thrombospondin-1
functions as a cell adhesion molecule and
also modulates cell movement, cell proliferation, neurite outgrowth and
angiogenesis. As such, there is substantial
interest in identifying novel polypeptides having homology to thrombospondin.
We herein describe the identification
and characterization of a novel polypeptide having homology to thrombospondin,
designated herein as PR01071.
46. 07
Studies have reported that the redox state of the cell is an important
determinant of the fate of the cell.
Furthermore, reactive oxygen species have been reported to be cytotoxic,
causing inflammatory disease, including
tissue necrosis, organ failure, atherosclerosis, infertility, birth defects,
premature aging, mutations and malignancy.
Thus, the control of oxidation and reduction is important for a number of
reasons, including the control and
prevention of strokes, heart attacks, oxidative stress, hypertension and may
be associated with the development of
malignancies. The levels of antioxidant enrymes, such as reductases, which
catalyze the conversion of reactive
oxygen species to water have been shown to be low in cancer cells. In
particular, malignant prostate epithelium may
have lowered expression of such antioxidant enzymes [Baker et al., Pro to
32(4):229-233 (1997)]. In this regard,
reductases, are of interest. In addition, the transcription factors, NF-kappa
B and AP-1, are known to be regulated
by redox state and to affect the expression of a large variety of genes
thought to be involved in the pathogenesis of
A)DS, cancer, atherosclerosis and diabetic complications. Publications further
describing this subject matter include
Fngcrtart et al., Anticancer Res. (Greece), 17:4599-4605 (1997), Kelsey, et
al., Br. J. Cancer, 76(7):852-854 (1997);
Friedrich and Weiss, J. Th~r~Biol., 187(4):529-40 (1997) and Pieulle, et al.,
J. Bacteriol., 179(18):5684-92 (1997).
Given the physiological importance of redox reactions in vivo, efforts are
currently being under taken to identify new,
native proteins which are involved in redox reactions. We describe herein the
identification of a novel polypeptide
which has sequence similarity to reductase enzymes, desiignated herein as
PR01072.
47. PR0107i
Protein disulfide isort~rase is an enzymatic protein which is involved in the
promotion of correct refolding
of proteins through the establishment of correct disulfide bond formation.
Protein disulfide isomerase was initially
identified based upon its ability to catalyze the renaturation of reduced
denatured RNAse (Goldberger et al., J. Biol.
Chem. 239:1406-1410 (1964) and Epstein et al., Cold Sprring Harbor Sump.
Quart. Biol. 28:439-449 (1963)).
Protein disulfide isomerase has been shown to be a resident enzyme of the
endoplasmic reticulum which is retained
in the endoplasmic reticulum via a -KDEL or -HDEL amino acid sequence at its C-
terminus.
Given the importance of disulfide bond-forming enzymes and their potential
uses in a number of different
21
CA 02421372 2003-03-25
WO 99/46281 PC'f1US99/05028
applications, for example in increasing the yield of correct refolding of
recombinantly produced proteins, efforts are
currently being undertaken by both industry and academia to identify new,
native proteins having homology to protein
disulfide isomerase. Many of these efforts are focused on the screening of
mammalian recombinant DNA libraries
to identify the coding sequences for novel protein disulfide isomerase
homologs. Examples of screening methods and
techniques are described in the literature [see, for example, Klein et al.,
roc. Natl. Acad. Sci., 93:7108-7113 (1996);
U.S. Patent No. 5,536,637)]. We herein describe a novel polypeptide having
homology to protein disulfide
isomerase, designated herein as PR01075.
48. P 18
In Drosophila, the dorsal-ventral polarity of the egg chamber depends on the
localization of the oocyte
nucleus and the gurken RNA to the dorsal-anterior corner of the oocyte. Gurken
protein presumably acts as a ligand
for the drosophila EGF receptor (torpedo/DER) expressed in the somatic
follicle cells surrounding the oocyte.
Cornichon is a gene required in the germline for dorsal-ventral signaling
(Roth et al., Cell 81:967-978 (1995)).
Cornichon, gurken and torpedo also function in an earlier signaling event that
establishes posterior follicle cell fates
and specifies the anterior-posterior polarity of the egg chamber. Mutations in
any or all of these genes prevent the
formation of a correctly polarized microtubule cytoskeleton required for
proper localization of the anterior and
posterior determinants bicoid and oskar and for the asymmetric positioning of
the oocyte nucleus. Thus, it is clear
that the cornichon gene product plays an important role in early development.
We herein describe the identification
and characterization of a novel polypeptide having homology to the cornichon
protein, designated herein as PR0181.
49. PR0195
Efforts acre currently being undertaken to identify and characterize novel
transmembrane proteins. We
herein describe the identification and characterization of a novel
transmembrane polypeptide, designated herein as
PR0195.
50. PRO865
Efforts arre currently being undertaken to identify and characterize novel
secreted proteins. We herein
describe the identification and characterization of a novel secreted
polypeptide, designated herein as PR0865.
51. PR0827
VLA-2 is an cell-surface integrin protein that has been identified and
characterized in a number of
mammalian organisms, including both mouse and human. VLA-2 has been shown to
be a receptor on the surface
of cells for echovirus-1 (EV-1) which mediates infection of VLA-2-expressing
cells by EV-1 (Zhang et al., Virolosw
235(2):293-301 (1997) and Bergelson et al., c'e a 255:1718-1720 (1992)). VLA-2
has also been shown to mediate
the imeraction of collagen with endothelitun during in vitro vascular tube
formation (Jackson et al., Cell Biol. /nt.
18(9):859-867 (1994)). Various other integrin proteins that share various
degrees of amino acid sequence homology
with VLA-2 have been identified and characterized in a variety of mammalian
organism. These integrins have been
reported to play important roles in a variety of different physiological
functions. Therefore, there is significant
interest in identifying novel polypeptides having homology to one or more of
the integrin proteins. We herein
describe the identification and characterization of a novel polypeptide having
homology to VLA-2 integrin protein,
22
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
designated herein as PR0827.
52. 801114
Many important cytoltine proteins have been identified and characterized and
shown to signal through
specific cell surface receptor complexes. For example, the class II cytokine
receptor family (CRF2) includes the
interferon receptors, the interleulan-10 receptor and the tissue factor CRFB4
(Spencer et al., I. Exp. Med. 187:571
578 (1998) and Kotenko et al., EMBO J.J. 16:5894-5903 (1997)). Thus, the
multintde of biological activities exhibited
by the various cytokine proteins is absolutely dependent upon the presence of
cytokine receptor proteins on the
surface of target cells. There is, therefore, a significant interest in
identifying and characterizing novel polypeptides
having homology to one or more of the cytokine receptor family. We herein
describe the identification and
characterization of a novel polypeptide having homology to cytokine receptor
family-4 proteins, designated herein
as PROI117.
lnterferons (IFNs) encompass a large family of secreted proteins occurring in
venebrates. Although they
were originally named for their antiviral activity, growing evidence supports
a critical role for IFNs in cell growth
and differentiation (laramillo et al., Cancer Investigation 13(3):327-338
(1995)). IFNs belong to a class of negative
growth factors having the ability to inhibit the growth of a wide variety of
cells with both normal and transformed
phenotypes. IFN therapy has been shown to be beneficial in the treatment of
human malignancies such as Karposi's
sarcoma, chronic myelogenous leukemia, non-Hodgkin's lymphoma, and hairy cell
leukemia as well as in the
treatment of infectious diseases such as hepatitis B (Gamliel et al.,
Scanning.Microscony 2(1):485-492 (1988),
Einhorn et al., Med. Oncol. & Tumor Pharmacother. 10:25-29 (1993), Ringenberg
et al., Missouri Medicine
85(1):21-26 (1988), Saracco et al., Journal of Gastroenterology and Hematology
10:668-673 (1995), Gortzalez-Mateos
et al., Henato-Gastroenterology 42:893-899 (1995) and Malaguarnera et al.,
Pharmacotherapy 17(5):998-1005
(1997)).
Interferons can be classified into two major groups based upon their primary
sequence. Type I interferons,
IFN-a and IFN-Vii, are encoded by a superfamily of intronless genes consisting
of the IFN-a gene family and a single
IFN-~i gene that are thought to have arisen from a common ancestral gene. Type
I interferons may be produced by
most cell types. Type II IFN, or IFN-y, is restricted to lymphocytes (T cells
and natural killer cells) and is stimulated
by nonspecific T cell activators or specific antigens in vivo.
Although both type I and type II IFNs produce similar antiviral and
antiproliferative effects, they act on
distinct cell surface receptors, wherein the binding is generally species
specific (Larger et al., Imrtunol. Today 9:393
400 (1988)). Both 1FN-a and IFN-~i bind competitively to the same high
affinity type I receptor, whereas IFN-y
binds to a distinct type II receptor. The presence and number of 1FN receptors
on the surface of a cell does not
generally reflect the sensitivity of the cell to IFN, although it is clear
that the effects of the IFN protein is mediated
through binding to a cell surface interferon receptor. As such, the
identification and characterization of novel
interferon receptor proteins is of extreme interest.
We herein describe the identification and characterization of novel interferon
receptor polypeptides,
designated herein as "P801114 interferon receptor" polypeptides. Thus, the
PR01114 polypeptides of the present
invention represents a novel cell surface interferon receptor.
23
CA 02421372 2003-03-25
WO 99/46281 PCTIUS99/05028
53. 80237
Carbonic anhydrase is an enzymatic protein that which aids carbon dioxide
transport and release in the
mammalian blood system by catalyzing the synthesis (and the dehydration) of
carbonic acid from (and to) carbon
dioxide and water. Thus, the actions of carbonic anhydrase are essential for a
variety of important physiological
reactions in the mammal. As such, there is significant interest in the
identification and characterization of novel
polypeptides having homology to carbonic anhydrase. We herein describe the
identification and characterization of
a novel polypeptide having homology to carbonic anhydrase, designated herein
as PR0237.
54. P80541
Numerous trypsin inhibitory proteins have been identified and characterized
(see, e.g., Yamakawa et al.,
Biochim. Biophys. Acta 1395:202-208 (1998) and Mizuki et al., Mammalian Genome
3:274-280 (1992)). Trypsin
inhibitor proteins play important roles in a variety of different
physiological and biological pathways and are
specifically involved in such processes as the regulation of protein
degradation, digestion, and the like. Given the
important roles played by such enzymatic proteins, there is significant
interest in identifying and characterizing novel
polypeptides having homology to known trypsin inhibitor proteins. We herein
describe the identification and
characterization of a novel polypeptide having homology to a trypsin inhibitor
protein, designated herein as PR0541.
55. R~ 0273
Leukocytes include monocytes, macrophages, basophils, and eosinophils and play
an important role in the
immune response. These cells are important in the mechanisms initiated by T
and/or B lymphocytes and secrete a
range of cytokines which recruit and activate other inflammatory cells and
contribute to tissue destruction.
Thus, investigation of the regulatory processes by which leukocytes move to
their appropriate destination
and interact with other cells is critical. Currently, leukocytes are thought
to move from the blood to injured or
inflamed tissues by rolling along the endothelial cells of the blood vessel
wall. This movement is mediated by
transient interactions between selectins and their ligands. Next, the
leukocyte must move through the vessel wall and
into the tissues. This diapedesis and extravasation step involves cell
activation which promotes a more stable
leukocyte-endothelial cell interaction, again mediated by integrins and their
ligands.
Chemokines are a large family of structurally related polypeptide cytokines.
These molecules stimulate
leukocyte movement and may explain leukocyte trafficking in different
inflammatory situations. Chemokines mediate
the expression of particular adhesion molecules on endothelial cells, and they
produce chemoattractants which activate
specific cell types. in addition, the chemokines stimulate proliferation and
regulate activation of specific cell types.
In both of these activities, chemokines demonstrate a high degree of target
cell specificity.
The chemokine family is divided into two subfamilies based on whether two
amino terminal cysteine residues
are imr~diately adjacent (C-C) or separated by orte amino acid (C-X-C).
Chemokines of the C-X-C family generally
activate neutrophils and fibroblasts while the C-C chemokines act on a more
diverse group of target cells including
monocytes/macrophages, basophiLs, eosinophils and T lymphocytes. The known
chemokines of both subfamilies are
synthesized by many diverse cell types as reviewed in Thomson A. (1994) The
Cytokine Handbook, 2 d Ed.
Academic Press, N.Y. Chemokines are also reviewed in SchaI1 TJ (1994)
Chemotactic Cytokines: Targets for
Therapeutic Development. International Business Communications, Southborough
Mass. pp 180-270; and in Paul
WE (1993) Fundamental Immunology, 3rd Ed. Raven Press, N.Y. pp 822-826.
24
CA 02421372 2003-03-25
WO 99/46281 PCTlUS9y~..
Known chemokines of the C-X-C subfamily include macrophage inflammatory
proteins alpha and L,
(Mtr-i ...,d MIP-2 ), interleukin-8 (IL-8), and growth regulated protein (GRO-
alpha and beta).
MIP-2 was rt~~.:~entified as a 6 kDa heparin binding protein secreted by the
mouse macrophage cell line
RAW 264.? upon stimulation with lipopoty.ACCharide (LPS). MIP-2 is a member of
the C-X-C (or CXC) subfamily
of chemokines. Mouse MIP-2 is chemotactic for hurr» neutrophils and induces
local neutrophil infiltration when
injected into the foot pads of mice. Rat MIP-2 shows 86% amtnn scid homology
to the mouse M1P-2 and is
chemotactic for rat neutrophils but does not stimulate migration of rat
alveolar ma~opha~c~ or h~unatt peripheral
blood eosinophils or lymphocytes. In addition, the rat MIP-2 has been shown to
stimulate proliferation of rat alveolar
epithelial cells but not fibroblasts.
Current uechniques for diagnosis of abnormalities in inflamed or diseased
issues mainly rely on observation
of clinical symptoms or serological analyses of body tissues or fluids for
hormones, polypeptides or various
metabolites. Problems exist with these diagnostic techniques. First, patients
may not manifest clinical symptoms at
early stages of disease. Second, serological tests do not always differerniate
between invasive diseases and genetic
syndromes. Thus, the identification of expressed chemokines is important to
the development of new diagnostic
techniques, effective therapies, and to aid in the understanding of molecular
pathogenesis.
To date, chemokines have been implicated in at least the following conditions:
psoriasis, inflammatory
bowel disease, renal disease, arthritis, immune-mediated alopecia, stroke,
encephalitis, MS, hepatitis, and others.
In addition, non-ELR-containing chemokines have been implicated in the
inhibition of angiogenesis, thus indicating
that these chemokines have a rule in tumor vascuiarization and tumorigenesis.
Therefore it is the object of this invention to identify polypeptides and
nucleic acids encoding the same which
have sequence identity and similarity with cytokine-induced neutrophil
chemoattractants, MIP-1, MiP-2, and other
related proteins. The efforts of this object are provided herein.
56. PRO741
Beta neurexins and neuroligins are plasma tt>embrane proteins that are
displayed on the neuronal cell surface.
2S Neuroligin 1 is enriched in synaptic plasma membranes and acts as a splice
site-specific ligand for beta neurexins as
descn~bed in Ichtchenko, et al., ~e . 81(3):435-443 (1995). The extracellular
sequence of neuroligin 1 is composed
of a catalytically inactive esterase domain homologous to
acerylcholinesterase. Neuroligin 2 and 3 are similar in
structure and sequence to neuroligin 1. All neuroligins contain an N-terminal
hydrophobic sequence with the
characteristics of a cleaved signal peptide followed by a large esterase
homology domain, a highly conserved single
transmembratre region, and a short cytoplasmic domain. The three neuroligins
are alternatively spliced at the same
position and are expressed at high levels only in the brain. Tight binding of
the three neuroligins to beta neurexins
is observed only for beta neurexins lacking an insert in splice site 4. Thus,
neuroligins constitute a multigene family
of brain-specific proteins with distinct isofotms that may have overlapping
functions in mediating recognition
processes between neurons, see Ichtchenko, et al., I,,B,jQ], Chem.,
2?1(5):2676-2682 (1996). Moreover, neurexins
3S and neuroligins have been reported as functioning as adhesion molecules in
a Ca'-' dependent reaction that is regulated
by altetirative splicing of beta neurexins, i.e., see Nguycn and Sudhof,
J,,~iol. C~tem., 272(41):26032-26039 (199?).
Given the foregoing, membrane bound proteins are of interest. More generally,
membrane-bound proteins
and receptors can play an irr~ortant role in the formation, differentiation
and maintenance of multicellular organisms.
The fart of many individual cells, e.g.. proliferation, migration,
differentiation, or interaction with other cells, is
CA 02421372 2003-03-25
JO 99/46281 PCT/US99/05028
.tally governed by information received from other cells and/or the immediate
environment. This iT~f~,r; . r,
often transmitted by secreted polypeptides (for instance. mitogenic factors,
survival factor ;:~r,,
differentiation factors, neuropeptides, and hormones) which are, in turn,
reccimw ,d " ::,. ~~y drverse cell
receptors or membrane-bound proteins. Such membrane-bound proteirL~ ,~~::
,.:~" ; gars rnclude, but are not limited
to, cytokine receptors, receptor kinases, receptor y12~~ :5~~~~ ...~I>rurs
involved in cell-cell interactions, and
cellular adhesin molecules like selectins and integrir.> ~ ;:.m.urce,
transduction of signals that regulate cell growth
and differentiation is regulated in pan b~~ ;mosphorylation of various
cellular proteins. Protein tyrosine kinases,
enzymes that catalyze that pr: =.-' an also act as growth factor receptors.
Examples include fibroblast growth factor
receptor y~~ nerve growt, ~ r,:ceptor.
Men:l~, ~ ,.,.n!! ;~rourrus and receptor molecules have various industrial
applications, including as
ph:rrrm~ceuucal acrd diagnostic agents. Receptor immunoadhesuts. for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are being undertaken by both industry and academia to identify new,
native membrane-bound
receptor proteins, particularly those having sequence identity and/or
similarity with neuroligins l, 2 and 3. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel secreted and membrane-bound receptor proteins. Examples of screening
methods and techniques are described
in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci.,
93:7108-7113 (1996); U.S. Patent No.
5,536,637)). The results of such efforts are provided herein.
57. PR0704
VIP36 is localized to the Golgi apparatus and the cell surface, and belongs to
a family of legume lectin
homologues in the animal secretory pathway that might be involved in the
trafficking of glycoproteins, glycolipids,
or both. It is fittther believed that VIP36 binds to sugar residues of
glycosphingolipids and/or gycosylphosphatidyl-
inositol anchors and might provide a link between the extracellular/luminal
face of glycokipid rafts and the cytoplastnic
protein segregation machinery. Further regarding VIP36, it is believed that
there is a signal at its C-terminus that
matches an internalization consensus sequence which confers its ability to
cycle between the plasma membrane and
Golgi. See, Fiedler, et al, EMBO l., 13(7):1729-1740 (1994); Fiedler and
Simons, J. Cell Sci., 109(1):271-276
(1996); Itin, et al., MBO l., 14(10):2250-2256 (1995). It is believed that
VIP36 is either the same as or very closely
related to the human GP36b protein. V1P36 and/or GP36b are of interest.
More generally, vesicular, cytoplasmic, extracellular and membrane-bound
proteins play important roles
in the formation, differentiation and maintenance of multicellular organisms.
The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with other cells, is
typically governed by information received
from other cells and/or the immediate environment. This information is often
transmitted by secreted polypeptides
(for instance. mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and
hormones) which are, in turn, received and interpreted by diverse cell
receptors or membrane-bound proteins. These
secreted polypeptides or sigrtalirtg molecules normally pass through the
cellular secretory pathway to reach their site
of action in the extracellular environment, usually at a membrane-bound
receptor protein.
Secreted proteins have various industrial applications, including use as
pharmaceuticals, diagnostics,
biosensors and bioreactors. In fact, most protein drugs available at present,
such as thrombolytic agents, interferons,
26
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
ittterleukins, erythropoietins, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane-bound proteins, also have potential as
therapeutic or diagnostic agents. Receptor
immunoadhesins, for instance, can be employed as therapeutic agents to block
receptor-ligand interaction.
Membrane-bound proteins can also be employed for screening of potential
peptide or small molecule inhibitors of
the relevant receptor/ligand interaction. Such membrane-bound proteins and
cell receptors include, but are not limited
to, cytokine receptors, receptor kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and
cellular adhesin molecules like seleetins and integrins. Transduetion of
signals that regulate cell growth and
differentiation is regulated in part by phosphorylation of various cellular
proteins. Protein tyrosine kinases, enzymes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
Efforts are being undertaken by both industry and academia to identify new,
native vesicular, cytoplasmic,
secreted and membrane-bound receptor proteins, panicularly those having
sequence idemin~ and/or similarity with
VIP36. Many efforts are focused on the screening of marntnalian recombinant
DNA libraries to identify the coding
sequences for novel secreted and membrane-bound receptor proteins. Examples of
screening methods and techniques
are described in the literature [see, for example, Klein et al., Proc. Natl.
Acad. Sci., Q~:7108-7113 {1996); U.S.
Patent No. 5,536,637)].
58. PR0706
Acid phophatase proteins are secreted proteins which dephophorylate terminal
phosphate groups under acidic
pH conditions. Acid phophatases contain a RHGXRXP amino acid sequence, which
is predicted to be mechanistically
significant. Acid phosphatases may have important functions in the diagnosis
and treatment of human diseases. For
example, prostatic acid phosphatase is a secreted protein uniquely expressed
in prostatic tissue and prostate cancer.
The level of prostatic acid phosphatase is a potential prognostic factor for
local and biochemical control in prostate
cancer patients treated with radiotherapy, as described in lanldord et al.,
Int. J. Radiat. Oncol. Biol. Phvs. 38(2):
327-333 (1997). Research suggests that a cellular immune response to prostatic
acid phosphatase may mediate
destructive autoimmune prostatitis, and that xenogeneic forms of prostatic
acid phosphatase may prove useful for
immunotherapy of prostate cancer. See Fong et al., J. Immunol. 169(7): 3113-
3117 (1997). Seminal prostatic acid
phosphatase levels correlate significantly with very low sperm levels
(oligospermia) in individuals over 35, see Singh
et al., Singapore Med. J. 37(6): 598-599 (1996). Thus, prostatic acid
phosphatase has been implicated in a variety
of human diseases, and may have an important function in diagnosis and therapy
of these diseases. A series of
aminobenzylphosphatic acid compounds are highly potent inhibitors of prostatic
acid phosphatase, as described in
Beers et al., Bioorg. Med. Chem. 4(10): 1693-1701 (1996).
More generally, extracellular proteins play an important role in the
formation, differentiation and
maintenance of multicellular organisms. The fate of many individual cells,
e.g., proliferation, migration,
differentiation, or interaction with other cells, is typically governed by
information received from other cells and/or
the immediate environment. This information is often transmitted by secreted
polypeptides (for instance, mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides, and hotzttones) which are, in turn,
received and interpreted by diverse cell receptors or membrane-bound proteins.
These secreted polypeptides or
signaling molecules normally pass through the cellular secretory pathway to
reach their site of action in the
extracellular environment.
27
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents. Efforts are being undertaken
by both industry and academia to identify new, native secreted proteins,
particularly those having sequence identit)-
with prostate acid phosphatase precursor and lysosomal acid phosphatase
precursor and in some cases, those having
identity with DNA found in fetal heart. Many efforts are focused on the
screening of mammalian recombinant DNA
libraries to identify the coding sequences for novel secreted proteins.
Examples of screening methods and techniques
are described in the literature see, for example, Klein et al., Proc. Natl.
Acad. Sci., x:7108-7I 13 (1996); U.S.
Patent No. 5,536,637)].
59. PRO? 7
Cadherins are a large family of transmembrane proteins. At least cadherins I-
13 as well as types B, E, EP,
M, N, P and R have been characterized. Among the functions cadherins are known
for, with some exceptions,
cadherins participate in cell aggregation and are associated with cell-cell
adhesion sites. Cadherins are further
described in Tanihara, et al., J. Cell Sci., 107(6):1697-1704 (1994) and
Tanihara, et al., Cell Adhes. Commun.,
2(1):15-26 (1994). Moreover, it has been reported that some members of the
cadherin superfamily are involved in
general cell~ell interaction processes including transduction. See, Suzuki, 1.
Celt Biochem., 61(4):53I-542 (1996).
Therefore, novel members of the cadherin superfamily are of interest.
More generally, all novel proteins are of interest, including membrane-bound
proteins. Membrane-bound
proteins and receptors can play an important role in the formation,
differentiation and maintenance of multicellular
organisms. The fate of many individual cells, e.g., proliferation, migration,
differentiation, or interaction with other
cells, is typically governed by information received from other cells and/or
the immediate environment. This
information is often transmitted by secreted polypeptides (for instance,
mitogenic factors, survival factors, cytotoxic
factors, differentiation factors, neuropeptides, and hormones) which are, in
turn, received and interpreted by diverse
cell receptors or membrane-bound proteins. Such membrane-bound proteins and
cell receptors include, but are not
limited to, cytokine receptors, receptor kinases, receptor phosphatases,
receptors involved in cell-cell interactions,
and cellular adhesin molecules like selectins and integrins. For instance,
transduction of signals that regulate cell
growth and differentiation is regulated in pan by phosphorylation of various
cellular proteins. Protein tyrosine
kinases, enzymes that catalyze that process, can also act as growth factor
receptors. Examples include fibroblast
growth factor receptor and nerve growth factor receptor.
Membrane-bound proteins and receptor molecules have various indusuial
applications, including as
pharmaceutical and diagnostic agents. Receptor itztrnunoadhesins, for
instance, can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are being undertaken by both industry and academia to identify new,
native secreted and membrane-
bound receptor proteins, particularly membrane bound proteins having identity
with cadherins. The results of such
efforts are provided herein.
28
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
60. PR
Proteases are enzymatic proteins which are involved in a large number of very
important biological
processes in mammalian and non-mammalian organisms. Numerous different
protease enzymes from a variety of
different marr>rnalian and non-mammalian organisms have been both identified
and characterized, including the serine
proteases which exhibit specific activity toward various serine~ontaining
proteins. The mammalian protease enzymes
play important roles in biological processes such as, for example, protein
digestion, activation, inactivation, or
modulation of peptide hormone activity, and alteration of the physical
properties of proteins and enzymes.
Neuropsin is a novel serine protease whose mRNA is expressed in the central
nervous system. Mouse
neuropsin has been cloned, and studies have shown that it is involved in the
hippocampal plasticity. Neuropsin has
also been indicated as associated with extracellular matrix modifications and
cell migrations. See, generally, Chen,
et al., eurosc'., 7(2):5088-5097 (1995) and Chen, et al., J. Histochem.
Cytochem., 46:313-320 (1998).
Efforts are being undertaken by both industry and academia to identify new,
native membrane-bound or
secreted proteins, particularly those having homology to neuropsin, serine
protease, neurosin and trypsinogen. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel secreted arid membrane-bound receptor proteins. Examples of screening
methods and techniques are described
in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci.,
Q~:7108-7113 (1996); U.S. Patent No.
5,536,637)).
61. PR 6
Protein-protein interactions include those involved with receptor and antigen
complexes and signaling
mechanisms. As more is known about the structural and functional mechanisms
underlying protein-protein
iraeractions, protein-protein interactions can be more easily rt~nipulaned to
regulate the pat2icular result of the protein-
protein interaction. Thus, the underlying mechanisms of protein-protein
interactions are of interest to the scientific
and medical community.
All proteins containing leucine-rich repeats are thought to be involved in
protein-protein interactions.
Leucine-rich repeats are shop sequence motifs present in a number of proteins
with diverse functions and cellular
locations. The crystal structure of ribonuclease inhibitor protein has
revealed that leucine-rich repeats correspond
to beta-alpha structural units. These units are arranged so that they form a
parallel beta-sheet with one surface
exposed to solvent, so that the protein acquires an unusual, nonglobular
shape. These two features have been
indicated as responsible for the protein-binding functions of proteins
containing leucine-rich repeats. See, Kobe and
Deisenhofer, Trends Biochem. Sci., 19(10):415-421 (Oct. 1994).
A study has been reported on leucine-rich proteoglycans which serve as tissue
organizers, orienting and
ordering collagen fibrils during ontogeny and are involved in pathological
processes such as wound healing, tissue
repair, and tumor stroma formation. lozzo, R. V., Crit. gv. Biochem. Mol.
Biol., 32(2):141-174 (1997). Others
studies implicating leucine rich proteins in wound healing and tissue repair
are De La Salle, C., et al., Vouv. Rev.
Fr. Hematol. (Germany), 37(4):215-222 (1995), reporting mutations in the
leucine rich motif in a complex associated
with the bleeding disorder Bernard-Soulier syndrome, Chlemetson, K. 1.,
Thr~amb. Haemost. (Germany), 74(1):111-
116 (July 1995), reporting that platelets have leucine rich repeats and
Ruoslahti, E. L. et al., W09110727-A by La
Jolla Cancer Research Foundation reporting that decorin binding to
transforming growth factor(i has involvement in
a treatment for cancer, wound healing and scarring. Related by function to
this group of proteins is the insulin like
29
CA 02421372 2003-03-25
WO 99/46281 PCT/US99l05028
growth factor (IGF), in that it is useful in wound-healing and associated
therapies concerned with re-growth of tissue,
such as connective tissue, skin and bone; in promoting body growth in humans
and animals; and in stimulating other
growth-related processes. The acid labile subunit (ALS) of IGF is also of
interest in that it increases the half life of
IGF and is pan of the IGF complex in vivo. ALS is further described in Leong
and Baxter, Mol. Endocrinol.,
6(6):870-876 (1992); Baxter, J. Biol. Chem., 264(20):11843-11848 (1989): and
Khosravi, et al., J. Clin. Endocrinol.
Metab., 82(12):3944-3951 (1997).
Another protein which has been reported to have leucine-rich repeats is the
SLIT protein which has been
reported to be useful in treating neuro-degenerative diseases such as
Alzheimer's disease, nerve damage such as in
Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S.
and Rothberg, J. M., W09210518-A1
by Yale University. Also of interest is LIG-1, a membrane glycoprotein that is
expressed specifically in glial cells
in the mouse brain, and has leucine rich repeats and immunoglobulin-like
domains. SuzuJti, et al., J. Biol. Chem.
(U.S.), 271(37):22522 (1996). Other studies reporting on the biological
functions of proteins having leucine rich
repeats include: Tayar, N., et al., Mol. Cell Endocrinol., (Ireland), 125(1-
2):65-70 (Dec. 1996) (gonadotropin
receptor involvement); Miura, Y., et al., Nippon Rinsho ()apart), 54(7):1784-
1789 (July 1996) (apoptosis
involvement); Hams, P. C., et a1.,1. Am. Soc. Nephrol., 6(4):1125-1133 (Oct.
1995) (kidney disease involvement).
Efforts are therefore being undertaken by both industry and academia to
identify new proteins having leucine
rich repeats to better understand protein-protein interactions. Of particular
interest are those proteins having leucine
rich repeats and identity or similarity to known proteins having leucine rich
repeats such as ALS. Many efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
secreted and membrane-bound proteins having leucine rich repeats. Examples of
screening methods and techniques
are described in the literature [see, for example, Klein et al., Proc. Nat).
Acad. Sci., x:7108-7113 (1996); U.S.
Patent No. 5,536,637)].
62. ~R0531
Cadherins are a large family of transmembrane proteins. Cadherins comprise a
family of calcium-dependent
glycoproteins that function in mediating cell-cell adhesion in virtually all
solid tissues of multicellular organisms.
At least cadherins 1-13 as well as types B, E, EP, M, N, P and R have been
characterized. Among the functions
cadhetins are known for, with some exceptions, cadherins participate in cell
aggregation and are associated with cell-
cell adhesion sites. Recently, it has been reported that while all cadherins
share multiple repeats of a cadherin
specific motif believed to correspond to folding of extracellular domains,
members of the cadherin superfamily have
divergent structures and, possibly, functions. In particular it has been
reported that members of the cadherin
superfamily are involved in signal transduction. See, Suzuki, J. Cell
Biochem., 61(4):531-542 (1996). Cadherins
are further described in Tattihara, et al., a i., 107(6):1697-1?04 (1994),
Aberle, et al., 1. Cell Biochem.,
61(4):514-523 (1996) and Tanihara, et al., Cell Adhes. Commun., 2(1):15-26
(1994).
Protocadherins are members of the cadherin superfamily which are highly
expressed in the brain. In some
studies, protocadherins have shown cell adhesion activity. See, Sano, et al.,
EMBO J., 12(6):2249-2256 (1993}.
However, studies have also shown that some protocadherins, such as
protocadherin 3 (also referred to as Pcdh3 or
pc3), do not show strong calcium dependent cell aggregauon activity. See,
Sago, et al., Genotnics, 29(3):631-640
(1995) for this study and further characteristics of Pcdh3.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Therefore, novel members of the cadhetin superfatnily are of interest. More
generally, all membrane-bound
proteins and receptors are of interest. Such proteins can play an important
role in the formation, differentiation and
maintenance of multicellular organisms. The fate of many individual cells,
e.g., proliferation, migration,
differentiation, or interaction with other cells, is typically governed by
information received from other cells andlor
the immediate environment. This information is ofren transmitted by secreted
polypeptides (for instance, mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides, and hormones) which are, in turn,
received and interpreted by diverse cell receptors or membrane-bound proteins.
Such membrane-bound proteins and
cell receptors include, but are not limited to, cytokine receptors, receptor
kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and cellular adhesin molecules like
selectins and integrins. For instance,
vansduction of signals that regulate cell growth and differentiation is
regulated in part by phosphorylation of various
cellular proteins. Protein tyrosine kinases, enzymes that catalyze that
process, can also act as growth factor
receptors. Examples include fibroblast growth factor receptor and nerve growth
factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are therefore being undertaken by both industry and academia to
identify new, native membrane
bound proteins, particular those having sequence identity with protocadherins,
especially 3 and 4. Many efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
membrane-bound proteins. Provided herein are the results of such efforts.
63. PR 4
Protein disulfide isomerase is an enzymatic protein which is involved in the
promotion of correct refolding
of proteins through the establishment of correct disulfide bond formation.
Protein disulfide isomerase was initially
identified based upon its ability to catalyze the renaturation of reduced
denatured RNAse (Goldberger et al., J. Biol.
Chem. 239:1406-1410 (1964) and Epstein et al., Cold SPrir~ Harbor SymD. uant.
Biol. 28:439449 (1963)).
Protein disulfide isomerase has been shown to be a resident enzyme of the
endoplasmic reticulum which is retained
in the endoplasmic reticulum via a -KDEL or -HDEL amino acid sequence at its C-
terminus. Protein disulfide
isomerase and related proteins are further described in Laboissiere, et al.,
J. Biol. Chem., 270(47:28006-28009
(1995); Jeenes, et al., Wig, 193(2):151-156 (1997; Koivunen, et al., en 'cs,
42(3):397-404 (1997); and Desilva,
et al., DNA dell Biol., 15(1):9-16 (1996). These studies indicate the
importance of the identification of protein
disulfide related proteins.
More generally, and also of interest are all novel membrane-bound proteins and
receptors. Such proteins
can play an important role in the formation, differentiation and maintenance
of multicellular organisms. The fate of
many individual cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically
governed by information received from other cells and/or the immediate
environment. This information is often
transmitted by secreted polypeptides (for instance, mitogenic factors,
survival factors, cytotoxic factors, differentiation
factors, neuropeptides, and hormones) which are,in turn, received and
interpreted by diverse cell receptors or
membrane-bound proteins. Such membrane-bound proteins and cell receptors
include, but are not limited to, cytokine
receptors, receptor kinases, receptor phosphatases, receptors involved in cell-
cell interactions, and cellular adhesin
31
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
molecules like selectins and integrins. For instance, transduction of signals
that regulate cell growth and
differentiation is regulated in pan by phosphorylation of various cellular
proteins. Protein tyrosine kinases, enzymes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Given the importance of membrane bound proteins, efforts are under way to
identity novel membrane bound
proteins. Moreover, given the importance of disulfide bond-forming enzymes and
their potential uses in a number
of different applications, for example in increasing the yield of correct
refolding of recombinantly produced proteins,
efforts are currently being undertaken by both industry and academia to
identify new, native proteins having sequence
identity with protein disulfide isomerase. Many of these efforts are focused
on the screening of mammalian
recombinant DNA libraries to identify the coding sequences for novel protein
disulfide isomerase homologs. We
herein describe a novel polypeptide having sequence identity with protein
disulfide isomerase and the nucleic acids
encoding the same.
64. PR0697
Secreted frizzled related proteins (sFRPs) are related to the frizzled family
of transmembrane receptors.
The sFRPs are approximately 30 kDa in size, and each contains a putative
signal sequence, a frizzled-like cysteine-
rich domain, and a conserved hydrophilic carboxy-terminal domain. It has been
reported that sFRPs may function
to modulate Wnt signaling, or function as ligands for certain receptors.
Rattner, et al., PNAS USA, 94(7):2859-2863
(1997). Therefore, sFRPs and proteins having sequence identity andlor
similarity to sFRPs are of interest.
Another secreted protein of interest is any member of the family of secreted
apoptosis-related proteins
(SARPs). Expression of SARPs modifies the intracellular levels of beta-
catenin, suggesting that SARPs interfere with
the Wnt-frizzled proteins signaling pathway. Melkonyan, et al., PNAS USA,
94(25):13636-13641 (1997).
Therefore, SARPs and proteins having sequence identity and/or similarity to
SARPs are of interest.
In addition to sFRPs and SARPs, many extracellular proteins are of interest.
Extracellular proteins play
an important role in the formation, differentiation and maintenance of
multicellular organisms. The fate of many
individual cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically governed
by information received from other cells and/or the immediate environment.
This information is often transmitted
by secreted polypeptides (for instance, mitogenic factors, survival factors,
cytotoxic factors, differentiation factors,
neuropeptides, and hormones) which are, in turn, received and interpreted by
diverse cell receptors or membrane-
bound proteins. These secreted polypeptides or signaling molecules normally
pass through the cellular secretory
pathway to reach their site of action in the extracellular environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents.
32
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Efforts are being undertaken by both industry and academia to identify new,
native secreted proteins,
patucularly those having sequence identity or similarity with sFRP-2 and SARP-
1. Many effons are focused on the
screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel secreted proteins.
Examples of screening methods and techniques are described in the literature
[see, for example, Klein et al., Proc.
~latl. Acad. Sci., Q3_:7108-7113 (1996); U.S. Patent No. 5,536,637)].
65. PR0717
Efforu are being undertaken by both industry and academia to identify new,
native transmembrane receptor
proteins. Many efforts are focused on the screening of mammalian recombinant
DNA libraries to identify the coding
sequences for novel receptor proteins. The results of such efforts are
provided herein.
66. PR 73
Cadherins are a large family of transmembrane proteins. Cadherins comprise a
family of calcium-dependent
glycoproteins that function in mediating cell-cell adhesion in virtually all
solid tissues of multicellular organisms.
At least cadherins 1-13 as well as types B, E, EP, M, N, P and R have been
characterized. Among the functions
cadherins are known for, with some exceptions, cadherins participate in cell
aggregation and are associated with cell-
cell adhesion sites. Recently, it has been reported that while all cadherins
share multiple repeats of a cadherin
specific motif believed to correspond to folding of extracellular domains,
members of the cadherin superfamily have
divergent structures and, possibly, functions. In particular it has been
reported that members of the cadherin
superfamily are involved in signal transduction. See, Suzuki, j~ Cell
Biochem., 61(4):531-542 (1996). Cadherins
are further described in Tanihara, et al., J. e1 c'., 107(6):1697-1704 (1994),
Aberle, et al., J. Cell Biochem.,
61(4):514-523 (1996) and Tanihara, et al., Cell Adhes. Commun., 2(1):15-26
(1994).
Protocadherins are members of the cadherin superfamily which are highly
expressed in the brain. In some
studies, protocadherins have shown cell adhesion activity. See, Sano, et al.,
MBO l., 12(6):2249-2256 (1993).
However, studies have also shown that some protocadherins, such as
protocadherin 3 (also referred to as Pedh3 or
pc3), do not show strong calcium dependent cell aggregation activity. See,
Sago, et al., 'es, 29(3):631-640
(1995) for this study and further characteristics of Pcdh3.
Therefore, novel members of the cadherin superfamily are of interest. More
generally, all membrane-bound
proteins and receptors are of interest. Such proteins can play an important
role in the formation, differentiation and
maintenance of multicellular organisms. The fate of many individual cells,
e.g., proliferation, migration,
differentiation, or interaction with other cells, is typically governed by
information received from other cells and/or
the immediate environment. This information is often transmitted by secreted
polypeptides (for instance, mitogenic
factors, survival factors, cytotozic factors, differentiation factors,
neuropeptides, and hormones) which are, in turn,
received and interpreted by diverse ceU receptors or membrane-bound proteins.
Such membrane-bound proteins and
cell receptors include, but are not limited to, cytokine receptors, receptor
kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and cellular adhesin molecules like
seleetins and integrins. For instance,
transduction of signals that regulate cell growth and differentiation is
regulated in pan by phosphorylation of various
cellular proteins. Protein tyrosine ldttases, enzymes that catalyze that
process, can also act as growth factor
receptors. Examples include fibrobiast growth factor receptor and nerve growth
factor receptor.
33
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are therefore being undertaken by both industry and academia to
identify new, native membrane
bound proteins, particular those having sequence identity with protocadherins,
especially 4, 68, 43, 42, 3 and 5.
Many efforts are focused on the screening of mamtttalian recombinant DNA
libraries to identify the coding sequences
for novel membrane-bound proteins. Provided herein are the results of such
efforts.
67. PR0218
Efforts are being undertaken by both industry and academia to identify new,
native membrane bound
proteins, particularly those having sequence identity with membrane regulator
proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel receptor
proteins.
68. PR 0768
The integrins comprise a supergene family of cell-surface glycoprotein
receptors that promote cellular
adhesion. Each cell has numerous receptors that define its cell adhesive
capabilities. Integrins are involved in a wide
variety of interaction between cells and other cells or matrix components. The
integrins are of particular importance
in regulating movement and function of immune system cells. The platelet
IIb/1IIA integrin complex is of particular
importance in regulating platelet aggregation. A member of the integrin
family, integrin ~i-6, is expressed on epithelial
cells and modulates epithelial inflammation. Another integrin, leucocyte-
associated antigen-1 (LFA-1) is important
in the adhesion of lymphocytes during an immune response.
Of particular interest is H36-alpha 7, an integrin alpha chain that is
developmentally regulated during
myogenesis as described in Song, et a1.,1. Cell Biol., 117(3):643-657 (1992).
The expression pattern of the laminin-
binding alpha 7 beta 1 integrin is developmentally regulated in skeletal,
cardiac, and smooth muscle. Ziober, et al.,
Mol. Biol. Cell, 8(9):1723-1734 (1997). It has been reported that expression
of the alpha 7-XI/X2 integrin is a novel
mechanism that regulates receptor affinity states in a cell-specific comext
and may modulate integrin-dependent events
during muscle development and repair. Id. It has further been reported that
laminins promote the locomotion of
skeletal myoblasts via the alpha 7 integrin receptor. In particular it was
reported that alpha 7 beta 1 receptor can
promote myoblast adhesion and motility on a restricted number of laminin
isoforms and may be important in
myogenic precursor rectvianent during regeneration and differentiation. Yao,
et al., 1. Cell Sci., 109(13):3139-3150
(1996). Spliced variants of integrin alpha 7 are also described in Leung, et
al., Biochem. Biophys. Res. Commun.,
243(1):317-325 (1998) and Fornaro and Languino, Matrix Biol., 16(4):185-193
(1997). Moreover, it has been
reported that absence of integrin alpha 7 causes a form of muscular dystrophy.
Thus integrins, particularly those
related to integrin 7 and related molecules, are of interest.
In addition to the interest of integrins, more generally, all membrane-bound
proteins and receptors are of
interest since such proteins can play an important role in the formation,
differentiation and maintenance of
multicellular organisms. The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or
interaction with other cells, is typically governed by information received
from other cells andlor the immediate
34
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
environment. This information is often transmitted by secreted polypeptides
(for instance, mitogenic factors, survival
factors, cytotoxic factors, differentiation factors, neuropeptides, and
hormones) which are, in turn, received and
interpreted by diverse cell receptors or membrane-bound proteins. Such
membrane-bound proteins and cell receptors
include, but are not limited to, cytokine receptors, receptor kinases,
receptor phosphatases, receptors involved in cell-
cell interactions, and cellular adhesin molecules like selectins and
integrins. For instance, transduction of signals that
regulate cell growth and differentiation is regulated in part by
phosphorylation of various cellular proteins. Protein
tyrosine kinases, enzymes that catalyze that process, can also act as growth
factor receptors. Examples include
fibroblast growth factor receptor and nerve growth factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
phatzrtaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Therefore, efforts are being undertaken by both industry and academia to
identify new, native receptor
proteins. Many efforts are focused on the screening of mammalian recombinant
DNA libraries to identify the coding
sequences for novel receptor proteins. The results of such efforts,
particularly those focused on identifying new
polypeptides having sequence identity with integrins, are provided herein.
69. PR0771
Testican is a multidomain testicular proteoglycan which is expressed in
numerous tissue types including,
but not limited to neuromuscular tissue, the brain and reproductive tissues.
Testican resembles modulators of cell
social behavior such as the regulation of cell shape, adhesion, migration and
proliferation. [Bonnet, F. et al., J. Bio .
hem , x(8):4373 (1996), Perin, J.P. et al., EXS (Switzerland), 70:191 (1994),
Alliel, P.M., et al, Eur. ).J.
Biochem., 214(1):346 (1993), Charbonnier, F., et al., C. R. Seances Soc. Biol.
Fil. (France), x(1):127 (1997)].
Among other reasons, since testican has been implicated in neuronal processes
and may be associated with the growth
of connective tissue, testican and related molecules are of interest.
More generally, all extracellular proteins are of interest. Exuacellular
proteins play an impot~tattt role in
the fotittation, differentiation and maintenance of multicellular organisms.
The fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with other cells, is
typically governed by information received
from other cells and/or the immediate environment. This information is often
transmitted by secreted polypeptides
(for instance, mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and
hormones) which are, in turn, received and interpreted by diverse cell
receptors or membrane-bound proteins. These
secreted polypeptides or signaling molecules normally pass through the
cellular secretory pathway to reach their site
of action in the extracellular environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interlettkins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents. Efforts are being undertaken
by both industry and academia to identify new, native secreted proteins. Many
efforts are focused on the screening
of mammalian recombinant DNA libraries to identify the coding sequences for
novel secreted proteins. Examples
of screening methods and techniques are described in the literature [see, for
example, Klein et al., Proc. Natl. Acad.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Sci., Q~:7108-7113 (1996); U.S. Patent No. 5.536.637)]. The results of such
efforts, particularly those focused on
identifying molecules having identity andlor similarity with testican are of
interest.
70. P 733
T1/ST2 is a receptor-like molecule homologous to the type I interleultin-1
receptor, believed to be involved
S in cell signaling. The T1/ST2 receptor and/or putative ligands are further
described in Gayle, et al., J. Biol. Chem.,
271(10):5784-5789 (1996), Kttmar, et al., J. Biol. Chem., 270(46):27905-27913
(1995), and Mitcham, et al., J. 'o1.
Chem., 271(10):5777-5783 (1996). These proteins, and proteins related thereto
are of interest.
More generally all membrane-bound proteins and receptors are of interest since
they can play an important
role in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells,
e.g., proliferation, migration, differentiation, or interaction with other
cells, is typically governed by information
received from other cells and/or the immediate envirorunent. This information
is often transmitted by secreted
polypeptides (for instance, tnitogenic factors, survival factors, cytotoxic
factors, differentiation factors, neuropeptides,
and hormones) which are, in turn, received and interpreted by diverse cell
receptors or membrane-bound proteins.
Such membrane-bound proteins and cell receptors include, but are not limited
to, cytokine receptors, receptor kinases,
receptor phosphatases, receptors involved in cell-cell interactions, and
cellular adhesin molecules like selectins and
integrins. For instance, transduction of signals that regulate cell growth and
differentiation is regulated in part by
phosphorylation of various cellular proteins. Protein tyrosine kinases,
enzymes that catalyze that process, can also
act as growth factor receptors. );xamples include fibroblast growth factor
receptor and nerve growth factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-botmd proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are being undertaken by both industry and academia to identify new,
native receptor proteins. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel receptor proteins. The results of such efforts are provided herein.
71. PR0162
Pancreatitis-associated protein (PAP) is a secretory protein that is
overexpressed by the pancreas during
acute pancreatitis. Serum PAP concentrations have been shown to be abnormally
high in patients with acute
pancreatitis. Pezzilli et al., Am. J. Gastroenterol., 92(10):1887-1890 (1997).
PAP is synthesized by the pancreas due to pancreatic inflammation and has been
shown to be a good serum
marker for injury of the pancreas. In addition, serum PAP levels appear to
strongly correlate with creatinine
clearance measurements. In patients with a pancreas-kidney uansplantation, PAP
may prove to be a useful biological
and histological marker of pancreatic graft rejection. Van der Pijl et al.,
~i"_ransnlantation, 63(7):995-1003 (1997).
Further, PAP has been shown to be useful in screening neonates for cystic
fibrosis. In fact, PAP may discriminate
cystic fibrosis neonates with better specificity than the current
immunoreactive ttypsis assay. Iovanna et al., C-R.
Acad. Aci. In, 317(6):561-564.
Secreted proteins such as PAP have various indusuial applications, including
pharmaceuticals, diagnostics,
biosensors and bioreactors. Most protein drugs available at present, such as
thrombolytic agents, interferons,
36
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
interleukins, erythropoietins, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane proteins, also have potential as therapeutic or
diagnostic agents.
Efforts are being undertaken by both industry and academia to identify new,
native secreted proteins. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel secreted proteins. Examples of screening methods and techniques are
described in the literature [see, for
example, Klein et al., Proc. Natl. Acad. Sci., Q3_:7108-7113 (1996): U.S.
Patent No. 5,536,637)]. The resuhs of such
efforts are presented herein.
72. PR 788
Anti-neoplastic urinary protein (ANUP) was identified as the major protein
present in a fraction of human
urine which exhibits antiproliferative activity against human tumor cell lines
without affecting the growth of several
normal diploid cell lines or tumor cells of mouse or hamster origin. Sloane et
al., Biochem. l., 234{2).355-362
(1986).
ANUP is a unique cytokine that has been found in human granulocytes. The N-
terminal amino acid
sequence has been shown to be unique. A synthetic peptide corresponding to the
first nine residues, with Cys at
positions 4 and 7, was found to be an anti-tumor agent in viuo. Ridge and
Sloane, C to ~ , 8(1):1-5 (1996).
Secreted proteins such as ANUP have various industrial applications, including
pharmaceuticals, diagnostics,
biosensors and bioreactors. Most protein drugs available at present, such as
thrombolytic agents, interferons,
interleukins, erythropoietins, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane proteins, also have potential as therapeutic or
diagnostic agents. Efforts are being
undertaken by both industry and academia to identify new, native secreted
proteins. Many efforts are focused on the
screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel secreted proteins.
Examples of screening methods and techniques are described in the literature
[see, for example, Klein et al., roc
N~tl. Acad. Sci., 93:7108-7113 (199; U.S. Patent No. 5,536,637)].
73. 008
Dickkopf 1 (dkk-1) is a member of a family of secreted proteins and functions
in head induction. Dkk-1
is an inducer of Spemanrt organizer in amphibian embryos. Glinka, et al.,
Nature, 391(6665):357-362 (1998). Dkk-1
is a potent antagonist of Wnt signalling, suggesting that dkk genes encode a
family of secreted Wnt inhibitors. Thus,
dkk-1 family members and related molecules are of interest.
More generally, all eztracellular proteins are of interest since they can play
an important role in the
formation, differentiation and maintenance of multicellular organisms. The
fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with other cells, is
typically governed by information received
from other cells andlor the immediate environment. This information is often
transmitted by secreted polypeptides
(for instance, mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and
hormones) which are, in tum, received and interpreted by diverse cell
receptors or membrane-bound proteins. These
secreted polypeptides or signaling molecules normally pass through the
cellular secretary pathway to reach their site
of action in the eztracellular environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
37
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
erythropoieuns, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents.
Efforts are being undertaken by both industry and academia to identify new,
native secreted proteins,
particularly those related to dkk-1. Many efforts are focused on the screening
of mammalian recombinant DNA
libraries to identify the coding sequences for novel secreted proteins.
Examples of screening methods and techniques
are described in the literature [see, for example, Klein et al., Proc. Natl.
Acad. Sci., 93:7108-7113 (1996); U.S.
Patent No. 5,536,637)]. The results of such efforts to identify molecules
related to dkk-1 are provided herein.
74. R01 12
Protein disulfide isomerase is an enzymatic protein which is involved in the
promotion of correct refolding
of proteins through the establishment of correct disulfide bond formation.
Protein disulfide isomerase was initially
identified based upon its ability to catalyze the renaturation of reduced
denatured RNAse (Goldberger et al., J. ~ol.
Chem. 239:1406-1410 (1964) and Epstein et al., Cold Sprine Harbo~Symp. ,Quant.
Biol. 28:439-449 (1963)).
Protein disulfide isomerase has been shown to be a resident enzyme of the
endoplasmic reticulum which is retained
in the endoplasmic reticulum via a -KDEL or -HDEL amino acid sequence at its C-
terminus. Protein disulfide
isomerase and related proteins are further described in Laboissiere, et al.,
J. Biol. Chem., 270(47:28006-28009
(1995); Jeenes, et al., Ge~n , 193(2):151-156 (1997; Koivunen, et al.,
Genomics, 42(3):39704 (1997); and Desilva,
et al., DNA Cell Biol., 15(1):9-16 (1996). These studies indicate the
imporrartce of the identification of protein
disulfide related proteins.
More generally, the identification of all extracellular and membrane-bound
proteins is of interest since they
play important roles in the formation, differentiation and maintenance of
multicellular organisms. The fate of many
individual cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically governed
by information received from other cells and/or the immediate environment.
This information is often transmitted
by secreted polypeptides (for instance, mitogenic factors, survival factors,
cytotoxic factors, differentiation factors,
neuropepiides, and hormones) which are, in turn, received and interpreted by
diverse cell receptors or membrane-
bound proteins. These secreted polypeptides or signaling molecules normally
pass through the cellular secretory
pathway to reach their site of action in the extracellular environment,
usually at a membrane-bound receptor protein.
Secreted proteins have various industrial applications, including use as
pharmaceuticals, diagnostics,
biosensors and bioreactors. In fact, most protein drugs available at present,
such as thrombolytic agents, interferons,
interleukins, erythropoietins, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane-bound proteins, also have potential as
therapeutic or diagnostic agents. Receptor
immunoadhesins, for instance, can be employed as therapeutic agents to block
receptor-ligand interaction.
Membrane-bound proteins can also be employed for screening of potential
peptide or small molecule inhibitors of
the relevant receptor/ligand interaction. Such membrane-bound proteins and
cell receptors include, but are not limited
to, cytokine receptors, receptor kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and
cellular adhesin molecules like selectins and integrins. Transduction of
signals that regulate cell growth and
differentiation is regulated in pan by phosphorylation of various cellular
proteins. Protein tyrosine kinases, et>rytttes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
38
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Of particular interest are cellular proteins having endoplasmic reticulum (ER)
retention signals. These
proteins are retained in the cell and function closely with endoplasmic
reticulum in protein production. Such proteins
have been described previously, i.e., see Shorrosh and Dixon, Plant J.,
2(1):51-58 (1992).
Efforts are being undertaken by both industry and academia to identify new,
native secreted and membrane
bound receptor proteins, and in particular, cellular proteins having ER
retension signals. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel secreted and
membrane-bound receptor proteins. Examples of screening methods and techniques
are described in the literature
(see, for example, Klein et al., Proc. Natl. Acad. Sci., X3:7108-7113 (1996);
U.S. Patent No. 5,536,637)). The
results of such efforts, particularly the identification of novel polypeptides
and nucleic acids encoding the same, which
have sequence identity and similarity to protein disulfide isomerase are
presented herein.
75. PR01014
Oxygen free radicals and antioxidants appear to play an important role in the
central nervous system after
cerebral ischemia and reperfitsion. Moreover, cardiac injury, related to
ischaemia and reperfusion has been reported
to be caused by the action of free radicals. Additionally, studies have
reported that the redox state of the cell is a
pivotal detem irtant of the fate of the cells. Furthermore, reactive oxygen
species have been reported to be cytotoxic,
causing inflammatory disease, including tissue necrosis, organ failure,
atherosclerosis, infertility, birth defects,
premature aging, mutations and malignancy. Thus, the control of oxidation and
reduction is important for a number
of reasons including for control and prevention of strokes, heap attacks,
oxidative stress and hypertension. In this
regard, reductases, and panicularly, oxidoreductases, are of interest.
Publications further describing this subject
matter include Kelsey, et al., Br. 1. Cancer, 76(7):852-4 (1997); Friedrich
and Weiss, 1. Theor. Biol., 187(4):529-40
(1997) and Pieulle, et al., J. Bacteriol., 17908):5684-92 (1997).
In addition to reductases in particular, novel polypeptides are generally of
interest. Extracellular proteins
play an important role in the formation, differentiation and maintenance of
multicellular organisms. The fate of many
individual cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically governed
by information received from other cells and/or the immediate environment.
This information is often transmitted
by secreted polypeptides (for instance, mitogenic factors, survival factors,
cytotoxic factors, differentiation factors,
neuropeptides, and hormones) which are, in turn, received and interpreted by
diverse cell receptors or membrane-
bound proteins. These secreted polypeptides or signaling molecules normally
pass through the cellular secretory
pathway to reach their site of action in the exvacellular environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents. Efforts are being undertaken
by both industry and academia to identify new, native secreted proteins. Many
efforts are focused on the screening
of mammalian recombinant DNA libraries to identify the coding sequences for
novel secreted proteins. Examples
of screening methods and techniques are described in the literature (see, for
example, Klein et al., Proc. Nat[. Acad.
$~j~, 9:7108-7113 (1996); U.S. Patent No. 5,536,637)]. The results of such
efforts, particularly those identifying
polypeptides having sequence identity with reductases, and the nucleic acids
encoding the same, are presented herein.
39
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
76. PR01017
Enzymatic proteins play important roles in the chemical reactions involved in
the digestion of foods, the
biosynthesis of macromolecules, the controlled release and utilization of
chemical energy, and other processes
necessary to sustain life. Sulfotransferases are enzymes which transfer
sulfate from a sulfate donor to acceptor
substrates, particularly those containing terminal glucoronic acid. The HNK-1
carbohydrate epitope is expressed
on several neural adhesion glycoproteins and a glycolipid, and is involved in
cell interactions. The
glucuronyltransferase and sulfotransferase are considered to be the key
enzymes in the biosynthesis of this epitope
because the rest of the structure occurs often in glycoconjugates. HNK-I
sulfotransfererase is further described in
Bakker, H., et al., J. Biol. Chem., 272(47):29942-29946 (1997).
In addition to HNK-I sulfotransfererase, and novel proteins related thereto,
all novel proteins are of
interest. Extracellular and membrane-bound proteins play important roles in
the formation, differentiation and
maintenance of multicellular organisms. The fate of many individual cells,
e_g., proliferation, migration,
differentiation, or interaction with other cells, is typically governed by
information received from other cells and/or
the immediate environment. This information is often transmitted by secreted
polypeptides (for instance, mitogettic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides, and hotzrtones) which are, in turn,
received and interpreted by diverse cell receptors or membrane-bound proteins.
These secreted polypeptides or
signaling molecules normally pass through the cellular secretory pathway to
reach their site of action in the
extracellular environment, usually at a membrane-bound receptor protein.
Secreted proteins have various industrial applications, including use as
pharmaceuticals, diagnostics,
biosensors and bioreactors. In fact, most protein drugs available at present,
such as thrombolytic agents, interferons,
interleukins, erythropoietins, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane-bound proteins, also have potential as
therapeutic or diagnostic agents. Receptor
immunoadhesins, for instance, can be employed as therapeutic agents to block
receptor-ligand interaction.
Membrane-bound proteins can also be employed for screening of potential
peptide or small molecule inhibitors of
the relevant receptor/ligand interaction. Such membrane-bound proteins and
cell receptors include, but are not limited
to, cytokine receptors, receptor kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and
cellular adhesin molecules like selectins and integrins. Transduction of
signals that regulate cell growth and
differentiation is regulated in pan by phosphorylation of various cellular
proteins. Protein tyrosine kinases, enzymes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
Efforts are being undertaken by both industry and academia to identify new,
native secreted and membrane
bound receptor proteins, patvcularly those having sequence identity with HNK-1
sulfotransferase. Many efforts are
focused on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel
secreted and membrane-bound receptor proteins. Examples of screening methods
and techniques are described in
the literature see, for example, Klein et al., Proc. Natl. Acad. Sci., x:7108-
7113 (1996); U.S. Patent No.
5,536,637)]. The results of such efforts are provided herein.
77. PR 74
Enzymatic proteins play important roles in the chemical reactions involved in
the digestion of foods, the
biosynthesis of macromolecules, the controlled release and utilization of
chemical energy, and other processes
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
necessary to sustain life. Glucose dehydrogenase functions in the oxidation of
glucose to gluconate to generate
metabolically useful energy. The regulation of the PQQ-linked glucose
dehydrogenase in different organisms is
reviewed in Neijssel, et al., Antonie Van Leeuwenhoek, 56(1):51-61 (1989).
Glucose dehydrogenase functions as
an auxiliary energy generating mechanism, because it is maximally synthesized
under conditions of energy stress.
In addition to molecules related to glucose dehydrogenase, all novel proteins
are of interest. Extracellular
and membrane-bound proteins play important roles in the formation,
differentiation and maintenance of multicellular
organisms. The fate of many individual cells, e.g., proliferation, migration,
differentiation, or interaction with other
cells, is typically governed by information received from other cells and/or
the immediate environment. This
information is often transmitted by secreted polypeptides (for instance,
mitogenic factors, survival factors, cytotoxic
factors, differentiation factors, neuropeptides, and hormones) which are, in
turn, received and interpreted by diverse
cell receptors or membrane-bound proteins. These secreted polypeptides or
signaling molecules normally pass
through the cellular secretory pathway to reach their site of action in the
extracellular environment, usually at a
membrane-bound receptor protein.
Secreted proteins have various industrial applications, including use as
pharmaceuticals, diagnostics,
biosensors and bioreactors. In fact, most protein drugs available at present,
such as thrombolytic agents, interferons,
interleukins, eryihropoiettns, colony stimulating factors, and various other
cytokines, are secretory proteins. Their
receptors, which are membrane-bound proteins, also have potential as
therapeutic or diagnostic agents. Receptor
immunoadhesins, for instance, can be employed as therapeutic agents to block
receptor-ligand interaction.
Membrane-bound proteins can also be employed for screening of potential
peptide or small molecule inhibitors of
the relevant receptor/ligand inuetaction. Such membrane-bound proteins and
cell receptors include, but are not limited
to, cytokine receptors, receptor kinases, receptor phosphatases, receptors
involved in cell-cell interactions, and
cellular adhesin molecules like selectins and integrins. Transduction of
signals that regulate cell growth and
differentiation is regulated in pan by phosphorylation of various cellular
proteins. Protein tyrosine kinases, enzymes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
Efforts are being undertaken by both industry and academia to identify new,
native secreted and membrane-
bound receptor proteins, and particularly cellular proteins and those related
to dehydrogenase or oxidoreductase.
Marry efforts are focused on the screening of tnarrunalian recombinant DNA
libraries to identify the coding sequences
for novel secreted and membrane-bound receptor proteins. Examples of screening
methods and techniques are
described in the literature [see, for example, Klein et al., ploc. Nati. Acad.
Sci., x:7108-7113 (1996); U.S. Patent
No. 5,536,637)]. The results of such efforts are presented herein.
78. PR01031
It has been reported that the cytokine interleukin 17 (11.r17) stimulates
epithelial, endothelial, and fibroblastic
cells to secrete cytokines such as IL-6, IL-8, and granulocyte-colony-
stimulating factor, as well as prostaglandin E2.
Moreover, it has been shown that when cultured in the presence of IL-17,
fibroblasts could sustain proliferation of
CD34+ preferential maturation into neutrophils. Thus it has been suggested
that IL-17 constitutes an early initiator
of the T cell-dependent inflammatory reaction and/or an element of the
cytokine network that bridges the immune
system to hematopoiesis. See, Yao, et al., jij~]., 155(12):5483-5486 (1995);
Fossiez, et al., 1. Exn. Med.,
183(6):2593-2603 (1996); Kennedy, et al., J. interferon C~ okine Res.,
16(8):611-61? (1996). Thus, proteins related
41
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
to IL-17 are of interest.
More generally, all novel proteins are of interest. Extracellular proteins
play an important role in the
formation, differentiation and maintenance of multicellular organisms. 'The
fate of many individual cells, e.g.,
proliferation, migration, differentiation, or interaction with other cells, is
typically governed by information received
from other cells and/or the immediate environment. This information is often
transmitted by secreted polypeptides
(for instance, mitogenic factors, survival factors, cytotoxic factors,
differentiation factors, neuropeptides, and
hormones) which are, in turn, received and interpreted by diverse cell
receptors or membrane-bound proteins. These
secreted polypeptides or signaling molecules normally pass through the
cellular secretory pathway to reach their site
of action in the extracellular environment.
Secreted proteins have various industrial applications, including
pharmaceuticals, diagnostics, biosensors
and bioreactors. Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins,
erythropoietins, colony stimulating factors, and various other cytokines, are
secretory proteins. Their receptors,
which are membrane proteins, also have potential as therapeutic or diagnostic
agents.
Efforts are being undertaken by both industry and academia to identify new,
native secreted proteins,
particularly those related to IL-17. Many efforts are focused on the screening
of mammalian recombinant DNA
libraries to identify the coding sequences for novel secreted proteins.
Examples of screening methods and techniques
are described in the literature [see, for example, Klein et al., Proc. Natl.
Acad. Sci., ~-3_:7108-7113 (1996); U.S.
Patent No. 5,536,637)]. The results of such efforts are presented herein.
79. PR 0938
Protein disulfide isomerase is an enzymatic protein which is involved in the
promotion of correct refolding
of proteins through the establishment of correct disulfide bond formation.
Protein disulfide isomerase was initially
identified based upon its ability to catalyze the renaturation of reduced
denatured RNAse (Goldberger et al., 1. Biol.
Chem. x:1406-1410 (1964) and Epstein et al., Cold Spring Harbor Svm~ Ouant.
Biol. 28:439-449 (1963)).
Protein disulfide isomerase has been shown to be a resident enzyme of the
endoplasmic reticulum which is retained
in the endoplasmic reticulum via a -KDEL or -HDEL amino acid sequence at its C-
terminus. Protein disulfide
isomerase and related proteins are further described in Laboissiere, et al.,
~. Biol. Chem., 270(47):28006-28009
(1995); Ieenes, et al., Gene, 193(21:151-156 (1997); Koivunen, et al.,
enomics, 42(,x:397-404 (1997); Desilva, et
al., DNA Cell Biol., ~:9-16 (1996); Freedman, et al. Trends in Biochem. Sci.
1_2:331-336 (1994); Bulleid, N.l.
Advances in Prot. Chem. 44:125-50 (1993); and Noiva, R., Prot. E~. and
Purification 5_:1-13 (1994). These studies
indicate the importance of the identification of protein disulfide related
proteins.
More generally, and also of interest are all novel membrane-bound proteins and
receptors. Such proteins
can play an important role in the formation, differentiation and maintenance
of multicellular organisms. The fate of
many individual cells, e.g., proliferation, migration, differentiation, or
interaction with other cells, is typically
governed by information received from other cells and/or the immediate
environment. This information is often
transmitted by secreted polypeptides (for instance, miwgenic factors, survival
factors, cytotoxic factors, differentiation
factors, neuropeptides, and hormones) which are, in turn, received and
interpreted by diverse cell receptors or
taembrane-bound proteins. Such membrane-bound proteins and cell receptors
include, but are not limited to, cytokine
receptors, receptor kinases, receptor phosphatases, receptors involved in cell-
cell interactions, and cellular adhesin
molecules like selectins and integrins. For instance, transduction of signals
that regulate cell growth and
42
CA 02421372 2003-03-25
WO 99146281 PCT/US99/05028
differentiation is regulated in part by phosphorylation of various cellular
proteins. Protein tyrosine kinases, enzymes
that catalyze that process, can also act as growth factor receptors. Examples
include fibroblast growth factor receptor
and nerve growth factor receptor.
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
phatznaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Given the importance of membrane bound proteins, efforts are under way to
identity novel membrane bound
proteins. Moreover, given the importance of disulfide bond-forming enzymes and
their potential uses in a number
of different applications, for example in increasing the yield of correct
refolding of recombinantly produced proteins,
efforts are currently being undertaken by both industry and academia to
identify new, native proteins having sequence
identity with protein disulfide isomerase. Many of these efforts are focused
on the screening of mammalian
recombinant DNA libraries to identify the coding sequences for novel protein
disulfide isomerase homologs.
We herein describe the identification and characterization of a novel
polypeptide having homology to protein
disulfide isomerase.
80. P 0
The low density lipoprotein (LDL) receptor is a membrane-bound protein that
plays a key role in cholesterol
homeostasis, mediating cellular uptake of lipoprotein particles by high
affinity binding to its ligands, apolipoprotein
(apo) B-100 and apoE. The ligand-binding domain of the LDL receptor contains 7
cysteine-rich repeats of
approximately 40 amino acids, wherein each repeat contains 6 cysteines, which
form 3 intra-repeat disulfide bonds.
These unique structural features provide the LDL receptor with its ability to
specifically interact with apo B-100 and
apoE, thereby allowing for transport of these lipoprotein particles across
cellular membranes and metabolism of their
corrtpornnts. Soluble fragments containing the cxtracellular domain of the LDL
receptor have been shown to retain
the ability to interact with its specific lipoprotein ligands (Sitnmons et
al., 1. Biol. Chem. 272:25531-25536 (1997)).
LDL receptors are further described in lavitt, FASEB l., 9(13):1378-1381
(1995) and Herz and Willnow, A~4 NY
ci., 737:14-19 (1994). Thus, proteins having sequence identity with LDL
receptors are of interest. ,
More generally, all membrane-bound proteins and receptors can play an
important role in the formation,
differentiation and maintenance of multicellular organisms. The fate of many
individual cells, e.g., proliferation,
migration, differentiation, or interaction with other cells, is typically
governed by information received from other
cells arullor the irrunediate environment. This information is often
transmitted by secreted polypeptides (for instance,
mitogenic factors, survival factors, cytotnxic factors, differentiation
factors, neuropeptides, and hormones) which are,
in turn, received and interpreted by diverse cell receptors or membrane-bound
proteins. Such membrane-bound
proteins and cell receptors include, but are not limited to, cytokine
receptors, receptor kinases, receptor phosphatases,
receptors involved in cell~ell interactions, and cellular adhesin molecules
like selectins and integrins. For instance,
transduction of signals that regulate cell growth and differentiation is
regulated in part by phosphorylation of various
cellular proteins. Protein tyrosine kinases, enzymes that catalyze that
process, can also act as growth factor
receptors. Examples include fibroblast growth factor receptor and nerve growth
factor receptor. Of particular
interest are membrane bound proteins that have type II transmembrane domains.
43
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Membrane-bound proteins and receptor molecules have various indusuial
applications, including as
phat~taceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are thus being undertaken by both industry and academia to identify
new, native proteins, particularly
membrane bound proteins including type II transmembrane bound proteins. Many
efforts are focused on the
screening of mammalian recombinant DNA libraries to identify the coding
sequences for novel receptor proteins.
The results of such efforts are provided herein.
81. PR01083
Of particular interest are membrane bound proteins that belong to the seven
transmembrane (7TM) receptor
superfamily. Examples of these receptors include G-protein coupled receptors
such as ion receptors. Another
example of a 7TM receptor superfamily member is described in Osterhoff, et
al., DNA Cell Biol., 16(4):379-389
(1997).
Membrane-bound proteins and receptor molecules have various industrial
applications, including as
pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance,
can be employed as therapeutic agents
to block receptor-ligand interaction. The membrane-bound proteins can also be
employed for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand
interaction.
Efforts are being undertaken by both industry and academia to identify new,
native receptor proteins. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel receptor proteins. The results of such efforts are presented herein.
82. PR0200
Polypeptides involved in survival, proliferation and/or differentiation of
cells are of interest. Polypeptides
known to be involved in the survival, proliferation andlor differentiation of
cells include VEGF and members of the
bone morphogenetic protein family. Therefore, novel polypeptides which are
related to either VEGF or the bone
motphogenetic protein are of interest.
The heparin-binding endothelial cell-growth factor, VEGF, was identified and
purified from media
conditioned by bovine pituitary follicular or folliculo-stellate cells over
several years ago. See Ferrara et al.,
Biophys. Res. Comm. 161, 851 (1989). VEGF is a naturally occurring compound
that is produced in follicular or
folliculo-stellate cells (FC), a morphologically well characterized population
of granular cells. The FC are stellate
cells that send cytoplasmic processes between secretory cells.
VEGF is expressed in a variety of tissues as multiple homodimeric forms (121,
165, 189 and 206 amino
acids per monomer) resulting from alternative RNA splicing. VEGF,:, is a
soluble mitogen that does not bind
heparin; the longer forms of VEGF bind heparin with progressively higher
affmiry. The heparin-binding forms of
VEGF can be cleaved in the carboxy terminus by plasmin to release (a)
diffusible forms) of VEGF. Amino acid
sequencing of the carboxy terminal peptide identified after plasmin cleavage
is Arg"o Ala,". Amino terminal "core"
protein, VEGF (1-110) isolated as a homodimer, binds neutralizing monoclonal
antibodies (4.6.1 and 2E3) and soluble
forms of FMS-like tyrosine kinase (FLT-1), kinase domain region (KDR) and
fetal liver kinase (FLK) receptors with
similar affinity compared to the intact VEGF,65 homodimer.
44
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
As noted, VEGF contains two domains that are responsible respectively for
binding to the KDR and FLT-1
receptors. These receptors exist only on endothelial (vascular) cells. As
cells become depleted in oxygen, because
of uauma and the like, VEGF production increases in such cells which then bind
to the respective receptors in order
to signal ultimate biological effect. The signal then increases vascular
permeability and the cells divide and expand
to form new vascular pathways - vasculogenesis and angiogenesis.
Thus, VEGF is useful for treating conditions in which a selected action on the
vascular endothelial cells,
in the absence of excessive tissue growth, is important, for example, diabetic
ulcers and vascular injuries resulting
from uauma such as subcutaneous wounds. Being a vascular (artery and venus)
endothelial cell growth factor, VEGF
restores cells that are damaged, a process referred to as vasculogenesis, and
stimulates the formulation of new
vessels, a process referred to as angiogenesis.
VEGF would also find use in the restoration of vasculature after a myocardial
infarct, as well as other uses
that can be deduced. In this regard, inhibitors of VEGF are sometimes
desirable, particularly to mitigate processes
such as angiogenesis and vasculogenesis in cancerous cells.
Regarding the bone morphogenetic protein family, members of this family have
been reported as being
involved in the differentiation of cartilage and the promotion of
vascularization and osteoinduction in preformed
hydroxyapatite. Zou, et al., Gene~Dev. (U.S.), 11(17):2191 (1997); L,evine, et
al., Ann. Plast. Sub., 39(2):158
(1997). A number of related bone morphogenetic proteins have been identified,
all members of the bone
morphogenetic protein (BMP) family. Bone morphogenetic native and mutant
proteins, nucleic acids encoding
therefor, related compounds including receptors, host cells and uses are
further described in at least: U.S. Patent Nos.
5,670,338; 5,454,419; 5,661,007; 5,637,480; 5,631,142; 5,166,058; 5,620,867;
5,543,394; 4,877,864; 5,013,649;
55,106,?48; and 5,399,677. Of particular interest are proteins having homology
with bone motphogenetic protein
1, a procollagen C-proteinase that plays key roles in regulating matrix
deposition.
The present invention is predicated upon research intended to identify novel
polypeptides which are related
to VEGF and the BMP family, and in particular, polypeptides which have a role
in the survival, proliferation and/or
differentiation of cells. While the novel polypeptides are not expected to
have biological activity identical to the
known polypeptides to which they have homology, the known polypeptide
biological activities can be used to
determine the relative biological activities of the novel polypeptides. In
particular, the novel polypeptides described
herein can be used in assays which are intended to determine the ability of a
polypeptide to induce survival,
proliferation or differentiation of cells. In tum, the results of these assays
can be used accordingly, for diagnostic
and therapeutic purposes. The results of such research is the subject of the
present invention.
83. PR0285 and PR0286
The cloning of the Toll gene of Drosophila, a maternal effect gene that plays
a central role in the
establishment of the embryonic dorsal-venual pattern, has been reported by
Hashimoto et al., feel[ 5,~, 269-279
(1988). The Drosophila Toll gene encodes an integral membrane protein with an
exuacytoplasmic domain of 803
amino acids and a cycoplasmic domain of 269 amino acids. The exuacytoplasmic
domain has a potential membrane-
spanning segment, and contains multiple copies of a leucine-rich segment, a
structural motif found in many
uansmembrane proteins. The Toll protein controls dorsal-venual patterning in
Drosophila embryos and activates
the transcription factor Dorsal upon binding to its ligand Spatzle. (Morisato
and Anderson, r1 76, 677-688 (1994).)
In adult Drosophila, the ToD/Dorsal signaling pathway participates in the anti-
fungal immune response. (Lenaiue et
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
al., Cell ~6, 973-983 (1996).)
A human homologue of the Drosophila Toll protein has been described by
Medzhitov et al., Nature 3~,
394-397 (1997). This human Toll, just as Drosophila Toll, is a type I
transmembrane protein, with an extracellular
domain consisting of 21 tandemly repeated leucine-rich motifs (leucine-rich
region - LRR), separated by a non-LRR
region, and a cytoplasmic domain homologous to the cytoplasmic domain of the
human interleukin-1 (IL-1) receptor.
A constitutively active mutant of the human Toll transfected into human cell
lines was shown to be able to induce
the activation of NF-xB and the expression of NF-xB-controlled genes for the
inflammatory cytokines IL-1, IL-6 and
IL-8, as well as the expression of the constimulatory molecule B7.1, which is
required for the activation of native
T cells. It has been suggested that Toll functions in vertebrates as a non-
clonal receptor of the immune system, which
can induce signals for activating both an innate and an adaptive immune
response in vertebrates. The human Toll
gene reported by Medzhitov et al., supra was most strongly expressed in spleen
and peripheral blood leukocytes
(PBL), and the authors suggested that its expression in other tissues may be
due to the presence of macrophages and
dendritic cells, in which it could act as an early-warning system for
infection. The public GenBank database contains
the following Toil sequences: Tolll (DNAXfI HSU88540-1, which is identical
with the random sequenced full-length
cDNA tlHUMRSC786-1); To112 (DNAXtI HSU88878-1); To113 (DNAXt/ HSU88879-1); and
To114 (DNAX/I
HSU88880-1, which is identical with the DNA sequence reported by Medzhitov et
al., supra). A partial Toll
sequence (To115) is available from GenBank under DNAX/t HSU88881-1.
Further human homologues of the Drosophila Toll protein, designated as Toll-
like receptors (huTLRsl-5)
were recently cloned and shown to mirror the topographic structure of the
Drosophila counterpart (Rock et al., Proc.
Natl. Acad. Sci. ~JSA 95, 588-593 [1998]). Overexpression of a constitutively
active mutant of one human TLR
(Toll-protein homologue - Medzhitov er al., supra; TLR4 - Rock et al., supra)
leads to the activation of NF-xB and
induction of the inflammatory cytokines and constimulatory molecules.
Medzhitov et al., supra.
84. PR0213-l, PRQ1330 and PR91449
Cancer is characterized by the increase in the number of abnormal, or
neoplastic, cells derived from a
normal tissue which proliferate to form a tumor mass, the invasion of adjacent
tissues by these neoplastic tumor cells,
and the generation of malignant cells which eventually spread via the blood or
lymphatic system to regional lymph
nodes and to distant sites (metastasis). In a cancerous state a cell
proliferates under conditions in which normal cells
would not grow. Cancer manifests itself in a wide variety of forms,
characterized by different degrees of
invasiveness and aggressiveness.
Alteration of gene expression is intimately related to the uncontrolled cell
growth and de-differentiation
which are a common feature of all cancers. The genomes of certain well studied
tumors have been found to show
decreased expression of recessive genes, usually referred to as tumor
suppression genes, which would normally
function to prevent malignant cell growth, and/or overexpression of certain
dominant genes, such as oncogenes. that
act to promote malignant growth. Each of these genetic changes appears to be
responsible for importing some of the
traits that, in aggregate, represent the full neoplastic phenotype (Hunter,
Cell 64, 1129 [1991]; Bishop, Cell 64, 235-
248 [1991]).
A weD known mechanism of gene (e.g. or~ogene) overexpression in cancer cells
is gene amplification. This
is a process where in the chromosome of the ancestral cell multiple copies of
a particular gene are produced. The
process involves unscheduled replication of the region of chromosome
comprising the gene, followed by
46
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
recombination of the replicated segments back into the chromosome (Alitalo et
al., Adv. Cancer Res. 47, 235-281
[1986]). It is believed that the overexpression of the gene parallels gene
amplification, i.e. is proportionate to the
number of copies trade.
Proto-oncogenes that encode growth factors and growth factor receptors have
been identified to play
important roles in the pathogenesis of various human malignancies, including
breast cancer. For example, it has been
found that the human ErbB2 gene (erbB2, also known as her2, or c-erbB-2),
which encodes a 185-kd transmembrane
glycoprotein receptor (p185HER2; HER2) related to the epidermal growth factor
receptor (EGFR), is overexpressed
in about 25% to 30% of human breast cancer (Slamon et al., Science 235:177-182
(1987]; Slamon et al., Science
244:707-712 ~ 1989]).
It has been reported that gene amplification of a protooncogene is an event
typically involved in the more
malignant forms of cancer, and could act as a predictor of clinical outcome
(Schwab et al., Genes Chromosomes
Cancer 1, 181-193 [1990]; Alitalo et al., supra). Thus, erbB2 overexpression
is commonly regarded as a predictor
of a poor prognosis, especially in patients with primary disease that involves
axillary lymph nodes (Slamon et al.,
[1987) and [1989], supra; Ravdin and Chamness, Gene 159:19-27 [1995]; and
Hynes and Stern, Biochem Biophys
Acta 1198: 165-184 [1994]), and has been linked to sensitivity and/or
resistance to hormone therapy and
chemotherapeutic regimens, including CMF (cyclophosphamide, methotrexate, and
fluoruracil) and anthracyclines
(Baselga et al., Oncology 11 (3 Suppl 1): 43-48 [1997]). However, despite the
association of erbB2 overexpression
with poor prognosis, the odds of HER2-positive patients responding clinically
to treatment with taxanes were greater
than three times those of HER2-negative patients (/bid). A recombinant
humanized anti-ErbB2 (anti-HER2)
monoclonal antibody (a humanized version of the murine anti-ErbB2 antibody
4D5, referred to as rhuMAb HER2
or Herceptin 7d) has been clinically active in patients with ErbB2-
overexpressing metastatic breast cancers that had
received extensive prior anticancer therapy. (Baselga et al., J. Clin. Oncol.
14:737-744 [1996)).
The protein Notch and its homologues are key regulatory receptors in
determining the cell fate in various
development processes. The protein Notch-4, also known as int-3 oncogene, was
originally identified as a frequent
target in mouse mammary tumor virus (MMVS). Notch-4 is believed to be a
uansgene which affects the
differentiation capacity of stem cells and leads to neoplastic proliferation
in epithelial cells. Shirayoshi et al., Genes
Cells 2(3): 213-224 (1997). During embryogenesis, the expression of Notch-0
was detected in endothelial cells of
blood vessels forming tissues such as the dorsal aorta, intersegmental
vessels, yolk sac vessels, cephalic vessels,
heart, vessels in branchial arches, and capillary plexuses. Notch-4 expression
in these tissues was also associated
with flk-I, the major regulatory gene of vasculogenesis and angiogenesis.
Notch-4 is also upregulated in vitro during
the differentiation of endothelial stem cell. The endothelial cell specific
expression pattern of Notch-4, as well as its
structural similarity to Notch suggest that Notch-4 is an endothelial cell
specific homologue of Notch and that it may
play a role in vaculogenesis and angiogenesis.
$5. PR0298
Efforts are being undertaken by both industry and academia to identify new,
native receptor proteins. Many
efforts are focused on the screening of mammalian recombinant DNA libraries to
identify the coding sequences for
novel receptor proteins. We herein describe the identification and
characterization of novel transmembrane
polypeptides, designated herein as PR0298 polypeptides.
47
CA 02421372 2003-03-25
WO 99/46281 PCT/lJS99/05028
86. P 37
Neuronal development in higher vertebrates is characterized by processes that
must successfully navigate
distinct cellular environment en route to their synaptic targets. The result
is a functionally precise formation of neural
circuits. The precision is believed to result form mechanisms that regulate
growth cone pathfmding and target
recognition, followed by latter refinement and remodeling of such projections
by events that require neuronal activity,
Goodman and Shatz, CelllNeuron [Suppl.] 72(10): 77-98 (1993). It is further
evident that different neurons extend
nerve fibers that are biochemically distinct and rely on specific guidance
cues provided by cell-cell, cell-matrix, and
chemotrophic interactions to reach their appropriate synaptic targets, Goodman
et al., supra.
One particular means by which diversity of the neuronal cell surface may be
generated is through differential
expression of cell surface proteins referred to as cell adhesion molecules
(CAMS). Neuronally expressed CAMS have
been implicated in diverse developmental processes, including migration of
neurons along radial glial cells, providing
permissive or repulsive substrates for neurite extension, and in promoting the
selective fasciculation of axons in
projectional pathways. Jessel, Neuron l: 3-13 (1988); Edelman and Crossin,
Annu. Rev. Biochem. 60: 155-190
(1991). Interactions between CAMS present on the growth cone membrane and
molecules on opposing cell
membranes or in the extracellular matrix are thought to provide the specific
guidance cues that direct nerve fiber
outgrowth along appropriate projectional pathways. Such interactions are
likely to result in the activation of various
second messenger systems within the growth cone that regulate neurite
outgrowth. Doherry and Walsh, Curr. Opin
Neurobiol. 2: 595-601 (1992).
In higher vertebrates, most neural CAMs have been found to be members of three
major structural families
of proteins: the integrinc, the cadherins, and the immunoglobulin gene
superfamily (IgSF). Jessel, supra.; Takeichi,
Annu. Rev. Biochem. 59: 237-252 (1990); Reichardt and Tomaselli, Annu. Rev.
Neurosci. 14: 531-570 (1991). Cell
adhesion molecules of the IgSF (or Ig-CAMs), in particular, constitute a large
family of proteins frequently implicated
in neural cell interactions and nerve fiber outgrowth during development,
Salzer and Cohnatt, Dev. Neurosci. 11:
377-390 (1989); Brummendorf and Rathjen, J. Neurochem. 61: 1207-1219 (1993).
However, the majority of
mammalian Ig-CAMs appear to be too widely expressed to specify navigational
pathways or synaptic targets
suggesting that other CAMS, yet to be identified, have role in these more
selective interactions of neurons.
Many of the lrnown neural Ig-CAMs have been found to be attached to the plasma
membrane via a
glycosylphosphatidylinositol (GPI) anchor. Additionally, many studies have
implicated GPl-anchored proteins in
providing specific guidance cues during the outgrowth on neurons in specific
pathways. In studies of the grasshopper
nervous system, treattment of embryos with phosphatidylinositol-specific
phopholipase C (PIPLC), which selectively
removes GPI-anchored proteins from the surfaces of cells, resulted in
misdirection and faulty navigation among
subsets of pioneering growth cones, as well as inhibited migratory patterns of
a subset of early neurons, Chang et
al., Devel. 114: 507-519 (1992). The projection of retinal fibers to the optic
rectum appears to depend, in part, on
a 33 kDa GPI-anchored protein, however, the precise nature of this protein is
unknown. Stahl et al., Neuron 5: 735-
743 (1990).
The expression of various GPI-anchored proteins has been characterized amongst
the different populations
of primary rat neurons amongst dorsal root ganglion, sympathetic neurons of
the cervical ganglion, sympathetic
neurons of the superior cervical ganglion, and cerebellar granule neurons.
Rosen et al., J. Cell Biol. 117: 617-627
(1992). In contrast to the similar pattern of total membrane protein
expression by these different types of neurons,
stzi>ang differences were observed in the expression of GPI-anchored proteins
between these neurons. Recently, a
48
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
65 kDa protein band known as neurotrimin was discovered and found to be
differentially expressed by primary
neurons (Rosen et al., supra), and restricted to the nervous system and found
to be the most abundant and earliest
expressed of the GPI-anchored species in the CNS. Struyk et al., J.
Neuroscience 15(3): 2141-2156 (1995). The
discovery of neurotrimirt has further lead to the identification of a family
of IgSF members, each containing three Ig-
like domains that share significant amino acid identity, now termed IgLON.
Struyk et al., supra; Pimenta et al., Gene
170(2): 189-95 (1996).
Additional members of the IgLON subfamily include opiate binding cell adhesion
molecule (OBCAM),
Schofield et al., EMBO J. 8: 489-495 (1989); limbic associated membrane
protein (LAMP), Pimenta et al., supra;
CEPU-1; GP55, Wilson et al., J. Cell Sci. 109: 3129-3138 (1996); Eur. J.
Neurosci. 9(2): 334-41 (1997); and
AvGp50, Hancox et al., Brain Res. Mol. Brain Res. 44{2): 273-85 (1997).
While the expression of neurotrimin appears to be widespread, it does appear
to correlated with the
development of several neural circuits. For example, between E18 and P10,
neurotimin mRNA expression within
the forebrain is maintained at high levels in neurons of the developing
thalamus, cortical subplate, and cortex,
particularly laminae V and VI (with less intense expression in II, 11, and 1V,
and minimal expression in lamina I).
Cortical subplate neurons may provide an early, temporary scaffold for the
ingrowing thalamic afferents en route to
their final synaptic targets in the cortex. Allendoerfer and Shatz. Annu. Rev.
Neurosci. 17: 185-218 (1994).
Conversely, subplate neurons have been suggested to be required for cortical
neurons from layer V to select VI to
grow into the thalamus, and neurons from layer V to select their targets in
the colliculus, pons, and spinal cord
(McConnell et al., J. Neurosci. 14: 1892-1907 (1994). The high level
expression of neurotrimin in many of these
projections suggests that it could be involved in their development.
in the hindbrain, high levels of neurotrimirt message expression were observed
within the pontine nucleus
and by the internal granule cells and Purkinje cells of the cerebellum. The
pontine nucleus received afferent input
from a variety of sources including corticopotitine fibers of layer V, and is
a major source of afferent input, via mossy
fibers, to the granule cells which, in turn, are a major source of afferent
input via parallel fibers to Purkinje cells.
(Palay and Chart-Palay, The cerebellar cortex: cytology and organization. New
York: Springer (1974). High level
expression of neurotrimin these neurons again suggests potential involvement
in the establishment of these circuits.
Neurotrimin also exhibits a graded expression pattern in the early postnatal
striatum. Increased neurotrimin
expression is found overlying the dorsolateral striatum of the rat, while
lesser hybridization intensity is seen overlying
the ventromedial striatum. Struyk et al., supra. This region of higher
neurotrimitt hybridization intensity does not
correspond to a cytoarchitecturally differentiable region, rather it
corresponds to the primary area of afferent input
from layer VI of the contralateral sensorimotor cortex (Gerfen, Nature 311:
461-464 (1984); Donoghue and
Herkenbam, Brain Res. 365: 397-403 (1986)). The ventromedial striatum, by
contrast, receives the majority of its
afferent input from the perirhinal and association cortex. It is noteworthy
that a complementary graded pattern of
LAMP expression, has been observed within the striatium, with highest
expression in ventromedial regions, and
lowest expression dorsolaterally. Levitt, Science 223: 299-301 (1985);
Chesselet et al., Neuroscience 40: 725-733
(1991).
87. PR0403
Type II transmembrane proteins, also known as single pass transmembrane
proteins have an N-terminal
portion lodged in the cytoplasm while the C-terminal portion is exposed to the
exaracellular domain.
49
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Endothelia is a family of vasoconstrictor peptides about which much activity
has been focused to better
understand its basic pharmacological, biochemical and molecular biological
features, including the presence and
structure of isopeptides and their genes (endothelia-1, -2 and ti3),
regulation of gene expression, intracellular
processing, specific endothelia converting enzymes (ECE), receptor subtypes
(ET-A and ET-B), intracellular signal
transduction following receptor activation, etc.
The endothelia (ET) family of peptides have potent vascular, cardiac and renal
actions which may be of
pathophysiological importance in many human disease states. ET-1 is expressed
as an inactive 212 amino acid
prepropeptide. The prepropeptide is first cleaved at Arg52-Cys53 and Arg92-
A1a93 and then the carboxy terminal
Lys91 and Arg92 are trimmed from the protein to generate the propeptide big ET-
1.
Endothelia is generated from inactive intermediates, the big endothelins, by a
unique processing event
catalyzed by the zinc metalloprotease, endothelia converting enzyme (ECE). ECE
was recently cloned, and its
structure was shown to be a single pass transmembrane protein with a short
intracellular N-terminal and a long
extracellular C-terminal that contains the catalytic dornain and numerous N-
glycosylation sites. ECEs cleave the
endothelia propeptide between Trp73 and Va174 producing the active peptide,
ET, which appears to function as a
local rather than a circulating hormone (Rubanyi, G.M. & Polokoff, M.A.,
Pharmachological Reviews 46: 325-415
(1994). Thus ECE activity is a potential site of regulation of endothelia
production and a possible target for
therapeutic intervention in the endothelia system. 13y blocking ECE activity,
it is possible stop the production of ET-1
by inhibiting the conversion of the relatively inactive precursor, big ET-1,
to the physiologically active forth.
Endothelins may play roles in the pathophysiology of a number of disease
states including: 1) cardiovascular
diseases (vasospasm, hypertension, myocardial ischemia; reperfusion injury and
acute myochardial infarction, stroke
(cerebral ischemia), congestive heart failure, shock, atherosclerosis,
vascular thickening); 2) kidney disease (acute
and chronic renal failure, glouierulonephritis, cirrhosis); 3) lung disease
(bronchial asthma, pulmonary hypertension);
4) gastrointestinal disorders (gastric ulcer, inflammatory bowel diseases); 5)
reproductive disorders (premature labor,
dysmenorhea, preeclampsia) and 6) carcinogenesis_ Rubanyi & Polokoff, supra.
SUMMARY OF THE INVENTION
1. PR
Applicants have identified a cDNA clone that encodes a novel polypeptide,
wherein the polypeptide is
designated in the present application as "PR0213".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0213 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0213 polypeptide
having amino acid residues 1 to 295 of Figure 2 (SEQ ID N0:2), or is
complementary to such encoding nucleic acid
sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency conditions.
In another embodiment, the invention provides isolated PR0213 polypeptide. In
particular, the invention
provides isolated native sequence PR0213 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 295 of Figure 2 (SEQ ID N0:2).
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
2. P 7
Applicants have identified a cDNA clone that encodes a novel polypeptide,
wherein the polypeptide is
designated in the present application as " PR0274".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0274 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0274 polypeptide
having amino acid residues 1 to 492 of Figure 4 (SEQ ID N0:7), or is
complementary to such encoding nucleic acid
sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency conditions.
The isolated nucleic acid sequetlce may comprise the cDNA insert of the
DNA3998'7-1184 vector deposited on April
21, 1998 as ATCC 209786 which includes the nucleotide sequence encoding
PR0274.
In another embodiment, the invention provides isolated PR0274 polypeptide. In
particular, the invention
provides isolated native sequence PR0274 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 492 of Figure 4 (SEQ ID N0:7). An additional
embodiment of the present invention is
directed to an isolated extracellular domain of a PR0274 polypeptide.
Optionally, the PR0274 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the DNA39987-1184 vector
deposited on April 21, 1998 as ATCC 209786.
In another embodiment, the invention provides three expressed sequence tags
(FST) comprising the
nucleotide sequences of SEQ ID N0:8 (herein designated as DNA17873), SEQ ID
N0:9 (herein designated as
DNA36157) and SEQ ID NO:10 (herein designated as DNA28929) (see Figure 5-7,
respactively).
3. PR030o
Applicants have identified a cDNA clone that encodes a novel polypeptide,
wherein the polypeptide is
designated in the present application as "PR0300".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0300 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0300 polypeptide
having an>i~ acid residues 1 to 457 of Figure 9 (SEQ ID N0:19), or is
complementary to such encoding nucleic acid
sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency conditions.
The isolated nucleic acid sequence may comprise the cDNA insert of the
DNA40625-1189 vector deposited on April
21, 1998 as ATCC 209788 which includes the nucleotide sequence encoding
PR0300.
In another embodiment, the invention provides isolated PR0300 polypeptide. In
particular, the invention
provides isolated native sequence PR0300 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 457 of Figure 9 (SEQ ID N0:19). An additional
embodiment of the present invention is
directed to an isolated extracellular domain of a PR0300 polypeptide.
Optionally, the PR0300 polypeptide is
o~ainod or is obtainable by expressing the polypeptide encoded by the eDNA
insert of the DNA40625-1189 vector
deposited on April 21, 1998 as ATCC 209788.
4. PR0284
Applicants have identified a cDNA clone that encodes a novel transmembrane
polypeptide, wherein the
polypeptide is designaud in the present application as "PR0284".
In mte embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0284 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR02$4 polypeptide
51
CA 02421372 2003-03-25
WO 99/46281 PCT/US99l05028
having amino acid residues 1 to 285 of Figure 11 (SEQ ID NO:28), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0284 polypeptide having
amino acid residues about 25 to 285 of Figure I 1 (SEQ ID N0:28) or I or about
25 to X of Figure 11 (SEQ ID
N0:28), where X is any amino acid from 71 to 80 of Figure 11 (SEQ ID N0:28),
or is complementary to such
encoding nucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high
stringency conditions. The isolated nucleic acid sequence may comprise the
cDNA insert of the DNA23318-1211
vector deposited on April 21, 1998 as ATCC 209787 which includes the
nucleotide sequence encoding PR0284.
In another embodiment, the invention provides isolated PR0284 polypeptide. In
particular, the invention
provides isolated native sequence PR0284 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 285 of Figure 11 (SEQ ID N0:28). Additional
embodiments of the present invention are
directed to isolated PR0284 polypeptides comprising amino acids about 25 to
285 of Figure 11 (SEQ ID N0:28) or
1 or about 25 to X of Figure 11 (SEQ ID N0:28), where X is any amino acid from
71 to 80 of Figure 11 (SEQ ID
N0:28). Optionally, the PR0284 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded by
the cDNA insert of the DNA23318-1211 vector deposited on April 21, 1998 as
ATCC 209787.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA12982 which comprises the nucleotide sequence of SEQ ID N0:29.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA15886 which comprises the nucleotide sequence of SEQ ID N0:30.
5. P 96
Applicants have identified a eDNA clone that encodes a novel polypeptide
having homology to the sarcoma-
amplified protein SAS, wherein the polypeptide is designated in the present
application as "PR0296".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0296 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0296 polypeptide
having amino acid residues 1 to 204 of Figure 15 (SEQ ID N0:36), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0296 polypeptide having
amino acid residues about 35 to 204 of Figure 15 (SEQ ID N0:36) or amino acid
1 or about 35 to X of Figure 15
(SEQ )D N0:36), where X is any amino acid from 42 to 51 of Figure 15 (SEQ ID
N0:36), or is complementary to
such encoding nucleic acid sequence, and remains stably bound to it under at
least moderate, and optionally, under
high stringency conditions. The isolated nucleic acid sequence may comprise
the cDNA insert of the DNA39979-
1213 vector deposited on April 21, 1998 as ATCC 209789 which ir~ludes the
nucleotide sequence encoding PR0296.
In another embodiment, the invention provides isolated PR0296 polypeptide. In
particular, the invention
provides isolated native sequence PR0296 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 204 of Figure 15 (SEQ ID N0:36). Additional
embodiments of the present invention are
directed to PR0296 polypeptides comprising amino acids about 35 to 204 of
Figure 15 (SEQ ID N0:36) or amino
acid 1 or about 35 to X of Figure 15 (SEQ 1D N0:36), where X is any amino acid
from 42 to 51 of Figure 15 (SEQ
ID N0:36). Optionally, the PR0296 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA39979-1213 vector deposited on April 21, 1998 as
ATCC 209789.
52
CA 02421372 2003-03-25
WO 99/46281 PCT/13S99/05028
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA23020 comprising the nucleotide sequence of SEQ ID N0:37.
In another embodiment, the invention provides an expressed sequence tag (F.ST)
designated herein as
DNA21971 comprising the nucleotide sequence of SEQ ID N0:38.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA29037 comprising the nucleotide sequence of SEQ 1D N0:39.
6. PR0329
Applicarns have identified a cDNA clone that encodes a novel polypeptide
having homology to a high affinity
immunoglobulin F~ receptor, wherein the polypeptide is designated in the
present application as "PR0329" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0329 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0329 polypeptide
having amino acid residues 1 to 359 of Figure 20 (SEQ ID N0:45), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA40594-1233 vector
deposited on February 5, 1998 as ATCC 209617 which includes the nucleotide
sequence encoding PR0329.
In another embodiment, the invention provides isolated PR0329 polypeptide. In
particular, the invention
provides isolated native sequence PR0329 polypeptide, which in orn embodiment,
includes an amino acid sequence
comprising residues 1 to 359 of Figure 20 (SEQ ID N0:45). Optionally, the
PR0329 polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA40594-1233 vector deposited on
February 5, 1998 as ATCC 209617.
7. PR0362
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to A33 antigen
arid HCAR membrane-bound protein, wherein the polypeptide is designated in the
present application as "PR0362".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0362 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0362 polypeptide
having amino acid residues 1 to 321 of Figure 22 (SEQ ID N0:52), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0362 polypeptide having
amino acid residues 1 to X of Figure 22 (SEQ ID N0:52) when X is any amino
acid from amino acid 271 to 280,
or is complementary to such encoding nucleic acid sequence, and, remains
stably bound to it under at least moderate,
and optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert
of the DNA45416-1251 vector deposited on February 5, 1998 as ATCC 209620 which
includes the nucleotide
sequence encoding PR0362.
In another embodiment, the invention provides isolated PR0362 polypeptide. In
particular, the invention
provides isolated native sequence PR0362 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 321 of Figure 22 (SEQ ID N0:52). An additional
embodiment of the present invention is
directed to an isolated extracellular domain of a PR0362 polypeptide
comprising amino acids I to X of the amino
acid sequence shown in Figure 22 (SEQ ID N0:52), wherein X is any amino acid
from amino acid 271 to 280.
53
CA 02421372 2003-03-25
WO 99146281 PCT/tJS99/05028
Optionally, the PR0362 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA4S416-1251 vector deposited on February 5, 1998 as ATCC
209620.
8. PR 363
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to the cell
surface receptor protein HCAR, wherein the polypeptide is designated in the
present application as "PR0363".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0363 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0363 polypeptide
having amino acid residues 1 to 373 of Figure 24 (SEQ ID N0:59), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding a PR0363 exuacellular domain
polypeptide having amino acid residues 1 to X of Figure 24 (SEQ ID NO:S9)
where X is any amino acid from amino
acid 216 to amino acid 225, or is complementary to such encoding nucleic acid
sequence, and remains stably bound
to it under at least moderate, and optionally, under high suingency
conditions. The isolated nucleic acid sequence
may comprise the cDNA insert of the DNA4S419-1252 vector deposited on February
5, 1998 as ATCC 209616
1S which includes the nucleotide sequence encoding PR0363.
In another embodiment, the invention provides isolated PR0363 polypeptide. In
particular, the invention
provides isolated native sequence PR0363 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 373 of Figure 24 (SEQ ID N0:59). An additional
embodiment of the present invention is
directed to an isolated extracellular domain of a PR0363 polypeptide, wherein
that exuacellular domain may
comprise amino acids 1 to X of the sequence shown in Figure 24 (SEQ ID N0:59),
where X is any amino acid from
amino acid 216 to 225. Optionally, the PR0363 polypeptide is obtained or is
obtainable by expressing the
polypeptide encoded by the cDNA insert of the DNA45419-1252 vector deposited
on February S, 1998 as ATCC
209616.
2S 9. PR0868
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to tumor
necrosis factor receptor, wherein the polypeptide is designated in the present
application as "PR0868".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0868 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0868 polypeptide
having amino acid residues 1 to 655 of Figure 26 (SEQ ID N0:64), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0868 polypeptide having
amino acid residues 1 to X of Figure 26 (SEQ ID N0:64), where X is any amino
acid from amino acid 343 to 352
of the sequence shown in Figure 26 (SEQ ID N0:64), or is complementary to such
encoding nucleic acid sequence,
and remains stably bound to it under at least moderate, and optionally, under
high stringency conditions. In yet
another aspect, the isolated nucleic acid comprises DNA encoding the PR0868
polypeptide having amino acid
residues X to 65S of Figure 26 (SEQ ID N0:64), where X is any amino acid from
amino acid 371 to 380 of the
sequence shown in Figure 26 (SEQ ID N0:64), or is complementary to such
encoding nucleic acid sequence, and
remains stably bound to it under at least moderate, and optionally, under high
stringency conditions. The isolated
54
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
nucleic acid sequence may comprise the cDNA insert of the DNA52594-1270 vector
deposited on March 17, 1998
as ATCC 209679 which includes the nucleotide sequence encoding PR0868.
In another embodiment, the invention provides isolated PR0868 polypeptide. In
particular, the invention
provides isolated native sequence PR0868 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 655 of Figure 26 (SEQ ID N0:64). In another aspect,
the isolated PR0868 polypeptide
comprises amino acid residues 1 to X of Figure 26 (SEQ ID N0:64), where X is
any amino acid from amino acid
343 to 352 of the sequence shown in Figure 26 (SEQ ID N0:64). In yet another
aspect, the PR0868 polypeptide
comprises amino acid residues X to 655 of Figure 26 (SEQ ID N0:64), where X is
any amino acid from amino acid
371 to 380 of the sequence shown in Figure 26 (SEQ ID N0:64). Optionally, the
PR0868 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the DNA52594-1270 vector deposited
on March 17, 1998 as ATCC 209679.
10. PR0382
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to serine
proteases, wherein the polypeptide is designated in the present application as
"PR0382".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0382 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0382 polypeptide
having amino acid residues 1 to 453 of Figure 28 (SEQ ID N0:69), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA45234-1277 vector
deposited on March 5, 1998 as ATCC 209654 which includes the nucleotide
sequence encoding PR0382.
In another embodiment, the invention provides isolated PR0382 polypeptide. In
particular, the invention
provides isolated native sequence PR0382 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 453 of Figure 28 (SEQ ID N0:69). An additional
embodiment of the present invention is
directed to an isolated extracelluLtr domain of a PR0382 polypeptide, with or
without the signal peptide. Optionally,
the PR0382 polypeptide is obtained or is obtainable by expressing the
polypeptide encoded by the cDNA insert of
the DNA45234-1277 vector deposited on March 5, 1998 as ATCC 209654.
11. PR0545
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to meltrin,
wherein the polypeptide is designated in the present application as "PR0545".
In one embodiment, the invention provides an isolated nucleic acid moleculc
comprising DNA encoding a
PR0545 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0545 polypeptide
having amino acid residues 1 to 735 of Figure 30 (SEQ ID N0:74), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nuclcic acid sequence may comprise the cDNA insert of
the vector deposited on Maach S,
1998 as ATCC 209655 which includes the nucleotide sequence encoding PR0545.
In another embodiment, the invention provides isolated PR0545 polypeptide. In
particular, the invention
provides isolated native sequence PR0545 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 735 of Figure 30 (SEQ 1D N0:74). An additional
embodiment of the present invention is
$S
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
directed to an isolated extracellular domain of a PR0545 polypeptide.
Optionally, the PR0545 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on March
5, 1998 as ATCC 209655.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13217 comprising the nucleotide sequence of SEQ ID N0:75 (Figure 31).
12. PRO
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to CD24,
wherein the polypeptide is designated in the present application as "PR0617".
in one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0617 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0617 polypeptide
having amino acid residues 1 to 67 of Figure 33 (SEQ 1D N0:85), or is
complementary to such encoding nucleic acid
sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency conditions.
The isolated nucleic acid sequence may comprise the cDNA insert of the
DNA48309-1280 vector deposited on March
5, 1998 as ATCC 209656 which includes the nucleotide sequence encoding PR0617.
In another embodiment, the invention provides isolated PR0617 polypeptide. In
particular, the invention
provides isolated native sequence PR0617 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 67 of Figure 33 (SEQ ID N0:85). Optionally, the
PR0617 polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA48309-1280 vector deposited on
March 5, 1998 as ATCC 209656.
13. PR0700
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
protein disulfide isomerase, wherein the polypeptide is designated in the
present application as "PR0700".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0700 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0700 polypeptide
having amino acid residues 1 to 432 of Figure 35 (SEQ 1D N0:90), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0700 polypeptide having
amino acid residues from about 34 to 432 of Figure 35 (SEQ ID N0:90), or is
complementary to such encoding
trucleic acid sequence, and retrains stably bound to it under at least
moderate, and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 31,
1998 as ATCC 209721 which includes the nucleotide sequence encoding PR0700.
In another embodiment, the invention provides isolated PR0700 polypeptide. In
particular, the invention
provides isolated native sequence PR0700 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 432 of Figure 35 (SEQ ID N0:90). In another
embodiment, the invention provides an
isolated PR0700 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
from about 34 to 432 of Figure 35 (SEQ 1D N0:90). Optionally, the PR0700
polypeptide is obtained or is obtainable
by expressing the polypeptide encoded by the cDNA insert of the vector
deposited on March 31, 1998 as ATCC
209721.
56
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
14. PR0702
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to conglutinin,
wherein the polypeptide is designated in the present application as "PR0702".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0702 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0702 polypeptide
having amino acid residues 1 to 277 of Figure 37 (SEQ ID N0:97), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0702 polypeptide having
amino acid residues 26 to 277 of Figure 37 (SEQ ID N0:97), or is complementary
to such encoding nucleic acid
sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency conditions.
The isolated nucleic acid sequence may comprise the cDNA insert of the
DNA50980-1286 vector deposited on March
3I, 1998 as ATCC 209717 which includes the nucleotide sequence encoding
PR0702.
In another embodiment, the invention provides isolated PR0702 polypeptide. In
particular, the invention
provides isolated native sequence PR0702 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I to 277 of Figure 37 (SEQ ID N0:97). An additional
embodiment of the present invention is
directed to an isolated PR0702 polypeptide comprising amino acid residues 26
to 277 of Figure 37 (SEQ ID N0:97).
Optionally, the PR0702 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA50980-1286 vector deposited on March 31, 1998 as ATCC 209717.
15. PR0703
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
VLCAS, wherein the polypeptide is designated in the present application as
"PR0703".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0703 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0703 polypeptide
having amino acid residues I to 730 of Figure 39 (SEQ ID N0:102), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0703 polypeptide having
amino acid residues from about 43 to 730 of Figure 39 (SEQ ID N0:102), or is
complementary to such encoding
tntcleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA50913-1287 vector
deposited on March 31, 1998 as ATCC 209716 which includes the nucleotide
sequence encoding PR0703.
In another embodiment, the invention provides isolated PR0703 polypeptide. In
particular, the invention
provides isolated native sequence PR0703 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 730 of Figure 39 (SEQ ID N0:102). In another
embodiment, the invention provides an
isolated PR0703 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
from about 43 to 730 of Figure 30 (SEQ ID N0:102). Optionally, the PR0730
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA50913-1287 vector deposited on
March 31, 1998 as ATCC 209716.
57
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
16. PR0705
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to K-glypican,
wherein the polypeptide is designated in the present application as "PR0705".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0705 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0705 polypeptide
having amino acid residues 1 to 555 of Figure 41 (SEQ ID N0:109), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0705 polypeptide having
amino acid residues about 24 to 555 of Figure 41 (SEQ ID N0:109), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence rnay comprise the cDNA insert
of the DNA50914-1289 vector
deposited on March 31, 1998 as ATCC 209722 which includes the nucleotide
sequence encoding PR0705.
In another embodiment, the invention provides isolated PR0705 polypeptide. In
particular, the invention
provides isolated native sequence PR0705 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 555 of Figure 41 (SEQ 1D N0:109). An additional
embodiment of the present invention
is directed to an isolated PR0705 polypeptide comprising amino acid residues
about 24 to 555 of Figure 41 (SEQ
ID N0:109). Optionally, the PR0705 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA50914-1289 vector deposited on March 31, 1998 as
ATCC 209722.
17. RP O?08
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to the aryl
sulfatases, wherein the polypeptide is designated in the present application
as "PR0708" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0708 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0708 polypeptide
having amino acid residues 1 to 515 of Figure 43 (SEQ ID N0:114), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA48296-1292 vector
deposited on March l I, 1998 as ATCC 209668 which includes the nucleotide
sequence encoding PR0708.
In another embodiment, the invention provides isolated PR0708 polypeptide. In
particular, the invention
provides isolated native sequence PR0708 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I to 515 of Figure 43 (SEQ ID N0:114). Another embodiment
is directed to a PR0708
polypeptide comprising residues 38-515 of the amino acid sequence shown in
Figure 43 (SEQ ID N0:114).
Optionally, the PR0708 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA48296-1292 vector deposited on March 11, 1998 as ATCC 209668.
18. PR0320
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to fibulin,
wherein the polypeptide is designated in the present application as "PR0320".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0320 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0320 polypeptide
58
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
having amino acid residues 1 to 338 of Figure 45 (SEQ ID N0:119), or is
complementary to such encoding nucleic
acid sequence, and remains stabiy bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 11,
1998 as ATCC 209670 which includes the nucleotide sequence encoding PR0320.
In another embodiment, the invention provides isolated PR0320 polypeptide. in
particular, the invention
provides isolated native sequence PR0320 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 338 of Figure 45 (SEQ ID N0:119). Optionally, the
PR0320 polypeptide is obtained or
is obtainable by expressing the polypeptide encoded by the cDNA insert of the
vector deposited on March 11, 1998
as ATCC 209670.
19. PR 3 4
Applicants have identified a cDNA clone that encodes a novel polypeptidc
having homology to
oxidoreductases, wherein the polypeptide is designated in the present
application as "PR0324".
In one embodiment, the invention provides an isolated nuclcic acid molecule
comprising DNA encoding a
PR0324 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0324 polypeptide
having amino acid residues 1 to 289 of Figure 47 (SEQ ID N0:124), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0324 polypeptide having
amino acid residues 1 or about 32 to X of Figure 47 (SEQ ID N0:124), where X
is any amino acid from 131 to 140,
or is complementary to such encoding nucleic acid sequence, and remains stably
bound to it under at least moderate,
and optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert
of the DNA36343-1310 vector deposited on March 30, 1998 as ATCC 209718 which
includes the nucleotide sequence
encoding PR0324.
In another embodiment, the invention provides isolated PR0324 polypeptide. In
particular, the invention
provides isolated native sequence PR0324 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 289 of Figure 47 (SEQ ID N0:124). The invention also
provides isolated PR0324
polypeptide comprising residues 1 or about 32 to X of Figure 47 (SEQ ID
N0:124), wherein X is any amino acid
from about 131-140. Optionally, the PR0324 polypeptide is obtained or is
obtainable by expressing the polypcptide
encoded by the cDNA insert of the DNA36343-1310 vector deposited on March 30,
1998 as ATCC 209718.
20. PR0351
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
prostasin, wherein the polypeptide is designated in the present application as
"PR0351".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0351 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0351 polypeptide
having amino acid residues 1 to 571 of Figure 49 (SEQ ID N0:132), or is
complcmentary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0351 polypeptide having
amino acid residues about 16 to 571 of Figure 49 (SEQ ID N0:132), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
59
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA40571-1315 vector
deposited on April 21, 1998 as ATCC 209784 which includes the nucleotide
sequence encoding PR0351.
In another embodiment, the invention provides isolated PR0351 polypeptide. In
particular, the invention
provides isolated native sequence PR0351 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 571 of Figure 49 (SEQ ID N0:132). In another
embodiment, the invention provides an
isolated PR0351 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
from about 16 to 571 of Figure 49 (SEQ ID N0:132). Optionally, the PR0351
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA40571-1315 vector deposited on
April 21, 1998 as ATCC 209784.
21. ~R0352
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to buryrophilin,
wherein the polypeptide is designated in the present application as "PR0352".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0352 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0352 polypeptide
having amino acid residues 1 to 316 of Figure 51 (SEQ ID N0:137), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0352 polypeptide having
amino acid residues of about 29 to 316 of Figure 51 (SEQ ID N0:137), or 1 or
about 29 to X of Figure 51, where
X is any amino acid from 246 to 255, or is complementary to such encoding
nucleic acid sequence, and remains
stably bour~ to it under at least moderate, and optionally, under high
stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of the DNA41386-1316 vector deposited on
March 26, 1998 as ATCC
209703 which includes the nucleotide sequence encoding PR0352.
In another embodiment, the invention provides isolated PR0352 polypeptide. In
particular, the invention
provides isolated native sequence PR0352 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 316 of Figure 51 (SEQ ID N0:137). In other
embodiments, the invention provides isolated
PR0352 polypcptide comprising residues about 29 to 316 of Figure 51 (SEQ ID
N0:137) and 1 or about 29 to X of
Figure 51 (SEQ ID N0:137), wherein X is any amino acid from 246 to 255.
Optionally, the PR0352 polypeptide
is obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the DNA41386-1316 vector
deposited on March 26, 1998 as ATCC 209703.
22. PR0381
Applicants have identified a cDNA clone that etxodes a novel polypeptide
having homology to immunophilin
proteins, wherein the polypeptide is designated in the present application as
"PR0381 ".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0381 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0381 polypeptide
having amino acid residues 1 to 211 of Figure 53 (SEQ ID N0:145), or is
complementary to such encoding nucleic
acid sequence, and remains stabty bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0381 polypeptide having
amino acid residues about 21 to 211 of Figure 53 (SEQ ID N0:145), or is
complementary to such encoding nucleic
CA 02421372 2003-03-25
WO 99/46281 PCTNS99/05028
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA44194-1317 vector
deposited on April 28, 1998 as ATCC 209808 which includes the nucleotide
sequence encoding PR0381.
In another embodiment, the invention provides isolated PR0381 polypeptide. In
particular, the invention
provides isolated native sequence PR0381 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 211 of Figure 53 (SEQ ID N0:145). Another embodiment
is directed to a PR0381
plypeptide comprising amino acids about 21 to 211 of Figure 53 (SEQ ID
N0:145). Optionally, the PR0381
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the DNA44194-
1317 vector deposited on April 28, 1998 as ATCC 209808.
23. PR0386
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to the beta-2
subunit of a sodium channel, wherein the polypeptide is designated in the
present application as "PR0386".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0386 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0386 polypeptide
having amino acid residues 1 to 215 of Figure 55 (SEQ ID N0:150), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0386 polypeptide having
amino acid residues about 21 to 215 of Figure 55 (SEQ ID N0:150) or 1 or about
21 to X, where X is any amino
acid from 156 to 165 of Figure 55 (SEQ ID N0:150), or is complementary to such
encoding nucleic acid sequence,
and remains stably bound to it under at least moderate, and optionally, under
high stringency conditions. The isolated
nucleic acid sequence may comprise the cDNA insert of the DNA45415-1318 vector
deposited on April 28, 1998 as
ATCC 209810 which includes the nucleotide sequence encoding PR0386.
In another embodiment, the invention provides isolated PR0386 polypeptide. In
particular, the invention
provides isolated native sequence PR0386 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 215 of Figure 55 (SEQ ID N0:150). Other embodiments
of the present invention are
directed to PR0386 polypeptides comprising amino acids about 21 to 215 of
Figure 55 (SEQ ID N0:150) and 1 or
about 21 to X of Figure 55 (SEQ ID N0:150), wherein X is any amino acid from
156 to 165 of Figure 55 (SEQ ID
N0:150). Optionally, the PR0386 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA45415-1318 vector deposited on April 28, 1998 as
ATCC 209810.
In another embodiment, the invention provides an expressed sequence tag (EST
comprising the nucleotide
sequence of SEQ 1D N0:151 which corrsponds to an EST designated herein as
DNA23350.
In another embodiment, the invention provides an expressed sequence tag (EST)
comprising the nucleotide
sequence of SEQ ID N0:152 which corrsponds to an EST designated herein as
DNA23536.
24. PR0540
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
LCAT, wherein the polypeptide is designated in the present application as
"PR0540" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0540 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0540 polypeptide
61
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
having amino acid residues 1 to 412 of Figure 59 (SEQ ID N0:157), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0540 polypeptide having
amino acid residues about 29 to 412 of Figure 59 (SEQ ID N0:157), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA44189-1322 vector
deposited on March 26, 1998 as ATCC 209699 which includes the nucleotide
sequence encoding PR0540.
In another embodiment, the invention provides isolated PR0540 polypeptide. In
particular, the invention
provides isolated native sequence PR0540 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 412 of Figure 59 (SEQ ID N0:157). The invention also
provides isolated PR0540
polypeptide, which in one embodiment, includes an amino acid sequence
comprising residues about 29 to 412 of
Figure 59 (SEQ ID N0:157). Optionally, the PR0540 polypeptide is obtained or
is obtainable by expressing the
polypeptide encoded by the cDNA insert of the DNA44189-1322 vector deposited
on March 26, 1998 as ATCC
209699.
25. PR0615
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
synaptogyrin, wherein the polypeptide is designated in the present application
as "PR0615".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0615 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0615 polypeptide
having amino acid residues I to 224 of Figure 61 (SEQ ID N0:162), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0615 polypeptide having
amino acid residues X to 224 of Figure 61 (SEQ ID N0:162), where X is any
amino acid from 157 to 166, or is
complementary to such encoding nucleic acid sequence, and remains stably bound
to it under at least moderate, and
optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of
the DNA48304-1323 vector deposited on April 28, 1998 as ATCC 20981 I which
includes the nucleotide sequence
encoding PR0615.
In another embodiment, the invention provides isolated PR0615 polypeptide. In
particular, the invention
provides isolated native sequence PR0615 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I to 224 of Figure 61 (SEQ ID N0:162). An additional
embodiment of the present invention
is directed to an isolated extracellular domain of a PR0615 polypeptide which
comprises amino acid residues X to
224 of Figure 61 (SEQ ID N0:162), where X is any amino acid from 157 to 166 of
Figure 61 (SEQ ID N0:162).
Optionally, the PR0615 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA48304-1323 vector deposited on April 28, 1998 as ATCC 209811.
26. PR0618
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
enteropeptidase, wherein the polypeptide is designated in the present
application as "PR0618".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
62
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
PR0618 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0618 polypeptide
having amino acid residues 1 to 802 of Figure 63 (SEQ ID N0:169), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding an isolated extracellular domain
of a PR0618 polypeptide having amino acid residues X to 802 of Figure 63 (SEQ
ID N0:169), where X is any amino
acid from 63 to 72 of Figure 63 (SEQ ID N0:169), or is complementary to such
encoding nucleic acid sequence, and
remains stably bound to it under at least moderate, and optionally, under high
stringency conditions. The isolated
nucleic acid sequence may comprise the cDNA insert of the DNA49152-1324 vector
deposited on April 28, 1998 as
ATCC 209813 which includes the nucleotide sequence encoding PR0618.
In another embodiment, the invention provides isolated PR0618 polypeptide. In
particular, the invention
provides isolated native sequence PR0618 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 802 of Figure 63 (SEQ ID N0:169). An additional
embodiment of the present invention
is directed to an isolated exuacellular domain of a PR0618 polypeptide
comprising amino acid X to 802 where X
is any amino acid from 63 to 72 of Figure 63 (SEQ ID N0:169). Optionally, the
PR0618 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the DNA49152-1324 vector deposited
on April 28, 1998 as ATCC 209813.
In another embodiment, the invention provides an expressed sequence tag (EST)
comprising the nucleotide
sequence of SEQ ID N0:170, designated herein as DNA3559? (see Figure 64).
27. PR0719
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to lipoprotein
lipase H, wherein the polypeptide is designated in the present application as
"PR0719".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0719 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0719 polypeptide
having amino acid residues 1 to 354 of Figure 66 (SEQ ID N0:178), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0719 polypeptide having
amino acid residues about 17 to 354 of Figure 66 (SEQ ID N0:178), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA49646-1327 vector
deposited on March 26, 1998 as ATCC 209705 which includes the nucleotide
sequence encoding PR0719.
In another embodiment, the invention provides isolated PR0719 polypeptide. In
particular, the invention
provides isolated native sequence PR0719 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 354 of Figure 66 (SEQ ID N0:178). In another
embodiment, the invention provides isolated
PR0719 polypeptide which comprises residues about 17 to 354 of Figure 66 (SEQ
ID N0:178). Optionally, the
PR0719 polypeptide is obtained or is obtainable by expressing the polypeptide
encoded by the cDNA insert of the
DNA49646-1327 vector deposited on March 26, 1998 as ATCC 209705.
63
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
28. PR0724
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to the LDL
receptor, wherein the polypeptide is designated in the present application as
"PR0724".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0724 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0724 polypeptide
having amino acid residues 1 to 713 of Figure 68 (SEQ ID N0:183), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding a soluble PR0724 polypeptide
having amino acid residues 1 to X of Figure 68 (SEQ ID N0:183) where X is any
amino acid from amino acid 437
to 446, or is complementary to such encoding nucleic acid sequence, and
remains stably bound to it under at least
moderate, and optionally, under high stringency conditions. The above two
polypeptides may either possess or not
possess the signal peptide. The isolated nucleic acid sequence may comprise
the cDNA insen of the DNA49631-1328
vector deposited on April 28, 1998 as ATCC 209806 which includes the
nucleotide sequence encoding PR0724.
In another embodiment, the invention provides isolated PR0724 polypeptide. In
particular, the invention
provides isolated native sequence PR0724 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I to 713 of Figure 68 (SEQ ID N0:183). In another
embodiment, the invention provides isolated
soluble PR0724 polypeptide. In particular, the invention provides isolated
soluble PR0724 polypeptide, which in
one embodiment, includes an amino acid sequence comprising residues 1 to X of
Figure 68 (SEQ ID N0:183), where
X is any amino acid from 437 to 446 of the sequence shown in Figure 68 (SEQ 1D
N0:183). Optionally, the PR0724
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the DNA49631-
1328 vector deposited on April 28, 1998 as ATCC 209806.
29. 772
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to A4 protein,
wherein the polypeptide is designated in the present application as "PR0772".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0772 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0772 polypeptide
having amino acid residues 1 to 152 of Figure 70 (SEQ ID N0:190), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0772 polypeptide having
amino acid residues 1 to X of Figure 70 (SEQ ID N0:190), where X is any amino
acid from 21 to 30 of Figure 70
(SEQ ID N0:190), or is complementary to such encoding nucleic acid sequence,
and remains stably bound to it under
at least moderate, and optionally, utter high stringency conditions. The
isolated nucleic acid sequence may comprise
the cDNA insert of the DNA49645-1347 vector deposited on April 28, 1998 as
ATCC 209809 which includes the
nucleotide sequence encoding PR0772.
In another embodiment, the invention provides isolated PR0772 polypeptide. In
particular, the invention
provides isolated native sequence PR0772 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 152 of Figure 70 (SEQ ID N0:190). Additional
embodiments of the present invention are
directed to PR0772 polypeptides comprising amino acids 1 to X of Figure 70
(SEQ ID N0:190), where X is any
amino acid from 21 to 30 of Figure 70 (SEQ ID N0:190). Optionally, the PR0772
polypeptide is obtained or is
64
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA49645-1347 vector deposited on
April 28, 1998 as ATCC 209809.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA43509 comprising the nucleotide sequence of SEQ ID N0:191 (Figure 71).
S 30. PR
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to various
protease enrymes, wherein the polypeptide is designated in the present
application as "PR0852".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0852 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0852 polypeptide
having amino acid residues 1 to 518 of Figure 73 (SEQ ID N0:196), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0852 polypeptide having
amino acid residues about 21 to 518 of Figure 73 (SEQ ID N0:196) or 1 or about
21 to X of Figure 73 (SEQ ID
N0:196) where X is any amino acid from amino acid 461 to amino acid 470 of
Figure 73 (SEQ ID N0:196), or is
complementary to such encoding nucleic acid sequence, and remains stably bound
to it under at least moderate, and
optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of
the DNA45493-1349 vector deposited on April 28, 1998 as ATCC 209805 which
includes the nucleotide sequence
encoding PR0852.
In another embodiment, the invention provides isolated PR0852 polypeptide. In
particular, the invention
provides isolated native sequence PR0852 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 518 of Figure 73 (SEQ ID N0:196). In other
embodiments, the PR0852 comprises amino
acids about 21 to amino acid 518 of Figure 73 (SEQ ID N0:196) or amino acids 1
or about 21 to X of Figure 73
(SEQ ID N0:196), where X is any amino acid from amino acid 461 to amino acid
470 of Figure 73 (SEQ ID
N0:196). Optionally, the PR0852 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA45493-1349 vector deposited on April 28, 1998 as
ATCC 209805.
31. PR0853
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
reductase, wherein the polypeptide is designated in the present application as
"PR0853".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0853 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0853 polypeptide
having amino acid residues 1 to 377 of Figure 75 (SEQ ID N0:206), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0853 polypeptide having
amino acid residues about 17 to 377 of Figure 75 (SEQ ID N0:206), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA48227-1350 vector
deposited on April 28, 1998 as ATCC 209812 which includes the nucleotide
sequence encoding PR0853.
In another embodiment, the invention provides isolated PR0853 polypeptide. In
particular, the invention
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
provides isolated native sequence PR0853 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 377 of Figure 75 (SEQ ID N0:206). In another
embodiment, the invention provides an
isolated PR0853 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
from about 17 to 377 of Figure 75 (SEQ ID N0:206). Optionally, the PR0853
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA48227-1350 vector deposited on
April 28, 1998 as ATCC 209812.
32. PR0860
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence simiiariry to
neurofascin, wherein the polypeptide is designated in the present application
as "PR0860".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0860 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0860 polypeptide
having amino acid residues 1 to 985 of Figure 77 (SEQ 1D N0:211), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0860 polypeptide having
amino acid residues 1 to X of Figure 77 (SEQ ID N0:211), where X is any amino
acid from 443-452 of Figure 77
(SEQ ID N0:211), or is complementary to such encoding nucleic acid sequence,
and remains stably bound to it under
at least moderate, and optionally, under high stringency conditions. The
isolated nucleic acid sequence may comprise
the cDNA insert of the DNA41404-1352 vector deposited on May 6, 1998 as ATCC
209844 which includes the
trucleotide sequence encoding PR0860.
In another embodiment, the invention provides isolated PR0860 polypeptide. In
particular, the invention
provides isolated native sequence PR0860 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 985 of Figure 77 (SEQ ID N0:211). In another
embodiment, the invention provides an
isolated PR0860 polypeptide which includes an amino acid sequence comprising
residues 1 to X of Figure 77 (SEQ
ID N0:211), where X is any amino acid residue from 443 to 452 of Figure 77
(SEQ ID N0:211). Optionally, the
PR0860 polypeptide is obtained or is obtainable by expressing the polypeptide
encoded by the cDNA insert of the
DNA41404-1352 vector deposited on May 6, 1998 as ATCC 209844.
33. PR0846
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
CMRF35, wherein the polypeptide is designated in the present application as
"PR0846".
In otte embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0846 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0846 polypeptide
having amino acid residues 1 to 332 of Figure 79 (SEQ ID N0:216), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, tinder high suingency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0846 polypeptide having
amino acid residues about 18 to 332 of Figure 79 (SEQ ID N0:216) or 1 or about
18 to X of SEQ ID N0:216, where
X is arty amino acid from 243 to 252 of Figure 79 (SEQ ID N0:216), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA44196-1353 vector
66
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
deposited on May 6, 1998 as ATCC 209847 which includes the nucleotide sequence
encoding PR0846.
In another embodiment, the invention provides isolated PR0846 polypeptide. In
particular, the invention
provides isolated native sequence PR0846 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 332 of Figure 79 (SEQ ID N0:2I6). In other
embodiments, the invention provides an
isolated PR0846 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
S from about 18 to 332 of Figure 79 (SEQ ID N0:216). Additional embodiments of
the present invention are directed
to an isolated PR0846 polypeptide comprising amino acid 1 or about 18 to X of
Figure 79 (SEQ ID N0:216), where
X is any amino acid from 243 to 252 of Figure 79 (SEQ ID N0:216). Optionally,
the PR0846 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the DNA44196-1353 vector
deposited on May 6, 1998 as ATCC 209847.
34. PRQ862
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
lysozyme, wherein the polypeptide is designated in the present application as
"PR0862".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0862 polypeptide. in one aspect, the isolated nucleic acid comprises DNA
encoding the PR0862 polypeptide
having amino acid residues 1 to 146 of Figure 81 (SEQ ID N0:221), or is
complementary to such encoding nucleic
acid sequence, and rennains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0862 polypeptide having
amino acid residues about 19 to 146 of Figure 81 (SEQ ID N0:221), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the eDNA insert of
the DNA52187-1354 vector
deposited on May 6, 1998 as ATCC 209845 which includes the nucleotide sequence
encoding PR0862.
In another embodiment, the invention provides isolated PR0862 polypeptide. In
particular, the invention
provides isolated native sequence PR0862 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 146 of Figure 81 (SEQ ID N0:221). In another
embodiment, the invention provides an
isolated PR0862 polype~de absent the signal sequence, which includes an amino
acid sequence comprising residues
from about 19 to 146 of Figure 81 (SEQ ID N0:221). Optionally, the PR0862
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA52187-1354 vector deposited on
May 6, 1998 as ATCC 209845.
35. PR0864
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence similarity to
Wnt~, wherein the polypeptide is designated in the present application as
"PR0864".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0864 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0864 polypeptide
having amino acid residues 1 to 351 of Figure 83 (SEQ ID N0:226), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. in another aspect, the isolated nucleic acid comprises DNA
encoding the PR0864 polypeptide having
amino acid residues about 23 to 351 of Figure 83 (SEQ ID N0:226). or is
complementary to such encoding nucleic
67
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA48328-1355 vector
deposited on May 6, 1998 as ATCC 209843 which includes the nucleotide sequence
encoding PR0864.
1n another embodiment, the invention provides isolated PR0864 polypeptide. In
particular, the invention
provides isolated native sequence PR0864 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 351 of Figure 83 (SEQ ID N0:226). in another
embodiment, the invention provides an
isolated PR0864 polypeptide absent the signal sequence, which includes an
amino acid sequence comprising residues
from about 23 to 351 of Figure 83 (SEQ ID N0:226). Optionally, the PR0864
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA48328-1355 vector deposited on
May 6, 1998 as ATCC 209843
36. PR0792
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to CD23,
wherein the polypeptide is designated in the present application as "PR0792" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0792 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0792 polypeptide
having amino acid residues 1 to 293 of Figure 85 (SEQ ID N0:231), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0792 polypeptide having
amino acid residues X to 293 of Figure 85 (SEQ ID N0:231) where X is any amino
acid from 50 to 59 of Figure 85
(SEQ m N0:231), or is complementary to such encoding nucleic acid sequence,
and remains stably bound to it under
at least moderate, and optionally, under high stringency conditions. The
isolated nucleic acid sequence may comprise
the cDNA insert of the DNA56352-1358 vector deposited on May 6, 1998 as ATCC
209846 which includes the
nucleotide sequence encoding PR0792.
In another embodiment, the invention provides isolated PR0792 polypeptide. In
particular, the invention
provides isolated native sequence PR0792 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 293 of Figure 85 (SEQ ID N0:231). An additional
embodiment of the present invention
is directed to PR0792 polypeptide comprising amino acids X to 293 of Figure 85
(SEQ ID N0:231), where X is any
amino acid from 50 to 59 of Figure 85 (SEQ ID N0:231). Optionally, the PR0792
polypeptide is obtained or is
obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA56352-1358 vector deposited on
May 6, 1998 as ATCC 209846.
37. PR0866
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to mindin and
spondin proteins, wherein the polypeptide is designated in the present
application as "PR0866" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0866 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0866 poiypeptide
having amino acid residues 1 to 331 of Figure 87 (SEQ ID N0:236), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the isolated nucleic acid comprises DNA
encoding the PR0866 polypeptide having
68
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
amino acid residues about 27 to 229 of Figure 87 (SEQ ID N0:236), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA539?I-1359 vector
deposited on April 7, 1998 as ATCC 209750 which includes the nucleotide
sequence encoding PR0866.
In another embodiment, the invention provides isolated PR0866 polypeptide. In
particular, the invention
provides isolated native sequence PR0866 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I to 331 of Figure 87 (SEQ ID N0:236). Another embodiment
of the present invention is
directed to PR0866 polypeptides comprising amino acids about 27 to 331 of
Figure 87 (SEQ ID N0:236).
Optionally, the PR0866 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA53971-1359 vector deposited on April 7, 1998 as ATCC 209750.
38. PR0871
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to CyP-60,
wherein the polypeptide is designated in the present application as "PR0871".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0871 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0871 polypeptide
having amino acid residues 1 to 472 of Figure 89 (SEQ ID N0:245), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0871 polypeptide having
amino acid residues about 22 to 472 of Figure 89 (SEQ ID N0:245), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA50919-1361 vector
deposited on May 6, 1998 as ATCC 209848 which includes the nucleotide sequence
encoding PR0871.
In another embodiment, the invention provides isolated PR0871 polypeptide. In
particular, the invention
provides isolated native sequence PR0871 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 472 of Figure 89 (SEQ ID N0:245). An additional
embodiment of the present invention
is directed to PR0871 polypeptides comprising amino acids about 22 to 472 of
Figure 89 (SEQ ID N0:245).
Optionally, the PR0871 polypeptide is obtained or is obtainable by expressing
the polypepcide encoded by the cDNA
insert of the DNA50919-1361 vector deposited on May 6, 1998 as ATCC 209848.
39. PR0873
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to
carboxylesterase, wherein the polypeptide is designated in the present
application as "PR0873".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0873 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0873 polypeptide
having amino acid residues 1 to 545 of Figure 91 (SEQ ID N0:254), or is
complementary co such encoding nucleic
acid sequence, and remains stably bound to it under at lease moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0873 polypeptide having
amino acid residues about 30 to about 545 of Figure 91 (SEQ ID N0:254), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
69
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA44179-1362 vector
deposited on May 6, 1998 as ATCC 209851 which includes the nucleotide sequence
encoding PR0873.
In another embodiment, the invention provides isolated PR0873 polypeptide. In
particular, the invention
provides isolated native sequence PR0873 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 545 of Figure 91 (SEQ ID N0:254). Additional
embodiments of the present invention are
directed to PR0873 polypeptides comprising amino acids about 30 to about 545
of Figure 91 (SEQ ID N0:254).
Optionally, the PR0873 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA44179-1362 vector deposited on May 6, 1998 as ATCC 209851.
40. PR0940
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to CD33 and
OB binding protein-2, wherein the polypeptide is designated in the present
application as "PR0940".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0940 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0940 polypeptide
having amino acid residues 1 to 544 of Figure 93 (SEQ ID N0:259), or is
complementary to such encoding nucleic
IS acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0940 polypeptide having
amino acid residues about 16 to 544 of Figure 93 (SEQ ID N0:259) or 1 or about
16 to X of Figure 93 (SEQ ID
N0:259), where X is any amino acid from 394 to 403 of Figure 93 (SEQ ID
N0:259), or is complementary to such
encoding nucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high
stringency conditions. The isolated nucleic acid sequence may comprise the
cDNA insert of the DNA54002-1367
vector deposited on April 7, 1998 as ATCC 209754 which includes the nucleotide
sequence encoding PR0940.
In another embodiment, the invention provides isolated PR0940 polypeptide. In
particular, the invention
provides isolated native sequence PR0940 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 544 of Figure 93 (SEQ ID N0:259). Other embodiments
of the present invention are
directed to PR0940 polypeptides comprising amino acids about 16 to 544 of
Figure 93 (SEQ ID N0:259) or 1 or
about 16 to X of Figure 93 (SEQ ID N0:259), where X is any amino acid from 394
to 403 of Figure 93 (SEQ ID
N0:259). Optionally, the PR0940 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA54002-1367 vector deposited on April 7, 1998 as
ATCC 209754.
41. PR0941
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to a cadherin
protein, wherein the polypeptide is designated in the present application as
"PR0941".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0941 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0941 polypeptide
having amid acid residues l to 772 of Figure 95 (SEQ ID N0:264), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0941 polypeptide having
amino acid residues about 22 to 772 of Figure 95 (SEQ ID N0:264) or 1 or about
22 to X of Figure 95 (SEQ ID
N0:264), where X is airy amino acid from 592 to 601 of Figure 95 (SEQ ID
N0:264), or is complementary to such
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
encoding nucleic acid sequence, and remains stably botmd to it under at least
moderate, and optionally, under high
stringency conditions. The isolated nucleic acid sequence may comprise the
cDNA insert of the DNA53906-1368
vector deposited on April 7, 1998 as ATCC 209747 which includes the nucleotide
sequence encoding PR0941.
In another embodiment, the invention provides isolated PR0941 polypeptide. In
particular, the invention
provides isolated native sequence PR0941 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 772 of Figure 95 (SEQ ID N0:264). Additional
embodiments of the present invention are
directed to PR0941 polypeptides which comprise amino acid about 21 to 772 of
Figure 95 (SEQ ID N0:264) or 1
or about 22 to X of Figure 95 (SEQ ID N0:264), where X is any amino acid from
592 to 601 of Figure 95 (SEQ ID
N0:264). Optionally, the PR0941 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA53906-1368 vector deposited on April 7, 1998 as
ATCC 209747.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA6415 comprising the nucleotide sequence of Figure 96 (SEQ ID N0:265).
42. PR0944
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to Clostridium
perfringens enterotoxin receptor (CPE-R), wherein the polypeptide is
designated in the present application as
"PR0944".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0944 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0944 polypeptide
having anW o acid residues 1 to 211 of Figure 98 (SEQ 1D N0:270), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0944 polypeptide having
amino acid residues about 22 to 229 of Figure 98 (SEQ ID N0:270) or amino acid
1 or about 22 to X of Figure 98
(SEQ ID N0:270) where X is any amino acid from 77 to 80 of Figure 98 (SEQ ID
N0:270), or is complementary
to such etxoding nucleic acid sequence, and remains stably bound to it under
at least moderate, and optionally, under
high stringency conditions. The isolated nucleic acid sequence may comprise
the cDNA insert of the DNA52185-
1370 vector deposited on May 14, 1998 as ATCC 209861 which includes the
nucleotide sequence encoding PR0944.
In another embodiment, the invention provides isolated PR0944 polypeptide. In
particular, the invention
provides isolated native sequence PR0944 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 211 of Figure 98 (SEQ ID N0:270). Additional
embodiments of the present invention are
directed to PR0944 polypeptides comprising amino acids about 22 to 211 of
Figure 98 (SEQ ID N0:270) or amino
acid 1 or about 22 to X of Figure 98 (SEQ >D N0:270), where X is any amino
acid from 77 to 86 of Figure 98 (SEQ
>D N0:270). Optionally, the PR0944 polypeptide is obtained or is obtainable by
expressing the polypeptide encoded
by the cDNA insert of the DNA52185-1370 vector deposited on May 14, 1998 as
ATCC 209861.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA14007 comprising the nucleotide sequence of Figure 99 (SEQ ID N0:271).
In another embodiment, the invention provides an expressed sequence tag (FST)
designated herein as
DNA12733 comprising the nucleotide sequence of Figure 100 (SEQ ID N0:272).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA12746 comprising the nucleotide sequence of Figure 101 (SEQ ID N0:273).
71
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA12834 comprising the nucleotide sequence of Figure 102 (SEQ ID N0:274).
1n another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA12846 comprising the nucleotide sequence of Fiugure 103 (SEQ ID N0:275).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13104 comprising the nucleotide sequence of Figure 104 (SEQ ID N0:276).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13259 comprising the nucleotide sequence of Figure 105 (SEQ ID N0:277).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13959 comprising the nucleotide sequence of Figure 106 (SEQ ID N0:278).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13961 comprising the nucleotide sequence of Figure 107 (SEQ ID N0:279).
43. PR0983
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to a vesicle
associated protein, VAP-33, wherein the polypeptide is designated in the
present application as "PR0983".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0983 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0983 polypeptide
having amino acid residues 1 to 243 of Figure 109 (SEQ ID N0:284), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0983 polypeptide having
amino acid residue 1 to X of Figure 109 (SEQ 1D N0:284) where X is any amino
acid from 219 to 228 of Figure
109 (SEQ ID N0:284), or is complementary to such encoding nucleic acid
sequence, and remains stably bound to
it under at least moderate, and optionally, under high stringency conditions.
The isolated nucleic acid sequence may
comprise the cDNA insert of the DNA53977-1371 vector deposited on May 14, 1998
as ATCC 209862 which
includes the nucleotide sequence encoding PR0983.
In another embodiment, the invention provides isolated PR0983 polypeptide. In
particular, the invention
provides isolated native sequence PR0983 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 243 of Figure 109 (SEQ ID N0:284). Additionai
embodiments of the present invention are
directed to PR0983 poiypeptides comprising amino acid 1 to X of Figure 109
(SEQ ID N0:284), where X is any
amino acid from 219 to 228 of Figure 109 (SEQ ID N0:284). Optionally, the
PR0983 polypeptide is obtained or
is obtainable by expressing the polypeptide encoded by the cDNA insert of the
DNA53977-1371 vector deposited on
May 14, 1998 as ATCC 209862.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA17130 comprising the nucleotide sequence of Figure 110 (SEQ ID N0:285).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA23466 comprising the nucleotide sequence of Figure 111 (SEQ ID N0:286).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA26818 comprising the nucleotide sequence of Figure 112 (SEQ ID N0:287).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
72
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
DNA37618 comprising the nucleotide sequence of Figure 113 (SEQ ID N0:288).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA41732 comprising the nucleotide sequence of Figure 114 (SEQ ID N0:289).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA45980 comprising the nucleotide sequence of Figure 115 (SEQ ID N0:290).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA46372 comprising the nucleotide sequence of Figure 116 (SEQ ID N0:291).
44. RP 01057
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to proteases,
wherein the polypeptide is designated in the present application as "PR01057".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01057 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01057 polypeptide
having amino acid residues 1 to 413 of Figure 118 (SEQ ID N0:296), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR01057 polypeptide having
amino acid residues about 17 to 413 of Figure 118 (SEQ ID N0:296), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA57253-1382 vector
deposited on May 14, 1998 as ATCC 209867 which includes the nucleotide
sequence encoding PR01057.
In another embodiment, the invention provides isolated PR01057 polypeptide. In
particular, the invention
provides isolated native sequence PR01057 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 to 413 of Figure 118 (SEQ 1D N0:296). Additional
embodiments of the present invention are
directed to PR01057 polypeptides comprising amino acids about 17 to 413 of
Figure 118 (SEQ ID N0:296).
Optionally, the PR01057 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA57253-1382 vector deposited on May 14, 1998 as ATCC 209867.
45. PR01071
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to
thrombospondin, wherein the polypeptide is designated in the present
application as "PR01071".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01071 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01071 polypeptide
having amino acid residues 1 to 525 of Figure 120 (SEQ ID N0:301), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR01071 polypeptide having
amino acid residues about 26 to 525 of Figure 120 (SEQ ID N0:301), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence rnay comprise the cDNA insert
of the DNA58847-1383 vector
deposited on May 20, 1998 as ATCC 209879 which includes the nucleotide
sequence encoding PR01071.
In another embodiment, the invention provides isolated PR01071 polypeptide. In
particular, the invention
73
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
provides isolated native sequence PR01071 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 to 525 of Figure 120 (SEQ ID N0:301). Additional
embodiments of the present invention are
directed to PR01071 polypeptides comprising amino acids about 26 to 525 of
Figure 120 (SEQ ID N0:301).
Optionally, the PR01071 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA58847-1383 vector deposited on May 20, 1998 as ATCC 209879.
46. PR01072
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to reductase
proteins, wherein the polypeptide is designated in the present application as
"PR01072".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01072 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01072 polypeptide
having amino acid residues 1 to 336 of Figure 122 (SEQ ID N0:303), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR01072 polypeptide having
amino acid residues about 22 to 336 of Figure 122 (SEQ ID N0:303), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA58747-1384 vector
deposited on May 14, 1998 as ATCC 209868 which includes the nucleotide
sequence encoding PR01072.
In another embodiment, the invention provides isolated PRO10?2 polypeptide. In
particular, the invention
provides isolated native sequetxe PR01072 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 to 336 of Figure 122 (SEQ ID N0:303). Additional
embodiments of the present invention are
directed to PR01072 polypeptides comprising amino acids about 22 to 336 of
Figure 122 (SEQ ID N0:303).
Optionally, the PR01072 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA58747-1384 vector deposited on May 14, 1998 as ATCC 209868.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA40210 comprising the nucleotide sequence of Figure 123 (SEQ 1D N0:304).
47. PR01075
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to protein
disulfide isomerase, wherein the polypeptide is designated in the present
application as "PR01075".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01075 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01075 polypeptide
having amino acid residues 1 to 406 of Figure 125 (SEQ 1D N0:309), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, tinder high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR01075 polypeptide having
amino acid residues about 30 to 406 of Figure 125 (SEQ ID N0:309), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the eDNA insert of
the DNA57689-1385 vector
deposited on May 14, 1998 as ATCC 209869 which includes the nucleotide
sequence encoding PR01075.
In another embodiment, the invention provides isolated PR01075 polypeptide. In
particular, the invention
74
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
provides isolated native sequence PR01075 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 to 406 of Figure 125 (SEQ ID N0:309). Additional
embodiments of the present invention are
directed to PR01075 polypeptides comprising amino acids about 30 to 406 of
Figure 125 (SEQ ID N0:309).
Optionally, the PR01075 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA57689-1385 vector deposited on May 14, 1998 as ATCC 209869.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNAi3059 comprising the nucleotide sequence of Figure 126 (SEQ ID N0:310).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA19463 comprising the nucleotide sequence of Figure 127 (SEQ ID N0:311).
48. PRO181
Applicants have identified a cDNA clone that etxodes a novel polypeptide
having homology to the comichon
protein, wherein the polypeptide is designated in the present application as
"PR0181".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0181 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0181 polypeptide
IS having amino acid residues 1 to 144 of Figure 129 (SEQ ID N0:322), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PRO181 polypeptide having
amino acid residues about 21 to 144 of Figure 129 (SEQ ID N0:322) or amino
acid I or about 21 to X of Figure 129
(SEQ ID N0:322) where X is any amino acid from 52 to 61 of Figure 129 (SEQ ID
N0:322), or is complementary
to such encoding nucleic acid sequence, and remains stably bound to it under
at least moderate, and optionally, under
high stringency conditions. The isolated nucleic acid sequence may comprise
the cDNA insert of the DNA23330-
1390 vector deposited on April 14, 1998 as ATCC 209775 which includes the
nucleotide sequence encoding PR0181.
In another embodiment, the invention provides isolated PR0181 polypeptide. In
particular, the invention
provides isolated native sequence PR0181 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 144 of Figure 129 (SEQ ID N0:322). Additional
embodiments of the present invention are
directed to PR0181 polypeptides comprising amino acids about 21 to 144 of
Figure 129 (SEQ ID N0:322) or amino
acid I or about 21 to X of Figure 129 (SEQ ID N0:322), where X is any amino
acid froth 52 to 61 of Figure 129
(SEQ ID N0:322). Optionally, the PR0181 polypeptide is obtained or is
obtainable by expressing the polypeptide
encoded by the cDNA insert of the DNA23330-1390 vector deposited on April 14,
1998 as ATCC 209775.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA13242 comprising the nucleotide sequence of Figure 130 (SEQ ID N0:323).
49. PR0195
Applicants have identified a cDNA clone that encodes a novel transmembrane
polypeptide, wherein the
polypeptide is designated in the present application as "PR0195".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0195 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0195 polypeptide
having amino acid residues 1 to 323 of Figure 132 (SEQ ID N0:330), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0195 polypeptide having
amino acid residues about 32 to 323 of Figure 132 (SEQ ID N0:330) or amino
acid 1 or about 32 to X of Figure 132
(SEQ ID N0:330) where X is any amino acid from 236 to 245 of Figure 132 (SEQ
ID N0:330), or is complementary
to such encoding nucleic acid sequence, and remains stably bound to it under
at least moderate, and optionally, under
high stringency conditions. The isolated nucleic acid sequence may comprise
the cDNA insert of the DNA26847-
1395 vector deposited on April 14, 1998 as ATCC 209772 which includes the
nucleotide sequence encoding PR0195
In another embodiment, the invention provides isolated PR0195 polypeptide. In
particular, the invention
provides isolated native sequence PR0195 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 323 of Figure 132 (SEQ ID N0:330). Additional
embodiments of the present invention are
directed to PR0195 polypeptides comprising amino acids about 32 to 323 of
Figure 132 (SEQ ID N0:330) or amino
acid 1 or about 32 to X of Figure 132 (SEQ ID N0:330), where X is any amino
acid from 236 to 245 of Figure 132
(SEQ 1D N0:330). Optionally, the PR0195 polypeptide is obtained or is
obtainable by expressing the polypeptide
encoded by the cDNA insert of the DNA26847-1395 vector deposited on April 14,
1998 as ATCC 209772.
In another embodiment, the invention provides an expressed sequence tag (EST)
comprising the nucleotide
sequence of Figure 133 (SEQ ID N0:331), herein designated DNA15062.
In another embodiment, the invention provides an expressed sequence tag (EST)
comprising the nucleotide
sequence of Figure 134 (SEQ ID N0:332), herein designated DNA13199.
50. 80865
Applicants have identified a cDNA clone that encodes a novel secreted
polypeptide, wherein the polypeptide
is designated in the present application as "P80865".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0865 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0865 polypeptide
having amino acid residues 1 to 468 of Figure 136 (SEQ ID N0:337), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0865 polypeptide having
amino acid residues about 24 to 229 of Figure 136 (SEQ ID N0:337), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA53974-1401 vector
deposited on April 14, 1998 as ATCC 209774 which includes the nucleotide
sequence encoding PR0865.
In another embodiment, the invention provides isolated PR0865 polypeptide. In
particular, the invention
provides isolated native sequence PR0865 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 468 of Figure 136 (SEQ ID N0:337). An additional
embodiment of the present invention
is directed to a PR0865 polypeptide comprising amino acids about 24 to 468 of
Figure 136 (SEQ ID N0:337).
Optionally, the PR0865 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA53974-1401 vector deposited on April 14, 1998 as ATCC 209774.
In another embodiment, the invention provides an expressed sequence tag (EST)
comprising the nucleotide
sequence of Figure 137 (SEQ ID N0:338), herein designated as DNA37642.
76
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
51. PRQ82?
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to integrin
proteins, wherein the polypeptide is designated in the present application as
"PR0827".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0827 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0827 polypeptide
having amino acid residues 1 to 124 of Figure 139 (SEQ ID N0:346), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects. the isolated nucleic acid comprises DNA encoding
the PR0827 polypeptide having
amino acid residues about 23 to 124 of Figure 139 (SEQ ID N0:346), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the eDNA insert of
the DNA57039-1402 vector
deposited on April 14, 1998 as ATCC 209777 which includes the nucleotide
sequence encoding PR0827.
In another embodiment, the invention provides isolated PR0827 polypeptide. In
particular, the invention
provides isolated native sequence PR0827 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 124 of Figure 139 (SEQ ID N0:346). An additional
embodiment of the present invention
is directed to a PR0827 polypeptide comprising amino acids about 23 to 124 of
Figure 139 (SEQ ID N0:346).
Optionally, the PR0827 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA57039-1402 vector deposited on April 14, 1998 as ATCC 209777.
52. PR01114
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to cytokirte
receptor family-4 proteins, wherein the polypeptide is designated in the
present application as "PR01114".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PRO11I4 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01114 polypeptide
having amino acid residues 1 to 311 of Figure 142 (SEQ ID N0:3S2), or is
complementary to such encoding nucleic
2S acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR01114 polypeptide having
amino acid residues about 30 to 311 of Figure 142 (SEQ ID N0:352) or amino
acid l or about 30 to X of Figure 142
(SEQ ID N0:352), where X is any amino acid from 225 to 234 of Figure 142 (SEQ
ID N0:352), or is
complemet>tary w such encoding nucleic acid sequence, and remains stably bound
to it under at least moderate, and
optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of
the DNA57033-1403 vector deposited on May 27, 1998 as ATCC 209905 which
includes the nucleotide sequence
encoding PR01114.
In another embodiment, the invention provides isolated PR01114 polypeptide. In
particular, the invention
provides isolated native sequerrx PROs I 14 polypeptide, which in one
embodiment, includes an amino acid sequence
3S comprising residues I to 31 I of Figure 142 (SEQ 1D N0:352). Additional
embodiments of the present invention are
directed to PR01114 polypeptides comprising amino acids about 30 to 311 of
Figure 142 (SEQ ID N0:352) or amino
acid 1 or about 30 to X of Figure 142 (SEQ ID N0:352), where X is any amino
acid from 225 to 234 of Figure 142
(SEQ ID N0:352). Optionally, the PR01114 polypeptide is obtained or is
obtainable by expressing the polypeptide
encoded by the cDNA insert of the DNA57033-1403 vector deposited on May 2?,
1998 as ATCC 209905.
77
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA48466 comprising the nucleotide sequence of Figure 143 (SEQ ID N0:353).
A cDNA clone (DNA57033-1403) has been identified that encodes a novel
interferon receptor polypeptide,
designated in the present application as "PR01114 interferon receptor".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01114 interferon receptor polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about
809b sequence identity,
preferably at least about 85% sequence identity, more preferably at least
about 90% sequence identity, most
preferably at least about 95 % sequence identity to (a) a DNA molecule
encoding a PR01114 interferon receptor
polypeptide having the sequence of amino acid residues from about 1 or about
30 to about 311, inclusive of Figure
142 (SEQ ID N0:352), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule
encoding a PR01114 interferon
re<xptor polypeptide comprising DNA hybridizing to the complement of the
nucleic acid between about nucleotides
250 or about 337 and about I 182, inclusive, of Figure 141 (SEQ 117 N0:351).
Preferably, hybridization occurs under
stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule
comprising DNA having at least
about 80% sequence identity, preferably at least about 85% sequence identity,
more preferably at least about 90%
sequence identity, most preferably at least about 95 ~ sequence identity to
(a) a DNA molecule encoding the same
mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.
209905 (DNA57033-1403) or (b)
the complement of the nucleic acid molecule of (a). In a preferred embodiment,
the nucleic acid comprises a DNA
encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 209905
(DNA57033-1403).
In still a further aspect, the invention concerns an isolated nucleic acid
molecule comprising (a) DNA
e>xoding a polypeptide having at least about 80% sequence identity, preferably
at least about 8596 sequence identity,
more preferably at least about 90% sequence identity, most preferably at least
about 95% sequence identity to the
sequence of amino acid residues 1 or about 30 to about 311, inclusive of
Figure 142 (SEQ ID N0:352), or (b) the
complement of the DNA of (a).
In a fitnher aspect, the invention concerns an isolated nucleic acid molecule
having at least 10 nucleotides
and produced by hybridizing a test DNA molecule under stringent conditions
with (a) a DNA molecule encoding a
PR01114 interferon receptor polypeptide having the sequence of ammo acid
residues from 1 or about 30 to about
311, inchtsive of Figure 142 (SEQ ID N0:352), or (b) the complement of the DNA
molecule of (a), and, if the DNA
molecule has at least about an 80 % sequence identity, prefereably at least
about an 85 % sequence identity, more
preferably at least about a 9096 sequence identity, most preferably at least
about a 9596 sequence identity to (a) or
(b), isolating the test DNA molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01114 interferon receptor polypeptide, with or without the N-terminal signal
sequence and/or the initiating
methia~ine, and its sohtble, i.e.. transmeznbra~ domain deleted or inactivated
variants, or is complementary to such
encoding nucleic acid molecule. The signal peptide has been tentatively
identified as extending from about amino
acid position I to about amino acid position 29 in the sequence of Figure 142
(SEQ ID N0:352). The transmembrane
domain has been tentatively identified as extending from about amino acid
position 230 to about amino acid position
78
CA 02421372 2003-03-25
h
WO 99/46281 PCT/US99/05028
255 in the PR01114 interferon receptor amino acid sequence (Figure 142, SEQ ID
N0:352).
In another aspect, the invention concerns an isolated nucleic acid molecule
comprising (a) DNA encoding
a polypeptide scoring at least about 80% positives, preferably at least about
85% positives, more preferably at least
about 90% positives, most preferably at least about 95 % positives when
compared with the amino acid sequence of
residues 1 or about 30 to about 311, inclusive of Figure 142 (SEQ ID N0:352),
or (b) the complement of the DNA
of (a).
Another embodiment is directed to fragmezns of a PR01114 interferon receptor
polypeptide coding sequence
that may find use as hybridization probes. Such nucleic acid fragments are
from about 20 to about 80 nucleotides
in length, preferably from about 20 to about 60 nucleotides in length, more
preferably from about 20 to about 50
nucleotides in length and most preferably from about 20 to about 40
nucleotides in length and may be derived from
the nucleotide sequence shown in Figure 141 (SEQ ID N0:351).
In another embodiment, the invention provides a vector comprising DNA encoding
PROI114 interferon
receptor or its variants. The vector may comprise any of the isolated nucleic
acid molecules hereinabove identified.
A host cell comprising such a vector is also provided. By way of example, the
host cells may be CHO cells,
E. coli, or yeast. A process for producing PR01114 interferon receptor
polypeptides is further provided and
comprises culturing host cells under conditions suitable for expression of
PR01114 interferon receptor and recovering
PR01114 interferon receptor from the cell culture.
In another embodiment, the invention provides isolated PR01114 interferon
receptor polypeptide encoded
by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR01114
interferon receptor
polypeptide, which in certain embodiments, includes an amino acid sequence
comprising residues 1 or about 30 to
about 311 of Figure 142 (SEQ ID N0:352).
In another aspect, the invention concerns an isolated PR01114 interferon
receptor polypeptide, comprising
an amino acid sequence having at least about 80% sequence identity, preferably
at least about 85 % sequence identity,
more preferably at least about 90% sequence identity, most preferably at least
about 9596 sequence identity to the
sequence of amino acid residues 1 or about 30 to about 311, inclusive of
Figure 142 (SEQ ID N0:352).
In a further aspect, the inve>mon coixxtns an isolated PR01114 interferon
receptor polypeptide, comprising
an amino acid sequence scoring at least about 80% positives, preferably at
least about 85 % positives, more preferably
at least about 90 ~ positives, most preferably at least about 95 % positives
when compared with the amino acid
sequence of residues 1 or about 30 to about 3I 1, inclusive of Figure 142 (SEQ
ID N0:352).
In yet another aspect, the invention concerns an isolated PR01114 interferon
receptor polypeptide,
comprising the sequence of amino acid residues 1 or about 30 to about 311,
inehtsive of Figure 142 (SEQ ID
N0:352), or a fragment thereof sufficient to provide a binding site for an
anti-PROI 114 interferon receptor antibody.
Preferably, the PR01114 interferon receptor fragment retains a qualitative
biological activity of a native PR01114
inurferon receptor polypeptide.
In a still further aspect, the invention provides a polypeptide produced by
(i) hybridizing a test DNA
t~lecule under stringent conditions with (a) a DNA molecule encoding a PR01114
interferon receptor polypeptide
having the sequence of amino acid residues from about I or about 30 to about
311, inclusive of Figure 142 (SEQ ID
N0:352), or (b) the complement of the DNA molecule of (a), and if the test DNA
molecule has at least about an 80?6
sequence identity, preferably at least about an 85 % sequence identity, more
preferably at least about a 90~fo sequence
79
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
identity, most preferably at least about a 95 % sequence identity to (a) or
(b), (ii) culturing a host cell comprising the
test DNA molecule under conditions suitable for expression of the polypeptide,
and (iii) recovering the polypeptide
from the cell culture.
In another embodiment, the invention provides chimeric molecules comprising a
PRO11I4 interferon
receptor polypeptide fused to a heterologous polypeptide or amino acid
sequence. An example of such a chimeric
molecule comprises a PR01114 interferon receptor polypeptide fused to an
epitope tag sequence or a Fc region of
an immunoglobulin.
In another emboditt~nt. the invention provides an antibody which specifically
binds to a PROl 114 interferon
receptor polypeptide. Optionally, the antibody is a monoclonal antibody.
In yet another embodiment, the invention concerns agonists and antagonists of
a native PR01114 interferon
receptor polypeptide. In a particular embodiment, the agonist or antagonist is
an anti-PR01114 interferon receptor
antibody.
In a further embodiment, the invention concerns a method of identifying
agonists or antagonists of a native
PR01114 interferon receptor polypeptide by contacting the native PR01114
interferon receptor polypeptide with a
candidate molecule and monitoring a biological activity mediated by said
polypeptide.
In a still further embodiment, the invention concerns a composition comprising
a PROI114 interferon
receptor polypeptide, or an agonist or antagonist as hereinabove defined, in
combination with a pharmaceutically
acceptable carrier.
53. R 7
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to carbonic
anhydrase, wherein the polypeptide is designated in the present application as
"PR0237".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0237 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0237 polypeptide
having amino acid residues I to 328 of Figure 145 (SEQ ID N0:358), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0237 polypeptide having
amino acid residues about 24 to 328 of Figure 145 (SEQ ID N0:358) or amino
acid 1 or about 24 to X of Figure 145
(SEQ ID N0:358), where X is any amino acid from 172 to 181 of Figure 145 (SEQ
ID N0:358), or is
complementary to such encoding nucleic acid sequence, and remains stably bound
to it under at feast moderate, and
optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of
the DNA34353-1428 vector deposited on May 12, 1998 as ATCC 209855 which
includes the nucleotide sequence
encoding PR0237.
In another embodiment, the invention provides isolated PR0237 polypeptide. In
particular, the invention
provides isolated native sequence PR0237 polypeptide, which in one embodiment,
includes an amino acid sequence
cott~rising residues 1 to 328 of Figure 145 (SEQ ID N0:358). Additional
embodiments of the present invention are
directed to PR0237 polypeptides comprising amino acids about 24 to 328 of
Figure 145 (SEQ ID N0:358) or amino
acid 1 or about 24 to X of Figure 145 (SEQ ID N0:358), where X is any amino
acid from 172 to 181 of Figure 145
(SEQ 1D N0:358). Optionally, the PR0237 polypeptide is obtained or is
obtainable by expressing the polypeptide
encoded by the cDNA insert of the DNA34353-1428 vector deposited on May 12,
1998 as ATCC 209855.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
54. PR 41
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to a trypsin
inhibitor protein, wherein the polypeptide is designated in the present
application as "PR0541 ".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0541 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0541 polypeptide
having amino acid residues 1 to 500 of Figure 147 (SEQ ID N0:363), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0541 polypeptide having
amino acid residues about 21 to 500 of Figure 147 (SEQ ID N0:363), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the DNA45417-1432 vector
deposited on May 2?, 1998 as ATCC 209910 which includes the nucleotide
sequence encoding PR0541.
In another embodiment, the invention provides isolated PR0541 polypeptide. In
particular, the invention
provides isolated native sequence PR0541 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 500 of Figure 147 (SEQ ID N0:363). Additional
embodiments of the present invention are
directed to PR0541 polypeptides comprising amino acids about 21 to 500 of
Figure 147 (SEQ ID N0:363).
Optionally, the PR0541 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the DNA45417-1432 vector deposited on May 27, 1998 as ATCC 209910.
55. PR0273
Applicants have identified a cDNA clone that encodes a novel polypeptide,
wherein the polypeptide is
designated in the present application as "PR0273".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0273 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0273 polypeptide
having amino acid residues 1 through 111 of Figure 149 (SEQ ID N0:370), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions.
In another embodiment, the invention provides isolated PR0273 polypeptide. In
particular, the invention
provides isolated native sequence PR0273 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues l through 111 of.Figure 149 (SEQ ID N0:3?0).
56. PR0701
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to neuroligins
1, 2, and 3, wherein the polypeptide is designated in the present application
as "PR0701".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0701 polypepade. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0701 polypeptide
having amino acid residues 1 through 816 of Figure 151 (SEQ ID N0:375), or is
complementary to such encoding
rntcleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited with the ATCC
on March 31, 1998 which includes the nucleotide sequence encoding PR0701.
81
CA 02421372 2003-03-25
WO 99/46281 PCTIUS99/05028
In another embodiment, the invention provides isoiated PR0701 polypeptide. In
particular, the invention
provides isolated native sequence PR0701 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 816 of Figure 151 (SEQ ID N0:375). An additional
embodiment of the present
invention is directed to an isolated extracellular domain of a PR0701
polypeptide. Optionally, the PR0701
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited with the ATCC on March 31, 1998.
57. PR0704
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
VIP36, wherein the polypeptide is designated in the present application as
"PR0704".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0704 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0704 polypeptide
having amino acid residues 1 through 348 of Figure 153 (SEQ ID N0:380), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 31,
1998 with the ATCC as DNA50911-1288, which includes the nucleotide sequence
encoding PR0704.
In another embodiment, the invention provides isolated PR0704 polypeptide. In
particular, the invention
provides isolated native sequence PR0704 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 348 of Figure 153 (SEQ ID N0:380). An additional
embodiment of the present
invention is directed to an isolated extracellular domain of a PR0704
polypeptide. Optionally, the PR0704
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on March 31, 1998 with the ATCC as DNA50911-1288.
58. P 7 6
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to prostatic acid
phosphatase precursor and lysosomal acid phosphatase precursor, wherein the
polypeptide is designated in the present
application as "PR0706" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0706 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0706 polypeptide
having amino acid residues 1 through 480 of Figure 155 (SEQ ID N0:385), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on April 21,
1998 with the ATCC as DNA48329-1290 which includes the nucleotide sequence
encoding PR0706.
In another embodiment, the invention provides isolated PR0706 polypeptide. In
particular, the invention
provides isolated native sequence PR0706 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 480 of Figure 155 (SEQ 1D N0:385), or comprising
residues 19 through 480 of Figure
155 (SEQ ID N0:385). Optionally, the PR0706 polypeptide is obtained or is
obtainable by expressing the
polypeptide encoded by the cDNA insert of the vector deposited on April 21,
1998 with the ATCC as DNA48329-
1290.
82
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
59. R0 07
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to cadherins,
particularly cadherin FIB3, wherein the polypeptide is designated in the
present application as "PR0707".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0707 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0707 polypeptide
having amino acid residues 1 to 916 of Figure 157 (SEQ ID N0:390), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 27,
1998 with the ATCC as DNA48306-1291 which includes the nucleotide sequence
encoding PR0707.
In another embodiment, the invention provides isolated PR0707 polypeptide. In
particular, the invention
provides isolated native sequence PR0707 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 916 of Figure 157 (SEQ ID N0:390). An additional
embodiment of the present invention
is directed to an isolated extracellular domain of a PR0707 polypeptide.
Optionally, the PR0707 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
27,.1998 with the ATCC as DNA48306-1291.
60. PR0322
Applicants have identified a cDNA clone that encodes a novel polypeptide
having homology to neuropsin,
wherein the polypeptide is designated in the present application as "PR0322".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0322 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0322 polypeptide
having amino acid residues 1 or 24 through 260 of Figure 159 (SEQ ID N0:395),
or is complementary to such
encoding nucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high
stringency conditions. The isolated nucleic acid sequence may comprise the
cDNA insert of the vector deposited on
March 11, 1998 as ATCC no. 209669 which includes the nucleotidc sequence
encoding PR0322.
In another embodiment, the invention provides isolated PR0322 polypeptide. In
particular, the invention
provides isolated native sequence PR0322 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 or 24 through 260 of Figure 159 (SEQ ID N0:395). An
additional embodiment of the present
invention is directed to an isolated extracellular domain of a PR0322
polypeptide. Optionally, the PR0322
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on March 11, 1998 as ATCC no. 209669.
61. PR0526
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
ALS, wherein the polypeptide is designated in the present application as
"PR0526".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0526 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0526 polypeptide
having amino acid residues 1 to 473 of Figure 161 (SEQ ID N0:400), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 26,
83
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
1998 with the ATCC as DNA44184-1319 which includes the nucleotide sequence
encoding PR0526.
In another embodiment, the invention provides isolated PR0526 polypeptide. In
particular, the invention
provides isolated native sequence PR0526 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 473 of Figure 161 (SEQ ID N0:400). Optionally, the
PR0526 polypeptide is obtained or
is obtainable by expressing the polypeptide encoded by the cDNA insert of the
vector deposited on March 26, 1998
with the ATCC as DNA44184-1319 which includes the nucleotide sequencc encoding
PR0526.
62. R 1
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
protocadherins, wherein the polypeptide is designated in the present
application as "PR0531".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0531 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0531 polypeptide
having amino acid residues 1 to 789 of Figure 163 (SEQ ID N0:405), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 26,
1998 as DNA48314-1320 which includes the nucleotide sequence encoding PR0531.
In another embodiment, the invention provides isolated PR0531 polypeptide. In
particular, the invention
provides isolated native sequence PR0531 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 789 of Figure 163 (SEQ ID N0:405). An additional
embodiment of the present invention
is directed to an isolated extracellular domain of a PR0531 polypeptide.
Optionally, the PR0531 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on March
26, 1998 as DNA48314-1320.
63. PR0534
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
disulfide isomerase (sometimes referred to herein as protein disulfide
isomerase), wherein the polypeptide is
designated in the present application as "PR0534".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0534 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0534 polypeptide
having amino acid residues 1 to 360 of Figure 165 (SEQ ID N0:410), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on March 26,
1998 as DNA48333-1321 which includes the nucleotide sequence encoding PR0534.
In another embodiment, the invention provides isolated PR0534 polypeptide. In
particular, the invention
provides isolated native sequence PR0534 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 360 of Figure 165 (SEQ ID N0:410). An additional
embodiment of the present invention
is directed to an isolated extracellular domain of a PR0534 polypeptide.
Optionally, the PR0534 polypeptide is
obtained or is obtai~ble by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on March
26, 1998 as DNA48333-1321.
84
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
64. PR0697
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
sFRPs, wherein the polypeptide is designated in the present application as
"PR0697".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0697 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0697 polypeptide
having amino acid residues 1 through 295 of Figure 167 (SEQ 1D N0:415), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited with the ATCC
on March 26, 1998 as DNA50920-1325 which includes the nucleotide sequence
encoding PR0697.
In another embodiment, the invention provides isolated PR0697 polypeptide. In
particular, the invention
provides isolated native sequence PR0697 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I through 295 of Figure 167 (SEQ ID N0:415). Optionally,
the PR0697 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the vector deposited with the ATCC
on March 26, 1998 as DNA50920-1325.
65. PR0717
Applicants have identified a cDNA clone that encodes a novel 12 transmembrane
polypeptide, wherein the
polypeptide is designated in the present application as "PR0717".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0717 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0717 polypeptide
having amino acid residues 1 through 560 of Figure 169 (SEQ ID N0:420), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on April 28~,
1998 with the ATCC as DNA50988-1326 which includes the nucleotide sequence
encoding PR0717.
In another embodiment, the invention provides isolated PR0717 polypeptide. In
particular, the invention
provides isolated native sequence PR0717 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues I through 560 of Figure 169 (SEQ ID N0:420). An additional
embodimcnt of the present
invention is directed to an isolated extracellular domain of a PR0717
polypeptide. Optionally, the PR0717
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on April 28, 1998 with the ATCC as DNA50988-1326.
66. PR
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
protocadherin 4, wherein the polypeptide is designated in the prcsent
application as "PR0731".
In otie embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0731 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0731 polypeptide
having amino acid residues 1 through 1184 of Figure 17i (SEQ ID N0:425), or is
complementary to such encoding
t>ucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector depositcd on March 31,
1998 with the ATCC as DNA48331-1329 which includes the nucleotide sequence
encoding PR0731.
CA 02421372 2003-03-25
WO 99/46281 ~ PCT/US99/05028
In another embodiment, the invention provides isolated PR0731 polypeptide_ In
particular, the invention
provides isolated native sequence PR0731 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 1184 of Figure 171 (SEQ ID N0:425). An
additional embodiment of the present
invention is directed to an isolated extracellular domain of a PR0731
polypeptide. Optionally, the PR073I
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on March 31, 1998 with the ATCC as DNA48331-1329.
67. RP 0218
Applicants have identified a cDNA clone that encodes a novel multi-
uansmembrane protein having sequence
identity with membrane regulator proteins, wherein the polypeptide is
designated in the present application as
"PR0218".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0218 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0218 polypeptide
having amino acid residues 1 through 455 of Figure 173 (SEQ ID N0:430), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high suingency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on April 28,
1998 with the ATCC as DNA30867-1335 which includes the nucleotide sequence
encoding PR0218.
In another embodiment, the invention provides isolated PR0218 polypeptide. In
particular, the invention
provides isolated native sequence PR0218 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 455 of Figure 173 (SEQ ID N0:430). Optionally,
the PR0218 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the vector deposited on April 28, 1998
with the ATCC as DNA30867-1335.
In another embodiment, the invention provides an expressed sequence tag (EST)
sequence comprising the
nucleotide sequence of Figure 174 (SEQ ID N0:431), designated herein as
DNA14472.
In another embodiment, the invention provides an expressed sequence tag (EST)
sequence comprising the
nucleotide sequence of Figure 175 (SEQ ID N0:432), designated herein as
DNA15846.
68. PR 7
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
integrins, wherein the polypeptide is designated in the present application as
"PR0768".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0768 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0768 polypeptide
having amino acid residues 1 through 1141 of Figure 177 (SEQ ID N0:437), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on April 6,
1998 as DNA55737-1345 which includes the nucleotide sequence encoding PR0768.
In another embodiment, the invention provides isolated PR0768 polypeptide. In
particular, the invention
provides isolated native sequence PR0768 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 1141 of Figure 177 (SEQ ID N0:437). An
additional embodiment of the present
invention is directed to an isolated extracellular domain of a PR0768
polypeptide. Optionally, the PR0768
86
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
polypeptide is obtained or is obtainable by expressing the polypeptidc encoded
by the cDNA insert of the vector
deposited on April 6, 1998 as DNA55737-1345.
69. PR0771
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
testican, wherein the polypeptide is designated in the present application as
"PR0771".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0771 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0771 polypeptide
having amino acid residues 1 through 436 of Figure 179 (SEQ ID N0:442), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on April 7,
1998 with the ATCC as DNA49829-1346 which includes the nucleotide sequence
encoding PR0771.
In another embodiment, the invention provides isolated PR0771 polypeptide. In
particular, the invention
provides isolated native sequence PR0771 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 436 of Figure 179 (SEQ ID N0:442). Optionally,
the PR0771 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the vector deposited on April 7, 1998
with the ATCC as DNA49829-1346.
70. PR0733
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
the T1/ST2 receptor binding protein, wherein the polypeptide is designated in
the present application as "PR0733".
In orie embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0733 polypeptide. In one aspect, the isolated nucleic acid compriscs DNA
encoding the PR0733 polypeptide
having amino acid residues 1 through 229 of Figure 181 (SEQ ID N0:447), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insen of
the vector deposited on April 7,
1998 with the ATCC as DNA52196-1348 which includes the nucleotide sequence
encoding PR0733.
In another embodiment, the invention provides isolated PR0733 polypeptide. In
particular, the invention
provides isolated native sequence PR0733 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 229 of Figure 181 (SEQ ID N0:447). An additional
embodiment of the present
invention is directed to an isolated extracellular domain of a PR0733
polypeptide. Optionally, the PR0733
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on April 7, 1998 as DNA52196-1348.
71. PR0162
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
pancreatitis-associated protein, wherein the poiypeptide is designated in the
present application as "PR0162" .
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0162 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0162 polypeptide
having amino acid residues 1 through 175 of Figure 183 (SEQ ID N0:452), or is
complementary to such encoding
87
CA 02421372 2003-03-25
n
WO 99/46281 PCT/US99/05028
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 6,
1998 with the ATCC as DNA56965-1356 which includes the nucleotide sequence
encoding PR0162.
In another embodiment, the invention provides isolated PR0162 polypeptide. In
particular, the invention
provides isolated native sequence PR0162 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 175 of Figure 183 (SEQ ID N0:452). Optionally,
the PR0162 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the vector deposited on May 6, 1998
with the ATCC as DNA56965-1356.
72. PR0788
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
anti-neoplastic urinary protein, wherein the polypeptide is designated in the
present applicatiotl as "PR0788".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0788 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0788 polypeptide
having amino acid residues 1 through 125 of Figure 185 (SEQ ID N0:454), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 6,
1998 with the ATCC as DNA56405-1357 which includes the nucleotide sequence
encoding PR0788.
In another embodiment, the invention provides isolated PR0788 polypeptide. In
particular, the invention
provides isolated native sequence PR0788 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 125 of Figure 185 (SEQ ID N0:454). An additional
embodiment of the present
invention is directed to an isolated extracellular domain of a PR0788
polypeptide. Optionally, the PR0788
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on May 6, 1998 with the ATCC as DNA56405-1357.
73. PR01008
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
dickkopf 1 (dkk-1), wherein the polypeptide is designated in the present
application as "PR01008".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01008 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01008 polypeptide
having amino acid residues 1 through 266 of Figure 187 (SEQ ID N0:456), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 20,
1998 with the ATCC as DNA57530-1375 which includes the nucleotide sequence
encoding PR01008.
In another embodiment, the invention provides isolated PRO1008 polypeptide. In
particular, the invention
provides isolated native sequence PR01008 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 through 266 of Figure 187 (SEQ ID N0:456). Optionally,
the PR01008 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
20, 1998 with the ATCC as DNA57530-1375.
88
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA16508 comprising the nucleotide sequence of Figure 188 (SEQ ID N0:457).
74. PRO1012
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
disulfide isomerase and phospholipase C, wherein the polypeptide is designated
in the present application as
"PR01012".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01012 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01012 polypeptide
having amino acid residues 1 through 747 of Figure 190 (SEQ ID N0:459), or is
complementary to such encoding
nucleic acid sequetxe, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 14,
1998 with the ATCC as DNA56439-1376, which includes the nucleotide sequence
encoding PR01012.
In another embodiment, the invention provides isolated PR01012 polypeptide. In
particular, the invention
provides isolated native sequence PR01012 polypeptide, which in one
embodiment, includes an amitw acid sequence
comprising residues 1 through 747 of Figure 190 (SEQ ID N0:459). Optionally,
the PR01012 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
14, 1998 with the ATCC as DNA56439-1376.
75. PR01014
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
reductase, wherein the polypeptide is designated in the present application as
"PR01014" ,
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01014 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01014 polypeptide
having amino acid residues 1 through 300 of Figure 192 (SEQ ID N0:464), or is
complementary to such encoding
rrucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high stringency
conditions. The isolated nucleic acid sequence may compnise the cDNA insert of
the vector deposited on May 20,
1998 as DNA55409-1377 with the ATCC which includes the nucleotide sequence
encoding PR01014.
In another embodiment, the invention provides isolated PR01014 polypeptide. In
particular, the invention
provides isolated native sequence PR01014 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 through 300 of Figure 192 (SEQ ID N0:464). Optionally,
the PR01014 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
20, 1998 as DNASlr409-1377 with the ATCC.
76. pR01017
Applicants have identified a eDNA clone that encodes a novel polypeptide
having sequence identity with
HNK-1 sulfotransferase, wherein the polypeptide is designated in the present
application as "PR01017".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01017 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR010I7 polypeptide
having amino acid residues 1 through 414 of Figure 194 (SEQ ID N0:466), or is
complementary to such encoding
89
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 20,
1998 with the ATCC as DNA56112-1379 which includes the nucleotide sequence
encoding PR01017.
In another embodiment, the invention provides isolated PR01017 polypeptide. In
particular, the invention
provides isolated native sequence PR01017 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 through 414 of Figure 194 (SEQ ID N0:466). Optionally,
the PR01017 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
20, 1998 with the ATCC as DNA56112-1379.
77. PR0474
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
dehydrogenase, wherein the polypeptide is designated in the present
application as "PR0474".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0474 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0474 polypeptide
having amino acid residues 1 through 270 of Figure 196 (SEQ ID N0:468), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 14,
1998 with the ATCC as DNA56045-1380 which includes the nucleotide sequence
encoding PR0474.
In another embodiment, the invention provides isolated PR0474 polypeptide. In
particular, the invention
provides isolated native sequence PR0474 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 through 270 of Figure 196 (SEQ >D N0:468). Optionally,
the PR0474 polypeptide is obtained
or is obtainable by expressing the polypeptide encoded by the cDNA insert of
the vector deposited on May 14, 1998
with the ATCC as DNA56045-1380.
78. PROl 31
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
IL-17, wherein the polypeptide is designated in the present application as
"PR01031".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01031 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01031 polypeptide
having amino acid residues 1 through 180 of Figure 198 (SEQ ID N0:470), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 14,
1998 with the ATCC as DNA59294-1381 which includes the nucleotide sequence
encoding PR01031.
In another embodiment, the invention provides isolated PR01031 polypeptide. In
particular, the invention
provides isolated native sequence PR01031 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues I through 180 of Figure 198 (SEQ ID N0:470). Optionally,
the PR01031 polypeptide is
obtained or is obtainable by expressing the polypeptide encoded by the cDNA
insert of the vector deposited on May
14, 1998 with the ATCC as DNA59294-1381.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
79. PR 8
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity to
protein disulfide isomerase, wherein the polypeptide is designated in the
present application as "PR0938".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR0938 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR0938 polypeptide
having amino acid residues 1 to 349 of Figure 200 (SEQ ID N0:472), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In other aspects, the isolated nucleic acid comprises DNA encoding
the PR0938 polypeptide having
amino acid residues about 23 to 349 of Figure 200 (SEQ 1D N0:472) or amino
acid 1 or about 23 to X of Figure 200
(SEQ ID N0:472), where X is any amino acid from 186 to 195 of Figure 200 (SEQ
ID N0:472), or is
complementary to such encoding nucleic acid sequence, and remains stably bound
to it under at least moderate, and
optionally, under high stringency conditions. The isolated nucleic acid
sequence may comprise the cDNA insert of
the DNA56433-1406 vector deposited on May 12, 1998, as ATCC Accession No.
209857 which includes the
nucleotide sequence encoding PR0938.
In another embodiment, the invention provides isolated PR0938 polypeptide. In
particular, the invention
provides isolated native sequence PR0938 polypeptide, which in one embodiment,
includes an amino acid sequence
cotttprising residues 1 to 349 of Figure 200 (SEQ ID N0:472). Additional
embodiments of the present invention are
directed to PR0938 polypeptides comprising amino acids about 23 to 349 of
Figure 200 (SEQ ID N0:472) or amino
acid 1 or about 23 to X of Figure 200 (SEQ ID N0:472), where X is any amino
acid from 186 to 195 of Figure 200
(SEQ 1D N0:472). Optionally, the PR0938 polypeptide is obtained or is
obtainable by expressing the polypeptide
encoded by the cDNA insert of the DNA56433-1406 vector deposited on May 12,
1998, as ATCC Accession No.
209857.
80. PR01082
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
a lectin-like oxidized LDL receptor, wherein the polypeptide is designated in
the present application as "PR01082".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01082 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01082 polypeptide
having amino acid residues 1 through 201 of Figure 202 (SEQ ID N0:477), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence may comprise the cDNA insert of
the vector deposited on May 14,
1998 with the ATCC as DNA53912-1457 which includes the nucleotide sequence
encoding PR01082.
In another embodiment, the invention provides isolated PR01082 polypeptide. In
particular, the invention
provides isolated native sequence PR01082 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 through 201 of Figure 202 (SEQ ID N0:4?7). An additional
embodiment of the present
invention is directed to an isolated domain of a PR01082 polypeptide,
excluding the cransmembrane domain.
Optionally, the PR01082 polypeptide is obtained or is obtainable by expressing
the polypeptide encoded by the cDNA
insert of the vector deposited on May 14, 1998 with the ATCC as DNA53912-1457.
91
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
81. PR01 83
Applicants have identified a cDNA clone that encodes a novel polypeptide
having sequence identity with
a 7TM receptor, latrophilin-related protein 1, and a macrophage resuicted cell
surface glycoprotein, wherein the
polypeptide is designated in the present application as "PR01083".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
PR01083 polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the PR01083 polypeptide
having amino acid residues 1 through 693 of Figure 204 (SEQ ID N0:483), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under at least moderate,
and optionally, under high stringency
conditions. The isolated nucleic acid sequence tray comprise the cDNA insert
of the vector deposited on May 12,
1998 with the ATCC as DNA50921-1458 which includes the nucleotide sequence
encoding PR01083.
In another embodiment, the invention provides isolated PR01083 polypeptide. In
particular, the invention
provides isolated native sequence PR01083 polypeptide, which in one
embodiment, includes an amino acid sequence
comprising residues 1 through 693 of Figure 204 (SEQ ID N0:483). An additional
embodiment of the present
invention is directed to an isolated exuacellular domain of a PR01083
polypeptide. Optionally, the PR01083
polypeptide is obtained or is obtainable by expressing the polypeptide encoded
by the cDNA insert of the vector
deposited on May 12, 1998 with the ATCC as DNA50921-1458.
In another embodiment, the invention provides an expressed sequence tag (EST)
designated herein as
DNA24256 which comprises the nucleotide sequence of Figure 205 (SEQ ID
N0:484).
82. PR0200
The objects of this invention, as defined generally supra, are achieved at
least in part by the provision of
a novel polypeptide, VEGF-E also herein designated PR0200, (SEQ ID N0:488) and
the nucleic acid encoding
therefor, SEQ ID N0:487, residues 259 through 1293.
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA encoding a
VEGF-E polypeptide. In one aspect, the isolated nucleic acid comprises DNA
encoding the VEGF-E polypeptide
having atnino acid residues 1 through 345 of Figure 207 (SEQ ID N0:488), or is
complementary to such encoding
nucleic acid sequence, and remains stably bound to it under low stringency
conditions. In another embodiment,
variants are provided wherein the VEGF-E nucleic acid has single or multiple
deletions, substitutions, insertions,
truncations or combinations thereof.
In another embodiment, the invention provides isolated VEGF-E polypeptide. In
particular, the invention
provides an isolated native sequence VEGF-E polypeptide, which in one
embodiment, includes an amino acid
sequence comprising residues 1 through 345 of Figure 207 (SEQ ID N0:488). In
another embodiment, variants are
provided wherein the VEGF-E polypeptide has single or multiple deletions,
substitutions, insertions, truncations or
combinations thereof.
In yet further embodiments, the present invention is directed to compositions
useful for treating indications
where proliferation, survival and/or differentiation of cells is desired,
comprising a therapeutically effective amount
of a VEGF-E polypeptide hereof in admixture with a phatzttaceutically
acceptable carrier.
The im~ention further includes associated embodiments of VEGF-E such as
modified VEGF-E polypeptides
and modified varianu which have the same biological applications as VEGF-E,
and pharmaceutical compositions
incorporating same. Inhibitors of VEGF-E are also provided.
92
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
83. PR0285 and PR0286
Applicants have identified two novel cDNA clones that encode novel human Toll
polypeptides, designated
in the present application as PR0285 (encoded by DNA40021-1154) and PR0286
(encoded by DNA42663-1154).
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising a DNA encoding
a polypeptide having at least about 80% sequence identity, preferably at least
about 85% sequence identity, more
preferably at least about 90% sequence identity, most preferably at least
about 95% sequence identity to (a) a DNA
molecule encoding a PR0285 polypeptide having amino acid residues 27 to $39 of
Figure 209 (SEQ 1D N0:496);
or {b) to a DNA molecule encoding a PR0286 polypeptide having amino acid
residues 27 to 825 of Figure 211 (SEQ
ID N0:498) or (c) the complement of the DNA molecule of (a) or (b). The
complementary DNA molecule preferably
remains stably bound to such encoding nucleic acid sequence under at least
moderate, and optionally, under high
stringency conditions.
In a further embodiment, the isolated nucleic acid molecule comprises a
polynucleotidc that has at least about
90%, preferably at least about 95% sequence identity with a polynucleotide
encoding a polypcptide comprising the
sequence of amino acids 1 to 839 of Figure 209 (SEQ ID N0:496); or at least
about 90%, preferably at least about
95 % sequence identity with a polynucleotide encoding a polypeptide comprising
the sequence of amino acids 1 to
1041 of Figure 211 (SEQ ID N0:498).
In a specific embodiment, the invention provides an isolated nucleic acid
molecule comprising DNA
encoding native or variant PR0285 and PR0286 polypeptides, with or without the
N-terminal signal sequence, and
with or without the transmembrane regions of the respective full-length
sequences. In one aspect, the isolated nucleic
acid comprises DNA encoding a mature, full-length native PR0285 or PR0286
polypeptide having amino acid
residues 1 to 1049 of Figure 209 (SEQ ID N0:496) and 1 to 1041 of Figure 211
(SEQ ID NO: 498), or is
complementary to such encoding nucleic acid sequence. In another aspect, the
invention concerns an isolated nucleic
acid molecule that comprises DNA encoding a native PR0285 or PR0286
polypeptide without an N-terminal signal
sequence, or is complementary to such encoding nucleic acid sequence. In yet
another embodiment, the invention
concerns nucleic acid encoding transmembrane-domain deleted or inactivated
forms of the full-length native PR0285
or PR0286 proteins.
In another embodiment, the invention the isolated nucleic acid molecule
comprises the clone (DNA40021-
1154) deposited on October 17, 1997, under ATCC number 209389; or the clone
(DNA42663-1154) deposited on
October 17, 1997, under ATCC number 209386.
In yet another embodiment, the invention provides a vector comprising DNA
encoding PR0285 and PR0286
polypeptides, or their variants. Thus, the vector may comprise any of the
isolated nucleic acid molecules hereinabove
defined.
In another embodiment, the invention provides isolated PR0285 and PR0286
polypeptides. In particular,
the irnention provides isolated native sequence PR0285 and PR0286
polypeptides, which in one embodiment, include
the amino acid sequences comprising residues 1 to 1049 and 1 to 1041 of
Figures 209 and 211 (SEQ ID NOS:496
and 498), respectively. The invention also provides for variants of the PR0285
and PR0286 polypeptides which are
encoded by any of the isolated nucleic acid molecules hereinabove defined.
Specific variants include, but are not
limited to, deletion (truncated) variants of the full-length native sequence
PR0285 and PR0286 polypeptides which
lack the respective N-terminal signal sequences and/or have their respective
uansmembrane and/or cytoplastnic
domains deleted or inactivated.
93
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The invention also specifically includes antibodies with dual specificities,
e.g., bispecific antibodies binding
more than one Toll polypeptide.
In yet another embodiment, the invention concetzts agonists and antagonists of
the native PR0285 and
PR0286 polypeptides. In a particular embodiment, the agonist or antagonist is
an anti-PR0285 or anti-PR0286
antibody.
In a further embodiment, the invention concerns screening assays to identify
agonists or antagonists of the
native PR0285 and PR0286 polypeptides.
In a still further embodiment, the invention concerns a composition comprising
a PR0285 or PR0286
polypeptide, or an agonist or antagonist as hereinabove defined, in
combination with a pharmaceutically acceptable
carrier.
The invention further concerns a composition comprising an antibody
specifically binding a PR0285 or
PR0286 polypeptide, in combination with a pharmaceutically acceptable carrier.
The invention also concerns a method of treating septic shock comprising
administering to a patient an
effective amount of an antagonist of a PR0285 or PR0286 polypeptide. In a
specific embodiment, the antagonist
is a blocking antibody specifically binding a native PR0285 or PR0286
polypeptide.
84. PR0213-1. PR01330 and PR01449
The present invention concerns compositions and methods for the diagnosis and
treatment of neoplastic cell
growth and proliferation in mammals, including humans. The present invention
is based on the identification of genes
that are amplified in the genome of tumor cells. Such gene amplification is
expected to be associated with the
overexpression of the gene product and contribute to tumorigenesis.
Accordingly, the proteins encoded by the
amplified genes are believed to be useful targets for the diagnosis and/or
treatment (including prevention) of certain
cancers, and may act as predictors of the prognosis of tumor treatment.
In one embodiment, the present invention provides an isolated nucleic acid
molecule comprising DNA encoding a
PR0213-1, PR01330 and/or PR01449 polypeptide. In one aspect, the isolated
nucleic acid comprises DNA
encoding the PR0213-1, PR01330 andlor PR01449 polypeptide having amino acid
residues 1 to 295 of Figure 213
(SEQ ID N0:506), 20 to 273 of Figure 215 (SEQ ID N0:508) and 20 to 273 of
Figure 217 (SEQ ID N0:510),
respectively, or is complementary to such encoding nucleic acid sequence, and
remains stably bound to it under at
least moderate, and optionally, under high stringency conditions. The isolated
nucleic acid sequence may comprise
the cDNA insert of the vector designated as DNA30943-1163 (ATCC 209791 )
deposited on April 21, 1998;
DNA64907-1163-1 (ATCC 203242) deposited on September 9, 1998 and/or DNA64908-
1163-1 (ATCC 203243)
deposited on September 9, 1998.
In another embodiment, the present invention comprises an isolated nucleic
acid molecule having at least
about 80% sequence identity, preferably at least about 85% sequence identity,
more preferably at least about 90%
sequence identity, most preferably at least about 95 % sequence identity to
(a) a DNA molecule encoding a PR0213-1,
PR01330 and/or PR01449 polypeptide having amino acid residues 1 to 295 of
Figure 213 (SEQ ID N0:506), 20
to 273 of Figure 215 (SEQ ID N0:508) and 20 to 273 of Figure 217 (SEQ ID
N0:510), respectively; or (b) the
complement of the DNA molecule of (a).
In another embodiment, the invention provides an isolated PR0213-1, PR01330
and/or PR01449
polypeptide. In particular, the invention provides isolated native sequence
PR0213-1, PR01330 and/or PR01449
94
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
polypeptide, which in one embodiment, includes an amino acid sequence
comprising residues 1 to 295 of Figure 213
(SEQ ID N0:506), 20 to 273 of Figure 215 (SEQ ID N0:508) or 20 to 273 of
Figure 217 (SEQ ID N0:510),
respectively. Optionally, the PR0213-1, PR01330 and/or PR01449 polypeptide is
obtained or obtainable by
expressing the polypeptide encoded by the cDNA insert of the DNA30943-1163
(ATCC 209791), DNA64907-1163-1
(ATCC 203242) or DNA64908-1163-1 (ATCC 203243).
In another aspect, the invention provides an isolated PR0213-1, PR01330,
and/or PR01449 poly~peptide,
comprising an amino acid sequence having at least about 80% sequence identity,
preferably at least about 85%
sequence identity, more preferably at least about 95 % sequence identity to
amino acid residues 1 to 295 of Figure
213 (SEQ ID N0:506), 20 to 273 of Figure 215 (SEQ ID N0:508) or 20 to 273 of
Figure 217 (SEQ ID N0:510),
inclusive.
In yet another embodiment, the invention provides an isolated PR0213-1,
PR01330, andlor PR01449
polypeptide, comprising the amino acid residues 1 to 295 of Figure 213 (SEQ ID
N0:506), 20 to 273 of Figure 215
(SEQ 1D N0:508) or 20 to 273 of Figure 217 (SEQ ID N0:510), or a fragment
thereof sufficient to provide a binding
site for an anti-PR0213-1, anti-PR01330 and/or anti-PR01449 antibody.
Preferably, the PR0213-1, PR01330,
and/or PR01449 fragment retains a qualitative biological activity of a native
PR0213-1, PR01330, and/or PR01449
polypeptide.
In a further aspect, the invention concerns an isolated PR0213-1, PR01330,
andlor PR01449 polypeptide,
comprising an amino acid sequence scoring at least about 80% positives,
preferably at least about 85% positives,
more preferably at least about 90~ positives, most preferably at least about
95% positives when compared with the
amino acid sequence of residues 1 to 295 of Figure 213 (SEQ ID N0:506), 20 to
273 of Figure 215 (SEQ ID
N0:508) and 20 to 273 of Figure 217 (SEQ ID N0:510), respectively.
In still a further aspect, the invention provides a polypeptide produced by
(i) hybridizing a test DNA
molecule under suingent conditions with: (a) a DNA molecule encoding a PR0213-
1, PR01330, and/or PR01449
polypeptide having the amino acid residues from 1 to 295 of Figure 213 (SEQ ID
N0:506), 20 to 273 of Figure 215
(SEQ ID N0:508) and 20 to 273 of Figure 217 (SEQ ID N0:510), respectively; or
the complement of the DNA
trtolecule of (a), and if said test DNA molecule has at least about an 80 %
sequence identity to (a) or (b), (ii) culturing
a host cell comprising said test DNA molecule under conditions suitable for
the expression of said polypeptide, and
(iii) recovering said polypeptide from the cell culture.
In one embodiment, the present invention concerns an isolated antibody which
binds a PR0213-1, PR01330
and/or PR01449 polypeptide. In one aspect, the antibody induces death of a
cell overexpressing a PR0213-1,
PR01330 and/or PR01449 polypeptide. In another aspect, the antibody is a
monoclonal antibody, which preferably
has nonhuman complementariry determining region (CDR) residues and human
framework region (FR) residues.
The antibody may be labeled and may be immobilized on a solid support. In a
further aspect, the antibody is an
antibody fragment, a single-chain antibody, or an anti-idiorypic antibody.
In another embodiment, the invention concerns a composition comprising an
antibody which binds a
PR0213-1, PR01330 and/or PR01449 polypeptide in admixture with a
pharmaceutically acceptable carrier. In one
aspect, the composition comprises a therapeutically effective amount of the
antibody. In another aspect, the
composition comprises a further active ingredient, which may, for example, be
a further antibody or a cytotoxic or
chemotherapeutic agent. Preferably, the composition is sterile.
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In a further embodiment, the invention concerns nucleic acid encoding an anti-
PR0213-1, anti-PR01330
and/or anti-PR01449 antibody, and vectors and recombinant host cells
comprising such nucleic acid.
The invention further concerns antagonists and agonists of a PR0213-1, PR01330
and/or PR01449
polypeptide that inhibit one or more of the functions or activities of the
PR0213-1, PR01330 and/or PR01449
polypeptide.
In a further embodiment, the invention concerns isolated nucleic acid
molecules that hybridize to the
complement of the nucleic acid molecules encoding the PR0213-1, PR01330 and/or
PR01449 polypeptides. The
nucleic acid preferably is DNA, and hybridization preferably occurs under
stringent conditions. Such nucleic acid
molecules can act as antisense molecules of the amplified genes identified
herein, which, in turn, can find use in the
modulation of the respective amplified genes, or as antisense primers in
amplification reactions. Furthermore, such
sequences can be used as part of ribozyme and/or triple helix sequence which,
in turn, may be used in regulation
of the amplified genes.
In another embodiment, the invention concerns a method for determining the
presence of a PR0213-1,
PR01330 and/or PR01449 polypeptide comprising exposing a cell suspected of
containing the PR0213-1, PR01330
andlor PR01449 polypeptide to an anti-PR0213-1, PR01330 and/or PR01449
antibody and determining binding of
the antibody to the cell.
In yet another embodiment, the present invention concerns a method of
diagnosing tumor in a mammal,
comprising detecting the level of expression of a gene encoding a PR0213-1,
PR01330 and/or PR01449 polypeptide
(a) in a test sample of tissue cells obtained from the marr>rnal, and (b) in a
control sample of known normal tissue cells
of the same cell type, wherein a higher expression level in the test sample
indicates the presence of tumor in the
mammal from which the test tissue cells were obtained.
In another embodiment, the present invention concerns a method of diagnosing
tumor in a mammal,
comprising (a) contacting an anti-PR0213-1, anti-PR01330 and/or anti-PR01449
antibody with a test sample of tissue
cells obtained from the mammal, and (b) detecting the formation of a complex
between the anti-PR0213-1, anti-
PR01330 and/or anti-PR01449 antibody and the PR0213-1, PR01330 and/or PR01449
polypeptide in the test
sample. The detection may be qualitative or quantitative, and may be performed
in comparison with monitoring the
complex formation in a control sample of known normal tissue cells of the same
cell type. A larger quantity of
complexes formed in the test sample indicates the presence of tumor in the
mammal from which the test tissue cells
were obtained. The antibody preferably carries a detectable label. Complex
formation can be monitored, for
example, by light microscopy, flow cytometry, fluorimetry, or other techniques
known in the art. The test sample
is usually obtained from an individual suspected to have neoplastic cell
growth or proliferation (e.g. cancerous cells).
In another embodiment, the present invention concerns a cancer diagnostic kit,
comprising an anti-PR0213-
1, anti-PR01330 and/or anti-PR01449 antibody and a carrier (e.g. a buffer) in
suitable packaging. The kit preferably
contains instructions for using the antibody to detect the PR0213-1, PR01330
andlor PR01449 polypeptide.
In yet another embodiment, the invention concerns a method for inhibiting the
growth of tumor cells
comprising exposing a cell which overexpresses a PR0213-1, PR01330 and/or
PR01449 polypeptide to an effective
amount of an agent inhibiting the expression and/or activity of the PR0213-1,
PR01330 and/or PR01449
polypeptide. The agent preferably is an anti-PR0213-1, anti-PR01330 and/or
anti-PR01449 antibody, a small
organic and inorganic molecule, peptide, phosphopeptide, antisense or ribozyme
molecule, or a triple helix molecule.
In a specific aspect, the agent, e.g. anti-PR0213-1, anti-PR01330 and/or anti-
PR01449 antibody induces cell death.
96
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In a further aspect, the tumor cells are further exposed to radiation
treatment and/or a cytotoxic or chemotherapeutic
agent.
In a further embodiment, the invention concerns an article of manufacture,
comprising:
a) a container;
b) a label on the container; and
c) a composition comprising an active agent contained within the container;
wherein the composition is
effective for inhibiting the growth of tumor cells, the label on the container
indicates that the composition can be used
for treating conditions characterized by overexpression of a PR0213-1, PR01330
and/or PR01449 polypeptide, and
the active agent in the composition is an agent inhibiting the expression
and/or activity of the PR0213-I , PR01330
and/or PR01449 polypeptide. In a preferred aspect, the active agent is an anti-
PR0213-1, anti-PR01330 and/or anti-
PR01449 antibody.
In yet a further embodiment, the invention provides a method for identifying a
compound capable of
inhibiting the expression and/or activity of a PR0213-1, PR01330 and/or
PR01449 polypeptide, comprising
contacting a candidate compound with a PR0213-1, PR01330 and/or PR01449
polypeptide under conditions and
for a time sufficient to allow these two components to interact. In a specific
aspect, either the candidate compound
or the PR0213-1, PR01330 and/or PR01449 polypeptide is immobilized on a solid
support. In another aspect, the
non-immobilized component carries a detectable label.
85. PR0298
Applicants have identified a cDNA clone that encodes a novel polypeptide. The
DNA is designated in the
present application as "DNA39975-1210", encoding a novel mufti-transmembrane
protein, referred to as "PR0298".
In one embodiment, the invention provides an isolated nucleic acid molecule
comprising DNA having at least
about 80% , preferably at least about 85%, more preferably at least about 90%,
most preferably at least about 95%
sequence identity to (a) a DNA molecule encoding PR0298, comprising the
sequence of amino acids 1 to 364 of
Figure 219 (SEQ )D N0:515), or (b) the complement of the DNA molecule of (a).
In one aspect, the isolated nucleic
acid comprises DNA encoding a PR0298 polypeptide having amino acid residues 1
to 364 of Figure 219 (SEQ ID
N0:515), or is complementary to such encoding nucleic acid sequence, and
remains stably bound to it under at least
moderate, and optionally, under high stringency conditions.
In a further embodiment, the invention concerns an isolated nucleic acid
molecule comprising DNA having
at least an 80% sequence identity to (a) a DNA molecule encoding the same
mature polypeptide encoded by the
human protein cDNA in ATCC Deposit No. 209783 (DNA39975-1210), or (b) the
complement of the DNA molecule
of (a).
In a still further embodiment, the invention concerns nucleic acid which
comprises a DNA molecule
encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 209783
(DNA39975-1210).
In another embodiment, the invention provides isolated PR0298 polypeptide. In
particular, the invention
provides isolated native sequence PR0298 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 364 of Figure 219 (SEQ ID N0:515).
In another embodiment, the invention provides an expressed sequence tag (EST)
designated DNA26832
comprising the nucleotide sequence of Figure 220 (SEQ ID N0:516).
97
CA 02421372 2003-03-25
WO 99/46281 PCTIUS99/05028
86. PR0337
Applicants have identified a cDNA clone (DNA43316-1237) that encodes a novel
polypeptide, designated
in the present application as, "PR0337".
In one embodiment, the invention provides an isolated nucleic acid molecule
having at least about 80%
sequence identity to (a) a DNA molecule encoding a PR0337 polypeptide
comprising the sequence of amino acids
1 to 344 of Figure 222 (SEQ ID N0:523), or (b) the complement of the DNA
molecule of (a). The sequence identity
preferably is about 85 % , more preferably about 90%, most preferably about 95
% . In one aspect, the isolated nucleic
acid has at least about 80%, preferably at least about 85%, more preferably at
least about 90%, and most preferably
at least about 95 (including 96, 97, 98 and 99 ~ ) sequence identity with a
polypeptide having amino acid residues 1
to 344 of Figure 222 (SEQ ID N0:523). Preferably, the highest degree of
sequence identity occurs within the
immunoglobulin and major histocompatibility domains (amino acids 113 to 130 of
Figure 222, SEQ ID N0:523).
In a further embodiment, the isolated nucleic acid molecule comprises DNA
encoding a neurotrirnin
polypeptide having amino acid residues 1 to 344 of Figure 222 (SEQ ID N0:523),
or is complementary to such
encoding nucleic acid sequence, and remains stably bound to it under at least
moderate, and optionally, under high
stringency conditions. In another aspect, the invention provides a nucleic
acid of the full length protein of clone
DNA43316-1237, deposited with the ATCC under accession number ATCC 209487,
alternatively the coding
sequence of clone DNA43316-1237, deposited under accession number ATCC 209487.
In yet another embodiment, the invention provides isolated PR0337 polypeptide.
In particular, the invention
provides isolated native sequence PR0337 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 344 of Figure 222 (SEQ ID N0:523). Native PR0337
polypeptides with or without the
native signal sequence (amino acids 1 to about 28 in Figure 222 (SEQ ID
N0:523), and with or without the initiating
methionine are specifically included. Altetmatively, the invention provides a
PR0337 polypeptide encoded by the
nucleic acid deposited under accession number ATCC 209487.
In yet another embodiment, the invention provides an expressed sequence tag
(EST) comprising the
nucleotide sequences identified in Figure 223 as DNA42301 (SEQ ID N0:524).
87. PR0403
Applicants have identified a cDNA clone (DNA55800-1263) that encodes a novel
polypeptide, designated
in the present application as "PR0403".
In one embodiment, the invention provides an isolated nucleic acid molecule
having at least about 80%
sequence identity to (a) a DNA molecule encoding a PR0403 polypeptide
comprising the sequence of amino acids
1 to 736 of Figure 225 (SEQ )D N0:526), or (b) the complement of the DNA
molecule of (a). The sequence identity
preferably is about 85%, more preferably about 90%, most preferably about 95%.
In one aspect, the isolated nucleic
acid has at least about 80%, preferably at least about 85 % , more preferably
at least about 90%, and most preferably
at least about 95 % sequence identity with a polypeptide having amino acid
residues 1 to 736 of Figure 225 (SEQ ID
N0:526). Preferably, the highest degree of sequence identity occurs within:
(1) the putative N-glycosylatation sites
(amino acid residues 132, 136, 177, 237, 282, 349, 505, 598 and 60b; (2) Cys
residues conserved with the Kell blood
group protein family (amino acid residues 65, 70, 88 and 96) and the putative
zinc binding motif (amino acid residues
570-579).
98
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In a further embodiment, the isolated nucleic acid molecule comprises DNA
encoding a PR0403 polypeptide
having amino acid residues l to 736 of Figure 225 (SEQ ID N0:526), or is
complementary to such encoding nucleic
acid sequence, and remains stably bound to it under at least moderate, and
optionally, under high stringency
conditions. In another aspect, the invention provides a nucleic acid of the
full length protein of clone DNA55800-
1263, deposited with the ATCC under accession number ATCC 209680,
alternatively the coding sequence of clone
DNA55800-1263, deposited under accession number ATCC 209680.
In yet another embodiment, the invention provides isolated PR0403 polypeptide.
In particular, the invention
provides isolated native sequence PR0403 polypeptide, which in one embodiment,
includes an amino acid sequence
comprising residues 1 to 736 of Figure 225 (SEQ ID N0:526). Native PR0403
polypeptides with or the initiating
methionine are specifically included. Alternatively, the invention provides a
PR0403 polypeptide encoded by the
nucleic acid deposited under accession number ATCC 209680.
In yet another embodiment, the invention provides an expressed sequence tag
(EST)~and other sequence
fragments comprising the nucleotide sequences identified herein as DNA34415
(Figures 226A-B; SEQ ID N0:527);
DNA49830 (Figure 227 ; SEQ ID N0:528) and DNA49831 (Figure 228; SEQ ID
N0:529).
88. Additional Embodiments
In other embodiments of the present invention, the invention provides vectors
comprising DNA encoding
any of the above or below described polypeptides. A host cell comprising any
such vector is also provided. By way
of example, the host cells may be CHO cells, E. coli, or yeast. A process for
producing any of the above or below
described polypeptides is further provided and comprises culturing host cells
under conditions suitable for expression
of the desired polypeptide and recovering the desired polypeptide from the
cell culture.
In other embodiments, the invention provides chimeric molecules comprising any
of the above or below
described polypeptides fused to a heterologous polypeptide or amino acid
sequence. An example of such a chimeric
molecule comprises any of the above or below described polypeptides fused to
an epitope tag sequence or a Fc region
of an immunoglobulin.
In another embodiment, the invention provides an antibody which specifically
binds to any of the above or
below described polypeptides. Optionally, the antibody is a monoclonal
antibody.
In yet other embodiments, the invention provides oligonucleotide probes useful
for isolating genomic and
cDNA nucleotide sequences, wherein those probes may be derived from any of the
above or below described
nucleotide sequences.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PR0213
cDNA, wherein SEQ
ID NO:1 is a clone designated herein as "UNQ187" and/or "DNA30943-1163".
Figure 2 shows the amino acid sequence (SEQ )D N0:2) derived from the coding
sequence of SEQ ID NO:I
shown in Figure 1.
Figure 3 shows a nucleotide sequence (SEQ ID N0:6) of a native sequence PR0274
cDNA, wherein SEQ
ID N0:6 is a clone designated herein as "UNQ241 " and/or "DNA39987-1184" .
Figure 4 shows the amino acid sequence (SEQ >D N0:7) derived from the coding
sequence of SEQ ID N0:6
shown in Figure 3.
99
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 5 shows an EST nucleotide sequence designated herein as DNA17873 (SEQ
ID N0:8).
Figure 6 shows an EST nucleotide sequence designated herein as DNA36157 (SEQ
ID N0:9).
Figure 7 shows an EST nucleotide sequence designated herein as DNA28929 (SEQ
ID NO:10).
Figure 8 shows a nucleotide sequence (SEQ ID N0:18) of a native sequence
PR0300 cDNA, wherein SEQ
ID N0:18 is a clone designated herein as "UNQ263" andlor "DNA40625-1189".
Figure 9 shows the amino acid sequence (SEQ 1D N0:19) derived from the coding
sequence of SEQ ID
N0:18 shown in Figure 8.
Figure 10 shows a nucleotide sequence (SEQ ID N0:27) of a native sequence
PR0284 cDNA, wherein SEQ
ID N0:27 is a clone designated herein as "UNQ247" and/or "DNA23318-1211 ".
Figure 11 shows the amino acid sequence (SEQ ID N0:28) derived from the coding
sequence of SEQ ID
N0:27 shown in Figure 10.
Figure 12 shows an EST nucleotide sequence designated herein as DNA12982 (SEQ
ID N0:29).
Figure 13 shows an EST nucleotide sequence designated herein as DNA15886 (SEQ
ID N0:30).
Figure 14 shows a nucleotide sequence (SEQ )D N0:35) of a native sequence
PR0296 cDNA, wherein SEQ
ID N0:35 is a clone designated herein as "UNQ260" and/or "DNA39979-1213".
Figure 15 shows the amino acid sequence (SEQ ID N0:36) derived from the coding
sequence of SEQ ID
N0:35 shown in Figure 14.
Figure 16 shows an EST nucleotide sequence designated herein as DNA23020 (SEQ
ID N0:37).
Figure 17 shows an EST nucleotide sequence designated herein as DNA21971 (SEQ
ID N0:38).
Figure 18 shows an EST nucleotide sequence designated herein as DNA29037 (SEQ
ID N0:39).
Figure 19 shows a nucleotide sequence (SEQ )D N0:44) of a native sequence
PR0329 cDNA, wherein SEQ
ID N0:44 is a clone designated herein as "UNQ291" and/or "DNA40594-1233".
Figure 20 shows the amino acid sequence (SEQ ID N0:45) derived from the coding
sequence of SEQ ID
N0:44 shown in Figure 19.
Figwe 21 shows a nucleotide sequence (SEQ )D NO:51} of a native sequence
PR0362 cDNA, wherein SEQ
ID NO:51 is a clone designated herein as "UNQ317" and/or "DNA45416-1251 ".
Figure 22 shows the amino acid sequence (SEQ ID N0:52) derived from the coding
sequence of SEQ ID
NO:51 shown in Figure 21.
Figure 23 shows a nucleotide sequence (SEQ ID N0:58) of a native sequence
PR0363 cDNA, wherein SEQ
ID N0:58 is a clone designated herein as "UNQ318" and/or "DNA45419-1252".
Figure 24 shows the amino acid sequence (SEQ ID N0:59) derived from the coding
sequence of SEQ ID
N0:58 shown in Figure 23.
Figure 25 shows a nucleotide sequence (SEQ )D N0:63) of a native sequence
PR0868 cDNA, wherein SEQ
ID N0:63 is a clone designated herein as "UNQ437" and/or "DNA52594-1270".
Figure 26 shows the amino acid sequence (SEQ ID N0:64) derived from the coding
sequence of SEQ ID
N0:63 shown in Figure 25.
Figure 27 shows a nucleotide sequence (SEQ 1D N0:68) of a native sequence
PR0382 cDNA, wherein SEQ
ID N0:68 is a clone designated herein as "UNQ323" andlor "DNA45234-1277".
Figure 28 shows the amino acid sequence (SEQ ID N0:69) derived from the coding
sequence of SEQ ID
N0:68 shown in Figure 27.
100
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 29 shows a nucleotide sequence (SEQ 1D N0:73) of a native sequence
PR0545 cDNA, wherein SEQ
ID N0:73 is a clone designated herein as "UNQ346" and/or "DNA49624-1279".
Figure 30 shows the amino acid sequence (SEQ ID N0:74) derived from the coding
sequence of SEQ ID
N0:73 shown in Figure 29.
Figure 31 shows an EST nucleotide sequence designated herein as DNA13217 (SEQ
ID N0:75).
Figure 32 shows a nucleotide sequence (SEQ ID N0:84) of a native sequence
PR0617 cDNA, wherein SEQ
ID N0:84 is a clone designated herein as "UNQ353" and/or "DNA48309-1280".
Figure 33 shows the amino acid sequence (SEQ ID N0:85) derived from the coding
sequence of SEQ ID
N0:84 shown in Figure 32.
Figure 34 shows a nucleotide sequence (SEQ ID N0:89) of a native sequence
PR0700 cDNA, wherein SEQ
ID N0:89 is a clone designated herein as "UNQ364" andlor "DNA46776-1284".
Figure 35 shows the amino acid sequence (SEQ ID N0:90) derived from the coding
sequence of SEQ ID
N0:89 shown in Figure 34.
Figure 36 shows a nucleotide sequence (SEQ )D N0:96) of a native sequence
PR0702 cDNA, wherein SEQ
ID N0:96 is a clone designated herein as "UNQ366" and/or "DNA50980-1286" .
Figure 37 shows the amino acid sequence (SEQ ID N0:97) derived from the coding
sequence of SEQ ID
N0:96 shown in Figure 36.
Figure 38 shows a nucleotide sequence (SEQ ID NO:101) of a native sequence
PR0703 cDNA, wherein
SEQ ID NO:101 is a clone designated herein as "UNQ367" and/or "DNA50913-1287".
Figure 39 shows the amino acid sequence (SEQ ID N0:102) derived from the
coding sequence of SEQ ID
NO:101 shown in Figure 38.
Figure 40 shows a nucleotide sequence (SEQ ID N0:108) of a native sequence
PR0705 cDNA, wherein
SEQ ID N0:108 is a clone designated herein as "UNQ369" and/or "DNA50914-1289".
Figure 41 shows the amino acid sequence (SEQ ID N0:109) derived from the
coding sequence of SEQ ID
N0:108 shown in Figure 40.
Figures 42A-B show a nucleotide sequence (SEQ 1D N0:113) of a native sequence
PR0708 eDNA, wherein
SEQ ID N0:113 is a clone designated herein as "UNQ372~ and/or "DNA48296-1292".
Figure 43 shows the amino acid sequence (SEQ ID N0:114) derived from the
coding sequence of SEQ ID
N0:113 shown in Figures 42A-B.
Figure 44 shows a nucleotide sequence (SEQ ID N0:118) of a native sequence
PR0320 cDNA, wherein
SEQ ID N0:118 is a clone designated herein as "UNQ281" and/or "DNA32284-1307~.
Figure 45 shows the amino acid sequence (SEQ ID N0:119) derived from the
coding sequence of SEQ ID
NO:1 l8 shown in Figure 44.
Figure 46 shows a nucleotide sequence (SEQ ID N0:123) of a native sequence
PR0324 cDNA, wherein
SEQ ID N0:123 is a clone designated herein as "UNQ285~ and/or "DNA36343-1310".
Figure 47 shows the amino acid sequence (SEQ ID N0:124) derived from the
coding sequence of SEQ ID
N0:123 shown in Figure 46.
Figure 48 shows a nucleotide sequence (SEQ ID N0:131) of a native sequence
PR0351 cDNA, wherein
SEQ ID N0:131 is a clone designated herein as "UNQ308" andlor "DNA40571-1315".
101
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 49 shows the amino acid sequence (SEQ ID N0:132) derived from the
coding sequence of SEQ ID
N0:131 shown in Figure 48.
Figure SO shows a nucleotide sequence (SEQ ID N0:136) of a native sequence
PR0352 cDNA, wherein
SEQ ID N0:136 is a clone designated herein as "UNQ309" and/or "DNA41386-1316".
Figure 51 shows the amino acid sequence (SEQ ID N0:137) derived from the
coding sequence of SEQ ID
NO:I36 shown in Figure 50.
Figure 52 shows a nucleotide sequence (SEQ ID N0:144) of a native sequence
PR0381 cDNA, wherein
SEQ ID N0:144 is a clone designated herein as "UNQ322" and/or "DNA44194-1317".
Figure 53 shows the amino acid sequence (SEQ 1D N0:145) derived from the
coding sequence of SEQ ID
N0:144 shown in Figure 52.
Figure 54 shows a nucleotide sequence (SEQ ID N0:149) of a native sequence
PR0386 cDNA, wherein
SEQ ID N0:149 is a clone designated herein as "UNQ326" and/or "DNA45415-1318".
Figure 55 shows the amino acid sequence (SEQ ID N0:150) derived from the
coding sequence of SEQ ID
N0:149 shown in Figure 54.
Figure 56 shows an EST nucleotide sequence designated herein as DNA23350 (SEQ
ID N0:151).
Figure 57 shows an EST nucleotide sequence designated herein as DNA23536 (SEQ
ID N0:152).
Figure 58 shows a nucleotide sequence (SEQ 1D N0:156) of a native sequence
PR0540 cDNA, wherein
SEQ ID N0:156 is a clone designated herein as "UNQ341 " and/or "DNA44189-
1322".
Figure 59 shows the amino acid sequence (SEQ ID N0:157) derived from the
coding sequence of SEQ ID
N0:156 shown in Figwe 58.
Figure 60 shows a nucleotide sequence (SEQ ID N0:161) of a native sequence
PR0615 cDNA, wherein
SEQ ID N0:161 is a clone designated herein as "UNQ352" andlor "DNA48304-1323".
Figure 61 shows the amino acid sequence (SEQ ID N0:162) derived from the
coding sequence of SEQ ID
N0:161 shown in Figure 60.
Figure 62 shows a nucleotide sequence (SEQ ID N0:168) of a native sequence
PR0618 cDNA, wherein
SEQ ID N0:168 is a clone designated herein as "UNQ354" andlor "DNA49152-1324".
Figure 63 shows the amino acid sequence (SEQ ID N0:169) derived from the
coding sequence of SEQ 1D
N0:168 shown in Figure 62.
Figure 64 shows an EST nucleotide sequence designated herein as DNA35597 (SEQ
ID N0:170).
Figure 65 shows a nucleotide sequence (SEQ ID N0:177) of a native sequence
PR0719 cDNA, wherein
SEQ ID N0:177 is a clone designated herein as "UNQ387" and/or "DNA49646-1327".
Figure 66 shows the arttino acid sequence (SEQ ID N0:178) derived from the
coding sequence of SEQ ID
NO:1?7 shown in Figure 65.
Figure 67 shows a nucleotide sequence (SEQ ID N0:182) of a native sequence
PR0724 cDNA, wherein
SEQ ID N0:182 is a clone designated herein as "UNQ389" and/or °DNA49631-
1328".
Figure 68 shows the amino acid sequence (SEQ ID N0:183) derived from the
coding sequence of SEQ ID
N0:182 shown in Figure 67.
Figure 69 shows a nucleotide sequence (SEQ ID N0:189) of a native sequence
PR0772 cDNA, wherein
SEQ ID N0:189 is a clone designated herein as "UNQ410" and/or "DNA49645-1347".
102
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 70 shows the amino acid sequence (SEQ ID N0:190) derived from the
coding sequence of SEQ ID
N0:189 shown in Figure 69.
Figure 71 shows an EST nucleotide sequence designated herein as DNA43509 (SEQ
ID N0:191).
Figure 72 shows a nucleotide sequence (SEQ ID N0:195) of a native sequence
PR0852 cDNA, wherein
SEQ ID N0:195 is a clone designated herein as "UNQ418" and/or "DNA45493-1349".
Figwe 73 shows the amino acid sequence (SEQ ID N0:196) derived from the coding
sequence of SEQ ID
N0:195 shown in Figure 72.
Figure 74 shows a nucleotide sequence (SEQ ID N0:205) of a native sequence
PR0853 cDNA, wherein
SEQ ID N0:205 is a clone designated herein as "UNQ419" and/or "DNA48227-1350".
Figure 75 shows the amino acid sequence (SEQ ID N0:206) derived from the
coding sequence of SEQ ID
N0:205 shown in Figure 74.
Figures 76A-B show a nucleotide sequence (SEQ ID N0:210) of a native sequence
PR0860 cDNA, wherein
SEQ 1D N0:210 is a clone designated herein as "UNQ421" andlor "DNA41404-1352".
Figure 77 shows the amino acid sequence (SEQ 1D N0:211) derived from the
coding sequence of SEQ ID
N0:210 shown in Figures 76A-B.
Figure 78 shows a nucleotide sequence (SEQ ID N0:215) of a native sequence
PR0846 cDNA, wherein
SEQ ID N0:215 is a clone designated herein as "UNQ422" and/or "DNA44196-1353".
Figure 79 shows the amino acid sequence (SEQ ID N0:216) derived from the
coding sequence of SEQ ID
N0:215 shown in Figure 78.
Figure 80 shows a nucleotide sequence (SEQ ID N0:220) of a native sequence
PR0862 cDNA, wherein
SEQ ID N0:220 is a clone designated herein as "UNQ424" and/or "DNA52187-1354".
Figure 81 shows the amino acid sequence (SEQ ID N0:221) derived from the
coding sequence of SEQ ID
N0:220 shown in Figure 80.
Figure 82 shows a nucleotide sequence (SEQ ID N0:225) of a native sequence
PR0864 cDNA, wherein
SEQ ID N0:225 is a clone designated herein as "UNQ42b" and/or "DNA48328-1355".
Figure 83 shows the amino acid sequence (SEQ ID N0:226) derived from the
coding scquenct of SEQ ID
N0:225 shown in Figure 82.
Figure 84 shows a nucleotide sequence (SEQ ID N0:230) of a native sequence
PR0792 cDNA, wherein
SEQ ID N0:230 is a clone designated herein as "UNQ431" andlor "DNA56352-1358",
Figure 85 shows the amino acid sequence (SEQ 1D N0:231) derived from the
coding sequence of SEQ ID
N0:230 shown in Figure 84.
Figure 86 shows a nucleotide sequence (SEQ ID N0:235) of a native sequence
PR0866 cDNA, wherein
SEQ ID N0:235 is a clone designated herein as "UNQ435" and/or "DNA53971-1359".
Figure 87 shows the amino acid sequence (SEQ ID N0:236) derived from the
coding sequence of SEQ ID
N0:235 shown in Figure 86.
Figure 88 shows a nucleotide sequence (SEQ ID N0:244) of a native sequence
PR0871 cDNA, wherein
SEQ ID N0:244 is a clone designated herein as "UNQ438" and/or "DNA50919-1361".
Figure 89 shows the amino acid sequence (SEQ ID N0:245) derived from the
coding sequence of SEQ ID
N0:244 shown in Figure 88.
103
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 90 shows a nucleotide sequence (SEQ ID N0:253) of a native sequence
PR0873 cDNA, wherein
SEQ ID N0:253 is a clone designated herein as "UNQ440" and/or "DNA44179-1362".
Figure 91 shows the amino acid sequence (SEQ ID N0:254) derived from the
coding sequence of SEQ ID
N0:253 shown in Figure 90.
Figure 92 shows a nucleotide sequence (SEQ ID N0:258) of a native sequence
PR0940 cDNA, wherein
SEQ ID N0:258 is a clone designated herein as "UNQ477" and/or "DNA54002-1367".
Figure 93 shows the amino acid sequence (SEQ ID N0:259) derived from the
coding sequence of SEQ ID
N0:258 shown in Figure 92.
Figure 94 shows a nucleotide sequence (SEQ ID N0:263) of a native sequence
PR0941 cDNA, wherein
SEQ ID N0:263 is a clone designated herein as "UNQ478" and/or "DNA53906-1368".
Figure 95 shows the amino acid sequence (SEQ ID N0:264) derived from the
coding sequence of SEQ ID
N0:263 shown in Figure 94.
Figure 96 shows an EST nucleotide sequence designated herein as DNA6415 (SEQ
ID N0:265).
Figure 97 shows a nucleotide sequence (SEQ ID N0:269) of a native sequence
PR0944 cDNA, wherein
SEQ ID N0:269 is a clone designated herein as "UNQ481" and/or "DNA52185-1370".
Figure 98 shows the amino acid sequence (SEQ ID N0:270) derived from the
coding sequence of SEQ 1D
N0:269 shown in Figure 97.
Figure 99 shows an EST nucleotide sequence designated herein as DNA14007 (SEQ
ID N0:271).
Figure 100 shows an EST nucleotide sequence designated herein as DNA12773 (SEQ
1D N0:272).
Figure 101 shows an EST nucleotide sequence designated herein as DNA12746 (SEQ
ID N0:273).
Figure 102 shows an EST nucleotide sequence designated herein as DNA12834 (SEQ
ID N0:274).
Figure 103 shows an EST nucleotide sequence designated herein as DNA12846 (SEQ
ID N0:275).
Figure 104 shows an EST nucleotide sequence designated herein as DNA13104 (SEQ
ID N0:276).
Figure 105 shows an EST nucleotide sequence designated herein as DNA13259 (SEQ
ID N0:277).
Figure 106 shows an EST nucleotide sequence designated herein as DNA13959 (SEQ
ID N0:278).
Figure 107 shows an EST nucleotide sequence designated herein as DNA13961 (SEQ
ID N0:279).
Figure 108 shows a nucleotide sequence (SEQ ID N0:283) of a native sequence
PR0983 cDNA, wherein
SEQ ID N0:283 is a clone designated herein as "UNQ484" and/or "DNA53977-1371".
Figure 109 shows the amino acid sequence (SEQ ID N0:284) derived from the
coding sequence of SEQ ID
N0:283 shown in Figure 108.
Figure 110 shows an EST nucleotide sequence designated herein as DNA17130 (SEQ
ID N0:285).
Figure 111 shows an EST nucleotide sequence designated herein as DNA23466 (SEQ
ID N0:286).
Figure 112 shows an EST nucleotide sequence designated herein as DNA26818 (SEQ
ID N0:287).
Figure 113 shows an EST nucleotide sequence designated herein as DNA37618 (SEQ
ID N0:288).
Figure 114 shows an EST nucleotide sequence designated herein as DNA41732 (SEQ
ID N0:289).
Figure I 15 shows an EST nucleotide sequence designated herein as DNA45980
(SEQ ID N0:290).
Figure 116 shows an EST nucleotide sequence designated herein as DNA46372 (SEQ
ID N0:291).
Figure I 17 shows a nucleotide sequence (SEQ ID N0:295) of a native sequence
PR01057 cDNA, wherein
SEQ ID N0:295 is a clone designated herein as "UNQ522" andlor "DNA57253-1382".
104
CA 02421372 2003-03-25
WO 9914b281 PC'T/US99/05028
Figure 118 shows the amino acid sequence (SEQ ID N0:296) derived from the
coding sequence of SEQ ID
N0:295 shown in Figure 117.
Figure 119 shows a nucleotide sequence (SEQ ID N0:300) of a native sequence
PR01071 cDNA, wherein
SEQ ID N0:300 is a clone designated herein as "UNQ528" and/or "DNA58847-1383".
Figure 120 shows the amino acid sequence (SEQ ID N0:301) derived from the
coding sequence of SEQ ID
N0:300 shown in Figure 119.
Figure 121 shows a nucleotide sequence (SEQ ID N0:302) of a native sequence
PR01072 cDNA, wherein
SEQ ID N0:302 is a clone designated herein as "UNQ529" and/or "DNA58747-1384".
Figure 122 shows the amino acid sequence (SEQ ID N0:303) derived from the
coding sequence of SEQ ID
N0:302 shown in Figure 121.
Figure 123 shows an EST nucleotide sequence designated herein as DNA40210 (SEQ
ID N0:304).
Figure 124 shows a nucleotide sequence (SEQ ID N0:308) of a native sequence
PR01075 cDNA, wherein
SEQ ID N0:308 is a clone designated herein as "UNQ532" and/or "DNA57689-1385".
Figure 125 shows tt~ amino acid sequence (SEQ ID N0:309) derived from the
coding sequence of SEQ ID
N0:308 shown in Figure 124.
Figure 126 shows an EST nucleotide sequence designated herein as DNA13059 (SEQ
ID N0:310).
Figure 127 shows an EST nucleotide sequence designated herein as DNA194b3 (SEQ
ID N0:311).
Figure 128 shows a nucleotide sequence (SEQ ID N0:321) of a native sequence
PR0181 cDNA, wherein
SEQ ID N0:321 is a clone designated herein as "UNQi55" and/or "DNA23330-1390".
Figure 129 shows the amino acid sequence (SEQ ID N0:322) derived from the
coding sequence of SEQ ID
N0:321 shown in Figure 128.
Figure 130 shows an EST nucleotide sequence designated herein as DNA13242 (SEQ
ID N0:323).
Figure 131 shows a nucleotide sequence (SEQ ID N0:329) of a native sequence
PR0195 eDNA, wherein
SEQ ID N0:329 is a clone designated herein as "UNQ169" and/or "DNA2684?-1395".
Figure 132 shows the amino acid sequence (SEQ ID N0:330) derived from the
coding sequence of SEQ ID
N0:329 shown in Figure 131.
Figure 133 shows an EST nucleotide sequence designated herein as DNA15062 (SEQ
ID N0:331).
Figure 134 shows an EST nucleotide sequence designated herein as DNA13199 (SEQ
ID N0:332).
Figure 135 shows a rntcleotide sequence (SEQ ID N0:336) of a native sequence
PR0865 cDNA, wherein
SEQ ID N0:336 is a clone designated herein as "UNQ434" and/or "DNA53974-1401".
Figure 136 shows the amino acid sequence (SEQ ID N0:337) derived from the
coding sequence of SEQ ID
N0:336 shown in Figure 135.
Figure 137 shows an EST nucleotide sequence designated herein as DNA37642 (SEQ
ID N0:338).
fiigure 138 shows a nucleotide sequence (SEQ ID N0:345) of a native sequence
PR0827 cDNA, wherein
SEQ ID N0:345 is a clone designated herein as "UNQ4b8" and/or "DNA57039-1402".
Figure 139 shows the amino acid sequence (SEQ ID N0:346) derived from the
coding sequence of SEQ ID
N0:345 shown in Figure 138.
Figure 140 shows an EST nucleotide sequence designated herein as DNA47751 (SEQ
ID N0:347).
Figure 141 shows a nucleotide sequence (SEQ ID N0:351) of a native sequenec
PR01114 cDNA, wherein
SEQ ID N0:351 is a clone designated herein as "UNQ557" and/or "DNA57033-1403".
1 OS
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 142 shows the amino acid sequence (SEQ ID N0:352) derived from the
coding sequence of SEQ ID
N0:351 shown in Figure 141.
Figure 143 shows an EST nucleotide sequence designated herein as DNA48466 (SEQ
ID N0:353).
Figure 144 shows a nucleotide sequence (SEQ ID N0:357) of a native sequence
PR0237 cDNA, wherein
SEQ ID N0:357 is a clone designated herein as "UNQ211 " and/or "DNA34353-1428"
.
Figure 145 shows the amino acid sequence (SEQ ID N0:358) derived from the
coding sequence of SEQ ID
N0:35? shown in Figure 144.
Figure 146 shows a nucleotide sequence (SEQ ID N0:362) of a native sequence
PR0541 cDNA, wherein
SEQ ID N0:362 is a clone designated herein as "UNQ342" and/or "DNA45417-1432".
Figure 147 shows the amino acid sequence (SEQ ID N0:363) derived from the
coding sequence of SEQ ID
N0:362 shown in Figure 146.
Figure 148 shows a nucleotide sequence (SEQ ID N0:369) of a native sequence
PR0273 cDNA, wherein
SEQ ID N0:369 is a clone designated herein as "UNQ240" andlor "DNA39523-1192".
Figure 149 shows the amino acid sequence (SEQ ID N0:370) derived from the
coding sequence of SEQ ID
N0:369 shown in Figure 148.
Figure 150 shows a nucleotide sequence (SEQ ID N0:374) of a native sequence
PR0701 cDNA, wherein
SEQ ID N0:374 is a clone designated herein as "UNQ365" and/or "DNA44205-1285".
Figure 151 shows the amino acid sequence (SEQ ID N0:375) derived from the
coding sequence of SEQ ID
N0:374 shown in Figure 150.
Figure 152 shows a nucleotide sequence (SEQ ID N0:379) of a native sequence
PR0704 cDNA, wherein
SEQ ID N0:379 is a clone designated herein as "UNQ368" and/or "DNA50911-1288".
Figure 153 shows the amino acid sequence (SEQ ID N0:380) derived from the
coding sequence of SEQ ID
N0:379 shown in Figure 152.
Figure 154 shows a nucleotide sequence (SEQ ID N0:384) of a native sequence
PR0706 cDNA, wherein
SEQ ID N0:384 is a clone designated herein as "UNQ370" and/or "DNA48329-1290".
Figure 155 shows the amino acid sequence (SEQ ID N0:385) derived from the
coding sequence of SEQ ID
N0:384 shown in Figure 154.
Figure 156 shows a nucleotide sequence (SEQ ID N0:389) of a native sequence
PR0707 cDNA, wherein
SEQ ID N0:389 is a clone designated herein as "UNQ371 " and/or "DNA48306-1291
".
Figure 157 shows the amino acid sequence (SEQ ID N0:390) derived from the
coding sequence of SEQ ID
N0:389 shown in Figure 156.
Figure 158 shows a nucleotide sequence (SEQ ID N0:394) of a native sequence
PR0322 cDNA, wherein
SEQ ID N0:394 is a clone designated herein as "UNQ283" and/or "DNA48336-1309".
Figure 159 shows the amino acid sequence (SEQ ID N0:395) derived from the
coding sequence of SEQ ID
N0:394 shown in Figure 158.
Figure 160 shows a nucleotide sequence (SEQ ID N0:399) of a native sequence
PR0526 cDNA, wherein
SEQ ID N0:399 is a clone designated herein as "UNQ330" and/or "DNA44184-1319".
Figure 161 shows the amino acid sequence (SEQ ID N0:400) derived from the
coding sequence of SEQ ID
N0:399 shown in Figure 160.
106
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/OSOZ8
Figure 162 shows a nucleotide scqticnce (SEQ !D N0:404) of a native stquence
PR0531 cDNA, wherein
SEQ ID N0:404 is a clone designated herein as "UNQ332' and/or "DNA48314-1320".
Figure 163 shows the amino acid sequcrxe (SEQ ID N0:405) derived from the
coding sequence of SEQ ID
N0:404 shown in Figure 162.
Figure 164 shows a nucleotide sequence (SEQ ID N0:409) of a native sequence
PR0534 cDNA, wherein
SEQ ID N0:409 is a clone designated herein as "UNQ335" and/or "DNA48333-1321".
Figure 165 shows the amino acid sequence (SEQ ID N0:410) derived from the
coding sequence of SEQ ID
N0:409 shown in Figure 164.
Figure 166 shows a nucleotide sequence (SEQ ID N0:414) of a native sequence
PR0697 cDNA, wherein
SEQ ID N0:414 is a clone designated herein as "UNQ361 ' and/or "DNA50920-
1325".
Figure 167 shows the amim acid sequence (SEQ ID N0:415) derived from the
coding sequence of SEQ ID
N0:414 shown in Figure 166. ,.
Figure 168 shows a nucleotide sequence (SEQ ID N0:419) of a native sequence
PR0717 cDNA, wherein
SEQ ID N0:419 is a clone designated herein as "UNQ385' and/or "DNA50988-1326".
Figure 169 shows the amino acid sequence (SEQ ID N0:420) derived from the
coding sequence of SEQ ID
IS N0:419 shown in Figure 168.
Figures 170A-B show a nucleotide sequence (SEQ ID N0:424) of a native sequence
PR0731 cDNA,
wherein SEQ ID N0:424 is a clone designated herein as 'UNQ395" andlor
"DNA4$331-1329".
Figure 171 shows the amino acid sequence (SEQ ID N0:425) derived from the
coding sequence of SEQ ID
N0:424 shown in Figures 170A-B.
figure In shows a nucleotide sequence (SEQ 1D N0:429) of a native sequence
PR0218 cDNA, wherein
SEQ ID N0:429 is a clone designated herein as "UNQ192" and/or "DNA30867-1335"_
Figure 173 shows the amino acid sequence (SEQ iD N0:430) derived from the
coding sequence of SEQ ID
N0:429 shown in Figure 172.
Figure 174 shows an EST nucleotide sequence designated herein as DNA14472 (SEQ
ID N0:431).
Figure 175 shows an EST nucleotide sequence designated herein as DNA15846 (SEQ
ID N0:432).
Figures 176A-B show a nucleotide sequence (SEQ ID N0:436) of a native sequence
PR0768 cDNA,
wherein SEQ ID N0:436 is a clone designated herein as "UNQ406" and/or
'DNA55737-1345"_ .
Figure 177 shows the amino acid sequettce (SEQ 1D N0:437) derived from the
coding sequence of SEQ ID
N0:436 shown in Figures 176A-B.
Figure 178 shows a nucleotide,sequcnce (SEQ ID N0:441) of a native sequence
PR0771 eDNA, wherein
SEQ ID N0:441 is a clone designated herein as "UNQ409" and/or "DNA49829-1346".
Figure 179 shows the amino acid sequence (SEQ ID N0:442) derived from the
coding sequence of SEQ ID
N0:441 shown in Figure 178.
Figures 180A-B show a nucleotide sequence (SEQ ID N0:446) of a native sequence
PR0733 cDNA,
wherein SEQ ID N0:446 is a clone designated herein as "UNQ411" andlor
'DNA52196-1348".
Figure 181 shows the amino acid sequence (SEQ ID N0:447) derived from the
coding sequence of SEQ ID
N0:446 shown in Figures I80A-8.
Figure 182 shows a nucleotide sequence (SEQ ID N0:451) of a native seauettce
PR0162 eDNA, wherein
SEQ ID N0:451 is a clone designated herein as "UNQ429" and/or "DNA56965-1356".
107
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 183 shows the amino acid sequcrxe (SEQ ID N0:452) derived from the
coding sequence of SEQ ID
N0:451 shown in Figure 182.
Figure 184 shows a nucleotide sequence (SEQ ID N0:453) of a native sequence
PR0788 cDNA, wherein
SEQ ID N0:453 is a clone designated herein as "UNQ430" and/or "DNA56405-1357".
Figure 185 shows the amino acid sequettee (SEQ ID N0:454) derived from the
coding sequence of SEQ ID
N0:453 shown in Figure 184.
Figure 186 shows a nucleotide sequence (SEQ ID N0:455) of a native sequence
PR01008 cDNA, wherein
SEQ ID N0:455 is a clone designated herein as "UNQ492" and/or "DNA57530-1375".
Figure 187 shows the amino acid sequence (SEQ ID N0:456) derived from the
coding sequence of SEQ ID
N0:455 shown in Figure 186.
Figure 188 shows an EST nucleotide sequence designated herein as DNA16508 (SEQ
ID N0:457).
Figures 189A-B show a nucleotide sequence (SEQ ID N0:458) of a native sequence
PR01012 cDNA,
wherein SEQ ID N0:458 is a clone designated herein as "UNQ495" and/or
"DNA56439-1376".
Figure 190 shows the amino acid sequence (SEQ ID N0:459) derived from the
coding sequence of SEQ ID
N0:458 shown in Figwes 189A-B.
Figure 191 shows a nucleotide sequence (SEQ ID N0:463) of a native sequence
PR01014 eDNA, wherein
SEQ ID N0:463 is a clone designated herein as "UNQ497" and/or "DNA56409-1377".
Figure 192 shows the amino acid sequence (SEQ ID N0:464) derived from the
coding sequence of SEQ ID
N0:463 shown in Figure 191.
Figure .193 shows a nucleotide sequence (SEQ ID N0:465) of a native sequence
PR01017 cDNA, wherein
SEQ >D N0:465 is a clone designated herein as "UNQ500" and/or "DNA56112-1379".
Figure 194 shows the amino acid sequence (SEQ ID N0:466) derived from the
coding sequence of SEQ ID
N0:465 shown in Figure 193.
Figure 195 shows a nucleotide sequence (SEQ ID N0:467) of a native sequence
PR0474 eDNA, wherein
SEQ ID N0:467 is a clone designated herein as "UNQ502" and/or "DNA56045-1380".
Figure 196 shows the amino acid sequerux (SEQ ID N0:468) derived from the
coding sequence of SEQ ID
N0:467 shown in Figure 195.
Figure 197 shows a nucleotide sequence (SEQ ID N0:469) of a native sequence
PR01031 eDNA, wherein
SEQ ID N0:469 is a clone designated herein as "UNQ516" and/or "DNA59294-1381".
Figure 198 shows the amino acid sequence (SEQ ID N0:470) derived from the
coding sequence of SEQ ID
N0:469 shown in Figure 197.
Figure 199 shows a nucleotide sequence (SEQ ID N0:471) of a native sequence
PR0938 cDNA, wherein
SEQ ID N0:471 is a clone designated herein as "UNQ475" and/or "DNA56433-1406".
Figure 200 shows the amino acid sequence (SEQ ID N0:472) derived from the
coding sequence of SEQ ID
N0:471 shown in Figure 199.
Figure 201 shows a nucleotide sequence (SEQ 1D N0:476) of a native sequence
PR01082 eDNA, wherein
SEQ ID N0:476 is a clone designated herein as "UNQ539" and/or "DNA53912-1457".
Figure 202 shows the amino acid sequence (SEQ ID N0:477) derived from the
coding sequence of SEQ ID
N0:476 shown in Figure 201.
108
CA 02421372 2003-03-25
WO 99/46281 PCTJUS99/05028
Figure 203 shows a nucleotide sequence (SEQ ID N0:482) of a native sequence
PR01083 cDNA, wherein
SEQ ID N0:482 is a clone designated herein as "UNQ540" and/or "DNA50921-1458".
Figure 204 shows the amino acid sequence (SEQ ID N0:483) derived from the
coding sequence of SEQ ID
N0:482 shown in Figure 203.
Figure 205 shows an EST nucleotide sequence designated herein as DNA24256 (SEQ
ID N0:484).
Figure 206 shows a nucleotide sequence (SEQ ID N0:487) of a native sequence
PR0200 cDNA, wherein
SEQ ID N0:487 is a clone designated herein as "UNQ174" and/or "DNA29101-1122".
Figure 207 shows the amino acid sequence (SEQ ID N0:488) derived from the
coding sequence of SEQ ID
N0:487 shown in Figure 206.
Figure 208 shows a nucleotide sequence (SEQ ID N0:495) of a native sequence
PR0285 eDNA, wherein
SEQ ID N0:495 is a clone designated herein as "DNA40021-1154".
Figure 209 shows the amino acid sequence (SEQ ID N0:496) derived from the
coding sequence of SEQ ID
N0:495 shown in Figure 208.
Figures 210A-B show a nucleotide sequence (SEQ ID N0:497) of a native sequence
PR0286 cDNA,
wherein SEQ ID N0:497 is a clone designated herein as "DNA42663-1154".
Figure 211 shows the amino acid sequence (SEQ ID N0:498) derived from the
coding sequence of SEQ ID
N0:497 shown in Figures 210A-8.
Figure 212 shows a nucleotide sequence (SEQ ID NO:505) of a native sequence
PR0213-1 cDNA, wherein
SEQ ID NO:505 is a clone designated herein as "DNA30943-1-1163-1 ".
Figure 213 shows the amino acid sequence (SEQ ID N0:506) derived from the
coding sequence of SEQ ID
NO:505 shown in Figure 212.
Figure 214 shows a nucleotide sequence (SEQ ID N0:507) of a native sequence
PR01330 cDNA, wherein
SEQ ID N0:507 is a clone designated herein as "DNA64907-1163-1".
Figure 215 shows the amino acid sequence (SEQ ID N0:508) derived from the
coding sequence of SEQ ID
N0:507 shown in Figure 214.
Figure 216 shows a nucleotide sequence (SEQ ID N0:509) of a native sequence
PR01449 cDNA, wherein
SEQ ID N0:509 is a clone designated herein as "DNA64908-1163-1".
Figure 217 shows the amino acid sequence (SEQ ID NO:510) derived from the
coding sequence of SEQ ID
N0:509 shown in Figure 216.
Figure 218 shows a nucleotide sequence (SEQ ID N0:514) of a native sequence
PR0298 cDNA, wherein
SEQ ID N0:514 is a clone designated herein as "UNQ261" and/or "DNA39975-1210".
Figure 219 shows the amino acid sequence (SEQ ID NO:515) derived from the
coding sequence of SEQ ID
N0:514 shown in Figure 218.
Figure 220 shows an EST nucleotide sequence designated herein as DNA26832 (SEQ
ID N0:516).
Figure 221 shows a nucleotide sequence (SEQ ID N0:522) of a native sequence
PR0337 cDNA, wherein
SEQ ID N0:522 is a clone designated herein as "DNA43316-1237".
Figure 222 shows the amino acid sequence (SEQ 1D N0:523) derived from the
coding sequence of SEQ ID
N0:522 shown in Figure 221.
Figure 223 shows an EST nucleotide sequence designated herein as DNA42301 (SEQ
ID N0:524).
109
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 224 shows a nucleotide sequence (SEQ ID N0:525) of a native sequence
PR0403 cDNA, wherein
SEQ ID N0:525 is a clone designated herein as "DNA55800-1263".
Figure 225 shows the amino acid sequence (SEQ ID N0:526) derived from the
coding sequence of SEQ ID
N0:525 shown in Figure 224.
Figures 226A-B show an EST nucleotide sequence designated herein as DNA3441S
(SEQ ID NO:S27).
Figure 227 shows an EST nucleotide sequence designated herein as DNA49830 (SEQ
1D N0:528).
Figure 228 shows an EST nucleotide sequence designated herein as DNA49831 (SEQ
1D N0:529).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Definitions
The terms "PRO polypeptide" and "PRO" as used herein and when immediately
followed by a numerical
designation refer to various polypeptides, wherein the complete designation
(i.e., PRO/number) refers to specific
polypeptide sequences as described herein. The terms "PRO/number polypeptide"
and "PRO/number" as used herein
encompass native sequence polypeptides and polypeptide variants (which are
further defined herein). The PRO
polypeptides described herein may be isolated from a variety of sources, such
as from human tissue types or from
another source, or prepared by recombinant or synthetic methods.
A "native sequence PRO polypeptide" comprises a polypeptide having the same
amino acid sequence as the
corresponding PRO polypeptide derived from nature. Such native sequence PRO
polypeptides can be isolated from
nature or can be produced by recombinant or synthetic means. The term "native
sequence PRO polypeptide"
specifically encompasses naturally-occurring truncated or secreted fortes of
the specific PRO polypeptide (e.g., an
extracellular domain sequence)> naturally-occurring variant forms (e.g.,
altetTtatively spliced forms) and naturally-
occurring allelic variants of the polypeptide. In various embodiments of the
invention, the native sequence PR0213
polypeptide is a mature or full-length native sequence PR0213 polypeptide
comprising amino acids 1 to 29S of Figure
2 (SEQ ID N0:2), the native sequence PR0274 polypeptide is a mature or full-
length native sequence PR0274
polypeptide comprising amino acids 1 to 492 of Figure 4 (SEQ ID N0:7), the
native sequence PR0300 polypeptide
is a mature or full-length native sequence PR0300 polypeptide comprising amino
acids 1 to 457 of Figure 9 (SEQ
m N0:19), the native sequence PR0284 polypeptide is a mature or full-length
native sequence PR0284 polypeptide
cotr>prising amino acids 1 to 285 of Figure 11 (SEQ ID N0:28), the native
sequence PR0296 polypeptide is a mature
or full-length native sequence PR0296 polypeptide comprising amino acids I to
204 of Figure IS (SEQ ID N0:36),
the native sequence PR0329 polypeptide is a mature or full-length native
sequence PR0329 polypeptide comprising
amino acids 1 to 3S9 of Figure 20 (SEQ ID N0:4S), the native sequence PR0362
polypeptide is a mature or full-
length native sequence PR0362 polypeptide comprising amino acids I to 321 of
Figure 22 (SEQ ID N0:52), the
native sequence PR0363 polypeptide is a mature or full-length native sequence
PR0363 polypeptide comprising
amino acids I to 373 of Figure 24 (SEQ ID NO:S9), the native sequence PR0868
polypeptide is a mature or full-
length native sequence PR0868 polypeptide comprising amino acids 1 to 655 of
Figure 26 (SEQ ID N0:64), the
native sequence PR0382 polypeptide is a mature or full-length native sequence
PR0382 polypeptide comprising
amino acids 1 to 453 of Figure 28 (SEQ ID N0:69), the native sequence PR0545
polypeptide is a mature or full-
length native sequence PROS4S polypeptide comprising amino acids 1 to 73S of
Figure 30 (SEQ ID N0:74), the
native sequence PR0617 polypeptide is a mature or full-length native sequence
PR0617 polypeptide comprising
amino acids 1 to 6? of Figure 33 (SEQ 1D N0:85), the native sequence PR0700
polypeptide is a mature or full-length
110
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
native sequence PR0700 polypeptide comprising amino acids 1 to 432 of Figure
35 (SEQ ID N0:90), the native
sequence PR0702 polypeptide is a mature or full-length native sequence PR0702
polypeptide comprising amino acids
1 to 277 of Figure 37 (SEQ ID N0:97), the native sequence PR0703 polypeptide
is a mature or full-length native
sequence PR0703 polypeptide comprising amino acids 1 to 730 of Figure 39 (SEQ
ID N0:102), the native sequence
PR0705 polypeptide is a mature or full-length native sequence PR0705
polypeptide comprising amino acids 1 to 555
of Figure 41 (SEQ ID N0:109), the native sequence PR0708 polypeptide is a
mature or full-length native sequence
PR0708 polypeptide comprising amino acids 1 to S15 of Figure 43 (SEQ ID
N0:114), the native sequence PR0320
polypeptide is a mature or full-length native sequence PR0320 polypeptide
comprising amino acids 1 to 338 of Figure
4S (SEQ ID N0:119), the native sequence PR0324 polypeptide is a mature or full-
length native sequence PR0324
polypeptide comprising amino acids 1 to 289 of Figure 47 (SEQ ID N0:124), the
native sequence PR03S1
polypeptide is a mature or full-length native sequence PR03S 1 polypeptide
comprising amino acids 1 to 571 of Figure
49 (SEQ ID N0:132), the native sequence PR0352 polypeptidc is a mature or full-
length native sequence PR03S2
polypeptide comprising amino acids 1 to 316 of Figure 51 (SEQ ID N0:137), the
native sequence PR0381
polypeptide is a mature or full-length native sequence PR0381 polypeptide
comprising amino acids 1 to 211 of Figure
53 (SEQ 1D N0:145), the native sequence PR0386 polypeptide is a mature or full-
length native sequence PR0386
1S polypeptide comprising amino acids 1 to 215 of Figure 55 (SEQ ID NO:150),
the native sequence PR0540
polypeptide is a mature or full-length native sequence PROS40 polypeptide
comprising amino acids 1 to 412 of Figure
59 (SEQ ID N0:157), the native sequence PR061S polypeptide is a mature or full-
length native sequence PR061S
polypeptide comprising amino acids I to 224 of Figure 61 (SEQ ID N0:162), the
native sequence PR0618
polypeptide is a mature or full-length native sequence PR0618 polypeptide
comprising amino acids 1 to 802 of Figure
63 (SEQ m N0:169), the native sequence PR0719 polypeptide is a mature or full-
length native sequence PR0719
polypeptide comprising amino acids 1 to 3S4 of Figure 66 (SEQ ID N0:178), the
native sequence PR0724
polypeptide is a mature or full-length native sequence PRO724 polypeptide
comprising amino acids 1 to 713 of Figure
68 (SEQ ID N0:183), the native sequence PR0772 polypeptide is a mature or full-
length native sequence PR0772
polypeptide comprising amino acids 1 to 152 of Figure 70 (SEQ ID N0:190), the
native sequence PR08S2
polypeptide is a mature or full-length native sequence PR08S2 polypeptide
comprising amino acids 1 to S 18 of Figure
73 (SEQ )D N0:196), the native sequence PR0853 polypeptide is a mature or full-
length native sequence PRO8S3
polypeptide comprising amino acids 1 to 377 of Figure 75 (SEQ 1D N0:206), the
native sequence PR0860
polypeptide is a mature or full-length native sequence PR0860 polypeptide
comprising amino acids 1 to 98S of Figure
77 (SEQ 1D N0:211), the native sequence PR0846 polypeptide is a mature or full-
length native sequence PR0846
polypeptide comprising amino acids 1 to 332 of Figure 79 (SEQ 1D N0:216), the
native sequence PR0862
polypeptide is a mature or full-length native sequence PR0862 polypeptide
comprising amino acids 1 to 146 of Figure
81 (SEQ ID N0:221 ), the native sequence PR0864 polypeptide is a mature or
full-length native sequence PR0864
polypeptide comprising amino acids 1 to 351 of Figure 83 (SEQ ID N0:226), the
native sequence PR0792
polypeptide is a mature or full-length native sequer~e PR0792 polypeptide
comprising amino acids 1 to 293 of Figure
3S 85 (SEQ ID N0:231), the native sequence PR0866 polypeptide is a mature or
full-length native sequence PR0866
polypeptide comprising amino acids 1 to 331 of Figure 87 (SEQ ID N0:236), the
native sequence PR0871
polypeptide is a mature or full-length native sequence PR0871 polypeptide
comprising amino acids 1 to 472 of Figure
89 (SEQ >D N0:24S), the native sequence PR0873 polypeptide is a mature or full-
length native sequence PR0873
polypeptide comprising amino acids 1 to 54S of Figure 91 (SEQ ID N0:2S4), the
native sequence PR0940
111
CA 02421372 2003-03-25
WO 99!46281 PCT/US99/05028
polypeptide is a mature or full-length native sequence PR0940 polypeptide
comprising amino acids 1 to 544 of Figure
93 (SEQ ID N0:259), the native sequence PR0941 polypeptide is a mature or full-
length native sequence PR0941
polypeptide comprising amino acids 1 to 772 of Figure 95 (SEQ ID N0:264), the
native sequence PR0944
polypeptide is a mature or full-length native sequence PR0944 polypeptide
comprising amino acids 1 to 21 !of Figure
98 (SEQ ID N0:270), the native sequence PR0983 polypeptide is a mature or full-
length native sequence PR0983
poiypeptide comprising amino acids 1 to 243 of Figure 109 (SEQ ID N0:284), the
native sequence PR01057
polypeptide is a mature or full-length native sequence PR01057 polypeptide
comprising amino acids 1 to 413 of
Figure 118 (SEQ ID N0:296), the native sequence PR01071 polypeptide is a
mature or full-length native sequence
PR01071 polypeptide comprising amino acids 1 to 525 of Figure 120 (SEQ ID
N0:301), the native sequence
PR01072 polypeptide is a mature or full-length native sequence PROI072
polypeptide comprising amino acids 1 to
336 of Figure 122 (SEQ ID N0:303), the native sequence PR01075 poiypeptide is
a mature or full-length native
sequence PR01075 polypeptide comprising amino acids 1 to 406 of Figure 125
(SEQ ID N0:309), the native
sequence PR0181 polypeptide is a mature or full-length native sequence PR0181
polypeptide comprising amino acids
1 to 144 of Figure 129 (SEQ )D N0:322), the native sequence PR0195 polypeptide
is a mature or full-length native
sequence PR0195 polypeptide comprising amino acids 1 to 323 of Figure 132 (SEQ
ID N0:330), the native sequence
PR0865 polypeptide is a mature or full-length native sequence PR0865
polypeptide comprising amino acids 1 to 468
of Figure 136 (SEQ ID N0:337), the native sequence PR0827 polypeptide is a
mature or full-length native sequence
PR0827 polypeptide comprising amino acids 1 to 124 of Figure 39 (SEQ ID
N0:346), the native sequence PR01114
polypeptide is a mature or full-length native sequence PR01114 polypeptide
comprising amino acids 1 to 311 of
Figure 142 (SEQ ID N0:352), the native sequence PR0237 polypeptide is a mature
or full-length native sequence
PR0237 polypeptide comprising amino acids 1 to 328 of Figure 145 (SEQ ID
N0:358), the native sequence PR0541
polypeptide is a mature or full-length native sequence PR0541 polypeptide
comprising amino acids 1 to 500 of Figure
147 (SEQ ID N0:363), the native sequence PR0273 polypeptide is a mature or
full-length native sequence PR0273
polypeptide comprising amino acids 1 through 111 of Figure 149 (SEQ ID
N0:370), the native sequence PR0701
polypeptide is a mature or full-length native sequence PR0701 polypeptide
comprising amino acids 1 to 816 of Figure
151 (SEQ ID N0:375), the native sequence PR0704 polypeptide is a full-length
or mature native sequence PR0704
polypeptide comprising amino acids I or 40 through 348 of Figure 153 (SEQ ID
N0:380), the native sequence
PR0706 polypeptide is a mature or full-length native sequence PR0706
polypeptide comprising amino acids 1 to 480
of Figure 155 (SEQ ID N0:385), the native sequence PR0707 polypeptide is a
full-length or mature native sequence
PR0707 polypeptide comprising amino acids 1 or 31 through 916 of Figure 157
(SEQ ID N0:390), the native
sequence PR0322 polypeptide is a mature or full-length native sequence PR0322
polypeptide comprising amino acids
24 or 1 to 260 of Figure 159 (SEQ ID N0:395), the native sequence PR0526
polypeptide is a full-length or mature
native sequence PR0526 polypeptide comprising amino acids 1 or 27 through 473
of Figure 161 (SEQ ID N0:400),
the native sequence PR0531 polypeptide is a mature PR0531 polypeptide
comprising amino acids 1 to 789 of Figure
163 (SEQ ID N0:405), the native sequence PR0534 polypeptide is a mature or
fitll-length native sequence PR0534
polypeptide comprising amino acids 1 to 360 of Figure 165 (SEQ ID N0:410), the
native sequence PR0697
polypeptide is a full-length or mature native sequence PR0697 polypeptide
comprising amino acids 1 or 21 through
295 of Figure 167 (SEQ ID N0:415), the native sequence PR0717 polypeptide is a
mature or full-length native
sequence PR07I7 polypeptide comprising amino acids 1 through 560 of Figure 169
(SEQ ID N0:420), the native
sequence PR0731 polypeptide is a full-length or mature native sequence PR0731
polypeptide comprising amino acids
112
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
1 or 14 through 1184 of Figure 171 (SEQ 1D N0:425), the native sequence PR0218
polypeptide is a full-length or
mature native sequence PR0218 polypeptide comprising amino acids 1 or 24
through 455 of Figure 173 (SEQ ID
N0:430), the native sequence PR0768 polypeptide is a full-length or mature
native sequence PR0768 polypeptide
comprising amino acids 1 or 34 through 1141 of Figure 177 (SEQ ID N0:437), the
native sequence PR0771
polypeptide is a full-length or mature native sequence PR0771 polypeptide
comprising amino acids 1 or 17 through
436 of Figure 179 (SEQ ID N0:442), the native sequence PR0733 polypeptide is a
mature or full-length native
sequence PRO733 polypeptide comprising amino acids 24 or 1 through 229 of
Figure 181 (SEQ ID N0:447), the
native sequence PR0162 polypeptide is a full-length or mature native sequence
PR0162 polypeptide comprising
amino acids 1 or 27 through 175 of Figure 183 (SEQ ID N0:452), the native
sequence PR0788 polypeptide is a full-
length or mature native sequence PR0788 polypeptide comprising amino acids 1
or 18 through 125 of Figure 185
(SEQ ID N0:454), the native sequence PR01008 polypeptide is a full-length or
mature native sequence PR01008
polypeptide comprising amino acids 1 or 24 through 266 of Figure 187 (SEQ ID
N0:456), the native sequence
PR01012 polypeptide is a mature or full-length native sequence PR01012
polypeptide comprising amino acids 1
through 747 of Figure 190 (SEQ ID N0:459), the native sequence PR01014
polypeptide is a full-length or mature
native sequence PR01014 polypepcide comprising amino acids 1 or 20 through 300
of Figure 192 (SEQ ID N0:464),
the native sequence PR01017 polypeptide is a full-length or rnatwe native
sequence PR01017 polypeptide comprising
amino acids 1 or 32 through 414 of Figure 194 (SEQ ID N0:466), the native
sequence PR0474 polypeptide is a
mature or full-length native sequence PR0474 polypeptide comprising amino
acids 1 through 270 of Figure 196 (SEQ
ID N0:468), the native sequence PR01031 polypeptide is a full-length or mature
native sequence PR01031
polypeptide comprising amino acids 1 or 21 through 180 of Figure 198 (SEQ ID
N0:470), the native sequence
PR0938 polypepti~ is a mature or full-length native sequence PR0938
polypeptide comprising amino acids 1 to 349
of Figure 200 (SEQ ID N0:472), the native sequence PR01082 polypeptide is a
full-length or mature native sequence
PR01082 polypeptide comprising amino acids 1 through 201 of Figure 202 (SEQ ID
N0:477), the native sequence
PR01083 polypeptide is a full-length or mature native sequence PR01083
polypeptide comprising amino acids 1 or
26 through 693 of Figure 204 (SEQ ID N0:483), the native sequence VEGF-E
polypeptide is a mature or full-length
native sequence VEGF-E polypeptide comprising amino acids 1 through 345 as
depicted in Figure 207 (SEQ ID
N0:488), the native sequence PR0285 is a mature or full-length native sequence
PR0285 polypeptide comprising
amino acids 1 to 1049 of Figure 209 (SEQ ID N0:496), the native sequence
PR0286 is a mature or full-length native
sequence PR0286 polypeptide comprising amino acids 1 to 1041 of Figure 211
(SEQ ID N0:298), the native
sequence PR0298 is a mature or full-length native sequence PR0298 comprising
amino acids 1 to 364 of Figure 219
(SEQ ID N0:515), the native sequence PR0337 is a mature or full-length native
sequence human neurotrimin
comprising amino acids 1 to 344 of Figure 222 (SEQ ID N0:523), with or without
the N-terminal signal sequence
(residues 1 to about 28), and with or without the initiating methionine at
position 1 and the native sequence PR0403
is a mature or full-length native sequence comprising amino acids 1 to 736 of
Figure 225 (SEQ ID N0:526), with
or without the initiating methionir>e at position 1.
The PRO polypeptidc "extracellular domain" or "ECD" refers to a form of the
PRO polypeptide which is
essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a
PRO polypeptide ECD will have less
than 196 of such transmembrane and/or cytoplasrnic domains and preferably,
will have less than 0.59b of such
domains. It will be understood that any transmembrane domains identified for
the PRO polypeptides of the present
invention are identified pursuant to criteria routinely employed in the art
for identifying that type of hydrophobic
113
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
domain. The exact boundaries of a uansmembrane domain may vary but most likely
by no more than about 5 amino
acids at either end of the domain as initially identified. Optionally,
therefore, an extracellular domain of a PRO
polypeptide may contain from about 5 or fewer amino acids on either or the
uansmembrane domain as initially
identified.
"PRO polypeptide variant" means an active PRO polypeptide as defined above or
below having at least about
80% amino acid sequence identity with the full-length native sequence PRO
polypeptide sequence as disclosed herein.
Such PRO polypeptide variants include, for instance, PRO polypeptides wherein
one or more amino acid residues
are added, or deleted, at the N- or C-terminus of the full-length native amino
acid sequence. Ordinarily, a PRO
polypeptide variant will have at least about 80 % amino acid sequence
identity, more preferably at least about 85
amino acid sequence identity, and even more preferably at least about 90%
amino acid sequence identity, even more
preferably at least about 91 % amino acid sequence identity, even more
preferably at least about 92% amino acid
sequence identity, even more preferably at least about 93 % amino acid
sequence identity, even more preferably at
least about 94 % amino acid sequence identity, even more preferably at least
about 95 % amino acid sequence identity,
yet more preferably at least about 96% amino acid sequence identity, yet more
preferably at least about 97% amino
acid sequence identity, yet more preferably at least about 98% amino acid
sequence identity and most preferably at
least about 99% amino acid sequence identity with the amino acid sequence of
the full-length native amino acid
sequence as disclosed herein.
"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide
sequences identified herein
is defined as the percentage of amino acid residues in a candidate sequence
that are identical with the amino acid
residues in the specific PRO polypeptide sequence, after aligning the
sequences and introducing gaps, if necessary,
to achieve the maximum percent sequence identity, and not considering any
conservative substitutions as part of the
sequence identity. Alignment for purposes of determining percent amino acid
sequence identity can be achieved in
various ways that are within the skill in the art, for instance, using
publicly available computer software such as
BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. The preferred software
alignment program is
BLAST. Those skilled in the art can determine appropriate parameters for
measuring alignment, including any
algorithms needed to achieve maacimal aligrunent over the full length of the
sequences being compared. The
identity values used herein have been generated using the WU-BLAST-2 computer
program (Altschul et al., ethods
in old 266:460-480 (1996); http://blast.wustlledu/blast/README.html). Most of
the WU-BLAST-2 search
parameters were set to the default values. The adjustable parameters were set
with the following values: overlap span
= 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix =
BLOSUM62. The HSP S and HSP
S2 parameters, which are dynamic values used by BLAST-2, are established by
the program itself depending upon
the composition of the sequence of interest and composition of the database
against which the sequence is being
searched. However, the values may be adjusted to increase sensitivity. A %
sequence identity value is determined
by the fraction of matching identical residues divided by the total number of
residues in the aligned region.
"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding
nucleic acid sequences identified
herein is defined as the percentage of nucleotides in a candidate sequence
that are identical with the nucleotides in
the PRO nucleic acid sequence of interest, after aligning the sequences and
introducing gaps, if necessary, to achieve
the maximum percent sequence identity. Alignment for purposes of determining
percent nucleic acid sequence
identity can be achieved in various ways that are within the skill in the art,
for instance, using publicly available
computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR)
software. Those skilled in the an
114
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
can determine appropriate parameters for measuring alignment, including any
algorithms needed to achieve maximal
alignment over the full length of the sequences being compared. The identity
values used herein were generated by
the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap
span and overlap fraction set to
1 and 0.125, respectively.
The term "positives", in the context of sequence comparison performed as
described above, includes
residues in the sequences compared that are not identical but have similar
properties (e.g. as a result of conservative
substitutions). The % value of positives is determined by the fraction of
residues scoring a positive value in the
BLOSUM 62 matrix divided by the total number of residues in the aligned
region, as defined above.
The term "epitope tagged" where used herein refers to a chimeric polypeptide
comprising a PRO
polypeptide, or domain sequence thereof, fused to a "tag polypeptide". The tag
polypeptide has enough residues to
provide an epitope against which an antibody may be made, or which can be
identified by some other agent, yet is
short enough such that it does not interfere with the activity of the PRO
polypeptide of interest. The tag polypeptide
preferably is also fairly unique so that the antibody does not substantially
cross-react with other epitopes. Suitable
tag polypeptides generally have at least six amino acid residues and usually
between about 8 to about 50 amino acid
residues (preferably, between about 10 to about 20 residues).
"Isolated," when used to describe the various polypeptides disclosed herein,
means polypeptide that has been
identified and separated andlor recovered from a component of its natural
environment. Contaminant components
of its natural environment are materials that would typically interfere with
diagnostic or therapeutic uses for the
polypeptide, and may include enzymes, hormones, and other proteinaceous or non-
proteinaceous solutes. In preferred
embodiments, the polypeptide wilt be purified (1) to a degree sufficient to
obtain at least 15 residues of N-terminal
or internal amino acid sequence by use of a spinning cup sequenator, or (2) to
homogeneity by SDS-PAGE under non-
reducing or reducing conditions using Coomassie blue or, preferably, silver
stain. Isolated polypeptide includes
polypeptide in situ within recombinant cells, since at least one component of
the PRO polypeptide natural environment
will not be present. Ordinarily, however, isolated polypeptide will be
prepared by at least one purification step.
An "isolated" PRO poiypeptide-encoding nucleic acid is a nucleic acid molecule
that is identified and
separated from at least one contaminant nucleic acid molecule with which it is
ordinarily associated in the natural
source of the PRO polypeptide nucleic acid. An isolated PRO polypeptide
nucleic acid molecule is other than in the
form or setting in which it is found in nature. Isolated PRO polypeptide
nucleic acid molecules therefore are
distinguished from the specific PRO polypeptide nucleic acid molecule as it
exists in natural cells. However, an
isolated PRO polypeptide nucleic acid molecule includes PRO polypeptide
nucleic acid molecules contained in cells
that ordinarily express the PRO polypeptide where, for example, the nucleic
acid molecule is in a chromosomal
location different from that of natural cells.
The term "control sequences" refers to DNA sequences necessary for the
expression of an operably linked
coding sequence in a particular host organism. The control sequences that are
suitable for prokaryotes, for example,
include a promoter, optionally an operator sequence, and a ribosome binding
site. Eukaryotic cells are known to
utilize promoters, polyadenylation signals, and etthancers.
Nucleic acid is "operably linked" when it is placed into a functional
relationship with another nucleic acid
sequence. For example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide
if it is expressed as a preprotein that participates in the secretion of the
polypeptide; a promoter or enhancer is
operably linked to a coding sequence if it affects the transcription of the
sequence; or a ribosome binding site is
115
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
operably linked to a coding sequence if it is positioned so as to facilitate
translation. Generally, "operably linked"
means that the DNA sequences being linked are contiguous, and, in the case of
a secretory leader, contiguous and
in reading phase. However, enhancers do not have to be contiguous. Linking is
accomplished by ligation at
convenient restriction sites. If such sites do not exist, the synthetic
oligonucleotide adaptors or linkers are used in
accordance with conventional practice.
The term "antibody" is used in the broadest sense and specifically covers
single anti-PRO polypeptide
monoclonal antibodies (including agortist, antagonist, and neutralizing
antibodies) and anti-PRO polypeptide antibody
compositions with polyepitopic specificity. The term "monoclonal antibody" as
used herein refers to an antibody
obtained from a population of substantially homogeneous antibodies, i.e., the
individual antibodies comprising the
population are identical except for possible naturally-occurring mutations
that may be present in minor amounts.
"Active" or "activity" for the purposes herein refers to fotmt(s) of PRO
polypeptide which retain the biologic
and/or immunologic activities of the specific native or naturally-occurring
PRO polypeptide.
"Treatment" or "treating" refers to both therapeutic treatment and
prophylactic or preventative measures.
Those in need of treatment include those already with the disorder as well as
those prone to have the disorder of those
in which the disorder is to be prevented.
"Mammal" for purposes of treatment refers to any animal classified as a
mammal, including humans,
domestic and farm animals, and zoo, sports, or pet animals, such as sheep,
dogs, horses, cats, cows, and the like.
Preferably, the mammal herein is a human.
"Carriers" as used herein include pharmaceutically acceptable carriers,
excipients, or stabilizers which are
nontoxic to the cell or mammal being exposed thereto at the dosages and
concentrations employed. Often the
physiologically acceptable carrier is an aqueous pH buffered solution.
Examples of physiologically acceptable
carriers itxlude buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid; low
molecular weight (less than about 10 residues) polypeptide; proteins, such as
serum albumin, gelatin, or
immtmoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino
acids such as glycine, glutamine,
asparagine, argittine or lysine; monosaccharides, disaccharides, and other
carbohydrates including glucose, trtatutose,
or dextrins; chelating agents such as EDTA; sugar alcohols such as tnannitol
or sorbitol; salt-forming counterions
such as sodium; andlor nonionic surfactants such as TWEENT"", polyethylene
glycol (PEG), and PLURONICST"'.
The term "agonist" is used to refer to peptide and non-peptide analogs of the
native PRO polypeptides
(where native PRO polypeptide refers to pro-PRO polypeptide, pre-PRO
polypeptide, prepro-PRO polypeptide, or
mature PRO polypeptide) of the present invention and to antibodies
specifically binding such native PRO
polypeptides, provided that they retain at least one biological activity of a
native PRO polypeptide. Preferably, the
agortists of the present invention retain the qualitative binding recognition
properties and receptor activation properties
of the native PRO polypeptide.
The term "antagonist" is used to refer to a molecule inhibiting a biological
activity of a native PRO
polypeptide of the present invention wherein native PRO polypeptide refers to
pro-PRO polypeptide, pre-PRO
polypeptide, prepro-PRO polypeptide, or mature PRO polypeptide. Preferably,
the antagonists herein inhibit the
binding of a native PRO polypeptide of the present invention to a binding
patmer. A PRO polypeptide "antagonist"
is a molecule which prevents, or interferes with, a PRO antagonist effector
function (e.g. a molecule which prevents
or interferes with binding and/or activation of a PRO polypeptide receptor by
PRO polypeptide). Such molecules
can be scrtened for their ability to competitively inhibit PRO polypeptide
receptor activation by monitoring binding
116
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
of native PRO polypeptide in the presence and absence of the test antagonist
molecule, for example. An antagonist
of the invention also encompasses an antisense polynucleotide against the PRO
polypeptide gene, which antisense
polynucleotide blocks transcription or translation of the PRO polypeptide
gene, thereby inhibiting its expression and
biological activity.
"Stringency" of hybridization reactions is readily determinable by one of
ordinary skill in the art, and
generally is an empirical calculation dependent upon probe length, washing
temperature, and salt concentration. In
general, longer probes require higher temperatures for proper annealing, while
shorter probes need lower
temperatures. Hybridization generally depends on the ability of denatured DNA
to reanneal when complementary
strands are present in an environment below their melting temperature. The
higher the degree of desired homology
between the probe and hybridizable sequence, the higher the relative
temperature which can be used. As a result,
it follows that higher relative temperatures would tend to make the reaction
conditions more stringent, while lower
temperatures less so. For additional details and explanation of stringency of
hybridization reactions, see Ausubel et
al., Current Protocols in Molecular Biology, Wiley Interscience Publishers,
(1995).
"Stringent conditions" means (I) employing low ionic strength and high
temperature for washing, for
example, 0.015 sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl
sulfate at 50°C, or (2) employing
during hybridization a denaturing agent, such as formamide, for example, 50%
(vol/vol) formamide with 0.1 % bovine
serum albumin/0.1 % Fico11/0.1 % polyvinylpyrrolidone/50 nM sodium phosphate
buffer at pH 6.5 with 750 mM
sodium chloride, 75 mM sodium citrate at 42°C. Another example is use
of 50% formamide, 5 x SSC (0.75 M
NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6/8), 0.1 % sodium
pyrophosphate, 5 x Denhardt's
solution, sonicated salmon sperm DNA (50 ~g/ml), 0.1 % SDS, and 10% dextran
sulfate at 42°C, with washes at
42°C in 0.2 x SSC and 0.1 % SDS. Yet another example is hybridization
using a buffer of 10% dextran sulfate, 2
x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C,
followed by a high-stringency wash consisting
of 0.1 x SSC containing EDTA at 55°C.
"Moderately stringent conditions" are described in Sambrook et al., supra, and
include the use of a washing
solution and hybridization conditions (e.g., temperature, ionic strength, and
%SDS) iess stringent than described
above. An example of moderately stringent conditions is a condition such as
overnight incubation at 37°C in a
solution comprising: 20% formamide, 5 x SSC (150 mM NaCI, 15 mM trisodium
citrate), 50 mM soditun phosphate
(pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mghnL denatured
sheared salmon sperm DNA,
followed by washing the filters in 1 x SSC at about 37-50°C. The
skilled artisan will recognize how to adjust the
temperature, ionic strength, etc., as necessary to accommodate factors such as
probe length and the like.
"Southern analysis" or "Southern blotting" is a method by which the presence
of DNA sequences in a
restriction endonuclease digest of DNA or a DNA-containing composition is
confirmed by hybridization to a known,
labeled oligonucleotide or DNA fragment. Southern analysis typically involves
electrophoretic separation of DNA
digests on agarose gels, denaturation of the DNA after electrophoretic
separation, and transfer of the DNA to
nitrocellulose, nylon, or another suitable membrane support for analysis with
a radiolabeled, biotinylated, or enzyme-
labeled probe as described in sections 9.37-9.52 of Sambrook et al., olecul~r
Clog: A Laboratory Manual (New
York: Cold Spring Harbor Laboratory Press, 1989).
"Northern analysis" or "Northern blotting" is a method used to identify RNA
sequences that hybridize to
a known probe such as an oligonucleotide, DNA fragment, cDNA or fragment
thereof, or RNA fragment. The probe
is labeled with a radioisotope such as'2P, or by biotinylation, or with an
enzyme. The RNA to be analyzed is usually
117
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
electrophoretically separated on an agarose or polyacrylamide gel, transferred
to nitrocellulose, nylon, or other
suitable membrane, and hybridized with the probe, using standard techniques
well known in the art such as those
described in sections 7.39-7.52 of Sambrook et al., supra.
As used herein, the term "itnmunoadhesin" designates antibody-like molecules
which combine the binding
specificity of a heterologous protein (an "adhesin") with the effector
functions of immunoglobulin constant domains.
Structurally, the immunoadhesins comprise a fusion of an amino acid sequence
with the desired binding specificity
which is other than the antigen recognition and binding site of an antibody
(i.e., is "heterologous"), and an
immunoglobulin constant domain sequence. The adhesin pan of an immunoadhesin
molecule typically is a contiguous
amino acid sequence comprising at least the binding site of a receptor or a
ligand. The immunoglobulin constant
domain sequence in the immunoadhesin may be obtained from any immunoglobulin,
such as IgG-1, IgG-2, IgG-3,
or IgG-4 subtypes, IgA (including 1gA-1 and IgA-2), IgE, IgD or IgM.
"Chronic" administration refers to adminisuation of the agents) in a
continuous mode as opposed to an acute
mode, so as to maintain the initial therapeutic effect (activity) for an
extended period of time. "Intermittent"
administration is treatment that is not consecutively done without
interruption, but rather is cyclic in nature.
Administration "in combination with" one or more funkier therapeutic agents
includes simultaneous
(concurrent) and consecutive administration in any order.
As used herein, "vascular endothelial cell growth factor-E," or "VEGF-E,"
refers to a mammalian growth
factor as described herein, including the human amino acid sequence of Figure
207, a sequence which has homology
to VEGF and bone morphogenetic protein 1 and which includes complete
conservation of all VEGF cysteine residues,
which have been shown to be required for biological activity of VEGF. VEGF-E
expression includes expression in
human fetal bone, thymus, and the gasuointestinal tract. The biological
activity of native VEGF-E is shared by any
analogue or variant thereof that is capable of promoting selective growth
and/or survival of umbilical vein endothelial
cells, induces proliferation of pluripotent fibroblast cells, induces
immediate early gene c-fos in human endothelial
cell lines and causes myocyte hypertrophy in cardiac cells, or which possesses
an immune epitope that is
itntttunologically cross-reactive with an antibody raised against at least one
epitope of the corresponding native VEGF-
E. The human VEGF-E herein is active on rat and mouse cells indicating
conservation across species. Moreover,
the VEGF-E herein is expressed at the growth plate region and has been shown
to embrace fetal myocytes.
As used herein, "vascular endothelial cell growth factor," or "VEGF," refers
to a mammalian growth factor
as defined in U.S. Patent 5,332,671. The biological activity of native VEGF is
shared by any analogue or variant
thereof that is capable of promoting selective growth of vascular endothelial
cells but not of bovine corneal endothelial
cells, lens epithelial cells, adrenal cortex cells, BHK-21 fibroblasts, or
keratinocytes, or that possesses an immune
epitope that is immunologically cross-reactive with an antibody raised against
at least one epitope of the corresponding
native VEGF.
The terms "VEGF-E polypeptide" and "VEGF-E" when used herein encompass native
sequence VEGF-E
poiypeptide and VEGF-E polypeptide variants (which are further defined
herein). The VEGF-E polypeptides may
be isolated from a variety of sources, such as from human tissue types or from
another source, or prepared by
recombinant or synthetic methods.
Inhibitors of VEGF-E include those which reduce or inhibit the activity or
expression of VEGF-E and
includes antisense molecules.
118
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The abbreviation "/CDR" refers to the kinase domain region of the VEGF
molecule. VEGF-E has no
homology with VEGF in this domain.
The abbreviation "FLT-1" refers to the FMS-like tyrosine kinase binding domain
which is known to bind
to the corresponding FLT-1 receptor. VEGF-E has no homology with VEGF in this
domain.
"Toll receptor2", "TLR2" and "huTLR2" are used interchangeably, and refer to a
human Toll receptor
designated as "HuTLR2" by Rock et al., Proc. Natl. Acad. Sci. USI3, ~5, 588-
593 (1998).
The term "expression vector" is used to define a vector, in which a nucleic
acid encoding a PRO polypeptide
herein is operably linked to control sequences capable of affecting its
expression is a suitable host cells. Vectors
ordinarily carry a replication site (although this is not necessary where
chromosomal integration will occur).
Expression vectors also include marker sequences which are capable of
providing phenotypic selection in transformed
cells. For example, E. coli is typically transformed using pBR322, a plasmid
derived from an E. coli species
(Bolivar, et al., Gene ~: 95 [1977]). pBR322 contains genes for ampicillin and
tetracycline resistance and thus
provides easy means for identifying transformed cells, whether for purposes of
cloning or expression. Expression
vectors also optimally will contain sequences which are useful for the control
of transcription and translation, e.g.,
promoters and Shine-Dalgamo sequences (for prokaryotes) or promoters and
enhancers (for mammalian cells). The
promoters may be, but need not be, inducible; even powerful constitutive
promoters such as the CMV promoter for
mammalian hosts have been found to produce the LHR without host cell toxicity.
While it is conceivable that
expression vectors need not contain any expression control, replicative
sequences or selection genes, their absence
may hamper the identification of hybrid transfortttartts and the achievement
of high level hybrid immunoglobulin
expression.
The term "lipopolysaccharide" or "LPS" is used herein as a synonym of
"endotoxin." Lipopolysaccharides
(LPS) are characteristic components of the outer membrane of Gram-negative
bacteria, e.g., Escherickia coli. They
consist of a polysaccharide part and a fat called lipid A. The polysaccharide,
which varies from one bacterial species
to another, is made up of the O-specific chain (built from repeating units of
three to eight sugars) and the two-part
core. Lipid A virtually always includes two glucosamine sugars modified by
phosphate and a variable number of fatty
acids. For further information see, for example, Rietschel and Brade,
Scientific American August 1992, 54-61.
The term "septic shock" is used herein in the broadest sense, including all
definitions disclosed in Bone, ~y~,t
Intern Med. 1~,~, 332-333 (1991). Specifically, septic shock starts with a
systemic response to infection, a syndrome
called sepsis. When this syndrome results in hypotension and organ
dysfunction, it is called septic shock. Septic
shock may be initiated by gram-positive organisms and fungi, as well as
endotoxin-containing Gram-negative
orgattistns. Accordingly, the present definition is not limited to "endotoxin
shock."
The phrases "gene amplification" and "gene duplication" are used
interchangeably and refer to a process
by which multiple copies of a gene or gene fragment are formed in a particular
cell or cell line. The duplicated region
(a stretch of amplified DNA) is often referred to as "amplicon". Usually, the
amount of the messenger RNA
(mRNA) produced, i.e., the level of gene expression, also increases in the
proportion of the number of copies made
of the particular gene expressed.
"Zhmor", as used herein, refers to all neoplastic cell growth and
proliferation, whether malignant or benign,
and all pre-cancerous and cancerous cells and tissues. The terms "cancer" and
"cancerous" refer to or describe the
physiological condition in mammals that is typically characterized by
unregulated cell growth. Examples of cancer
include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and
leukemia. More particular examples
119
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
of such cancers include breast cancer, prostate cancer, colon cancer, squamous
cell cancer, small-cell lung cancer,
non-small cell lung cancer, gasaointestinal cancer, pancreatic cancer,
glioblastoma, cervical cancer, ovarian cancer,
liver cancer, bladder cancer, hepatoma, colorectal cancer, endometrial
carcinoma, salivary gland carcinoma, kidney
cancer, wlval cancer, thyroid cancer, hepatic carcinoma and various types of
head and neck cancer.
The term "cytotoxic agent" as used herein refers to a substance that inhibits
or prevents the function of cells
and/or causes destruction of cells. The term is intended to include
radioactive isotopes (e.g. I131, I125, Y90 and
Re186), chemotherapeutic agents, and toxins such as enzymatically active
toxins of bacterial, fungal, plant or animal
origin, or fragments thereof.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of
cancer. Examples of
chemotherapeutic agents include adriamycin, doxorubicin, epirubicin, 5-
fluorouracil, cytosine arabinoside ("Ara-C"),
cyclophosphamide, thiotepa, busulfan, cytoxin, taxoids, e.g. paclitaxel
(Taxol, Bristol-Myers Squibb Oncology,
Princeton, Nl), and doxetaxel (?axotere~~, Rhone-Poulenc Rorer, Antony,
France), toxotere, methotrexate, cisplatin,
melphalan, vinblastine, bleomycin, etoposide, ifosfamide, mitomycin C,
mitoxantrone, vincristine, vinorelbine,
carboplatin, teniposide, daunomycin, carminomycin, aminopterin, dactinomycin,
mitomycins, esperamicins (see U.S.
Pat. No. 4,675,187), melphalan and other related nitrogen mustards. Also
included in this definition are hormonal
agents that act to regulate or inhibit hormone action on tumors such as
tamoxifen and onapristone.
A "growth inhibitory agent" when used herein refers to a compound or
composition which inhibits growth
of a cell, especially cancer cell overexpressing any of the genes identified
herein, either in vitro or in vivo. Thus,
the growth inhibitory agent is one which significantly reduces the percentage
of cells overexpressing such genes in
S phase. Examples of growth inhibitory agents include agents that block cell
cycle progression (at a place other than
S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-
phase blockers include the vincas
(vincristine and vinblastine), taxol, and topo II inhibitors such as
doxorubicin, epirubicin, daunorubicin, etoposide,
and bleomycin. Those agents that arrest G1 also spill over into S-phase
arrest, for example, DNA alkylating agents
such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin,
methotrexate, 5-fluorouracil, and ara-C.
Further information can be found in The Molecular Basis of Cancer, Mendelsohn
and Israel, eds., Chapter 1, entitled
"Cell cycle regulation, oncogens, and antineoplastic drugs "by Murakami et al.
(WB Saunders: Philadelphia, 1995),
especially p.13.
"Doxorubicin" is an athracycline antibiotic.
The term "cytokine" is a generic term for proteins released by one cell
population which act on another cell
as intercellular mediators. Examples of such cytokines are lymphokines,
monokines, and traditional polypeptide
hormones. Included among the cytokines are growth hormone such as human growth
hormone, N-methionyl human
growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine;
insulin; proinsulin; relaxin;
prorelaxin; and the like. As used herein, the term cytokine includes proteins
from natural sources or from
recombinant cell culture and biologically active equivalents of the native
sequence cytokines.
"Immunological cross-reactivity" as used herein means that the candidate
polypeptide is capable of
competitively inhibiting the qualitative biological activity of a PR0213-1,
PR01330, or PR01449 polypeptide having
this activity with polyclonal antisera raised against the known active PR0213-
1, PR01330, or PR01449 polypeptide.
Such antisera may be prepared in conventional fashion by injecting goats or
rabbits, for example, subcutaneously with
the known active analogue in complete Freund's adjuvant, followed by booster
intraperitoneal or subcutaneous
injection in incomplete Freunds. The immunological cross-reactivity preferably
is "specific", which means that the
120
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
binding affinity of the immunological cross-reactive molecule (e.g., antibody)
identified, to the corresponding
PR0213-1, PR01330, or PR01449 polypeptide is significantly higher (preferably
at least about 2-times, more
preferably at least about 4-times, even more preferably at least about 6-
times, most preferably at least about 8-times
higher) than the binding affinity of that molecule to any other known native
polypeptide.
"Native antibodies" and "native immunoglobulins" are usually heterotetrameric
glycoproteins of about
150,000 daltons, composed of two identical light (L) chains and two identical
heavy (H) chains. Each light chain
is linked to a heavy chain by one covalent disulfide bond, while the number of
disulfide linkages varies among the
heavy chains of different immunoglobulin isotypes. Each heavy and light chain
also has regularly spaced intrachain
disulfide bridges. Each heavy chain has at one end a variable domain (VH)
followed by a number of constant
domains. Each light chain has a variable domain at one end (VL) and a constant
domain at its other end; the constant
domain of the light chain is aligned with the first constant domain of the
heavy chain, and the light chain variable
domain is aligned with the variable domain of the heavy chain. Particular
amino acid residues are believed to form
an interface between the light- and heavy-chain variable domains.
The term "variable" refers to the fact that certain portions of the variable
domains differ extensively in
sequence among antibodies and are used in the binding and specificity of each
particular antibody for its particular
antigen. However, the variability is not evenly distributed throughout the
variable domains of antibodies. It is
concentrated in three segments called complementariry-determining regions
(CDRs) or hypervariable regions both
in the light-chain and the heavy-chain variable domains. The more highly
conserved portions of variable domains
are called the framework (FR). The variable domains of native heavy and light
chains each comprise four FR
regions, largely adopting a p-sheet configuration, connected by three CDRs,
which form loops connecting, and in
some cases forming pan of, the (i-sheet structure. The CDRs in each chain are
held together in close proximity by
the FR regions and, with the CDRs from the other chain, contribute to the
formation of the antigen-binding site of
antibodies (see Kabat et al., NIH Publ. No.91-3242, Vol. I, pages 647-669
(1991)). The constant domains are not
involved directly in binding an antibody to an antigen, but exhibit various
effector functions, such as participation
of the antibody in antibody-dependent cellular toxicity.
"Antibody fragments" comprise a portion of an intact antibody, preferably the
antigen binding or variable
region of the intact antibody. Examples of antibody fragments include Fab,
Fab', F(ab')2, and Fv fragments;
diabodies; linear antibodies (Zapata et al. , Protein Eng. 8(10): 1057-1062
[1995]); single-chain antibody molecules;
and multispecific antibodies formed from antibody fragments.
Papain digestion of antibodies produces two identical antigen-binding
fragments, called "Fab" fragments,
each with a single antigen-binding site, and a residual "Fc" fragment, a
designation reflecting the ability to crystallize
readily. Pepsin treatment yields an F(ab')2 fi~agment that has two antigen-
combining sites and is still capable of cross-
linking antigen.
"Fv" is the minimum antibody fragment which contains a complete antigen-
recognition and -binding site.
This region consists of a dimer of one heavy- and one light-chain variable
domain in tight, non-covalent association.
It is in this configuration that the three CDRs of each variable domain
interact to define an antigen-binding site on
the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-
binding specificity to the antibody.
However, even a single variable domain (or half of an Fv comprising only three
CDRs specific for an antigen) has
the ability to recognize and bind antigen, although at a lower affinity than
the entire binding site.
121
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The Fab fragment also contains the constant domain of the light chain and the
first constant domain (CH 1 )
of the heavy chain. Fab fragments differ from Fab fragments by the addition of
a few residues at the carboxy
terminus of the heavy chain CH1 domain including one or more cysteines from
the antibody hinge region. Fab'-SH
is the designation herein for Fab' in which the cysteine residues) of the
constant domains bear a free thiol group.
F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments
which have hinge cysteines between
them. Other chemical couplings of antibody fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species
can be assigned to one of
two clearly distinct types, called kappa and lambda, based on the amino acid
sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy
chains, immunoglobulins can
be assigned to different classes. There are five major classes of
immunoglobulins: IgA, IgD, IgE, IgG, and IgM,
and several of these may be funkier divided into subclasses (isorypes), e.g.,
IgGI, IgG2, IgG3, IgG4, IgA, and IgA2.
"Single-chain Fv" or "sFv" antibody fragments comprise the VH and VL domains
of antibody, wherein
these domains are present in a single polypeptide chain. Preferably, the Fv
polypeptide further comprises a
polypeptide linker between the VH and VL domains which enables the sFv to form
the desired structure for antigen
binding. For a review of sFv see Pluckthun in The Pharmacology of Monoclonal
Antibodies, vol. 113, Rosenburg
and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The term "diabodies" refers to small antibody fragments with two antigen-
binding sites, which fragments
comprise a heavy-chain variable domain (VH) connected to a light-chain
variable domain (VL) in the same
polypeptide chain (VH - VL). By using a linker that is too short to allow
pairing between the two domains on the
same chain, the domains are forced to pair with the complementary domains of
another chain and create two antigen-
binding sites. Diabodies are described more fully in, for example, EP 404,097;
WO 93/11161; and Hollinger et al.,
Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
An "isolated" antibody is one which has been identified and separated and/or
recovered from a component
of its natural environment. Contaminant components of its natural environment
are materials which would interfere
with diagnostic or therapeutic uses for the antibody, and may include enzymes,
hormones, and other proteinaceous
or nonproteinaceous solutes. In preferred embodiments, the antibody will be
purified (1) to greater than 95% by
weight of antibody as determined by the Lowry method, and most preferably more
than 99% by weight, (2) to a
degree sufficient to obtain at least 15 residues of N-terminal or internal
amino acid sequence by use of a spinning cup
sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing
conditions using Coomassie blue
or, preferably, silver stain. Isolated antibody includes the antibody in situ
within recombinant cells since at least one
component of the antibody's natural environment will not be present.
Ordinarily, however, isolated antibody will
be prepared by at least one purification step.
The word "label" when used herein refers to a detectable compound or
composition which is conjugated
directly or indirectly to the antibody so as to generate a "labelled"
antibody. The label may be detectable by itself
(e.g. radioisotope labels or fluorescent labels) or, in the case of an
enzymatic label, may catalyze chemical alteration
of a subsuate compound or composition which is detectable.
By "solid phase" is meant a non-aqueous matrix to which the antibody of the
present invention can adhere.
Examples of solid phases encompassed herein include those formed partially or
entirely of glass (e.g., controlled pore
glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene,
polyvinyl alcohol and silicones. In certain
embodiments, depending on the context, the solid phase can comprise the well
of an assay plate; in others it is a
122
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
purification column (e.g., an affinity chromatography column). This term also
includes a discontinuous solid phase
of discrete particles, such as those described in U.S. Patent No. 4,275,149.
A "liposome" is a small vesicle composed of various types of lipids,
phospholipids andlor surfactant which
is useful for delivery of a drug (such as the anti-ErbB2 antibodies disclosed
herein and, optionally, a chemotherapeutic
agent) to a mammal. The components of the liposome are cotnmonly arranged in a
bilayer formation, similar to the
lipid arrangement of biological membranes.
II. Com~Qitions ana Methods~f the Invention
1. Full- ength PR0213 Polvueotides
The present invention provides newly idemified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0213. In particular, Applicants
have identified and isolated cDNA
encoding a PR0213 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that a portion of the
PR0213 polypeptide has significant
homology with the human growth arrest-specific 6 (gash) protein. Accordingly,
it is presently believed that PR0213
polypeptide disclosed in the present application may have the same or simular
activity as does the gash protein.
2. _ Full-len~~"PR0274 Polypgptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0274. In particular, Applicants
have identified and isolated cDNA
encoding a PR0274 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0274 polypeptide have
significant homology with the 7 transmembrane segment receptor proteins and
Fn54 protein. Accordingly, it is
presently believed that PR0274 polypeptide disclosed in the present
application is a newly identified member of the
7 transmembrane segment receptor protein andlor Fn54 protein family.
3. Full-length PR0300 Polvneutides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0300. In particular, Applicants
have identified and isolated cDNA
encoding a PR0300 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0300 polypeptide have
significant horrwlogy with the human Dill' 33 protein. Accordingly, it is
presently believed that PR0300 polypeptide
disclosed in the present application is a newly identificd member of the Diff
33 family.
4. Fu,~jle~, Eth PR0284 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0284. In particular, Applicants
have identified and isolated cDNA
encoding a PR0284 polypeptide, as disclosed in further detail in the Examples
below. To Applicants present
lrnowledge, the UNQ247 (DNA23318-1211) nucleotide sequence encodes a novel
factor; using BLAST and FastA
sequence alignment computer programs, no sequence identities to any lmown
proteins were revealed.
123
CA 02421372 2003-03-25
WO 99/46281 PCT/US99i05028
5. Full-lennth PR0296 Polvpggtides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0296. In particular, Applicants
have identified and isolated cDNA
encoding a PR0296 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0296
polypeptide has significant similarity to
the sarcoma-amplified SAS protein. Accordingly, it is presently believed that
PR0296 polypeptide disclosed in the
present application is a newly identified SAS protein homolog.
6. Full-lert,8th PR0329 Polype tp ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0329. In particular, Applicants
have identified and isolated cDNA
encoding a PR0329 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0329
polypeptide has significant similarity to
a high affinity immunoglobulin F~ receptor. Accordingly, it is presently
believed that PR0329 polypeptide disclosed
in the present application is a newly identified F~ receptor homolog.
7. Full-length PR0362 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0362. In particular, Applicants
have identified and isolated cDNA
encoding a PR0362 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0362
polypeptide has significant similarity to
the A33 antigen protein as well as the HCAR protein and the NrCAM related cell
adhesion molecule. Accordingly,
it is presently believed that PR0362 polypeptide disclosed in the present
application is a newly A33 antigen and
HCAR protein homolog.
8. Full-length PR0363 PojYpe~ptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0363. In particular, Applicants
have identified and isolated cDNA
encoding a PR0363 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0363
polypeptide has significant similarity to
the cell surface protein HCAR. Accordingly, it is presently believed that
PR0363 polypeptide disclosed in the present
application is a newly HCAR homolog.
9. Full-ien~h PR0868 PoivRgpitides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0868. In particular, Applicants
have identified and isolated cDNA
encoding a PR0868 poiypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence aligtitnent computer programs, Applicants found that the PR0868
polypeptide has significant similarity to
the tumor necrosis factor receptor. Accordingly, it is presently believed that
PR0868 polypeptide disclosed in the
present application is a newly identified member of the tumor necrosis factor
receptor family of proteins.
124
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
10. Full-IenQth PR0382 Poly2eptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0382. In particular, Applicants
have identified and isolated cDNA
encoding a PR0382 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the native PR0382
polypeptide shares significant
homology with various serine protease proteins. Applicants have also found
that the DNA encoding the PR0382
polypeptide shares significant homology with nucleic acid encoding various
serine protease proteins. Accordingly,
it is presently believed that PR0382 polypeptide disclosed in the present
application is a newly identified serine
protease homolog.
11. Full-lengtth PR0545 Polvpe t
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0545. In particular, Applicants
have identified and isolated cDNA
encoding a PR0545 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0545 polypeptide have
significant homology with the sequences identified designated as; human
metalloproteinase ("P W01825"), mouse
meltrin alpha ("560257"), metalloprotease-disintegrin meltrin-alpha
("GEN13695"), ADAM 13 - Xenopus IaeviS
("XLU6G003_1 "), mouse meltrin beta ("S60258"), rabbit metalloprotease-
disintegrin meltrin-beta, ("GEN13696"),
human meltrin S ("AF023477_I "), human meltrin precursor ("AF023476-I "),
human ADAM 21 ("AF029900_1 "),
and human ADAM 20 ("AF029899-1 "), thereby indicating that PR0545 may be a
novel meltrin protein.
Accordingly, it is presently believed that the PR0545 polypeptide disclosed in
the present application is a newly
identified member of the meltrin family and possesses the cellular
adhesiveness typical of the meltrin proteins which
comprise both metalloprotease and disintegrin domains.
12. Full-length PR0617 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0617. In particular, Applicants
have identified and isolated cDNA
encoding a PR0617 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0617
polypeptide shares significant homology
with the CD24 protein. Applicants have also found that the DNA encoding the
PR0617 polypeptide has significant
homology with DNA encoding the CD24 protein. Accordingly, it is presently
believed that PR0617 polypeptide
disclosed in the present application is a newly identified CD24 homolog.
13. Full-IenQth ~R0700 Polyhg t
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0700. In particular, Applicants
have identified and isolated cDNA
encoding a PR0700 polypeptide, as disclosed in filrther detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0700 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0700 polypeptide possess significant
sequence similarity to various protein
disulfide isometases. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced
125
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
significant sequence similarity between the PR0700 amino acid sequence and the
following Dayhoff sequences;
polypeptide with protein disulfide isomerase activity, designated as ("P
P80664"), human PDI, designated as
("P 851696"), human PDI, designated as (P 825297"), probable protein disulfide
isomerase er-60 precursor,
designated as ("ER60 SCHMA"), protein disulfide isomerase precursor -
Drosophila melanogaster, designated as
("PDI DROME"), protein disulfide-isomerase precursor - Nicotiana tabaccum,
designated as ("NTPDIGENE 1 "),
protein disulfide isomerase - Onchocerca volvulus, designated as ("OVU12440_1
"), human probable protein disulfide
isomerase p5 precursor , designated as ("ERPS HUMAN"), human protein disulfide
isomerase-related protein 5,
(°HSU79278_1 "), and protein disulfide isomerase precursor / prolyl 4-
hydroxy, ("PDI_HUMAN"), thereby
indicating that PR0700 may be a novel protein disulfide isomerase.
Accordingly, it is presently believed that
PR0700 polypeptide disclosed in the present application is a newly identified
member of the protein disulfide
isomerase family and possesses the ability to catalyze the formation of
disulfide bonds typical of the protein disulfide
isomerase family.
14. Full-length PR0702 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0702. In particular, Applicants
have identified and isolated cDNA
encoding a PR0702 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0702
polypeptide has significant similarity to
the conglutinin protein. Accordingly, it is presently believed that PR0702
polypeptide disclosed in the present
application is a newly identified conglutinin homolog.
15. Full-IenEth PR0703 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0703. In particular, Applicants
have identified and isolated cDNA
encoding a PR0703 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0703 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0703 polypeptide possess significant
sequence similarity to the VLCAS
protein, thereby indicating that PR0703 may be a novel VLCAS protein. More
specifically, an analysis of the
Dayhoff database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0703 amino
acid sequence and the following Dayhoff sequences, human mRNA for very-long-
chain acyl-CoA, (°D88308"), tat
mRNA for very-long-chain acyl-CoA synthetase, ("D85100"), Mus musculus fatty
acid transport protein,
("MMU15976"), human very-long-chain acyl-CoA synthetase, (°D88308_1 "),
Mus musculus very-long-chain
acyl-CoA synthetase, ("AF033031_1 "), very-long-chain acyl-CoA synthetase -
Rattus, ("D85100 1 "). rat long-chain
fatty acid transpon protein, ("FATP RAT"), mouse long-chain fatty acid
transport protein, ("FATP MOUSE"),
probable long-chain fatty acid transport protein, ("FATI YEAST"), and fatty
acid transporter protein,
("CHY15839 2") , thereby indicating that PR0703 may be a novel VLCAS.
Accordingly, it is presently believed
that PR0703 polypeptide disclosed in the present application is a newly
identified member of the VLCAS family and
possesses the ability to facilitate the cellular transport of long and very
long chain fatty acids typical of the VLCAS
family.
126
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
16. Full-ienglh PR0705 Polypg~ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0705. In particular, Applicants
have identified and isolated cDNA
encoding a PR0705 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0705
polypeptide has significant similarity to
the K-glypican protein. Accordingly, it is presently believed that PR0705
polypeptide disclosed in the present
application is a newly identified member of the glypican family of
proteoglycan proteins.
17. Fu0-le g~h PR0708 Polvoeotides
The present invention provides newly identified and isolated nucleotide
sequences encoding poiypeptides
referred to in the present application as PR0708. In particular, Applicants
have identified and isolated cDNA
encoding a PR0708 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0708
polypeptide has significant homology with
the aryl sulfatase proteins. Applicants have also found that the DNA encoding
the PR0708 polypeptide has
significant homology with DNA encoding the aryl sulfatase proteins.
Accordingly, it is presently believed that
PR0708 polypeptide disclosed in the present application is a newly identified
aryl sulfatase homolog.
18. X11-length PR0320 Polyp~g tn ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0320. In particular, Applicants
have identified and isolated cDNA
encoding a FR0320 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0320 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0320 polypeptide have significant
homology to the fibulin protein. More
specifically, an analysis of the Dayhoff database (version 35.45 SwissProt 3S)
evidenced significant homology
between the PR0320 amino acid sequence and the following Dayhoff sequences,
human fibulin-2 precursor,
designated "FBL2_HUMAN", human fibulin-1 isoform a precursor, designated
"FBL.A_HUMAN", ZK783.1 -
Caenorhabditis elegans, designated "CELZK783~1", human-notch2, designated
"HSU77493_1", Nel protein
precursor - rattus norvegicus, designated "NEL RAT', Mus musculus cell surface
protein, designated "D32210 1 ",
mouse (fragment) Notch B protein, designated "A49175", C50H2.3a -
Caenorhabditis elegans, designated
"CECSOH2 3", MEC-9L - Caenorhabditis elegans, designated "CEU33933_1", and Mus
musculus notch 4,
designated "10 MMMHC29N7 2", thereby indicating that PR0320 may be a novel
fibulin or fibulin-like protein.
Accordingly, it is presently believed that PR0320 polypeptide disclosed in the
present application is a newly identified
member of the fibulin family and possesses biological activity typical of the
fibulin family.
19. X11-lentrth PR0324 Polyhg tn ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0324. In particular, Applicants
have identified and isolated cDNA
encoding a PR0324 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0324
polypeptide has significant similarity to
oxidoreductases. Accordingly, it is presently believed that PR0324 polypeptide
disclosed in the present application
127
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
is a newly identified oxidoreductase homolog.
20. Full-len~h PR0351 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0351. In particular, Applicants
have identified and isolated cDNA
encoding a PR0351 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0351 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0351 polypeptide possess significant
sequence similarity to the prostasin
protein, thereby indicating that PR0351 may be a novel prostasin protein. More
specifically, an analysis of the
Dayhoff database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0351 amino
acid sequence and the following Dayhoff sequences, "AC003965_1", "CELC07G1 7",
"GEN12917",
"HEPS HUMAN", "GEN14584", "MCT6 MOUSE", "HSU75329-1", "PLMN ERIEU", "TRYB-
HUMAN", and
"P W22987". Accordingly, it is presently believed that PR0351 polypeptide
disclosed in the present application is
a newly identified member of the prostasin family and possesses properties and
activities typical of the prostasin
family.
21. Full-IenEth PR0352 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0352. In particular, Applicants
have identified and isolated cDNA
encoding a PR0352 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0352
polypeptide has significant similarity to
the butyrophilin protein. Accordingly, it is presently believed that PR0352
polypeptide disclosed in the present
application is a newly identified buryrophilin homolog.
22. Full-lend PR0381 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0381. In particular, Applicants
have identified and isolated cDNA
encoding a PR0381 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0381
polypeptide has significant similarity to
immunophilin proteins. Accordingly, it is presently believed that PR0381
polypeptide disclosed in the present
application is a newly identified FKBP immunophilin homolog.
23. Full-length PR0386 Polvnet'tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0386. In particular, Applicants
have identified and isolated cDNA
encoding a PR0386 polypeptide, as disclosed in further detail in the Ezamples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0386
polypeptide has significant similarity to
the beta-2 subunit of a sodium chattrtel protein. Accordingly, it is presently
believed that PR0386 polypeptide
disclosed in the present application is homolog of a beta-2 subttnit of a
sodium channel expressed in mammalian cells.
128
CA 02421372 2003-03-25
WO 99!46281 PCT/US99f05028
24. Eull-len~h PR0540 Polvpe tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0540. In particular, Applicants
have identified and isolated cDNA
encoding a PR0540 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0540 polypeptide using BLAST and FasLA sequence
alignment computer programs,
suggests that various portions of the PR0540 polypeptide possess significant
sequence similarity to the LCAT protein,
thereby indicating that PR0540 may be a novel LCAT protein. More specifically,
an analysis of the Dayhoff
database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0540 amino acid
sequence and the following Dayhoff sequences, phosphatidylcholine-sterol
acyluansfcrase, designated
"LCAT HUMAN", hypothetical 75.4 kd protein, designated "YN84_YEAST", Bacillus
licheniformis esterase,
designated "BLU35855_1", macrotetrolide resistance protein - Streptomyces,
designated "JH0655", T-cell receptor
delta chain precursor, designated "C30583", Rhesus kringle 2, designated "P
W07551 ", RAGE-1 ORFS, designated
"HSU46191 3", human Ig kappa chain VKIII-JK3, designated "HSU07466 1", and
Alstroemeria inodora reverse
transcriptase, designated "ALI223606_1 ". Accordingly, it is presently
believed that PR0540 polypeptide disclosed
in the present application is a newly identified member of the LCAT protein
family and possesses lipid transport
capability typical of the LCAT family.
25. Full-length PR0615 Poly~e, tn ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0615. In particular, Applicants
have identified and isolated cDNA
encoding a PR0615 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0615 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various ponions of the PR0615 polypeptide possess significant
sequence similarity to the human
synaptogyrin protein, thereby indicating that PR0615 tray be a novel
synaptogyrin protein. More specifically, an
analysis of the Dayhoff database (version 35.45 SwissProt 35) evidenced
significant sequence similarity between the
PRO615 amino acid sequence and the following Dayhoff sequences, "AF039085_1",
"RNU39549_1",
"CELT08A9 8", "FSU62028_1 ", "573645", "Y348 MYCPN", "AC000103_5", "", "RT12
LETTA", and
"EBVLMP218 1". Accordingly, it is presently believed that PR0615 polypeptide
disclosed in the present application
is a newly identified member of the synaptogyrin family and possesses activity
and properties typical of the
synaptogytin family.
26. Full-len Qth PR0618 Polypgtides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0618_ In particular, Applicants
have identified and isolated cDNA
encoding a PR0618 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0618 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0618 polypeptide possess significant
sequence similarity to the
enteropeptidase protein, thereby indicating that PR0618 may be a novel
enteropeptidase. More specifically, an
analysis of tlx Dayhoff database (version 35.45 SwissProt 35) evidenced
significant sequence similarity between the
PR0618 amino acid sequence and the following Dayhoff sequences, "P W22987",
"KAL HUMAN",
129
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
"AC003965-1", "GEN12917", "ENTK-HUMAN", "FAIl_HUMAN", "HSU75329 1", "P
W22986", and
"PLMN HORSE". Accordingly, it is presently believed that PR0618 polypeptide
disclosed in the present application
is a newly identified member of the enteropeptidase family and possesses
catalytic activity typical of the
enteropeptidase family.
27. Full-length PR0719 Polvue~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0719. in particular, Applicants
have identified and isolated cDNA
encoding a PR0719 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0719
polypeptide has significant similarity to
the lipoprotein lipase H protein. Accordingly, it is presently believed that
PR0719 polypeptide disclosed in the
present application is a newly identified lipoprotein lipase H homolog.
28. Full-IenEth PR0724 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0724. In particular, Applicants
have identified and isolated cDNA
encoding a PR0724 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0724
polypeptide has significant similarity to
the human low density lipoprotein (LDL) receptor protein. Accordingly, it is
presently believed that PR0724
polypeptide disclosed in the present application is a newly identified LDL
receptor homolog.
29. Full-lenp~.h PR0772,'olvpe t- n ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0772. In particular, Applicants
have identified and isolated cDNA
encoding a PR0772 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
seqt~ce aligntrlent computer programs, Applicants found that the PR0772
polypeptide has significant similarity to
the human A4 protein. Accordingly, it is presently believed that PR0772
polypeptide disclosed in the present
application is a newly identified A4 protein homolog.
30. dull-lenEth PR0852 Poiypeyitides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0852. In particular, Applicants
have identified and isolated cDNA
encoding a PR0852 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0852
polypeptide has significant similarity to
various protease proteins. Accordingly, it is presently believed that PR0852
polypeptide disclosed in the present
application is a newly identified protease enzyme homolog.
31. dull-lenEth PR0853 Polypgyitides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the 'present application as PR0853. In particular, Applicants
have identified and isolated cDNA
130
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
encoding a PR0853 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0853 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0853 polypeptide possess significant
sequence similarity to the reductase
protein, thereby indicating that PR0853 may be a novel reductase. More
specifically, an analysis of the Dayhoff
database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0853 amino acid
sequence and the following Dayhoff sequences, "P W03198", "CEC15H11 6",
"MTV030 12", "P W15759",
"542651", "ATAC00234314", "MTV022_13", "SCU43704_1", "CELE04F6 7", and
"ALFA_1". Accordingly, it
is presently believed that PR0853 polypeptide disclosed in the present
application is a newly identified member of
the reductase family and possesses the antioxidant enzymatic activity typical
of the reductase family.
32. dull-length PR0860 Potypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0860. in particular, Applicants
have identified and isolated cDNA
encoding a PR0860 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0860 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0860 polypeptide possess significant
sequence similarity to the neurofascin
protein, thereby indicating that PR0860 may be a novel neurofascin. More
specifically, an analysis of the Dayhoff
database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0860 amino acid
sequence and the following Dayhoff sequences, "AF040990_1", "AF041053_1",
"CELZK377 2", "RNU81035_1",
"D86983 1", "S26180", "MMBIG2A 1", "S46216", and "RNU68726 1". Accordingly, it
is presently believed that
PR0860 polypeptide disclosed in the present application is a newly identified
member of the neurofascin family and
possesses the cellular adhesion properties typical of the neurofascin family.
33. Full-length PR0846 Poly2eptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0846. In particular, Applicants
have identified and isolated cDNA
encoding a PR0846 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0846 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0846 polypeptide possess significant
scquence similarity to the CMRF35
protein, thereby indicating that PR0846 tray be a novel CMRF35 protein. More
specifically, an analysis of the
Dayhoff database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0846 amino
acid sequence and the following Dayhoff sequences,"CM35 HUMAN", "AF035963_1",
°PIGR RABIT",
°AF043724_1", "RNU89744_1", "A52091_1", "S48841", "ELK06A9 3", and
"AF049588_1". Accordingly, it is
presently believed that PR0846 polypeptide disclosed in the present
application is a newly identified member of the
CMRF35 protein family and possesses properties typical of the CMRF35 protein
family.
34. Full-lenEth PR0862 Polyp~~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0862. In particular, Applicants
have identified and isolated cDNA
encoding a PR0862 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
131
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
sequence of the full-length PR0862 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0862 polypeptide possess significant
sequence similarity to the lysozyme
protein, thereby indicating that PR0862 may be a novel lysoryme protein. More
specifically, an analysis of the
Dayhoff database (version 35.45 SwissProt 35) evidenced significant sequence
similarity between the PR0862 amino
acid sequence and the following Dayhoff sequences, "P P90343", and "LYC_HUMAN.
Accordingly, it is presently
believed that PR0862 polypeptide disclosed in the present application is a
newly identified member of the lysoryme
family and possesses catalytic activity typical of the lysozyme family.
35. Full-lenEth PR0864 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding poiypeptides
referred to in the present application as PR0864. In particular, Applicants
have identified and isolated cDNA
encoding a PR0864 polypeptide, as disclosed in further detail in the Examples
below. Analysis of the amino acid
sequence of the full-length PR0864 polypeptide using BLAST and FastA sequence
alignment computer programs,
suggests that various portions of the PR0864 polypeptide possess significant
sequence similarity to the Wnt-4 protein,
thereby indicating that PR0864 tray be a novel Wnt~ protein. More
specifically, an analysis of the Dayhoff database
(version 35.45 Swissl'rot 35) evidenced significant sequence similarity
between the PR0864 amino acid sequence
and the following Dayhoff sequences, "WNT4 MOUSE", "WNT3-MOUSE", "WNSA HUMAN",
"WN7B MOUSE", "WN3A MOUSE", "XLU66288 1", "WN13 HUMAN", "WNSB ORYLA",
"WNT2_MOUSE",
and "WN7A MOUSE". Accordingly, it is presently believed that PR0864
polypeptide disclosed in the present
application is a newly identified member of the Wnt~ protein family and
possesses properties typical of the Wnt-4
protein family.
36. Full-IenEth PR0792 Po~peptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0792. In particular, Applicants
have identified and isolated cDNA
encoding a PR0792 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0792
polypeptide has significant similarity to
the CD23 protein. Accordingly, it is presently believed that PR0792
polypeptide disclosed in the present application
is a newly identified CD23 homolog.
37. Full-length PR0866 Poly~e t
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0866. In particular, Applicants
have identified and isolated cDNA
encoding a PR0866 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0866
polypeptide has significant similarity to
various mindin and spondin proteins. Accordingly, it is presently believed
that PR0866 polypeptide disclosed in the
present application is a newly identified mindin/spondin homolog.
132
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
38. Full-length PR0871 Polv~Qtide~
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0871. In particular, Applicants
have identified and isolated cDNA
encoding a PR0871 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0871
polypeptide has significant similarity to
the CyP-60 protein. Accordingly, it is presently believed that PR0871
polypeptide disclosed in the present
application is a newly identified member of the cyclophilin protein family and
possesses activity typical of the
cyclophilin protein family.
39. Full-length PR0873 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0873. In particular, Applicants
have identified and isolated cDNA
encoding a PR0873 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0873
polypeptide has significant similarity to
a human liver carboxylesterase. Accordingly, it is presently believed that
PR0873 poiypeptide disclosed in the
present application is a newly identified member of the carboxylesterase
family and possesses enzymatic activity
typical of the carboxylesterase family.
40. Full-length PR0940 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0940. In particular, Applicants
have identified and isolated cDNA
encoding a PR0940 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0940
polypeptide has significant similarity to
CD33 and the OB binding protein-2. Accordingly, it is presently believed that
PR0940 polypeptide disclosed in the
present application is a newly CD33 and/or OB binding protein-2 homolog.
41. Full-length PR0941 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0941. In particular, Applicants
have identified and isolated cDNA
encoding a PR0941 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0941
polypeptide has significant similarity to
o~ or more cadherin proteins. Accordingly, it is presently believed that
PR0941 polypeptide disclosed in the present
application is a newly identified cadherin homolog_
42. Full-ieng>th, PR0944 PolYpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0944. In particular, Applicants
have identified and isolated cDNA
encoding a PR0944 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0944
polypeptide has significant similarity to
the CPE-R cell surface protein. Accordingly, it is presently believed that
PR0944 polypeptide disclosed in the
133
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
present application is a newly identified CPE-R homolog.
43. Full-length PR0983 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0983. In particular, Applicants
have identified and isolated cDNA
encoding a PR0983 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0983
polypeptide has significant similarity to
the vesicle-associated protein, VAP-33. Accordingly, it is presently believed
that PR0983 polypeptide disclosed in
the present application is a newly identified member of the vesicle-associated
membrane protein family and possesses
activity typical of vesicle-associated membrane proteins.
44. Full-length PR01057 Polype~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01057. In particular, Applicants
have identified and isolated cDNA
encoding a PR01057 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
13 sequence alignment computer programs, Applicants found that the PR01057
polypeptide has significant similarity
to various protease proteins. Accordingly, it is presently believed that
PR01057 polypeptide disclosed in the present
application is a newly identified protease homolog.
45. Full-length PROIQ'11 Polyp~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01071. In particular, Applicants
have identified and isolated cDNA
encoding a PR01071 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR01071
polypeptide has significant similarity
to the thrombospondin protein. Accordingly, it is presently believed that
PR01071 polypeptide disclosed in the
present application is a newly identified thrombospondin homolog.
46. Full-lengtlsPR01072 Poly eon tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PRO1072. In particular, Applicants
have identified and isolated cDNA
encoding a PR01072 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR01072
poiypeptide has significant similarity
to various reductase proteins. Accordingly, it is presently believed that
PR01072 polypeptide disclosed in the present
application is a newly identified member of the reductase protein family.
47. Full-length PR01075 Polype~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01075. In particular, Applicants
have identified and isolated cDNA
encoding a PR01075 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR01075
polypeptide has significant similarity
134
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
to protein disulfide isomerase. Accordingly, it is presently believed that
PR01075 polypepdde disclosed in the
present application is a newly identified member of the protein disulfide
isomerase family and possesses activity
typical of that family.
48. Full-length PRO181 Polypeoti '[g~
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0181. In particular, Applicants
have identified and isolated cDNA
encoding a PR0181 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0181
polypeptide has significant similarity to
the cornichon protein. Accordingly, it is presently believed that PR0181
polypeptide disclosed in the present
application is a newly identified cornichon homolog.
49. Full-lensrth PR0195 Po~ypeptid~l
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0195. In particular, Applicants
have identified and isolated cDNA
encoding a PR0195 polypeptide, as disclosed in further detail in the Examples
below. The PR0195-encoding clone
was isolated from a human fetal placenta library using a napping technique
which selects for nucleotide sequences
encoding secreted proteins. To Applican~c present knowledge, the UNQ169
(DNA26847-1395) nucleotide sequence
encodes a novel factor; using BLAST and FastA sequence alignment computer
programs, no sequence identities to
any known proteins were revealed.
50. ~ul!-lengl.h pR0865 Polvoentides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0865. In particular, Applicants
have identified and isolated cDNA
encoding a PR0865 polypeptide, as disclosed in further detail in the Examples
below. The PR0865-encoding clone
was isolated from a hurnart fetal kidney library using a trapping technique
which selects for nucleotide sequences
encoding secreted proteins. Thus, the PR0865-encoding clone may encode a
secreted factor. To Applicants present
knowledge, the UNQ434 (DNA53974-1401) nucleotide sequence encodes a novel
factor; using BLAST and FastA
sequence alignment computer programs, no sequence identities to any known
proteins were revealed.
51. Fu~lenath PR0827 l~~y~~gptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0827. In particular, Applicants
have identified and isolated cDNA
encoding a PR0827 polypeptide, as disclosed in funkier detail in the Examples
below. Using BLAST and FastA
seQuence aligtttnern computer programs, Applicants found that the PR0827
polypeptide has significant similarity to
VLA-2 and various other integrin proteins. Accordingly, it is presently
believed that PR0827 polypeptide disclosed
in the present application is a novel integrin protein or splice variant
thereof.
135
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
52. Full-lenEth PR01114 Polyp~ptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01114. In particular, Applicants
have identified and isolated cDNA
encoding a PR01114 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR01114
polypeptide has significant similarity
to the cytokine receptor family of proteins. Accordingly, it is presently
believed that PR01114 polypeptide disclosed
in the present application is a newly identified member of the cytokine
receptor family of proteins and possesses
activity typical of that family.
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PRO1 l 14 interferon receptor
(UNQ557). In particular, cDNA encoding a
PR01114 interferon receptor polypeptide has been identified and isolated, as
disclosed in further detail in the
Examples below. It is noted that proteins produced in separate expression
rounds may be given different PRO
numbers but the UNQ number is unique for any given DNA and the encoded
protein, and will not be changed.
However, for sake of simplicity, in the present specification the protein
encoded by DNA57033-1403 as well as all
further native homologues and variants included in the foregoing definition of
PR01114 interferon receptor, will be
referred to as "PR01114 interferon receptor", regardless of their origin or
mode of preparation.
Using the WU-BLAST2 sequence alignment computer program, it has been found
that a full-length native
sequence PR01114 interferon receptor polypeptide (shown in Figure 142 and SEQ
ID N0:352) has sequence identity
with the other known interferon receptors. Accordingly, it is presently
believed that PR01114 interferon receptor
possesses activity typical of other interferon receptors.
53. Full-lengi~h PR0237 PolYpe t
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0237. In particular, Applicants
have identified and isolated cDNA
encoding a PR0237 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence aligrtment computer programs, Applicants found that the PR0237
polypeptide has significant similarity to
carbonic anhydrase. Accordingly, it is presently believed that PR0237
polypeptide disclosed in the present
application is a newly identified carbonic anhydrase homolog.
54. Full-lepEth PR0541 Poly, to ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0541. In particular, Applicants
have identified and isolated cDNA
encoding a PR0541 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that the PR0541
polypeptide has significant similarity to
a trypsin inhibitor protein. Accordingly, it is presently believed that PR0541
polypeptide disclosed in the present
application is a newly identified member of the trypsin inhibitor protein
family.
55. Full-ler~:h PR0273 Polypgg,_tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0273. In particular, Applicants
have identified and isolated cDNA
136
CA 02421372 2003-03-25
WO 99146281 PCT/US99/05028
encoding a PR0273 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0273 polypeptide have
significant sequence identity with various chemoldnes. Accordingly, it is
presently believed that PR0273 polypeptide
disclosed in the present application is a newly identified member of the
chemokine family and possesses activity
typical of the chemolcine family.
56. Full-length PR0701 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0701. In particular, Applicants
have identified and isolated cDNA
encoding a PR0701 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0701 polypeptide have
significant homology with the neuroligins 1, 2 and 3 and esterases including
carboxyesterases and
acytlcholinesterases. Accordingly, it is presently believed that PR0701
polypeptide disclosed in the present
application is a newly identified member of the neuroligin family and is
involved in mediating recognition processes
between neurons andlor functions as a cell adhesin molecule as is typical of
neuroligins.
20
30
57. Full-lenEth PR0704 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding poiypeptides
referred to in the present application as PR0704. In particular, Applicants
have identified and isolated cDNA
encoding a PR0704 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0704 polypeptide have
significant homology with the VIP36 and GP36b. Accordingly, it is presently
believed that PR0704 polypeptide
disclosed in the present application is a newly identified member of the
vesicular integral membrane protein family
and possesses the ability to bind to sugars and cycle between the plasma
membrane and the Golgi typical of this
family.
58. Fu 1-length PR0706 Polvoe~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0706. In particular, Applicants
have identified and isolated cDNA
encoding a PR0706 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs; Applicants found that various portions
of the PR0706 polypeptide have
sequence identity with the human prostatic acid phosphatase precursor and the
human lysosomal acid phosphatase
precursor. Accordingly, it is presently believed that PR0706 polypeptide
disclosed in the present application is a
newly identified member of the htttnan prostatic acid phosphatase precursor
family and possesses phosphatase typical
of the acid phosphatase family.
59. Full-length PR0707 Polvr~~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0707. In particular, Applicants
have identified and isolated cDNA
encoding a PR0707 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
137
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
sequence alignment computer programs, Applicants found that various portions
of the PR0707 polypeptide have
significant homology with cadherins, particularly cadherin FIB3 found in
fibroblasts. Accordingly, it is presently
believed that PR0707 polypeptide disclosed in the present application is a
newly identified member of the cadherin
family and possesses cell interaction signaling typical of the cadherin
family.
60. Full-length PR0322 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0322. In particular, Applicants
have identified and isolated cDNA
encoding a PR0322 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0322 polypeptide have
sigtuficant homology with human neuropsin, serine protease, neurosin and
trypsinogen. Accordingly, it is presently
believed that PR0322 polypeptide disclosed in the present application is a
newly identified member of the serine
protease family and possesses protease activity typical of this family. It is
also believed that PR0322 is involved in
hippocampal plasticity and is associated with extracellular matrix
modifications and cell migrations.
61. dull-length PR0526 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0526. In particular, Applicants
have identified and isolated cDNA
encoding a PR0526 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FaSLA
sequence alignment computer programs, Applicants found that various portions
of the PR0526 polypeptide have
significant homology with the acid labile subunit of the insulin-like growth
factor complex (ALS), as well
carboxypeptidase, SLTT, and platelet glycoprotein V. Accordingly, it is
presently believed that PR0526 polypeptide
disclosed in the present application is a newly identified member of the
leucine-repeat rich superfamily, and possesses
protein-protein interaction capabilities typical of this family.
62. Full-length PR0531 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0531. In particular, Applicants
have identified and isolated cDNA
encoding a PR0531 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0531 polypeptide have
significant sequence identity and similarity with members of the cadherin
superfamily, particularly, protocadherin
3. Accordingly, it is presently believed that PR053 l polypeptide disclosed in
the present application is a newly
identified member of the cadherin superfan>ily, and is a protocadherin. PR0531
is a transmembrane protein which
has extracelhtlar cadherin raotifs. PR0531 is believed to be involved in cell-
cell activity, in particular, cell signaling.
63. Full-length PR0534 Potv~eptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0534. In particular, Applicants
have identified and isolated cDNA
encoding a PR0534 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0534 polypeptide have
138
CA 02421372 2003-03-25
WO 99/46281 PCT1US99/05028
significant identity or similarity with the putative disulfide isomerase erp38
precursor and thioredoxin c-3.
Accordingly, it is presently believed that PR0534 polypeptide disclosed in the
present application is a newly identified
rr~mber of the disulfide isomerase family and possesses the ability to
recognize and unscramble either intermediate
or incorrect folding patterns typical of this family.
64. Ful__ 1-len,~th PR0697 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0697. In particular, Applicams
have identified and isolated cDNA
encoding a PR0697 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0697 polypeptide have
significant identity or similarity with sFRP-2, sFRP-1 and SARP-1, -2 and -3.
Accordingly, it is presently believed
that PR0697 polypeptide disclosed in the present application is a newly
identified member of the sFRP family and
possesses activity related to the Wnt signal pathway.
65. Full-length PR07~17 Polypeptides
!S The present invetnion provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PRO? 17. In particular, Applicants
have identified and isolated cDNA
encoding a PR0717 polypeptide, as disclosed in further detail in the Examples
below. To Applicants present
knowledge, the UNQ385 (DNA50988-1326) nucleotide sequence encodes a novel
factor; using BLAST and FastA
sequence alignment computer programs, no significant sequence identities to
any known human proteins were
revealed.
66. Full-length PR0731 Polvne~tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0731.. In particular, Applicants
have identified and isolated cDNA
encoding a PR0731 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0731 polypeptide have
significant homology with the protocadherins 4, 68, 43, 42, 3, and 5.
Accordingly, it is presently believed that
PR0731 polypeptide disclosed in the present application is a newly identified
member of the protocadherin family
and possesses cell-cell aggregation or signaling activity or signal
transduction involvement typical of this family.
67. dull-lgnEth PR021$ PolvOg~ttr saes
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0218. In particular. Applicants
have identified and isolated cDNA
encoding a PR0218 polypeptide, as disclosed in further detail in the Examples
below. The PROZI8-encoding clone
was isolated from a human fetal kidney library. To Applicants present
knowledge, the UNQ192 (DNA30867-1335)
nucleotide sequence encodes a novel factor; using BLAST and FastA sequence
alignment computer programs, no
significant sequence identities to any known proteins were revealed. Some
sequence identity was found with
membrane regulator proteins, indicating that PR0218 may function as a membrane
regulator.
139
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
68. Full-IenQth PRO768 Polvpep~ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0768. In particular, Applicants
have identified and isolated cDNA
encoding a PR0768 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0768 polypeptide have
significant homology with integrins, including integrin 7 and 6. Accordingly,
it is presently believed that PR0768
polypeptide disclosed in the present application is a newly identified member
of the integrin family, either a
homologue or a splice variant of integrin 7, and is involved with cell
adhesion and communication between muscle
cells and the extracellular matrix.
69. Full-length PR0771 Polygeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0771. In particular, Applicants
have identified and isolated cDNA
encoding a PR0771 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0771 polypeptide have
IS significant sequence identity and similarity with testican. Accordingly, it
is presently believed that PR0771
polypeptide disclosed in the present application is a newly identified member
of the testican family and possesses cell
signaling, binding, or adhesion properties, typical of this family.
70. Full-length PR0733 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0733. In panicular, Applicants
have identified and isolated cDNA
encoding a PR0733 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0733 polypeptide have
significant sequence identity with the Tl/ST receptor binding protein.
Accordingly, it is presently believed that
PR0733 polypeptide disclosed in the present application is a newly identified
member of the interieukin-like family
binding proteins which may be a cytokine and which may be involved in cell
signaling. It is believed that PR0733
is an ApoAIV homologue.
7I. Full-IenEth PR0162 Polypeptide~
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0162. In particular, Applicants
have identified and isolated cDNA
encoding a PR0162 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FasIA
sequence alignment computer programs, Applicants found that various portions
of the PR0162 polypeptide have
significant homology with human pancreatitis-associated protein (PAP).
Applicants have also found that the DNA
encoding the PR0162 polypeptide has significant homology with bovine
lithostathine precursor and bovine pancreatic
thread protein (PTP). Accordingly, it is presently believed that PR0162
polypeptide disclosed in the present
application is a newly identified member of the pancreatitis-associated
protein family and possesses activity typical
of the pancreatitis-associated protein family.
140
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
?2. Full-IenQth PR0788 Polype~i ' es
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0788. In particular, Applicants
have identified and isolated cDNA
encoding a PR0788 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0788 polypeptide have
significant homology with the anti-neoplastic urinary protein. Applicants have
also found that the DNA encoding
the PR0788 polypeptide has significant homology with human E48 antigen, human
component B protein, and human
prostate stem cell antigen. Accordingly, it is presently believed that PR0788
polypeptide disclosed in the present
application is a newly identified member of the anti-neoplastic urinary
protein family and possesses anti-neoplastic
activity typical of the anti-neoplastic urinary protein family.
?3. Full-length PR01008 Polype tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01008. in particular, Applicants
have identified and isolated cDNA
encoding a PR01008 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR01008 polypcptide have
significant sequence identity and similarity with mouse dkk-1 (mdkk-1).
Accordingly, it is presently believed that
PR01008 polypeptide disclosed in the present application is a newly identified
member of the dkk-1 family and
possesses head inducing activity typical of this family.
?4. Ful~ene~th PR01012 Poly~~g tR ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01012. In particular, Applicants
have identified and isolated cDNA
encoding a PR01012 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR01012 polypeptide have
sequence identity with disulfide isomerase. Accordingly, it is presently
believed that PR01012 polypeptide disclosed
in the present application is a newly identified rtiember of the ER retained
protein family and possesses activity related
to the processing, production and/or folding of polypeptides typical of the
disulfide isomerase family.
?5. Full-Ig~ t~h ,]'R01014 Potvueotides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01014. In particular, Applicants
have identified and isolated cDNA
encoding a PR01014 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR01014 polypeptide have
sequence identity with reductase and dehydrogenase. Accordingly, it is
presently believed that PR01014 polypeptide
disclosed in the present application is a newly identified member of the
reductase super family and possesses
reduction capabilities typical of this family.
141
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
76. Full-length PR01017 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01017. In particular, Applicants
have identified and isolated cDNA
encoding a PR01017 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR01017 polypeptide have
sequence identity with HNK-1 sulfotransferase. Accordingly, it is presently
believed that PR01017 polypeptide
disclosed in the present application is a newly identified member of the HNK-1
sulfotransferase family and is involved
with the synthesis of HNK-1 carbohydrate epitopes typical of this family.
77. Full-length PR0474 Polvpeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0474. In particular, Applicants
have identified and isolated cDNA
encoding a PR0474 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR0474 polypeptide have
sequence identity with dehydrogenase, glucose dehydrogenase and
oxidoreductase. Accordingly, it is presently
believed that PR0474 polypeptide disclosed in the present application is a
newly identified member of the
dehydrogenase family and is involved in the oxidation of glucose.
78. Fuli-lenEth PR01031 Polype_ptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01031. In particular, Applicants
have identified and isolated cDNA
encoding a PR01031 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
sequence alignment computer programs, Applicants found that various portions
of the PR01031 polypeptide have
sequence identity with IL-17 and CTLA-8. Accordingly, it is presently believed
that PR01031 polypeptide disclosed
in the present application is a newly identified member of the cytoldne family
and thus may be involved in
inflammation and/or the immune system.
79. Full-length PR0938 Polype_ptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0938. In particular, Applicants
have identified and isolated cDNA
encoding a PR0938 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FasIA
sequence alignment computer programs, Applicants found that the PR0938
polypeptide has significant similarity to
protein disulfide isort~rase. Accordingly, it is presently believed that
PR0938 polypeptide disclosed in the present
application is a newly identified member of the thioredoxin family proteins
and possesses activity typical of protein
disulfide isomerase.
80. Full-leneth PR01082 Poly~g tides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01082. In particular, Applicants
have identified and isolated cDNA
encoding a PR01082 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST and FastA
142
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
sequence alignment computer programs, Applicants found that various portions
of the PR01082 polypeptide have
sequence identity with a lectin-like oxidized LDL receptor appearing in the
database as "AB010710-1 ". Accordingly,
it is presently believed that 1'R01082 polypeptide disclosed in the present
application is a newly identified member
of the LDL receptor family.
81. Full-leneth PR01083 PolYpg ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR01083. In particular, Applicants
have identified and isolated cDNA
encoding a PR01083 polypeptide, as disclosed in further detail in the Examples
below. The PR01083-encoding clone
was isolated from a human fetal kidney library using a napping technique which
selects for nucleotide sequences
encoding secreted proteins. To Applicants present knowledge, the UNQ540
(DNA50921-1458) nucleotide sequence
encodes a novel factor; using BLAST and FastA sequence alignment computer
programs, some sequence identity with
a 7TM receptor, latrophilin related protein 1 and a macrophage restricted cell
surface glycoprotein was shown. The
kinase phosphorylation site and G-coupled receptor domain shown in Figure 204
indicate that PR01083 is a novel
member of the ?TM receptor superfamily.
82. Full-length PR0200 Polvp te~ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as VEGF-E. In particular, Applicants
have identified and isolated eDNA
encoding a VEGF-E polypeptide, as disclosed in further detail in the Examples
below. Using BLAST sequence
alignment computer programs, Applicants found that the VEGF-E polypeptide has
significant homology with VEGF
and bone morphogenetic protein 1. In particular, the cDNA sequet>ee of VEGF-E
exhibits 249'o amino acid similarity
with VEGF and has strucrural conservation. In addition, VEGF-E contains a N-
terminal half which is not present
in VEGF and that has 2896 homology to bone morphogenetic protein 1.
83. Full-length PR0285 and PR0286 Polvpg ides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0285 and PR0286 In particular,
Applicants have identified and isolated
cDNAs encoding PR0285 and PR0286 polypeptides, as disclosed in further detail
in the Examples below. Using
BLAST and FastA sequence alignment computer programs, Applicants found that
the coding sequences of PR0285
and PR0286 are highly homologous to DNA sequences HSU88540_l, HSU88878_l,
HSU88879_l, HSU88880 I,
and HSU88881 1 in the GenBank database.
Accordingly, it is presently believed that the PR0285 and PR0286 proteins
disclosed in the present
application are newly identified human homologues of the Drosophila protein
Toll, and are likely to play an important
role in adaptive imtnuniry. More specifically, PR0285 and PR0286 may be
involved in inflammation, septic shock,
and response to pathogens, and play possible roles in diverse medical
conditions that are aggravated by immune
response, such as, for example, diabetes, ALS, cancer, rheumatoid arthritis,
and ulcers. The role of PR0285 and
PR0286 as pathogen pattern recognition receptors, sensing the presence of
conserved molecular structures present
on microbes, is further supported by the data disclosed in the present
application, showing that a known human Toll-
like receptor, TLR2 is a direct mediator of LPS signaling.
143
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
84. Full-lenEth PR0213-I. PR01330 and PR01449 Polypetides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0213-1, PR01330 and/or PR01449. In
particular, cDNA encoding a
PR0213-1, PR01330 and/or PR01449 polypeptide has been identified and isolated,
as disclosed in further detail in
the Examples below. It is noted that proteins produced in separate expression
rounds may be given different PRO
numbers but the UNQ number is unique for any given DNA and the encoded
protein, and will not be changed.
However, for sake of simplicity, in the present specification the protein
encoded by DNA30943-1163-1, DNA64907-
1163-1 and DNA64908-1163-I as well as all further native homologues and
variants included in the foregoing
definition of PR0213-1, PR01330 and/or PR01449, will be referred to as "PR0213-
1, PR01330 and/or PR01449",
regardless of their origin or mode of preparation.
85. Full-length PR0298 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0298. (It is noted that PR0298 is
an arbitrary designation of a protein
encoded by the nucleic acid shown in Figure 218, SEQ ID NO: 514, and having
the amino acid sequence shown in
IS Figure 219, SEQ ID NO:S15. Further proteins having the same amino acid
sequence but expressed in different
rounds of expression, may be given different "PRO" numbers.)
In particular, Applicants have identified and isolated cDNA encoding a PR0298
polypeptide, as disclosed
in fiuther detail in the Examples below. Using BLASTX 2.Oa8MP-WashU computer
program, socring parameters:
T=12, S=68, S2=36, Matrix; BLOSUM62, Applicants found that the PR0298 protein
specifically disclosed herein
shows a limited (27-38 %) sequence identity with the following sequences found
in the GenBank database: S59392
(probable membrane protein YLR246w - yeast); S58154 (hypothetical protein
SPAC2F7.10 - yeast); CELF33D11 9
(F33D11.9b - Caenorhabditis elegans); Y041 CAEEL (hypothetical 68.7 kd protein
zk757.1); CEAC3 5 (AC3.4 -
Caenorhabditis elegans); 552691 (probable transmembrane protein YDR126w -
yeast); ATT12H17_14 (protein -
Arabidopsis thaliana); S55963 (probable membrane protein YNL326c - yeast);
CELC43H6 2 (C43H6.7 -
Caenorhabditis elegans); TM018A10 14 (A TM018A10.8 - Arabinosa thaliana).
86. Full-length PR0337 Polypeptides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0337. In particular, Applicants
have identified and isolated cDNA
encoding a PR0337 polypeptide, as disclosed in further detail in the Examples
below. Using BLAST, BLAST-2 and
FastA sequence alignment computer programs, Applicants found that a full-
length native sequence PR033? has 97 %
amino acid sequence identity with rat neurotrimin, 85% sequence identity with
chicken CEPU, 73°~ sequence identity
with chicken G55, 59% homology with human LAMP and 84% homology with human
OPCAM. Accordingly. it
is presently believed that PR0337 disclosed in the present application is a
newly identified member of the IgLON
sub family of the immunoglobulin superfamily and may possess neurite growth
and differentiation potentiating
propernes.
144
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
87. Full-length PR0403 Polypegtides
The present invention provides newly identified and isolated nucleotide
sequences encoding polypeptides
referred to in the present application as PR0403. In particular, Applicants
have identified and isolated cDNA
encoding a PR0403 polypeptide, as disclosed in further detail in the Examples
below. Using a BLAST, BLAST-2
and FastA sequence alignment computer programs, Applicants found that a full-
length native sequence PR0403 has
94% identity to bovine ECE-2 and 64% identity to human ECE-1. Accordingly is
presently believed that PR0403
is a new member of the ECE protein family and may posses ability to catalyze
the production of active endothelia.
88. PRO Polypeotide Variants
In addition to the full-length native sequence PRO polypeptides described
herein, it is contemplated that PRO
polypeptide variants can be prepared. PRO polypeptide variants can be prepared
by introducing appropriate
nucleotide changes into the PRO polypeptide DNA, or by synthesis of the
desired PRO polypeptide. Those skilled
in the art will appreciate that amino acid changes may alter post-
translational processes of the PRO polypeptides, such
as changing the number or position of glycosylation sites or altering the
membrane anchoring characteristics.
Variations in the native full-length sequence PRO polypeptides or in various
domains of the PRO
polypeptides described herein, can be made, for example, using any of the
techniques and guidelines for conservative
and non-conservative mutations set forth, for instance, in U.S. Patent No.
5,364,934. Variations may be a
substitution, deletion or insertion of one or more codons encoding the PRO
polypeptide that results in a change in
the amino acid sequence of the PRO polypeptide as compared with the native
sequence PRO polypeptide. Optionally
the variation is by substitution of at least one amino acid with any other
amino acid in one or more of the domains
of the PRO polypeptide. Guidance in determining which amino acid residue may
be inserted, substituted or deleted
without adversely affecting the desired activity may be found by comparing the
sequence of the PRO polypeptide with
that of homologous known protein molecules and minimizing the number of amino
acid sequence changes made in
regions of high homology. Amino acid substitutions can be the result of
replacing one amino acid with another amino
acid having similar structural and/or chemical properties, such as the
replacement of a leucine with a serine, i.e.,
conservative amino acid replacements. Insertions or deletions may optionally
be in the range of 1 to 5 amino acids.
The variation allowed may be determined by systematically making insertions,
deletions or substitutions of amino
acids in the sequence and testing the resulting variants for activity in the
in vitro assay described in the Examples
below.
In particular embodiments, conservative substitutions of interest are shown in
Table 1 under the heading of
preferred substitutions. 1:f such substitutions result in a change in
biological activity, then more substantial changes,
denominated exemplary substitutions in Table 1, or as further described below
in reference to amino acid classes,
are introduced and the products screened.
145
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Tab
Original Exemplary Preferred
esi Substitutions substitutions
Ala (A) val; leu; ile val
Arg (R) lys; gln; asn lys
Asn (N) gln; his; lys; arg gln
Asp (D) glu glu
Cys (C) ser ser
10Gln (Q) asn asn
Glu (E) asp asp
Gly (G) pro; ala ala
His (H) asn; gln; lys; arg arg
Ile (I) leu; val; met; ala; phe;
IS norleucine leu
Leu (L) norleucine; ile; val;
met; ala; phe ile
Lys (K) arg; gln; asn arg
Met t',M) leu; phe; ile leu
20Phe (F) leu; val; ile; ala; tyr leu
Pro (P) ala ala
Ser (S) thr thr
Thr ( I~ ser ser
Trp (VIA ryr; phe ryr
25Tyr (1~ trp; phe; thr; ser phe
Val (V) ile; leu; met; phe;
ala; norleucine leu
Substantial modifications in function or immunological identity of the PRO
polypeptide are accomplished
30 by selecting substitutions that differ significantly in their effect on
maintaining (a) the structure of the polypeptide
backbone in the area of the substitution, for example, as a sheet or helical
conformation, (b) the charge or
hydrophobiciry of the molecule at the target site, or (c) the bulk of the side
chain. Naturally occurring residues are
divided into groups based on common side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
35 (2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic. asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and
(6) aromatic: trp, ryr, phe.
40 Non-conservative substitutions will entail exchanging a member of one of
these classes for another class.
Such substituted residues also may be introduced into the conservative
substitution sites or, more preferably, into the
remaining (non-conserved) sites.
The variations can be made using methods known in the art such as
oligonucleotide-mediated (site-directed)
mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis
[Carter et al., ~,lucl. Acids Res.,
45 x:4331 (1986); Zoller et al., Tlucl. Acids Res., x:6487 (1987)], cassette
mutagenesis [Wells et al., Gene, x:315
(198], restriction selection mutagenesis [Wells et al., Philos.srans. R. Soc.
London SerA, X7:415 (1985)] or other
known techniques can be performed on the cloned DNA to produce the desired PRO
polypeptide variant DNA.
146
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Scanning amino acid analysis can also be employed to identify one or more
amino acids along a contiguous
sequence. Among the preferred scanning amino acids are relatively small,
neutral amino acids. Such amino acids
include alanine, glycine, serine, and cysteine. Alanine is typically a
preferred scanning amino acid among this group
because it eliminates the side-chain beyond the beta-carbon and is less likely
to alter the main-chain conformation of
the variant. Alanine is also typically preferred because it is the most common
amino acid. Further, it is frequently
found in both buried and exposed positions [Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J_.
Mol ' , ~:1 (1976)]. If alanine substitution does not yield adequate amounts
of variant, an isoteric amino acid
can be used.
89. Modifications of PRO Polypeptides
Covalent modifications of PRO polypeptides are included within the scope of
this invention. One type of
covalent modification includes reacting targeted amino acid residues of the
PRO polypeptide with an organic
derivatizing agent that is capable of reacting with selected side chains or
the N- or C- terminal residues of the PRO
polypeptide. Derivatization with bifunctional agents is useful, for instance,
for crosslinking a PRO polypeptide to
a water-insoluble support matrix or surface for use in the method for
purifying anti-PRO polypeptide antibodies, and
vice-versa. Commonly used crosslinking agents include, e.g., I,1-
bis(diazoaceryl~2-phenylethane, glutaraldehyde,
N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid,
homobifunetional imidoesters, including
disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate),
bifunctional maleimides such as bis-N-
maleimido-1,8-octane and agents such as methyl-3-((p-
azidophenyl)dithio]propioimidate.
Other modifications include deamidation of glutaminyl and asparaginyl residues
to the corresponding
glutamyl and aspartyl residues, respectively, hydroxylation of proline and
lysine, phosphorylation of hydroxyl groups
of seryl or threonyl residues, methylation of the a-amino groups of lysine,
arginine, and histidine side chains [T.E.
Creighton, Proteins: Structure and Molecular Propetties, W.H. Freeman & Co.,
San Francisco, pp. 79-86 (1983)],
acerylation of the N-terminal amine, and amidation of any C-terminal carboxyl
group.
Another type of covalent modification of the PRO polypeptides included within
the scopt of this invention
comprises altering the native glycosylation pattern of the polypeptide.
"Altering the native glycosylation pattern" is
intended for purposes herein to mean deleting one or more carbohydrate
moieties fotutd in a native sequence PRO
polypeptide, and/or adding one or more glycosylation sites that are not
present in the native sequence PRO
polypeptide, and/or alteration of the ratio and/or composition of the sugar
residues attached to the glycosylation
site(s).
Addition of glycosylation sites to the PRO polypeptide may be accomplished by
altering the amino acid
sequence. The alteration may be made, for example, by the addition of, or
substitution by, one or more serine or
threortine residues to the native sequence PRO polypeptide (for O-linked
glycosylation sites). The PRO polypeptide
amhto acid sequerxe may optionally be altered through changes at the DNA
level, particularly by mutating the DNA
encoding the PRO polypeptide at preselected bases such that codons are
generated that will translate into the desired
amino acids.
Another means of increasing the number of carbohydrate moieties on the PRO
polypeptide polypeptide is
by chemical or enz~mtatic coupling of glycosides to the polypeptide. Such
methods are described in the an, e.g., in
WO 87/05330 published 11 September 1987, and in Aplin and Wriston, ARC Crit.
Rev. Biochem., pp. 259-306
(1981).
147
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Removal of carbohydrate moieties present on the PRO polypeptide may be
accomplished chemically or
enzytnatically or by mutational substitution of codons encoding for amino acid
residues that serve as targets for
glycosylation. Chemical deglycosylation techniques are known in the an and
described, for instance, by Hakimuddin,
et al., Arch. Biochem. Bionhvs., 259:52 (1987) and by Edge et al., Anal.
Biochem., 118:131 (1981). Enzymatic
cleavage of carbohydrate moieties on polypeptides can be achieved by the use
of a variety of endo- and exo-
glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).
Another type of covalent modification of PRO polypeptides of the invention
comprises linking the PRO
polypeptide to one of a variety of nonproteinaceous polymers, e.g.,
polyethylene glycol, polypropylene glycol, or
polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835;
4,496,689; 4,301,144; 4,670,417;
4,791,192 or 4,179,337.
The PRO polypeptides of the present invention may also be modified in a way to
form a chimeric molecule
comprising a PRO polypeptide fused to another, heterologous polypeptide or
amino acid sequence. In one
embodiment, such a chimeric molecule comprises a fusion of the PRO polypeptide
with a tag polypeptide which
provides an epitope to which an anti-tag antibody can selectively bind. The
epitope tag is generally placed at the
amino- or carboxyl- terminus of the PRO polypeptide. The presence of such
epitope-tagged forms of the PRO
polypeptide can be detected using an antibody against the tag polypeptide.
Also, provision of the epitope tag enables
the PRO polypeptide to be readily purified by affinity purification using an
anti-tag antibody or another type of affinity
matrix that binds to the epitope tag. In an alternative embodiment, the
chimeric molecule may comprise a fusion of
the PRO polypeptide with an immunoglobulin or a particular region of an
immunoglobulin. For a bivalent form of
the chimeric molecule, such a fusion could be to the Fc region of an IgG
molecule.
Various tag polypeptides and their respective antibodies are well known in the
art. Examples include poly-
histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA
tag polypeptide and its antibody 12CA5
[Field et al., Mol. Cell. Biol., _8:2159-2165 (1988)]; the c-myc tag and the
8F9, 3C7, 6E10, G4, B7 and 9E10
antibodies thereto [Evan et al., Molecular and Cellular Biolo>ry, x:3610-3616
(1985)]; and the Herpes Simplex virus
glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein
Engineering, ,x(6):547-553 (1990)]. Other tag
polypeptides include the Flag-peptide (Hopp et al., BioTechnoloev, _6:1204-
1210 (1988)]; the KT3 epitope peptide
[Martin et al., Science, 55:192-194 (1992)]; an a-tubulin epitope peptide
[Skinner et al., J. Biol. Chem., 26~:15163-
15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyetmuth et al.,
Proc. Natl. Acad. Sci. USA, 87:6393-
6397 (1990)].
90. Preparation of PRO Polypeptides
The description below relates primarily to production of PRO polypeptides by
culturing cells transformed
or transfected with a vector containing the desired PRO polypeptide nucleic
acid. It is, of course, contemplated that
alteznative methods, which are well known in the art, may be employed to
prepare the PRO polypeptide. For
instance, the PRO polypeptide sequence, or portions thereof, may be produced
by direct peptide synthesis using solid-
phase techniques (see, e.g., Stewart et al., Solid-Phase Peptide Synthesis,
W.H. Freeman Co., San Francisco, CA
(1969); Merrifield, J. Am. Chem. Soc., X5:2149-2154 (1963)]. In vitro protein
synthesis may be performed using
manual techniques or by automation. Automated synthesis may be accomplished,
for instance, using an Applied
Biosystems Peptide Synthesizer (Foster Ciry, CA) using manufacturer's
instructions. Various portions of the desired
PRO polypeptide may be chemically synthesized separately and combined using
chemical or enzymatic methods to
148
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
produce the full-length PRO polypeptide.
A. Isolation of DNA Encodine PRO Polypgptides
DNA encoding PRO polypeptides may be obtained from a cDNA library prepared
from tissue believed to
possess the desired PRO polypeptide mRNA and to express it at a detectable
level. Accordingly, human PRO
polypeptide DNA can be conveniently obtained from a cDNA library prepared from
human tissue, such as described
in the Examples. The PRO polypeptide-encoding gene may also be obtained from a
genomic library or by
oligonucleotide synthesis.
Libraries can be screened with probes (such as antibodies to the desired PRO
polypeptide or oligonucleotides
of at least about 20-80 bases) designed to identify the gene of interest or
the protein encoded by it. Screening the
cDNA or genomic library with the selected probe may be conducted using
standard procedures, such as described
in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold
Spring Harbor Laboratory Press,
1989). An alternative means to isolate the gene encoding the desired PRO
polypeptide is to use PCR methodology
[Sambrook et al., supra; Dieffenbach et al., PCR Primer:A Laboratory Manual
(Cold Spring Harbor Laboratory
Press, 1995)].
The Examples below describe techniques for screening a cDNA library. The
oligonucleotide sequences
selected as probes should be of sufficient length and sufficiently unambiguous
that false positives are minimized. The
oligonucleotide is preferably labeled such that it can be detected upon
hybridization to DNA in the library being
screened. Methods of labeling are well known in the art, and include the use
of radiolabels like '2P-labeled ATP,
biotinylation or enzyme labeling. Hybridization conditions, including moderate
stringency and high stringency, are
provided in Sambrook et al., supra.
Sequences identified in such library screening methods can be compared and
aligned to other known
sequences deposited and available in public databases such as GenBank or other
private sequence databases.
Sequence identity (at either the amino acid or nucleotide level) within
defined regions of the molecule or across the
full-length sequence can be determined through sequence alignment using
computer software programs such as
BLAST, ALIGN, DNAstar, and INHERIT which employ various algorithms to measure
homology.
Nucleic acid having protein coding sequence may be obtained by screening
selected cDNA or genomic
libraries using the deduced amino acid sequence disclosed herein for the first
time, and, if necessary, using
conventional primer extension procedures as described in Sambrook et al.,
supra, to detect precursors and processing
intermediates of mRNA that may not have been reverse-transcribed into cDNA.
B. Selection and Transformation of Host Cells
Host cells are transfected or transformed with expression or cloning vectors
described herein for PRO
polypeptide production and cultured in conventional nutrient media modified as
appropriate for inducing promoters,
selecting transformants, or amplifying the genes encoding the desired
sequences. The culture conditions, such as
media, temperature, pH and the like, can be selected by the skilled artisan
without undue experimentation. In
general, principles, protocols, and practical techniques for maximizing the
productivity of cell cultures can be found
in Mammalian Cell BiotechnoloQV: a Practical Approach, M. Butler, ed. (IRL
Press, 1991) and Sambrook et al.,
149
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Methods of transfection are known to the ordinarily skilled artisan, for
example, CaPO, and electroporation.
Depending on the host cell used, transformation is performed using standard
techniques appropriate to such cells.
The calcium treatment employing calcium chloride, as described in Sambrook et
al., ,~nra, or electroporation is
generally used for prokaryotes or other cells that contain substantial cell-
wall barriers. Infection with Agrobacteriurn
tumefaciens is used for transformation of certain plant cells, as described by
Shaw et al., Gene, 2:315 (1983) and
WO 89!05859 published 29 June 1989. For mammalian cells without such cell
walls, the calcium phosphate
precipitation method of Graham and van der Eb, ViroloQV, 52:456-457 (1978) can
be employed. General aspects
of mammalian cell host system transformations have been described in U.S.
Patent No. 4,399,216. Transformations
into yeast are typically carried out according to the method of Van Solingen
et al., J. Bac , 130:946 (1977) and Hsiao
et al., hoc. Nat!. Acid. Sci~LJSAI, 76:3829 (1979). However, other methods for
introducing DNA into cells, such
as by nuclear microinjection, electroporation, bacterial protoplast fusion
with intact cells, or polycations, e.g.,
polybrene, polyornithine, may also be used. For various techniques for
transforming mammalian cells, see Keown
et al., ,~ylethods in Enzymology, _1$x:527-537 (1990) and Mansour et al., N
lure, X36:348-352 (1988).
Suitable host cells for cloning or expressing the DNA in the vectors herein
include prokaryote, yeast, or
higher eukaryote cells. Suitable prokaryotes include but are not limited to
eubacteria, such as Gram-negative or
Gram-positive organisms, for example, Enterobacteriaceae such as E. colt.
Various E. coli strains are publicly
available, such as E. coli K12 swain MM294 (ATCC 31,446); E, coti X1776 (ATCC
31,537); E. coli strain W3110
(ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells
include Enterobacteriaceae such
as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus,
Salmonella, e.g., Salmonella ryphimurium,
Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as
B. subtilis and B. licheniformis (e.g., B.
licheniformis 41P disclosed in DD 266,710 published 12 April 1989),
Pseudomonas such as P. aeruginosa, and
Streptomyces. Various E. co& strains are publicly available, such as E. coli
K12 strain MM294 (ATCC 31,446); E.
coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325); and K5 772 (ATCC
53,635). These examples
are illustrative rather than limiting. Strain W3110 is one particularly
preferred host or parent host because it is a
common host strain for recombinant DNA product fermentations. Preferably, the
host cell secretes minimal amounts
of proteolytic enzymes. For example, swain W3110 may be modified to effect a
genetic mutation in the genes
encoding proteins endogenous to the host, with examples of such hosts
including E. coli W3110 strain IA2, which
has the complete genotype tonA ; E. coli W3110 strain 9E4, which has the
complete genotype tonA ptr3; E. coli
W3110 strain 27C7 (ATCC 55,244), which has the complete genotype torrA ptr3
phoA E15 (argF lac)169 degP
ompT kin'; E. coli W3I 10 swain 37D6, which has the complete genotype tonA
ptr3 phoA EI S (argF lac)169 degP
ompT rbs7 ilvG kin'; E. coli W3110 strain 40B4, which is strain 37D6 with a
non-kanamycin resistant degP deletion
mutation; and an E. coli strain having mutant periplasmic protease disclosed
in U.S. Patent No. 4,946,783 issued 7
August 1990. AltetTtatively, in vitro methods of cloning, e.g., PCR or other
nucleic acid polymerise reactions, are
suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or
yeast are suitable cloning or
expression hosts for PRO polypeptide-encoding vectors. Saccharomyces
cerevisiae is a commonly used lower
eukaryotic host microorganism. Others include Schizosaccharomyces pombe (Beach
and Nurse, N tore, 2~: 140
(1981]; EP 139,383 published 2 May 1985); Kluvveromyces hosts (U.S. Patent No.
4,943,529; Fleer et al.,
BioITechnology, Q: 968-975 (1991)) such as, e.g., K, lactis (MW98-8C, CBS683,
CBS4574; Louvencourt et al., J.
Bactetiol., 737 [1983]), K. fragilis (ATCC 12.424), K. bulgaricus (ATCC
16,045), K. wickeramii (ATCC 24,178),
150
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906; Van den Berg et al.,
Bio/~echnoloev, $: 135 (1990)),
K. thetmotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris
(EP 183,070; Sreekrishna et al., J.
Basic Microbiol., 7$: 265-278 [1988]); Candida; Trichoderma reesia (EP
244,234); Neurospora crassa (Case et al.,
Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]); Schwanniomyces such as
Schwanniomyces occidentalis- (EP
394,538 published 31 October 1990); and filamentous fungi such as, e.g.,
Neurospora, Penicillium, Tolypocladium
(WO 91/00357 published 10 January 1991), and Aspergillus hosts such as A.
nidulans (Ballance et al., Biochem.
Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221
[1983]; Yelton et al., Proc. Natl.
Acad. Sci. USA, 81: 1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J.,
4_: 475-479 [1985]).
Methylotropic yeasts are suitable herein and include, but are not limited to,
yeast capable of growth on methanol
selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia,
Saccharomyces. Torulopsis, and
Rhodotorula. A list of specific species that are exemplary of this class of
yeasts may be found in C. Anthony, to
Biochemistry of Meth lotro~s_, 269 (1982).
Suitable host cells for the expression of glycosylated PRO polypeptides are
derived from multicellular
organisms. Examples of invertebrate cells include insect cells such as
Drosophila S2 and Spodoptera Sf9, as well
as plant cells. Examples of useful mammalian host cell lines include Chinese
hamster ovary (CHO) and COS cells.
More specific examples include monkey kidney CV1 line transformed by SV40 (COS-
7, ATCC CRL 1651); human
embryonic kidney line (293 or 293 cells subcloned for growth in suspension
culture, Graham et al., J. Gen Virol.,
$ø:59 (197?)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin,
Proc. Natl. Acad. Sci. USA, 77:4216
(1980)); mouse setwli cells ('TM4, Mather, Biol. Reprod., 23:243-251 (1980));
human lung cells (W138, ATCC CCL
75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562,
ATCC CCL51). The
selection of the appropriate host cell is deemed to be within the skill in the
art.
C. Selection and Use of a Replicable Vector
The nucleic acid (e.g., cDNA or genomic DNA) encoding a desired PRO
polypeptide may be inserted into
a replicable vector for cloning (amplification of the DNA) or for expression.
Various vectors are publicly available.
The vector may, for example, be in the fotmt of a plasmid, cosmid, viral
panicle, or phage. The appropriate nucleic
acid sequence may be inserted into the vector by a variety of procedures. In
general, DNA is inserted into an
appropriate restriction endonuclease sites) using techniques known in the an.
Vector components generally include,
but are not limited to, one or more of a signal sequence, an origin of
replication, one or more marker genes, an
enhancer element, a promoter, and a transcription termination sequence.
Construction of suitable vectors containing
one or more of these components employs standard ligation techniques which are
known to the skilled artisan.
The PRO polypeptide of interest may be produced recombinantly not only
directly, but also as a fusion
polypeptide with a heterologous polypeptide, which may be a signal sequence or
other polypeptide having a specific
cleavage site at the N-terminus of the mature protein or polypeptide. In
general, the signal sequence may be a
component of the vector, or it tnay be a part of the PRO polypeptide DNA that
is inserted into the vector. The signal
sequence may be a prokaryotic signal sequence selected, for example, from the
group of the alkaline phosphatase,
penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion
the signal sequence may be, e.g., the
yeast invettase leader, alpha factor leader (including Saccharomyces and
Khnweromyces a-factor leaders, the latter
described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the C.
albicans glucoamylase leader (EP
362,179 published 4 April 1990), or the signal described in WO 90/13646
published 15 November 1990. In
151
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
mammalian cell expression, mamrna~ian signal sequences may be used to direct
secretion of the protein, such as signal
sequences from secreted polypeptides of the same or related species, as well
as viral secretory leaders.
Both expression and cloning vectors contain a nucleic acid sequence that
enables the vector to replicate in
one or more selected host cells. Such sequences are well known for a variety
of bacteria, yeast, and viruses. The
origin of replication from the plasmid pBR322 is suitable for most Gram-
negative bacteria, the 2~ plasmid origin is
suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV
or BPV) are useful for cloning vectors
in mammalian cells.
Expression and cloning vectors will typically contain a selection gene, also
termed a selectable marker.
Typical selection genes encode proteins that (a) confer resistance to
antibiotics or other toxins, e.g., ampicillin,
neomycin, methotrexate, or tetracycline, (b) complement auxotrophic
deficiencies, or (c) supply critical nutrients not
available from complex media, e.g., the gene encoding D-alanine racetnase for
Bacilli.
An example of suitable selectable markers for mammalian cells are those that
enable the identification of
cells competent to take up the PRO polypeptide nucleic acid, such as DHFR or
thymidine kinase. An appropriate
host cell when wild-type DHFR is employed is the CHO cell line deficient in
DHFR activity, prepared and
propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216
(1980). A suitable selection gene
for use in yeast is the trill gene present in the yeast plasmid YRp7
[Stinchcomb et al., Nature, 282:39 (1979);
Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)].
The trill gene provides a selection
marker for a mutant strain of yeast lacking the ability to grow in tryptophan,
for example, ATCC No. 44076 or PEP4-
1 [Jones, Genetics, $5:12 (1977)].
Expression and cloning vectors usually contain a promoter operably linked to
the PRO polypeptide nucleic
acid sequence to direct mRNA synthesis. Promoters recognized by a variety of
potential host cells are well known.
Promoters suitable for use with prokaryotic hosts include the ~i-lactamase and
lactose promoter systems [Chang et
al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline
phosphatase, a tryptophan (trp)
promoter system [Goeddel, Nucleic Acids Res., _8:4057 (1980); EP 36,776], and
hybrid promoters such as the tac
promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)].
Promoters for use in bacterial systems also
will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA
encoding the desired PRO polypeptide.
Examples of suitable promoting sequences for use with yeast hosts include the
promoters for 3-
phosphoglycerate kinase [Hitzeman et a1.,1. Biol. Chem., x:2073 (1980)] or
other glycolytic enzymes [Hess et al.,
J. Adv. Enzvme Reg" 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such
as enolase, glyceraldehyde-3-
phosphate dehydrogenase, hexokinase, pyruvate decarboxylase,
phosphofructokinase, glucose-6-phosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase,
phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional
advantage of transcription
controlled by growth conditions, are the promoter regions for alcohol
dehydrogenase 2, isocytochrome C, acid
phosphatase, degradative enzymes associated with nitrogen metabolism,
metallothionein, glyceraldehyde-3-phosphate
dehydrogenase, and enzymes responsible for maltose and galactose utilization.
Suitable vectors and promoters for
use in yeast expression are further described in EP 73,657.
PRO polypeptide transcription from vectors in mammalian host cells is
controlled, for example, by
promoters obtained from the genomes of viruses such as polyoma virus, fowlpox
virus (UK 2,211,504 published 5
July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian
sarcoma virus, cytomegalovirus, a
retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous
mammalian promoters, e.g., the actin
152
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
promoter or an immtutogiobulin promoter, and from heat-shock promoters,
provided such promoters are compatible
with the host cell systems.
Transcription of a DNA encoding the desired PRO polypeptide by higher
eukaryotes may be increased by
inserting an enhancer sequence into the vector. Enhancers are cis-acting
elements of DNA, usually about from 10
to 300 bp, that act on a promoter to increase its transcription. Many enhancer
sequences are now known from
S mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin).
Typically, however, one will use an
enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on
the late side of the replication origin
(bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma
enhancer on the late side of the replication
origin, and adenovirus enhancers. The enhancer may be spliced into the vector
at a position 5' or 3' to the PRO
polypeptide coding sequence, but is preferably located at a site 5' from the
promoter.
Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant,
animal, human, or nucleated
cells from other multicellular organisms) will also contain sequences
necessary for the termination of aanscription
and for stabilizing the mRNA. Such sequences are commonly available from the
5' and, occasionally 3', untranslated
regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide
segments transcribed as
polyadenylated fragments in the untranslated portion of the mRNA encoding PRO
polypeptides.
Still other methods, vectors, and host cells suitable for adaptation to the
synthesis of PRO polypeptides in
recombinant vertebrate cell culture are described in Gething et al., Na e,
X93:620-625 (1981); Mantei et al.,
Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.
D. Detecting Gene Amlxlification/Expr~.,ssion
Gene amplification and/or expression may be measured in a sample directly, for
example, by conventional
Southern blotting, Northern blotting to quantitate the transcription of mRNA
[Thomas, Proc. Natl. Acad. Sci. USA,
77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization,
using an appropriately labeled probe,
based on the sequences provided herein. Alternatively, antibodies may be
employed that can recognize specific
duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or
DNA-protein duplexes. The
antibodies in turn may be labeled and the assay may be carried out where the
duplex is bound to a surface, so that
upon the formation of duplex on the surface, the presence of antibody bound to
the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such
as immunohistochemical
staining of cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene
product, Antibodies useful for immunohistochemical staining andlor assay of
sample fluids may be either monoclonal
or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies
may be prepared against a native
sequence PRO polypeptide or against a synthetic peptide based on the DNA
sequences provided herein or against
exogenous sequence fused to a PRO polypeptide DNA and encoding a specific
antibody epitope.
E. Purification of PolYpe t1 ide
Forms of PRO polypeptides may be recovered from culture medium or from host
cell lysates. If membrane-
bound, it can be released from the membrane using a suitable detergent
solution (e.g. Triton-X 100) or by enzytnatic
cleavage. Cells employed in expression of PRO polypeptides can be disrupted by
various physical or chemical
means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell
lysing agents.
It may be desired to purify PRO polypeptides from recombinant cell proteins or
polypeptides. The following
153
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
procedures are exemplary of suitable purification procedures: by fractionation
on an ion-exchange column; ethanol
precipitation; reverse phase HPLC; chromatography on silica or on a canon-
exchange resin such as DEAE;
chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration
using, for example, Sephadex G-75;
protein A Sepharose columns to remove contaminants such as IgG; and metal
chelating columns to bind epitope-
tagged forms of the PRO polypeptide. Various methods of protein purification
may be employed and such methods
are known in the art and described for example in Deutscher, Methods in
Enzvmoloev, 182 (1990); Scopes, Protein
Purification: Principles and Practice, Springer-Verlag, New York (1982). The
purification steps) selected will
depend, for example, on the nature of the production process used and the
particular PRO polypeptide produced.
9i. Uses for PRO Polypeptides
Nucleotide sequences (or their complement) encoding the PRO polypeptides of
the present invention have
various applications in the art of molecular biology, including uses as
hybridization probes, in chromosome and gene
mapping and in the generation of anti-sense RNA and DNA. PRO polypeptide-
encoding nucleic acid will also be
useful for the preparation of PRO polypeptides by the recombinant techniques
described herein.
The full-length native sequence PRO polypeptide-encoding nucleic acid or
portions thereof, may be used
as hybridization probes for a cDNA library to isolate the full-length PRO
polypeptide gene or to isolate still other
genes (for instance, those encoding naturally-occurring variants of the PRO
polypeptide or PRO polypeptides from
other species) which have a desired sequence identity to the PRO polypeptide
nucleic acid sequences. Optionally,
the length of the probes will be about 20 to about 50 bases. The hybridization
probes may be derived from the
nucleotide sequence of any of the DNA molecules disclosed herein or from
genomic sequences including promoters,
enhancer elements and introns of native sequence PRO polypeptide encoding DNA.
By way of example, a screening
method will comprise isolating the coding region of the PRO polypeptide gene
using the known DNA sequence to
synthesize a selected probe of about 40 bases. Hybridization probes may be
labeled by a variety of labels. including
radionucleotides such as '2P or'S S, or enzymatic labels such as alkaline
phosphatase coupled to the probe via
avidin/biotin coupling systems. Labeled probes having a sequence complementary
to that of the specific PRO
polypeptide gene of the present invention can be used to screen libraries of
human cDNA, genomic DNA or mRNA
to determine which members of such libraries the probe hybridizes to.
Hybridization techniques are described in
further detail in the Examples below.
The ESTs disclosed in the present application may similarly be employed as
probes, using the methods
disclosed herein.
The probes may also be employed in PCR techniques to generate a pool of
sequences for identification of
closely related PRO polypeptide sequences.
Nucleotide sequences encoding a PRO polypeptide can also be used to construct
hybridization probes for
mapping the gene which encodes that PRO polypeptide and for the genetic
analysis of individuals with genetic
disorders. The nucleotide sequences provided herein may be mapped to a
chromosome and specific regions of a
chromosome using known techniques, such as in situ hybridization, linkage
analysis against known chromosomal
markers, and hybridization screening with libraries.
When the coding sequence for the PRO polypeptide encodes a protein which binds
to another protein, the
PRO polypeptide can be used in assays to identify its ligands. Similarly,
inhibitors of the receptor/ligand binding
interaction can be identified. Proteins involved in such binding interactions
can also be used to screen for peptide
154
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
or small molecule inhibitors or agonists of the binding interaction. Screening
assays can be designed to find lead
compounds that mimic the biological activity of a native PRO polypeptide or a
ligand for the PRO polypeptide. Such
screening assays will include assays amenable to high-throughput screening of
chemical libraries, making them
particularly suitable for identifying small molecule drug candidates. Small
molecules contemplated include synthetic
organic or inorganic compounds. The assays can be performed in a variety of
formats, including protein-protein
binding assays, biochemical screening assays, immunoassays and cell based
assays, which are well characterized in
the art.
Nucleic acids which encode a PRO polypeptide or its modified forms can also be
used to generate either
transgenic animals or "knock out" animals which, in turn, are useful in the
development and screening of
therapeutically useful reagents. A uansgenic animal (e.g., a mouse or rat) is
an animal having cells that contain a
transgene, which transgene was introduced into the animal or an ancestor of
the animal at a prenatal, e.g., an
embryonic stage. A uansgene is a DNA which is integrated into the genome of a
cell from which a transgenic animal
develops. In one embodiment, cDNA encoding a PRO polypeptide of interest can
be used to clone genomic DNA
encoding the PRO polypeptide in accordance with established techniques and the
genomic sequences used to generate
transgenic animals that contain cells which express DNA encoding the PRO
polypeptide. Methods for generating
transgenic animals, particularly animals such as mice or rats, have become
conventional in the an and are described,
for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically,
particular cells would be targeted for PRO
polypeptide transgene incorporation with tissue-specific enhancers. Transgenic
animals that include a copy of a
uansgene encoding a PRO polypeptide inuoduced into the germ line of the animal
at an embryonic stage can be used
to examine the effect of increased expression of DNA encoding the PRO
polypeptide. Such animals can be used as
tester animals for reagents thought to confer protection from, for example,
pathological conditions associated with
its overexpression. In accordance with this facet of the invention, an animal
is ueated with the reagent and a reduced
incidence of the pathological condition, compared to untreated animals bearing
the transgene, would indicate a
potential therapeutic intervention for the pathological condition.
Alternatively, non-human homologues of PRO polypeptides can be used to
construct a PRO polypeptide
"knock out" animal which has a defective or altered gene encoding the PRO
polypeptide of interest as a result of
homologous recombination between the endogenous gene encoding the PRO
polypeptide and altered genomic DNA
encoding the PRO polypeptide introduced into an embryonic cell of the animal.
For example, cDNA encoding a PRO
polypeptide can be used to clone genomic DNA encoding the PRO polypeptide in
accordance with established
techniques. A portion of the genomic DNA encoding a PRO polypeptide can be
deleted or replaced with another
gene, such as a gene encoding a selectable marker which can be used to monitor
integration. Typically, several
kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included
in the vector (see e.g., Thomas and
Capecchi, CSI , ,5,x:503 (1987) for a description of homologous recombination
vectors]. The vector is introduced into
an embryonic stem cell line (e.g., by elecuoporation) and cells in which the
introduced DNA has homologously
recombined with the endogenous DNA are selected [see e.g., Li et al., ~r ,
øQ:915 (1992)]. The selected cells are
then injected into a blastocyst of an animal (e.g.. a mouse or rat) to form
aggregation chimeras [see e.g., Bradley,
in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J.
Robertson, ed. (IRL, Oxford, 1987),
pp. 113-1S2). A chimeric embryo can then be implanted into a suitable
pseudopregnant female foster animal and the
embryo brought to term to create a "knock out" animal. Progeny harboring the
homologously recombined DNA in
their germ cells can be identified by standard techniques and used to breed
animals in which all cells of the animal
1S5
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
contain the homologously recombined DNA. Knockout animals can be characterized
for instance, for their ability
to defend against certain pathological conditions and for their development of
pathological conditions due to absence
of the PRO polypeptide.
When in vivo administration of a PRO polypeptide is employed, normal dosage
amounts may vary from
about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day,
preferably about 1 ~g/kg/day to 10
mg/kg/day, depending upon the route of administration. Guidance as to
particular dosages and methods of delivery
is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760;
5,206,344; or 5,225,212. It is anticipated
that different formulations will be effective for different treatment
compounds and different disorders, that
administration targeting one organ or tissue, for example, may necessitate
delivery in a manner different from that
to another organ or tissue.
Where sustained-release administration of a PRO polypeptide is desired in a
formulation with release
characteristics suitable for the treatment of any disease or disorder
requiring administration of the PRO polypeptide,
microencapsulation of the PRO polypeptide is contemplated. Microencapsulation
of recombinant proteins for
sustained release has been successfully performed with human growth hormone
(rhGH), interferon- (rhIFN- ),
interleukin-2, and MN rgp120. Johnson et al., Nat. Med., ~: 795-799 (1996);
Yasuda. Biomed. Ther., 27: 1221-
1223 (1993); Hora et al., Bio/Technology, _8: 755-758 (1990); Cleland, "Design
and Production of Single
Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in
Vaccine Design: The Subunit and
Adju_vant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995),
pp. 439-462; WO 97/03692, WO
96/40072, WO 96/07399; and U.S Pat. No. 5,654,010.
The sustained-release formulations of these proteins were developed using poly-
lactic-coglycolic acid
(PLGA) polymer due to its biocompatibiliry and wide range of biodegradable
properties. The degradation products
of PLGA, lactic and glycolic acids, can be cleared quickly within the human
body. Moreover, the degradability of
this polymer can be adjusted from months to years depending on its molecular
weight and composition. Lewis,
"Controlled release of bioactive agents from lactide/glycolide polymer," in:
M. Chasm and R. Larger (Eds.),
Biodegradable Polymers as Drug Delivery s~ (Marcel Dekker: New York, 1990),
pp. 1-41.
For example, for a formulation that can provide a dosing of approximately 80
g/kg/day in mammals with
a maximum body weight of 85 kg, the largest dosing would be approximately 6.8
mg of the PRO polypeptide per day.
In order to achieve this dosing level, a sustained- release formulation which
contains a maximum possible protein
loading (15-20% w/w PRO polypeptide) with the lowest possible initial burst (
<20%) is necessary. A continuous
(zero-order) release of the PRO polypeptide from microparticles for 1-2 weeks
is also desirable. In addition, the
encapsulated protein to be released should maintain its integrity and
stability over the desired release period.
PR0213 polypeptides and portions thereof which possess the ability to regulate
the growth induction cascade
and/or the blood coagulation cascade may also be employed for such purposes
both in vivo therapy and in vitro.
Those of ordinary skill in the art will well know how to employ PR0213
polypeptides for such uses.
PR0274 polypeptides and portions thereof which have homology to 7TM protein
and Fn54 may also be
useful for in vivo therapeutic purposes, as well as for various other
applications. The identification of novel 7TM
protein and Fn54-like molecules may have relevance to a number of human
disorders which involve recognition of
ligands and the subsequent signal transduction of information contained within
those ligands in order to conaol
cellular processes. Thus, the identification of new 7TM protein and Fn54-like
molecules is of special importance
in that such proteins may serve as potential therapeutics for a variety of
different human disorders. Such polypeptides
156
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
may also play important roles in biotechnological and medical research as well
as in various industrial applications.
As a result, there is particular scientific and medical interest in new
molecules, such as PR0274.
PR0300 polypeptides and portions thereof which have homology to Diff 33 may
also be useful for in vivo
therapeutic purposes, as well as for various other applications. The
identification of novel Diff 33-like molecules may
have relevance to a number of human disorders such as the physiology of
cancer. Thus, the identification of new
Diff 33-like molecules is of special importance in that such proteins may
serve as potential therapeutics for a variety
of different human disorders. Such poiypeptides may also play important roles
in biotechnological and medical
research as well as various industrial applications. As a result, there is
particular scientific and medical interest in
new molecules, such as PR0300.
PR0296 polypeptides of the present invention which possess biological activity
related to that of the
sarcoma-amplified SAS protein may be employed both in vivo for therapeutic
purposes and in vitro. Those of
ordinary skill in the art will well know how to employ the PR0296 polypeptides
of the present invention for such
purposes.
PR0329 polypeptides of the present invention which possess biological activity
related to that of
immunoglobulin F~ receptor protein or subunit thereof may be employed both in
vivo for therapeutic purposes and
in vitro. Those of ordinary skill in the art will well know how to employ the
PR0329 polypeptides of the present
invention for such purposes.
PR0362 polypeptides of the present invention which possess biological activity
related to that of the A33
antigen protein, HCAR protein or the NrCAM related cell adhesion molecule may
be employed both in vivo for
therapeutic purposes and in vitro.
PR0363 polypeptides of the present invention which possess biological activity
related to that of the cell
surface HCAR protein may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill
in the art will well know how to employ the PR0363 polypeptides of the present
invention for such purposes.
Specifically, extracellular domains derived from the PR0363 polypeptides may
be employed therapeutically in vivo
for lessening the effects of viral infection.
PR0868 polypeptides of the present invention which possess biological activity
related to that of the tumor
necrosis factor protein may be employed both in vivo for therapeutic purposes
and in vitro. Those of ordinary skill
in the art will well lrnow how to employ the PR0868 polypeptides of the
present invention for such purposes.
PR0382 polypeptides of the present invention which possess biological activity
related to that of the serine
protease proteins may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0382 polypeptides of the present
invention for such purposes.
PR0545 polypeptides and portions thereof which have homology to meltrin may
also be useful for in vivo
therapeutic purposes, as well as for various other applications. The
identification of novel molecules associated with
cellular adhesion tray be relevant to a ntt.mber of human disorders. Given
that the meltrin proteins may play an
impot~tartt role in a number of disease processes, the identification of new
meltrin proteins and meluin-like molecules
is of special importance in that such proteins may serve as potential
therapeutics for a variety of different human
disorders. Such polypeptides may also play important roles in biotechnological
and medical research, as well as
various industrial applications. As a result, there is particular scientific
and medical interest in new molecules, such
as PR0545.
157
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
PR0617 polypeptides of the present invention which possess biological activity
related to that of the CD24
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0617 polypeptides of the present invention for
such purposes.
PR0700 polypeptides and portions thereof which have homology to protein
disulfide isomerase may also
be useful for in vivo therapeutic purposes, as well as for various other
applications. The identification of novel
protein disulfide isomerases and related molecules may be relevant to a number
of human disorders. Given that
formation of disulfide bonds and protein folding play important roles in a
number of biological processes, the
identification of new protein disulfide isomerases and protein disulfide
isomerase-like molecules is of special
importance in that such proteins may serve as potential therapeutics for a
variety of different human disorders. Such
polypeptides may also play important roles in biotechnological and medical
research, as well as various indusuial
applications. As a result, there is particular scientific and medical interest
in new molecules, such as PR0700.
PR0702 polypeptides of the present invention which possess biological activity
related to that of the
conglutinin protein may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR0702 polypeptides of the present
invention for such purposes. PR0702
polypeptides having conglutinin activity would be expected to be capable of
inhibiting haernagglutittin activity by
influenza viruses and/or function as immunoglobulin-independent defense
molecules as a result of a complement-
mediated mechanism.
PR0703 polypeptides of the present invention which possess biological activity
related to that of the VLCAS
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0703 polypeptides of the present invention for
such purposes.
PR0703 polypeptides and portions thereof which have homology to VLCAS may also
be useful for in vivo
therapeutic purposes, as well as for various other applications. The
identification of novel VLCAS proteins and
related molecules may be relevant to a number of human disorders. Thus, the
identification of new VLCAS proteins
and VLCAS protein-like molecules is of special importance in that such
proteins rnay serve as potential therapeutics
for a variety of different human disorders. Such polypeptides may also play
important roles in biotechnological and
medical research as well as various industrial applications. As a result,
there is particular scientific and medical
interest in new molecules, such as PR0703.
PR0705 polypeptides of the present invention which possess biological activity
related to that of the K-
glypican protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0705 polypeptides of the present
invention for such purposes.
PR0708 polypeptides of the present invention which possess biological activity
related to that of the aryl
sulfatase proteins may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in the
an will well know how to employ the PR0708 polypeptides of the present
invention for such purposes.
PR0320 polypeptides of the present invention which possess biological activity
related to that of the fibulin
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well lmow how to employ the PRO320 polypeptides of the present invention for
such purposes.
PR0320 polypeptides and portions thereof which have homology to fibulin tray
also be useful for in vivo
therapeutic ptltposes, as well as for various other applications. The
identification of novel fibulin proteins and related
molecules tray be relevant to a number of human disorders such as cancer or
those involving connective tissue,
attachment molecules and related mechanisms. Thus, the identification of new
fibulin proteins and fibulin
158
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
protein-like molecules is of special importance in that such proteins may
serve as potential therapeutics for a variety
of different human disorders. Such polypeptides may also play important roles
in biotechnological and medical
research as well as various industrial applications. As a result, there is
particular scientific and medical interest in
new molecules, such as PR0320.
PR0324 polypeptides of the present invention which possess biological activity
related to that of
oxidoreductases may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0324 polypeptides of the present
invention for such purposes.
PR0351 polypeptides of the present invention which possess biological activity
related to that of the
prostasin protein tray be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in the
art will well know how to employ the PR0351 polypeptides of the present
invention for such purposes.
PR0351 polypeptides and portions thereof which have homology to prostasin may
also be useful for in vivo
therapeutic purposes, as well as for various other applications. The
identification of novelprostasin proteins and
related molecules may be relevant to a number of human disorders. Thus, the
identification of new prostasin proteins
and prostasin -like molecules is of special importance in that such proteins
may serve as potential therapeutics for
a variety of different human disorders. Such polypeptides may also play
important roles in biotechnological and
medical research as well as various industrial applications. As a result,
there is particular scientific and medical
interest in new molecules, such as PR0351.
PR0352 polypeptides of the present invention which possess biological activity
related to that of the
butyrophilin protein may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR0352 polypeptides of the present
invention for such purposes.
PR0381 polypeptides of the present invention which possess biological activity
related to that of one or more
of the FKPB immunophilin proteins may be employed both in vivo for therapeutic
purposes and in vitro, for example
for enhancing immunosuppressant activity andlor for axonal regeneration. Those
of ordinary skill in the art will well
know how to employ the PR0381 polypeptides of the present invention for such
purposes.
PR0386 polypeptides of the present invention which possess biological activity
related to that of the beta-2
subunit of a sodium channel expressed in marnrnalian cells may be employed
both in vivo for therapeutic purposes
and in vitro. Those of ordinary skill in the art will well know how to employ
the PR0386 polypeptides of the present
invention for such purposes.
PR0540 polypeptides of the present invention which possess biological activity
related to that of the LCAT
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the' art will
well know how to employ the PR0540 polypeptides of the present invention for
such purposes.
PR0615 polypeptides of the present invention which possess biological activity
related to that of the
synaptogyrin protein may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR0615 polypeptides of the present
invention for such purposes.
PR0615 polypeptides and portions thereof which have homology to synaptogyrin
may also be useful for in
vivo therapeutic purposes, as well as for various other applications. The
identification of novel synaptogyrin proteins
and related molecules may be relevant to a number of human disorders. Thus,
the identification of new synaptogyrin
proteins and synaptogyrin-like molecules is of special importance in that such
proteins rnay serve as potential
therapeutics for a variety of different human disorders. Such polypeptides may
also play important roles in
biotechnological and medical research as well as various indusuial
applications. As a result, there is particular
159
CA 02421372 2003-03-25
WO 99146281 PCT/US99/05028
scientific and medical interest in new molecules, such as PR0615.
PR0618 polypeptides of the present invention which possess biological activity
related to that of an
enteropeptidase may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0618 polypeptides of the present
invention for such purposes.
PR0618 polypeptides and portions thereof which have homology to
enteropeptidase may also be useful for
in vivo therapeutic purposes, as well as for various other applications. The
identification of novel enteropeptidase
proteins and related molecules may be relevant to a number of human disorders.
Thus, the identification of new
enteropeptidase proteins and enteropeptidase-like molecules is of special
importance in that such proteins rnay serve
as potential therapeutics for a variety of different human disorders. Such
polypeptides may also play important roles
in biotechnological and medical research as well as various indusuial
applications. As a result, there is particular
scientific and medical interest in new molecules, such as PR0618.
PR0719 polypeptides of the present invention which possess biological activity
related to that of the
lipoprotein lipase H protein may be employed both in vivo for therapeutic
purposes and in vitro. Those of ordinary
skill in the art will well know how to employ the PR0719 polypeptides of the
present invention for such purposes.
PR0724 polypeptides of the present invention which possess biological activity
related to that of the human
LDL receptor protein may be employed both in vJvo for therapeutic purposes and
in vitro. Those of ordinary skill
in the art will well know how to employ the PR0724 polypeptides of the present
invention for such purposes.
PR0772 polypeptides of the present invention which possess biological activity
related to that of the human
A4 protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0772 polypeptides of the present invention for
such purposes.
PR0852 polypeptides of the present invention which possess biological activity
related to that of certain
protease protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
an will well know how to employ the PR0852 polypeptides of the present
invention for such purposes.
PR0853 polypeptides of the present invention which possess biological activity
related to that of the
reductase protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0853 polypeptides of the present
invention for such purposes.
PR0853 polypeptides and portions thereof which have homology to reductase
proteins may also be useful
for in vivo therapeutic purposes, as well as for various other applications.
Given that oxygen free radicals and
antioxidants appear to play important roles in a number of disease processes,
the identification of new reductase
proteins and reductase-like molecules is of special importance in that such
proteins may serve as potential therapeutics
for a variety of different human disorders. Such polypeptides may also play
important roles in biotechnological and
medical research as well as various industrial applications. As a result,
there is particular scientific and medical
interest in new molecules, such as PR0853.
PR0860 polypeptides of the present invention which possess biological activity
related to that of the
neurofascin protein may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR0860 polypeptides of the present
invention for such purposes.
PR0860 polypeptides and portions thereof which have homology to neurofascin
tray also be useful for in
vivo therapeutic purposes, as well as for various other applications. The
identification of novel neurofascin proteins
and related molecules may be relevant to a number of human disorders which
involve cellular adhesion. Thus, the
identification of new rteurofascin proteins arid neurofascin protein-like
molecules is of special importance in that such
160
CA 02421372 2003-03-25
WO 99/46281 PCTNS99/05028
proteins may serve as potential therapeutics for a variety of different human
disorders. Such polypeptides may also
play important roles in biotechnological and medical research as well as
various industrial applications. As a result,
there is particular scientific and medical interest in new molecules, such as
PR0860.
PR0846 polypeptides of the present invention which possess biological activity
related to that of the
CMRF35 protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0846 polypeptides of the present
invention for such purposes.
PR0846 polypeptides and portions thereof which have homology to the CMRF35
protein may also be useful
for in vivo therapeutic purposes, as well as for various other applications.
The identification of novel CMRF35
protein and related molecules may be relevant to a number of human disorders.
Thus, the identification of new
CMRF35 protein and CMRF35 protein-like molecules is of special importance in
that such proteins may serve as
potential therapeutics for a variety of different human disorders. Such
polypeptides may also play important roles
in biotechnological and medical research as well as various industrial
applications. As a result, there is particular
scientific and medical interest in new molecules, such as PR0846.
PR0862 polypeptides of the present invention which possess biological activity
related to that of the
lysozyme protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0862 polypeptides of the present
invention for such purposes.
PR0862 polypeptides and portions thereof which have homology to the lysozyme
protein may also be useful
for in vivo therapeutic purposes, as well as for various other applications.
The identification of novel lysozyme
proteins and related molecules may be relevant to a number of human disorders.
Thus, the identification of new
lysozymes and lysozyme-like molecules is of special importance in that such
proteins may serve as potential
therapeutics for a variety of different human disorders. Such polypeptides may
also play important roles in
biotechnological and medical research as well as various industrial
applications. As a result, there is particular
scientific and medical interest in new molecules, such as PR0862.
PR0864 polypeptides of the present invention which possess biological activity
related to that of the Wnt-4
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0864 polypeptides of the present invention for
such purposes.
PR0864 polypeptides and portions thereof which have homology to the Wnt-4
protein tray also be useful
for in vivo therapeutic purposes, as well as for various other applications.
The identification of novel Wnt-4 proteins
and related molecules may be relevant to a number of human disorders. Thus,
the identification of new Wnt-4 protein
and Wnt-4 protein-like molecules is of special importance in that such
proteins may serve as potential therapeutics
for a variety of different human disorders. Such polypeptides may also play
important roles in biotechnological and
medical research as well as various industrial applications. As a result,
there is particular scientific and medical
interest in new molecules, such as PR0864.
PR0792 polypeptides of the present invention which possess biological activity
related to that of the CD23
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0792 polypeptides of the present invention for
such purposes.
PR0866 polypeptides of the present invention which possess biological activity
related to that of mindin
andlor spondin protein may be employed both in vivo for therapeutic purposes
and in vitro. Those of ordinary skill
in the art will well know how to employ the PR0866 polypeptides of the present
invention for such purposes.
161
CA 02421372 2003-03-25
WO 99/46281 PCTNS99/05028
PR0871 polypeptides of the present invention which possess biological activity
related to that of the
cyciophilin protein family may be employed both in vivo for therapeutic
purposes and in vitro. Those of ordinary
skill in the art will well know how to employ the PR0871 polypeptides of the
present invention for such purposes.
PR0873 polypeptides of the present invention which possess biological activity
related to that of
carboxylesterases may be employed both in vivo for therapeutic purposes and in
vitro. For example, they be used
in conjunction with prodrugs to convert the prodrug to its active form (see
Danks et al.,supra). They may be used
to inhibit parasite infection (see van Pelt et al., supra). Methods for employ
the PR0873 polypeptides of the present
invention for these, and other purposes will be readily apparent to those of
ordinary skill in the art.
PR0940 polypeptides of the present invention which possess biological activity
related to that of the CD33
protein and/or OB binding protein-2 rnay be employed both in vivo for
therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know how to employ the PR0940 polypeptides
of the present invention for such
purposes.
PR0941 polypeptides of the present invention which possess biological activity
related to that of a cadherin
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the an will
well know how to employ the PR0941 polypeptides of the present invention for
such purposes.
PR0944 polypeptides of the present invention which possess biological activity
related to that of the CPE-R
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR0944 polypeptides of the present invention for
such purposes. PR0944 polypeptides
of the present invention that function to bind to Clostridium perfringens
enterotozin (CPE) may fmd use for effectively
treating infection by the CPE endotoxin.
PR0983 polypeptides of the present invention which possess biological activity
related to that of the vesicle-
associated membrane protein, VAP-33, may be employed both in vivo for
therapeutic purposes and in vitro, Those
of ordinary skill in the art will well know how to employ the PR0983
polypeptides of the present invernion for such
purposes.
PR01057 polypeptides of the present invention which possess biological
activity related to that of protease
proteins may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR01057 polypeptides of the present invention for
such purposes.
PR01071 polypeptides of the present invention which possess biological
activity related to that of the
thrombospondin protein may be employed both in vivo for therapeutic purposes
and in vitro. Those of ordinary skill
in the art will well know how to employ the PR01071 polypeptides of the
present invention for such purpDses.
PR01072 polypeptides of the present invention which possess biological
activity related to that of reductase
proteins may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR01072 polypeptides of the present invention for
such purposes.
PR01075 polypeptides of the present invention which possess biological
activity related to that of protein
disulfide isomerase may be employed both in viva for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR01075 polypeptides of the present
invention for such purposes.
PR0181 polypeptides of the present invention which possess biological activity
related to that of the
cornichon protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0181 polypeptides of the present
invention for such purposes.
162
CA 02421372 2003-03-25
WO 99/46281 PCT/I3S99105028
PR0827 polypeptides of the present invention which possess biological activity
related to that of various
integtin proteins may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0827 polypeptides of the present
invention for such purposes.
PR01114 polypeptides of the present invention which possess biological
activity related to that of the
cytokine receptor family of proteins may be employed both in vivo for
therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know how to employ the PR01114
polypeptides of the present invention for such
purposes.
In addition to the above, the PR01114 interferon receptor polypeptides may be
employed in applications,
both in vivo and in vitro, where the ability to bind to an interferon ligand
is desired. Such applications will be well
within the skill level in the art.
PR0237 polypeptides of the present invention which possess biological activity
related to that of the carbonic
anhydrase protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0237 polypeptides of the present
invention for such purposes.
PR0541 polypeptides of the present invention which possess biological activity
related to that of a trypsin
inhibitor protein may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0541 polypeptides of the present
invention for such purposes.
PR0273 polypeptides can be used in assays that other chemokines would be used
in to perform comparative
assays. The results can be used accordingly.
PR0701 polypeptides of the present invention which possess biological activity
related to that of the
neuroligin family may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0701 polypeptides of the present
invention for such purposes.
PR0701 can be used in assays with neurons and its activity thereon can be
compared with that of neuroligins
1, 2 and 3. The results can be applied accordingly.
PR0704 polypeptides of the present invention which possess biological activity
related to that of vesicular
integral membrane proteins may be employed both in vivo for therapeutic
purposes and in vitro. Those of ordinary
skill in the an will well know how to employ the PR0704 polypeptides of the
present invention for such purposes.
PR0704 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly. PR0704 can be
tagged or measured for activity to
measure endocytosis activity and thereby used to screen for agents which
effect endocytosis.
PR0705 polypeptides of the present invention which possess biological activity
related to that of the
endogenous prostatic acid phosphatase precursor may be employed both in vivo
for therapeutic purposes and in vitro.
Those of ordinary skill in the art will well know how to employ the PR0706
polypeptides of the present invention
for such purposes.
PR0706 can be used in assays with human prostatic acid phosphatase or human
lysosomal acid phosphatase
and its activity thereon can be compared with that of human prostatic acid
phosphatase or human lysosomal acid
phosphatase. The results can be applied accordingly.
PR0707 polypeptides of the present invention which possess biological activity
related to that of cadherins
may be employed both in vivo for therapeutic purposes and in vitro. Those of
ordinary skill in the art wilt well know
how to employ the PR0707 polypeptides of the present invention for such
purposes.
163
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
PR0707 can be used in assays to determine its activity in relation to other
cadherins, particularly cadherin
FIB3. The results can be applied accordingly.
PR0322 polypeptities of the present invention which possess biological
activity related to that of neuropsin
may be employed both in vivo for therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know
how to employ the PR0322 polypeptides of the present invention for such
purposes.
PR0322 can be used in assays to determine its activity relative to neuropsin,
trypsinogen, serine protease
and neurosin, and the results applied accordingly.
PR0526 polypeptides of the present invention which possess biological activity
related to that of protein-
protein binding proteins may be employed both in vivo for therapeutic purposes
and in vitro. Those of ordinary skill
in the art will well know how to employ the PR052fi polypeptides of the
present invention for such purposes,
Assays can be perfotmted with growth factors and other proteins which are
known to form complexes to
determine whether PR0526 binds thereto and whether there is increased half
life due to such binding. The results
can be used accordingly.
PR0531 polypeptides of the present invention which possess biological activity
related to that of the
protocadherins may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0531 polypeptides of the present
invention for such purposes.
PROS31 can be used in assays against protocadherin 3 and other protocadherins,
to determine their relative
activities. The results can be applied accordingly.
PROS34 polypeptides of the present invention which possess biological activity
related to that of the protein
disulfide isomerase may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the art will well know how to employ the PR0534 polypeptides of the present
invention for such purposes.
PR0534 can be used in assays with protein disulfide isomerase to determine the
relative activities. The
results can be applied accordingly.
PR0697 polypeptides of the present invention which possess biological activity
related to that of the sFRP
family may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will well
know how to employ the PR0697 polypeptides of the present invention for such
purposes.
PR0697 can be used in assays with sFRPs and SARPs to determine the relative
activities. The results can
be applied accordingly.
PR0731 polypeptides of the present invention which possess biological activity
related to that of any
protocadherin may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the art
will well know how to employ the PR0731 polypeptides of the present invention
for such purposes.
PR0731 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR0768 polypeptides of the present invention which possess biological activity
related to that of integrins
may be employed both in vivo for therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know
how to employ the PR0768 polypeptides of the present invention for such
purposes.
PR0768 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR0771 polypeptides of the present invention which possess biological activity
related to that of the testican
protein may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
164
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
well know how to employ the PR0771 polypeptides of the present invention for
such purposes.
PR0771 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR0733 polypeptides of the present invention which possess biological activity
related to that of the proteins
which bind the T11ST2 receptor may be employed both in vivo for therapeutic
purposes and in vitro. Those of
ordinary skill in the art will well latow how to employ the PR0733
polypeptides of the present invention for such
purposes.
PR0733 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR0162 polypeptides of the present invention which possess biological activity
related to that of the
pancreatitis-associated protein may be employed both in vivo for therapeutic
purposes and in vitro. Those of ordinary
skill in the art will well know how to employ the PR0162 polypeptides of the
present invention for such purposes.
PR0162 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR0788 polypeptides of the present invention which possess biological activity
related to that of the anti-
neoplastic urinary protein may be employed both in vivo for therapeutic
purposes and in vitro. Those of ordinary
skill in the art will well know how to employ the PR0788 polypeptides of the
present invention for such purposes.
PR0788 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
PR01008 polypeptides of the present invention which possess biological
activity related to that of dkk-1 may
be employed both in vivo for therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know how
to employ the PR01008 polypeptides of the present invention for such purposes.
PR01008 can be used in assays with the polypeptides to which they have
identity with to determine the
relative activities. The results can be applied accordingly.
PR01012 polypeptides of the present invention which possess biological
activity related to that of the protein
disulfide isomerase may be employed both in vivo and in vitro purposes. Those
of ordinary skill in the art will well
know how to employ the PR01012 polypeptides of the present invention for such
purposes.
PR01012 can be used in assays with the polypeptides to which they have
identity with to detertnirte the
relative activities. The results can be applied accordingly.
PR01014 polypeptides of the present invention which possess biological
activity related to that of reductase
rnay be employed both in tdvo for therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know
how to employ the PR01014 polypeptides of the present invention for such
purposes.
PR01014 can be used in assays with the polypeptides to which they have
identity with to determine the
relative activities. Inhibitors of PR01014 are particularly preferred. The
results can be applied accordingly.
PR01017 polypeptides of the present invention which possess biological
activity related to that of
sttlfottansferase may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR01017 polypeptides of the present
invention for such purposes.
PR01017 can be used in assays with the polypeptides to which they have
identity with to determine the
relative activities. The results can be applied accordingly.
165
CA 02421372 2003-03-25
WO 99/46281 PCTNS99105828
PR0474 polypeptides of the present invention which possess biological activity
related to that of
dehydrogenase may be employed both in vivo for therapeutic purposes and in
vitro. Those of ordinary skill in the
art will well know how to employ the PR0474 polypeptides of the present
invention for such purposes.
PR0474 can be used in assays with the polypeptides to which they have identity
with to determine the
relative activities. The results can be applied accordingly.
S PR01031 polypeptides of the present invention which possess biological
activity related to that of 1L-17 may
be employed both in vivo for therapeutic purposes and in vitro. Those of
ordinary skill in the art will well know how
to employ the PR01031 polypeptides of the present invention for such purposes.
PR01031 can be used in assays with the polypeptides to which they have
identity with to determine the
relative activities. The results can be applied accordingly.
PR0938 polypeptides of the present invention which possess biological activity
related to that of protein
disulfide isomerase may be employed both in vivo for therapeutic purposes and
in vitro. Those of ordinary skill in
the an will well know how to employ the PR0938 polypeptides of the present
invention for such purposes.
PR01082 polypeptides of the present invention which possess biological
activity related to that of the LDL
receptor may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art will
well know how to employ the PR01082 polypeptides of the present invention for
such purposes.
PR01082 can be used in assays with the polypeptides to which they have
identity with to determine the
relative activities. The results can be applied accordingly. PR01082 can also
be used in assays to identify candidate
agents which modulate the receptors.
PR01083 polypeptides of the present invention which possess biological
activity related to that of 7TM
receptors may be employed both in vivo for therapeutic purposes and in vitro.
Those of ordinary skill in the art wiU
well k110W how to employ the PR01083 polypeptides of the present invention for
such purposes.
In particular PR01083 can be used in assays to determine candidate agents
which control or modulate
PR01083, i.e., have an effect on the receptor.
The VEGF-E molecules herein have a number of therapeutic uses associated with
survival, proliferation
and/or differention of cells. Such uses include the treatment of umbilical
vein endothelial cells, in view of the
demonstrated ability of VEGF-E to increase survival of human umbilical vein
endothelial cells. Treatment may be
needed if the vein were subjected to traumata, or situations wherein
artificial means are employed to enhance the
survival of the umbilical vein, for example, where it is weak, diseased, based
on an artificial matrix, or in an
artificial environment. Other physiological conditions that could be improved
based on the selective mitogenic
character of VEGF-E are also included herein. Uses also include the treatment
of fibroblasts and myocytes, in view
of the demonstrated ability of VEGF-E to induce proliferation of fibroblasts
and hypertrophy in myocytes. In
particular, VEGF-E can be used in wound healing, tissue growth and musclt
generation and regeneration.
For the indications referred to above, the VEGF-E molecule will be formulated
and dosed in a fashion
consistent with good medical practice taking into account the specific
disorder to be treated, the condition of the
individual patient, the site of delivery of the VEGF-E, the method of
administration, and other factors known to
practitioners. Thus, for purposes herein, the "therapeutically effective
amount" of the VEGF-E is an amount that
is effective either to prevent, lessen the worsening of, alleviate, or cure
the ueated condition, in particular that amount
which is sufficient to enhance the survival, proliferation and/or
differentiation of the treated cells in vivo.
166
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
VEGF-E amino acid variant sequences and derivatives that are irnmunologically
crossreactive with antibodies
raised against native VEGF are useful in immunoassays for VEGF-E as standards,
or, when labeled, as competitive
reagents.
The VEGF-E is prepared for storage or administration by mixing VEGF-E having
the desired degree of
purity with physiologically acceptable carriers, excipients, or stabilizers.
Such materials are non-toxic to recipients
at the dosages and concentrations employed. If the VEGF-E is water soluble, it
may be formulated in a buffer such
as phosphate or other organic acid salt preferably at a pH of about 7 to 8. if
the VEGF-E is only partially soluble
in water, it may be prepared as a microemulsion by formulating it with a
nonionic surfactant such as Tween,
Pluronics, or PEG, e.g., Tween 80, in an amount of 0.04-0.OS% (w/v), to
increase its solubility.
Optionally other ingredients may be added such as antioxidants, e.g., ascorbic
acid; low molecular weight
(less than about ten residues) polypeptides, e.g., polyarginine or
tripeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino
acids, such as glycine, glutamic acid,
aspartic acid, or arginine; monosaccharides, disaccharides, and other
carbohydrates including cellulose or its
derivatives, glucose, mannose, or dextrins; chelating agents such as EDTA; and
sugar alcohols such as mannitol or
sorbitol.
The VEGF-E to be used for therapeutic administration must be sterile.
Sterility is readily accomplished by
filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
The VEGF-E ordinarily will be stored
in lyophilized form or as an aqueous solution if it is highly stable to
thermal and oxidative denaturation. The pH of
the VEGF-E preparations typically will be about from 6 to 8, although higher
or lower pH values may also be
appropriate in certain instances. It will be understood that use of certain of
the foregoing excipients, carriers, or
stabilizers will result in the formation of salts of the VEGF-E.
if the VEGF-E is to be used parenterally, therapeutic compositions containing
the VEGF-E generally are
placed into a container having a sterile access port, for example, an
intravenous solution bag or vial having a stopper
pierceable by a hypodermic injection needle.
Generally, where the disorder permits, one should formulate and dose the VEGF-
E for site-specific delivery.
This is convenient in the case of wounds and ulcers.
Sustained release formulations may also be prepared, and include the formation
of microcapsular particles and
itnplantable articles. For preparing sustained-release VEGF-E compositions,
the VEGF-E is preferably incorporated
into a biodegradable matrix or microcapsule. A suitable material for this
purpose is a polylactide, although other
polymers of poly-(a-hydroxycarboxylic acids), such as poly-D-(-)-3-
hydroxyburyric acid (EP 133,988A), can be used.
Other biodegradable polymers include poly(lactones), poly(acetals),
poly(orthoesters), or poly(orthocarbonates). The
initial consideration here must be that the carrier itself, or its dcgradation
products, is nontoxic in the target tissue
and will not further aggravate the condition. This can be determined by
routine screening in animal models of the
target disorder or, if such models are unavailable, in normal animals.
Numerous scientific publications document
such animal models.
For examples of sustained release compositions, see U.S. Patent No. 3,773,919,
EP 58,481A, U.S. Patent
No. 3,887,699, EP 158,277A, Canadian Patent No. 1176565, U. Sidman et al.,
Biopolymers 22, 547 [1983], and
R. Larger et al., Chem. Teclt. 12, 98 [1982].
When applied topically, the VEGF-E is suitably combined with other
ingredients, such as carriers and/or
adjuvants. There are no limitations on the nature of such other ingredients,
except that they must be pharmaceutically
167
CA 02421372 2003-03-25
WO 99!46281 PCT/US99/05028
acceptable and efficacious for their intended administration, and cannot
degrade the activity of the active ingredients
of the composition. Examples of suitable vehicles include ointments, creams,
gels, or suspensions, with or without
purified collagen. The compositions also may be impregnated into transdetmal
patches, plasters, and bandages,
preferably in liquid or semi-liquid form.
For obtaining a gel formulation, the VEGF-E formulated in a liquid composition
may be mixed with an
effective amount of a water-soluble polysaccharide or synthetic polymer such
as polyethylene glycol to form a gel
of the proper viscosity to lx applied topically. The polysaccharide that may
be used includes, for example, cellulose
derivatives such as etherified cellulose derivatives, including alkyl
celluloses, hydroxyalkyl celluloses, and
alkylhydroxyalkyl celluloses, for example, methylcellulose, hydroxyethyl
cellulose, carboxymethyl cellulose,
hydroxypropyl methylcellulose, and hydroxypropyl cellulose; starch and
fractionated starch; agar; alginic acid and
alginates; gum arabic; pullullan; agarose; carrageenan; dextrans; dextrins;
fructans; inulin; mannans; xylans;
arabinans; chitosans; glycogens; glucans; and synthetic biopolymers; as well
as gums such as xanthan gttm; guar
gum; locust bean gum; gum arabic; tragacanth gum; and karaya gum; and
derivatives and mixtures thereof. The
preferred gelling agent herein is one that is inert to biological systems,
nontoxic, simple to prepare, and not too runny
or viscous, and will not destabilize the VEGF-E held within it.
Preferably the polysaccharide is an etherified cellulose derivative, more
preferably one that is well defined,
purified, and listed in USP, e.g., methylcellulose and the hydroxyalkyl
cellulose derivatives, such as hydroxypropyl
cellulose, hydroxyethyl cellulose, and hydroxypropyl methylcellulose. Most
preferred herein is methylcellulose.
The polyethylene glycol useful for gelling is typically a mixture of low and
high molecular weight
polyethylene glycols to obtain the proper viscosity. For example, a mixture of
a polyethylene glycol of molecular
weight 400-600 with one of molecular weight 1500 would be effective for this
purpose when mixed in the proper ratio
to obtain a paste.
The term "water soluble" as applied to the polysaccharides and polyethylene
glycols is meant to include
colloidal solutions and dispersions. In general, the solubility of the
cellulose derivatives is determined by the degree
of substitution of ether groups, and the stabilizing derivatives useful herein
should have a sufficient quantity of such
ether groups per anhydroglucose unit in the cellulose chain to render the
derivatives water soluble. A degree of ether
substitution of at least 0.35 ether groups per anhydroglucose unit is
generally sufficient. Additionally, the cellulose
derivatives may be in the form of alkali metal salts, for example, the Li, Na,
K, or Cs salts.
If methylcellulose is employed in the gel, preferably it comprises about 2-5 %
, more preferably about 3 % ,
of the gel and the VEGF is present in an amount of about 300-1000 mg per ml of
gel.
The dosage to be employed is dependent upon the factors described above. As a
general proposition, the
VEGF-E is formulated and delivered to the target site or tissue at a dosage
capable of establishing in the tissue a
VEGF-E level greater than about 0.1 ng/cc up to a maximum dose that is
efficacious but not unduly toxic. This
infra-tissue concentration should be maintained if possible by continuous
infusion, sustained release, topical
application, or injection at empirically determined frequencies.
It is within the scope hereof to combine the VEGF-E therapy with other novel
or conventional therapies
(e.g., growth factors such as VEGF, aFGF, bFGF, PDGF, IGF, NGF, anabolic
steroids, EGF or TGF-a) for
enhancing the activity of any of the growth factors, including VEGF-E, in
promoting cell proliferation, survival,
differentiation and repair. It is not necessary that such cotreatment drugs be
included per se in the compositions of
this invention, although this will be convenient where such drugs are
proteinaceous. Such admixtures are suitably
168
CA 02421372 2003-03-25
WO 99/46281 PCTNS99/05028
administered in the same manner and for the same purposes as the VEGF-E used
alone. The useful molar ratio of
VEGF-E to such secondary growth factors is typically 1:0.1-10, with about
equimolar amounts being preferred.
The compounds of the present invention can be formulated according to known
methods to prepare
pharmaceutically useful compositions, whereby the PRO polypeptide hereof is
combined in adnuxture with a
pharmaceutically acceptable carrier vehicle. Suitable carrier vehicles and
their formulation, inclusive of other human
proteins, e.g., human sertun albumin, are described, for example, in
Remington's Pharmaceutical Sciences, 16th ed.,
1980, Mack Publishing Co., edited by Oslo et al. the disclosure of which is
hereby incorporated by reference. The
VEGF-E herein may be administered parenterally to subjects suffering from
cardiovascular diseases or conditions,
or by other methods that ensure its delivery to the bloodstream in an
effective form.
Compositions particularly well suited for the clinical administration of VEGF-
E hereof employed in the
practice of the present invention include, for example, sterile aqueous
solutions, or sterile hydratable powders such
as lyophilized protein. It is generally desirable to include further in the
formulation an appropriate amount of a
pharmaceutically acceptable salt, generally in an amount sufficient to render
the formulation isotonic. A pH regulator
such as arginine base, and phosphoric acid, are also typically included in
sufficient quantities to maintain an
appropriate pH, generally from 5.5 to 7.5. Moreover, for improvement of shelf
life or stability of aqueous
formulations, it may also be desirable to include further agents such as
glycerol. In this manner, variant t-PA
formulations are rendered appropriate for parenteral administration, and, in
particular, intravenous administration.
Dosages and desired drug concentrations of pharmaceutical compositions of the
present invention may vary
depending on the particular use envisioned. For example, in the treatment of
deep vein thrombosis or peripheral
vascular disease, "bolus" doses, will typically be preferred with subsequent
administrations being given to maintain
an approximately constant blood level, preferably on the order of about 3
pg/ml.
However, for use in connection with emergency medical care facilities where
infusion capability is generally
not available and due to the generally critical nature of the underlying
disease (e.g., embolism, infarct), it will
generally be desirable to provide somewhat larger initial doses, such as an
intravenous bolus.
For the various therapeutic indications referred to for the compounds hereof,
the VEGF-E molecules will
be formulated and dosed in a fashion consistent with good medical practice
taking into account the specific disorder
to be treated, the condition of the individual patient, the site of delivery,
the method of administration and other
factors known to practitioners in the respective art. Thus, for purposes
herein, the "therapeutically effective amount"
of the VEGF-E molecules hereof is an amount that is effective either to
prevent, lessen the worsening of, alleviate,
or cure the treated condition, in particular that amount which is sufficient
to enhance the survival, proliferation or
differentiation of targeted cells in vivo. In general a dosage is employed
capable of establishing in the tissue that is
the target for the therapeutic indication being treated a level of a VEGF-E
hereof greater than about 0.1 nglcm' up
to a maximum dose that is efficacious but not unduly toxic. It is contemplated
that inaa-tissue administration may
be the choice for certain of the therapeutic indications for the compounds
hereof.
The human Toll proteins of the present invention can also be used in assays to
identify other proteins or
molecules involved in Toll-mediated signal transduction. For example, PR0285
and PR0286 are useful in identifying
the as of yet unknown natural ligands of human Tolls, or other factors that
participate (directly or indirectly) in the
activation of and/or signaling through a human Toll receptor, such as
potential Toll receptor associated kinases. In
addition, inhibitors of the receptorlligand binding interaction can be
identified. Proteins involved in such binding
interactions can also be used to screen for -peptide or small molecule
inhibitors or agonists of the binding interaction.
169
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Screening assays can be designed to fmd lead compounds that mimic the
biological activity of a native Toll
polypeptide or a ligand for a native Toll polypeptide. Such screening assays
will include assays amenable to high-
throughput screening of chemical libraries, making them particularly suitable
for identifying small molecule drug
candidates. Small molecules contemplated include synthetic organic or
inorganic compounds. The assays can be
performed in a variety of formats, including protein-protein binding assays,
biochemical screening assays,
immunoassays and cell based assays, which are well characterized in the art.
In vitro assays employ a mixture of components including a Toll receptor
polypeptide, which may be pan
of fusion product with another peptide or polypeptide, e.g., a tag for
detecting or anchoring, etc. The assay mixtures
may further comprise (for binding assays) a natural infra- or extracellular
Toll binding target (i.e. a Toll Iigand, or
another molecule known to activate and/or signal through the Toll receptor).
While native binding targets may be
used, it is frequently preferred to use portion of such native binding targets
(e.g. peptides), so long as the portion
provides binding affinity and avidity to the subject Toll protein conveniently
measurable in the assay. The assay
mixture also contains a candidate pharmacological agent. Candidate agents
encompass numerous chemical classes,
through typically they are organic compounds, preferably small organic
compounds, and are obtained from a wide
variety of sources, including libraries of synthetic or natural compounds. A
variety of other reagents may also be
included in the mixture, such as, salts, buffers, neutral proteins, e.g.
albumin, detergents, protease inhibitors,
nuclease inhibitors, antimicrobial agents, etc.
In in vitro binding assays, the resultant mixture is incubated under
conditions whereby, but for the presence
of the candidate molecule, the Toll protein specifically binds the cellular
binding target, portion or analog, with a
reference binding affinity. The mixture components can be added in any order
that provides for the requisite bindings
and incubations may be performed at any temperature which facilitates optimal
binding. Incubation periods are
likewise selected for optimal binding but also minimized to facilitate rapid
high-throughput screening.
After incubation, the agent-biased binding between the Toll protein and one or
more binding targets is
detected by any convenient technique. For cell-free binding type assays, a
separation step is often used to separate
bound from unbound components. Separation may be effected by precipitation
(e.g. TCA precipitation,
immunoprecipitation, etc.), immobilization (e.g on a solid substrate), etc.,
followed by washing by, for example,
membrane filtration (e.g. Whatman's P-18 ion exchange paper, Polyfiltronic's
hydrophobic GFC membrane, etc.),
gel chromatography {e.g. gel filtration, affmiry, etc.). For Toll-dependent
vanscription assays, binding is detected
by a change in the expression of a Toll-dependent reporter.
Detection may be effected in any convenient way. For cell-free binding assays,
one of the components
usually comprises or is coupled to a label. The label may provide for direct
detection as radioactivity, luminescence,
optical or electron density, etc., or indirect detection, such as, an epitope
tag, an enzyme, etc. A variety of methods
may be used to detect the label depending on the nature of the label and other
assay components, e.g. through optical
or electron density, radiative emissions, nonradiative energy transfers, etc.
or indirectly detected with antibody
conjugates, etc.
Nucleic acid encoding the Toll polypeptides disclosed herein may also be used
in gene therapy. In gene
therapy applications, genes are introduced into cells in order to achieve in
vivo synthesis of a therapeutically effective
genetic product, for example for replacement of a defective gene. "Gene
therapy" includes both conventional gene
therapy where a lasting effect is achieved by a single aeatment, and the
administration of gene therapeutic agents,
which involves the one time or repeated administration of a therapeutically
effective DNA or mRNA. Antisense
17~
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
RNAs and DNAs can be used as therapeutic agents for blocking the expression of
certain genes in vivo. It has
already been shown that short antisense oligonucleotides can be imported into
cells where they act as inhibitors,
despite their low intracellular concentrations caused by their restricted
uptake by the cell membrane. (Zamecnik et
al., Proc. Natl. Acad. Sci. USA 83, 4143146 [1986)). The oligonucleotides can
be modified to enhance their
uptake, e.g. by substituting their negatively charged phosphodiester groups by
uncharged groups.
There are a variety of techniques available for introducing nucleic acids into
viable cells. The techniques
vary depending upon whether the nucleic acid is transferred into cultured
cells in vitro, or in vivo in the cells of the
intended host. Techniques suitable for the transfer of nucleic acid into
mammalian cells in vitro include the use of
liposomes, electroporation, microinjection, cell fusion, DEAF-dextran, the
calcium phosphate precipitation method,
etc. The currently preferred in vivo gene transfer techniques include
transfection with viral (typically retroviral)
vectors and viral coat protein-liposome mediated transfection (Dzau et al. ,
Trends in Biotechnoloev 11, 205-210
[1993]). In some situations it is desirable to provide the nucleic acid source
with an agent that targets the target cells,
such as an antibody specific for a cell surface membrane protein or the target
cell, a ligand for a receptor on the target
cell, etc. Where liposomes are employed, proteins which bind to a cell surface
membrane protein associated with
endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid
proteins or fragments thereof tropic for
a particular cell type, antibodies for proteins which undergo internalization
in cycling, proteins that target intracellular
localization and enhance intracellular half life. The technique of receptor-
mediated endocytosis is described, for
example, by Wu et al., ~. Biol. Chem. ~, 4429-4432 (1987); and Wagner et al.,
Proc. Natl. Acad. Sci. USA ~,
3410-3414 (1990). For review of the currently known gene marking and gene
therapy protocols see Anderson et al.,
'Science ~Sø, 808-813 (1992).
The various uses listed in connection with the Toll proteins herein, are also
available for agonists of the
native Toll receptors, which mimic at least one biological function of a
native Toll receptor.
Neurotrimin as well as other members of the IgLON subfamily of the
immunoglobulin superfamily have
been identified to have effect upon neural patterning, differentiation,
maturation and growth. As a result, PR0337
the human neurotrimin homolog polypeptides would be expected to have utility
in diseases which are characterized
by neural disfimction. For example, motoneuron disorders such as amyotrophic
lateral sclerosis (Lou Gehrig's
disease), Bell's palsy, and various conditions involving spinal muscular
atrophy, or paralysis. NGF variant
formulations of the invention can be used to treat human neurodegenerative
disorders, such as Alzheimer's disease,
Parkinson's disease, epilepsy, multiple sclerosis, Huncington's chorea, Down's
Syndrome, nerve deafness, and
Meniere's disease. Moreover PR0337 polypeptide may also be used as a cognitive
enhancer, to enhance learning
particularly in dementia or trauma, such as those associated with the above
diseases.
Further, PR0337 may be employed to treat neuropathy, and especially peripheral
neuropathy. "Peripheral
neuropathy" refers to a disorder affecting the peripheral nervous system, most
often manifested as one or a
combination of motor, sensory, sensorimotor, or autonomic neural dysfunction.
The wide variety of morphologies
exhibited by peripheral neuropathies can each be attributed uniquely to an
equally wide number of causes. For
example, peripheral neuropathies can be genetically acquired, can result from
a systemic disease, or can be induced
by a toxic agent. Examples include but are not limited to diabetic peripheral
neuropathy, distal sensorimotor
neuropathy, or autonomic neuropathies such as reduced motility of the
gastrointestinal tract or stony of the urinary
bladder. Examples of neuropathies associated with systemic disease include
post-polio syndrome or AIDS-associated
neuropathy; examples of hereditary neuropathies include Charcot-Marie-Tooth
disease, Refsum's disease,
171
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Abetalipoproteinemia, Tangier disease, Krabbe's disease, Metachromatic
leukodystrophy, Fabry's disease, and
Dejerine-Sottas syndrome; and examples of neuropathies caused by a toxic agent
include those caused by treatment
with a chemotherapeutic agent such as vincristine, cisplatin, methotrexate, or
3'-azido-3'-deoxythymidine.
Correspondingly, neurotrimin antagonists would be expected to have utility in
diseases characterized by excessive
neuronal activity.
Endothelia is generated from inactive intermediates, the big endothelins, by a
unique processing event
catalyzed by the zinc metalloprotease, endothelia converting enzyme (ECE). ECE
was recently cloned, and its
structure was shown to be a single pass transmembrane protein with a short
intracellular N-terminal and a long
extracellular C-terminal that contains the catalytic domain and numerous N-
glycosylation sites. ECEs cleave the
endothelia propeptide between Trp73 and Va174 producing the active peptide,
ET, which appears to function as a
local rather than a circulating hormone (Rubanyi, G.M. & Polokoff, M.A.,
Pharmachological Reviews 46: 325-415
(1994). Thus ECE activity is a potential site of regulation of endothelia
production and a possible target for
therapeutic intervention in the endothelia system. By blocking ECE activity,
it is possible stop the production of ET-1
by inhibiting the conversion of the relatively inactive precursor, big ET-1,
to the physiologically active form.
ECE-2 is 64% identical to bovine ECE-2 at the amino acid level. ECE-2 is
closely related to ECE-1 (63 %
identical, 80% conserved), neutral endopeptidase 24.1 I and the Kell blood
group protein. Bovine ECE-2 is a type
II membrane-bound metalloproteinase localized in the traps-Golgi network where
it acts as an intracellular enzyme
converting endogenous big endothelia-1 into active endothelia (Emoto, N. and
Yanangisawa, M., J. Biol. Chem. 270:
15262-15268 (1995). The bovine ECE-2 mRNA expression is highest in parts of
the brain, cerebral cortex,
cerebellum and adrenal medulla. It is expressed at lower levels in mymetrium,
testes, ovary, and endothelial cells.
Bovine ECE-2 and ECE-I both are more active on ET-1 as a substrate compared to
ET-2 or ET-3, Emoto and
Yanangisawa, supra.
Human ECE-2 is 736 amino acids in length with a 31 residue amino-terminal
tail, a 23 residue transmembrane helix
and a 682 carboxy-terminal domain. It is 94% identical to bovine ECE-2 and 64%
identical to human ECE-1. The
predicted transmembrane domain is highly conserved between the human and
bovine ECE-2 proteins and between
human ECE-1 and human ECE-2, as are the putative N-linked glycosylation sites,
Cys residues conserved in the
neutral endopeptidase 24.11 and the Kell blood group protein family and the
putative zinc binding motif. The
sequence suggests, that like other members of the NEP-ECE-Kell faatily, human
ECE-2 encodes a type II
transmembrane zinc-binding metalloproteinase, which, by extrapolation from
what is known about bovine ECE-2,
is an intracellular enzyme located within the secretory pathway which
processes endogenously produced big ET-1
while it is still in the secretory vesicles. Emoto and Yanangisawa, supra.
The expression pattern of ECE-2 differs from that observed for ECE-I. Northern
blot analysis of mRNA
levels indicated low levels of expression of a 3.3 kb transcript in adult
brain (highest in the cerebellum, putamen,
medulla and temporal lobe, and lower in the cerebral cortex, occipital lobe
and frontal lobe), spinal cord, lung and
pancreas and higher levels of a 4.5 kb transcript in fetal brain and kidney.
The two transcript sizes probably
represent the use of alternative polyadenylation sites as has been observed
for bovine ECE-2 (Emoto and
Yanangisawa, supra) and ECE-1 (Xu et al., Cell 78: 473-485 (1994). PCR on cDNA
libraries indicated low levels
of expression in fetal brain, fetal kidney, fetal small intestine and adult
testis. Fetal liver, fetal lung and adult
pancreas were all negative.
172
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The endothelia (ET) family of peptides have potent vascular, cardiac and renal
actions which may be of
pathophysiological importance in many human disease states. ET-1 is expressed
as an inactive 212 amino acid
prepropeptide. The prepropeptide is first cleaved at Arg52-Cys53 and Arg92-
A1a93 and then the carboxy terminal
Lys91 and Arg92 are trimmed from the protein to generate the propeptide big ET-
1. ECEs then cleave the propeptide
between Trp73 and Va174, producing the active peptide, ET, which appears to
function as a local rather than a
circulating hormone (Rubanyi and Polokoff, Phatma. R. 46: 325-415 (1994).
Endothelins may play roles in the pathophysiology of a number of disease
states including: 1) cardiovascular
diseases (vasospasm, hypertension, myocardial ischemia; reperfusion injury and
acute myochardial infarction, stroke
(cerebral ischemia), congestive heart failure, shock, atherosclerosis,
vascular thickening); 2) kidney disease (acute
and chronic renal failure, glomerulonephritis, cirrhosis); 3) lung disease
(bronchial asthma, pulmonary hypertension);
4) gastrointestinal disorders (gastric ulcer, inflammatory bowel diseases); 5)
reproductive disorders (premature labor,
dysmenorhea, preeclampsia) and 6) carcinogenesis. Rubanyi & Polokoff, supra.
Diseases can be evaluated for the impact of ET upon them by examining: 1)
increased production of ETs;
2) increased reactivity to ETs; and/or 3) efficacy of an ET receptor
antagonist, antibody or ECE inhibitor. Response
to the previous criteria suggest that ETs likely play roles in cerebral
vasospasm following subarachnoid hemorrhage,
hypertension (fuhninant/complications), acute renal failure and congestive
heart failure. While inhibitors of ET
production or activity have not been used in models of coronary vasospasm,
acute myocardial infarction, and
atherosclerosis, they do have elevated ET levels and increase reactivity to
ETs. Shock and pulmonary hypertension
also exhibit elevated ET levels (Rubanyi and Polokoff, supra). Inhibition of
ECEs in these conditions may be of
therapeutic value.
The expression pattern of ECE-2 differs from that observed for ECE-1. ECE-2
was observed at low levels in the
adult brain, lung and pancreas and higher levels in fetal brain and kidney by
Northern blot analysis (Fig. 8). PCR
revealed low levels of expression in additional tissues: fetal lung, fetal
small intestine and adult testis. Fetal liver was
negative. A similar pattern was reported for bovine ECE-2 (Emoto and
Yanangisawa, supra). It is expressed in brain
tissues (cerebral cortex, cerebellurrt and adrenal medulla), myometrium and
testis, and in low levels in ovary and very
low levels in marry other tissues. Bovine ECE-1 (Xu et al, supra) is more
widely and more abundantly expressed.
It is observed in vascular endothelial cells of most organs and in some
parenchymal cells. With the exception for
brain, bovine ECE-2 mRNA was present at lower levels than ECE-1. Applicants
believe ECE-2 to be a particularly
good target for the therapeutic intervention for diseases such as cerebral
vasospasm following subarachnoid
hemorrhage and stroke.
92. Anti-PRO Polvoeptide Antibodies
The present invention further provides anti-PRO polypeptide antibodies.
Exemplary antibodies include
polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.
A. Polyclonal Antibodies
The anti-PRO polypeptide antibodies may comprise polyclonal antibodies.
Methods of preparing polyclonal
artti'bodies are known to the skilled artisan. Polyclonal antibodies can be
raised in a mammal, for example, by one
or more injections of an immunizing agent and, if desired, an adjuvant.
Typically, the immunizing agent and/or
adjuvant will be injected in the mammal by multiple subcutaneous or
inuaperitoneal injections. The immunizing agent
173
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
may include the PRO polypeptide or a fusion protein thereof. It may be useful
to conjugate the immunizing agent
to a protein known to be immtlnogenic in the mammal being immunized. Examples
of such immunogenic proteins
include but are not limited to keyhole limpet hemocyanin, serum albumin,
bovine thyroglobulin, and soybean trypsin
inhibitor. Examples of adjuvants which may be employed include Freund's
complete adjuvant and MPL-TDM
adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The
immunization protocol may be
selected by one skilled in the art without undue experimentation.
B. Monoclonal Antibodies
The anti-PRO polypeptide antibodies may, alternatively, be monoclonal
antibodies. Monoclonal antibodies
may be prepared using hybridoma methods, such as those described by Kohler and
Milstein, Nature, x:495 ( 1975).
In a hybridoma method, a mouse, hamster, or other appropriate host animal, is
typically immunized with an
immunizing agent to elicit lymphocytes that produce or are capable of
producing antibodies that will specifically bind
to the immunizing agent. Alternatively, the lymphocytes may be immunized in
vitro.
The immunizing agent will typically include the PRO polypeptide of interest or
a fusion protein thereof.
Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of
human origin are desired, or spleen cells
or lymph node cells are used if non-human mammalian sources are desired. The
lymphocytes are then fused with
an immortalized cell line using a suitable fusing agent, such as polyethylene
glycol, to form a hybridoma cell [coding,
Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-
103]. Immortalized cell lines are
usually transformed mammalian cells, particularly myeloma cells of rodent,
bovine and human origin. Usually, rat
or mouse myeloma cell lines are employed. The hybridoma cells may be cultured
in a suitable culture medium that
preferably contains one or more substances that inhibit the growth or survival
of the unfused, immortalized cells.
For example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT or
HPRT), the culture medium for the hybridomas typically will include
hypoxanthine, aminopterin, and thymidine
("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support
stable high level expression of
antibody by the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. More
preferred immortalized cell lines are marine myeloma lines, which can be
obtained, for instance, from the Salk
Institute Cell Disuibution Center, San Diego, California and the American Type
Culture Collection, Rockville,
Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have
been described for the production
of human monoclonal antibodies [Kozbor, J. Immunol., 13:3001 (1984); Brodeur
et al., Monoclonal Anribody
Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987)
pp. S1-63].
The culture medium in which the hybridoma cells are cultured can then be
assayed for the presence of
monoclonal antibodies directed against the PRO polypeptide of interest.
Preferably, the binding specificity of
monoclonal antibodies produced by the hybridoma cells is determined by
immunoprecipitation or by an in vitro
binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent
assay (ELISA). Such techniques
and assays are known in the art. The binding affinity of the monoclonal
antibody can, for example, be determined
by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220
(1980).
After the desired hybridotna cells are identified, the clones may be subcloned
by limiting dilution procedures
and grown by standard methods [coding, surral. Suitable culture media for this
purpose include, for example,
Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Ahernatively, the
hybridotna cells may be grown
1?4
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclones may be isolated or
purified from the culture medium
or ascites fluid by conventional immunoglobulin purification procedures such
as, for example, protein A-Sepharose,
hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity
chromatography.
The monoclonal antibodies may also be made by recombinant DNA methods, such as
those described in
U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the
invention can be readily isolated and
sequenced using conventional procedures (e.g., by using oligonucleotide probes
that are capable of binding
specifically to genes encoding the heavy and light chains of marine
antibodies). The hybridoma cells of the invention
serve as a preferred source of such DNA. Once isolated, the DNA may be placed
into expression vectors, which
are then transfected into host cells such as simian COS cells, Chinese hamster
ovary (CHO) cells, or myeloma cells
that do not otherwise produce immunoglobulin protein, to obtain the synthesis
of monoclonal antibodies in the
recombinant host cells. The DNA also may be modified, for example, by
substituting the coding sequence for human
heavy and light chain constant domains in place of the homologous marine
sequences [U.S. Patent No. 4,816,567;
Morrison et al., su or by covalently joining to the itnmunoglobulin coding
sequence all or pan of the coding
sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin
polypeptide can be substituted for the
constant domains of an antibody of the invention, or can be substituted for
the variable domains of one antigen-
combining site of an antibody of the invention to create a chimeric bivalent
antibody.
The antibodies may be monovalent antibodies. Methods for preparing monovalent
antibodies are well known
in the art. For example, one method involves recombinant expression of
immunoglobulin light chain and modified
heavy chain. The heavy chain is truncated generally at any point in the Fc
region so as to prevent heavy chain
crosslinking. Alternatively, the relevant cysteine residues are substituted
with another amino acid residue or are
deleted so as to prevent crosslinking.
In vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to produce
fragments thereof, particularly, Fab fragments, can be accomplished using
routine techniques known in the art.
C. Humanized Antibodies
The anti-PRO polypeptide ann~bodies of the invention may fitrther comprise
humanized antibodies or human
antibodies. Humanized forms of non-human (e.g., marine) antibodies are
chimeric itnmunoglobulins,
itnmunoglobutin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or
other antigen-binding subsequences
of antibodies) which contain minimal sequence derived from non-human
immunoglobulin. Humanized antibodies
include human immunoglobulins (recipient antibody) in which residues from a
complementary determining region
(CDR) of the recipieru are replaced by residues from a CDR of a non-hurnan
species (donor antibody) such as mouse,
rat or rabbit having the desired specificity, affinity and capacity. In some
instanccs, Fv framework residues of the
human immunoglobulin are replaced by corresponding non-human residues.
Humanized antibodies may also
comprise residues which are found neither in the recipient antibody nor in the
imported CDR or framework
sequences. In general, the humanized antibody will comprise substantially all
of at least one, and typically two,
variable domains, in which all or substantially all of the CDR regions
correspond to those of a non-human
itnmunoglobulin and all or substantially all of the FR regions are thosc of a
human immunoglobulin consensus
sequence. The humanized antibody optimally also will comprise at least a
portion of an immunoglobulin constant
region (Fc), typically that of a human ittttnunoglobulin [lones et al.,
Ncuure, 3,~: 522-525 (1986); Riechmann et a1.>
175
CA 02421372 2003-03-25
PCT/US99/05028
WO 99146281
Nature, X32:323-329 (1988); and Presta, Curr. Op. Struct. Biol., _2:593-596
(1992)].
Methods for humanizing nvn-human antibodies are well known in the art.
Generally, a humanized antibody
has one or more amino acid residues introduced into it from a source which is
non-human. These aon-human amino
acid residues are often referred to as "import" residues, which are typically
taken from an "import" variable domain.
Humanization can be essentially performed following the method of Winter and
co-workers [Jones et al., Nature, 321:
522-52S (1986); Riechmarm et al.. Nature, X32:323-327 (1988); Verhoeyen et
al., Science, x:1534-1536 (1988)],
by substituting rodent CDRs or CDR sequences for the corresponding sequences
of a human antibody. Accordingly,
such "humanized" antibodies are chimeric antibodies (U.S. Patent No.
4,816,567), wherein substantially less than
an intact human variable domain has been substituted by the corresponding
sequence from a non-human species. In
practice, humanized antibodies are typically human antibodies in which some
CDR residues and possibly some FR
residues are substituted by residues from analogous sites in rodent
antibodies.
Human antibodies can also be produced using various techniques known in the
art, including phage display
libraries [Hoogenboom and Winter, J. Mol. Biol., x:381 (1991); Marks et al.,
J. Mol. Biol., x:581 (1991)]. The
techniques of Cole et al. and Boerner et al, are also available for the
preparation of human monoclonal antibodies
(Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77
(1985) and Boerner et al., J. Immunol.,
14?(11:86-95 (1991)].
D. Bisuecitic Antibodies
Bispecific antibodies are monoclonal, preferably htunan or humanized,
antibodies that have binding
specificities for at least two different antigens. In the present case, one of
the binding specificities is for the PRO
polypeptide, the other one is for any other antigen, and preferably for a cell-
surface protein or receptor or receptor
subunit.
Methods for malting bispecific antibodies are known in the art. Traditionally,
the recombinant production
of bispecific antibodies is based on the co-expression of two immunoglobulin
heavy-chain/light-chain pairs, where
the two heavy chains have different specificities [Milstein and Cuello,
Nature, x:537-539 (1983)]. Because of the
random assortment of immunoglobulin heavy and light chains, these hybridomas
(quadromas) produce a potential
mixture of ten different antibody molecules, of which only one has the correct
bispecific structure. The purification
of the correct molecule is usually accomplished by affinity chromatography
steps. Similar procedures are disclosed
in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J.,
>~:3655-3659 (1991).
Antibody variable domains with the desired binding specificities (antibody-
antigen combining sites) can be
fused to immunoglobulin constant domain sequences. The fusion preferably is
with an immunoglobulin heavy-chain
constant domain, comprising at least part of the hinge, CH2, and CH3 regions.
It is preferred to have the first heavy
chain constant region (CH1) containing the site necessary for light-chain
binding present in at least one of the fusions.
DNAs encoding the immunoglobutin heavy-chain fusions and, if desired, the
immunoglobulin light chain, are inserted
into separate expression vectors, and are co-transfected into a suitable host
organism. For further details of
generating bispecific antibodies see, for example, Suresh et al., Methods in
Enzymology, ?x:210 (1986).
E. Heteroconiueate Antibodies
Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies
are composed of two covalently joined antibodies. Such antibodies have, for
example, been proposed to target
176
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
immune system cells to unwanted cells [U.S. Patent No. 4,676,980), and for
treatment of HIV infection [WO
91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies may
be prepared in vitro using known
methods in synthetic protein chemistry, including those involving crosslinking
agents. For example, immunotoxins
may be constructed using a disulfide exchange reaction or by forming a
thioether bond. Examples of suitable reagents
for this purpose include iminothiolate and methyl-4-mercaptoburyrimidate and
those disclosed, for example, in U.S.
Patent No. 4,676,980.
93. Uses for Anti-PRO Polvpeptide Antibodies
The anti-PRO polypeptide antibodies of the invention have various utilities.
For example, anti-PRO
polypeptide antibodies may be used in diagnostic assays for a PRO polypeptide,
e.g., detecting its expression in
specific cells, tissues, or serum. Various diagnostic assay techniques known
in the arc may be used, such as
competitive binding assays, direct or indirect sandwich assays and
immunoprecipitation assays conducted in either
heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of
Techniques, CRC Press, Inc.
(1987) pp. 147-158). The antibodies used in the diagnostic assays can be
labeled with a detectable moiety. The
detectable moiety should be capable of producing, either directly or
indirectly, a detectable signal. For example, the
detectable moiety may be a radioisotope, such as 'H, '~C,'~ P,'S S, o1'25 l, a
fluorescent or chemiluminescent
compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an
enzyme, such as alkaline phosphatase,
beta-galactosidase or horseradish peroxidase. Any method known in the art for
conjugating the antibody to the
detectable moiety may be employed, including those methods described by Hunter
et al., Nature, 144:945 (1962);
David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth.,
4~f :219 (1981); and Nygren, J.
Histochem. and C~tochem., ~,Q:407 (1982).
Anti-PRO polypeptide antibodies also are useful for the affinity purification
of PRO polypeptide from
recombinant cell culture or natural sources. In this process, the antibodies
against the PRO polypeptide are
immobilized on a suitable support, such a Sephadex resin or filter paper,
using methods well known in the art. The
immobilized antibody then is contacted with a sample containing the PRO
polypeptide to be purified. and thereafter
the support is washed with a suitable solvent that will remove substantially
all the material in the sample except the
PRO polypeptide, which is bound to the immobilized antibody. Finally, the
support is washed with another suitable
solvent that will release the PRO polypeptide from the antibody.
Anti-Toll receptor (i.e., anti-PR0285 and anti-PR0286 antibodies) may also be
useful in blocking the
biological activities of the respective Toll receptors. The primary function
of the family of Toll receptors is believed
to be to act as pathogen pattern recognition receptors sensing the presence of
conserved molecular pattern present
on microbes. Lipopolysaccharides (LPS, also known as endotoxins), potentially
lethal molecules produced by
various bacteria, bind to the lipopolysaccharide binding protein (LBP) in the
blood. The complex formed then
activates a receptor known as CD14. There is no consensus in the art about
what happens next. According to a
hypothesis, CD14 does not directly instruct macrophages to produce cytokines,
cell adhesion proteins and enzymes
involved in the production of lower molecular weight proinflammatory
mediators, rather enables LPS to activate a
second receptor. Alternatively, it has been suggested that LPS may activate
certain receptors directly, without help
from LBP or CD14. The data disclosed in the present application indicate that
the human toll-like receptors are
signaling receptors that are activated by LPS in an LBP and CD14 responsive
manner. As this mechanism, under
pathophysiologic conditions can lead to an often fatal syndrome called septic
shock, anti-Toll receptor antibodies (just
177
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
as other Toll receptor antagonists) might be useful in the treatment of septic
shock. It is foreseen that the different
Toll receptors might recognize different pathogens, e.g., various strains of
Gram-negative or Gram-positive bacteria.
Accordingly, in certain situations, combination therapy with a mixture of
antibodies specifically binding different Toll
receptors, or the use of bispecific anti-Toll antibodies tnay be desirable.
It is specifically demonstrated that anti-huTLR2 antibodies are believed to be
specifically useful in blocking
the induction of this receptor by LPS. As it has been shown that LPS exposure
can lead to septic shock (Parrillo,
N. Engl. J. Med. ~, 1471-1477 [1993]), anti-huTLR2 antibodies are potentially
useful in the treatment of septic
shock.
The foregoing therapeutic and diagnostic uses listed in connection with the
anti-Toll receptor antibodies are
also applicable to other Toll antagonists, i.e., other molecules (proteins,
peptides, small organic molecules, etc.) that
block Toll receptor activation and/or signal transduction mediated by Toll
receptors.
In view of their therapeutic potentials, the Toll proteins (including variants
of the native Toll homologues),
and their agonists and antagonists (including but not limited to anti-Toll
antibodies) are incorporated in compositions
suitable for therapeutic use. Therapeutic compositions are prepared for
storage by mixing the active ingredient
having the desired degree of purity with optional physiologically acceptable
carriers, excipients or stabilizers
(Remington's Pharmaceutical Sciences 16th Edition, Osol, A. Ed. 1980) in the
form of lyophilized formulations or
aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic
to recipients at the dosages and
concentrations employed, and include buffers such as phosphate, citrate and
other organic acids; antioxidants
including ascorbic acid; low molecular weight (less than about 10 residues)
polypeptides; proteins, such as serum
albumin, gelatin or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone, amino acids such as
glycine, glutamine, asparagine, argirtine or lysine; monosaccharides,
disaccharides and other carbohydrates including
glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols
such as mannitol or sorbitol: salt-
forming cotutterions such as sodium; and/or nonionic surfactants such as
Tween, Pluronics or PEG.
The active ingredients may also be entrapped in microcapsules prepared, for
example, by coacervation
techniques or by interfacial polymerization, for example,
hydroxymethylcellulose or gelatin-microcapsules and poly
(methylmethacylate) microcapsules, respectively), in colloidal drug delivery
systems (for example, liposomes,
albumin microspheres, microemulsions, nano-particles and nanocapsules) or in
macroemulsions. Such techniques
are disclosed in R~ptington's Pharmaceutical Sciences, supra.
The formulations to be used for in vivo administration must be sterile. This
is readily accomplished by
filtration through sterile filvation membranes, prior to or following
lyophilization and reconstitution.
Therapeutic compositions herein generally are placed into a container having a
sterile access port, for
example, an intravenous solution bag or vial having a stopper pierceable by a
hypodermic injection needle.
The route of administration is in accord with known methods, e.g. injection or
infusion by intravenous,
intraperitorteal, itvracerebral, intramuscular, intraocular, intraarterial or
intralesional routes, topical administration,
or by sustained release systems.
Suitable examples of sustained release preparations include semipetmeable
polymer matrices in the form
of shaped articles, e.g. films, or microcapsules. Sustained release matrices
include polyesters, hydrogels,
polylactides (U.S. Patent 3,773,919, EP 58,481), copolymers of L-glutamic acid
and gamma ethyl-L-glutamate (L1.
Sidman ~t ~., Biopolvmers ~ (1): 547-556 [1983]), poly (2-hydroxyethyl-
methacrylate) (R. Langer, g1 ~., ~
Biomed. Mater. Res. ~: 167-277 [1981] and R. Langer, them. Tech. 12: 98-105
(1982]), ethylene vinyl acetate
178
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
(R. Langer et a_1., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
Sustained release compositions also include
liposomes. Liposomes containing a molecule within the scope of the present
invention are prepared by methods
known pe_r se: DE 3.218,121; Epstein e~ al., Proc. Natl. Acad. Sci. USA $?:
3688-3692 (1985); Hwang et al.,
Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52322; EP 36676A; EP
88046; EP 143949; EP 142641;
Japanese patent application 83-118008; U.S. patents 4,485,045 and 4,544,545;
and EP 102,324. Ordinarily the
liposomes are of the small (about 200-800 Angstroms) unilamelar type in which
the lipid content is greater than about
30 mol. % cholesterol, the selected proportion being adjusted for the optimal
NT-4 therapy.
An effective amount of the active ingredient will depend, for example, upon
the therapeutic objectives, the
route of administration, and the condition of the patient. Accordingly, it
will be necessary for the therapist to titer
the dosage and modify the route of administration as required to obtain the
optimal therapeutic effect. A typical daily
dosage might range from about 1 ~g/kg to up to 100 mg/kg or more, depending on
the factors mentioned above.
Typically, the clinician will administer a molecule of the present invention
until a dosage is reached that provides the
required biological effect. The progress of this therapy is easily monitored
by conventional assays.
The following examples are offered for illusuative purposes only, and are not
intended to limit the scope
of the present invention in any way.
All patent and literature references cited in the present specification are
hereby incorporated by reference
in their entirety.
EXAMPLES
Commercially available reagents referred to in the examples were used
according to manufacturer's
instructions unless otherwise indicated. The source of those cells identified
in the following examples, and throughout
the specification, by ATCC accession numbers is the American Type Culture
Collection, Rockville, Maryland.
EXAMPLE I: Extracellular Domain Homology Screening to Identify Novel
Polypeptides and cDNA Encodine
Therefor
The extracellular domain (ECD) sequences (including the secretion signal
sequence, if any) from about 950
known secreted proteins from the Swiss-Prot public database were used to
search EST databases. The EST databases
included public databases (e.g., Dayhoff, GenBank), and proprietary databases
(e.g. LIFESEQT"', Incyte
Pharmaceuticals, Palo Alto, CA). The search was performed using the computer
program BLAST or BLAST2
(Altschul and Gish, Methods in Enzymoloey X66: 460-480 (1996)) as a comparison
of the ECD protein sequences
to a 6 frame translation of the EST sequences. Those comparisons with a Blast
score of 70 (or in some cases 90) of
greater that did not encode known proteins were clustered and assembled into
consensus DNA sequences with the
program "phrap" (Phil Green, University of Washington, Seattle, WA;
(http://bozeman.mbt.washington.edu/phrap.docs/phrap.html).
Using this extracellular domain homology screen, consensus DNA sequences were
assembled relative to
the other identified EST sequences using phrap. In addition, the consensus DNA
sequences obtained were often (but
not always) extended using repeated cycles of BLAST and phrap to extend the
consensus sequence as far as possible
using the sources of EST sequences discussed above.
Based upon the consensus sequences obtained as described above,
oligonucleotides were then synthesized
and used to identify by PCR a cDNA library that contained the sequence of
interest and for use as probes to isolate
179
CA 02421372 2003-03-25
WO 99/46281 PCTlUS99/05028
a clone of the full-length coding sequence for a PRO polypeptide. Forward (.~
and reverse (.r) PCR primers
generally range from 20 to 30 nucleotides and are often designed to give a PCR
product of about 100-1000 by in
length. The probe (.p) sequences are typically 40-55 by in length. In some
cases, additional oligonucleotides are
synthesized when the consensus sequence is greater than about 1-l.5kbp. In
order to screen several libraries for a
full-length clone, DNA from the libraries was screened by PCR amplification,
as per Ausubel et al., Current
Protocols in Molecular Biology, with the PCR primer pair. A positive library
was then used to isolate clones
encoding the gene of interest using the probe oligonucleotide and one of the
primer pairs.
The cDNA libraries used to isolate the cDNA clones were constructed by
standard methods using
commercially available reagents such as those from Invitrogen, San Diego, CA.
The cDNA was primed with oligo
dT containing a NotI site, linked with blunt to SaII herrtikirtased adaptors,
cleaved with Notl, sized appropriately by
gel electrophoresis, and cloned in a defined orientation into a suitable
cloning vector (such as pRKB or pRKD;
pRKSB is a precursor of pRKSD that does not contain the SfiI site; see. Holmes
et al., Science, 253:1278-1280
(1991)) in the unique Xhol and NotI sites.
EXAMPLE 2: Isolation of cDNA clones by Amylase Screening
1. Preparation of oligo dT primed cDNA library
mRNA was isolated from a human tissue of interest using reagents and protocols
from Invitrogen, San
Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed
cDNA library in the vector pRKSD
using reagents and protocols from Life Technologies, Gaithersburg, MD (Super
Script Plasmid System). In this
procedure, the double stranded cDNA was sized to greater than 1000 by and the
SaII/Notl Tinkered cDNA was cloned
into XhoI/Not1 cleaved vector. pRKSD is a cloning vector that has an sp6
transcription initiation site followed by
an SfiI restriction enzyme site preceding the Xhol/Notl cDNA cloning sites.
2. PreRaration of random primed cDNA library
A secondary cDNA Hbrary was generated in order to preferentially represent the
5' ends of the primary
cDNA clones. Sp6 RNA was generated from the primary library (described above),
and this RNA was used to
generate a random primed cDNA library in the vector pSST-AMY.O using reagents
and protocols from Life
Technologies (Super Script Plasmid System, referenced above). In this
procedure the double stranded cDNA was
sized to 500-1000 bp, Tinkered with blunt to NotI adaptors, cleaved with Sfil,
and cloned into SfiI/Notl cleaved
vector. pSST-AMY.O is a cloning vector that has a yeast alcohol dehydrogenase
promoter preceding the cDNA
cloning sites and the mouse amylase sequence (the mature sequence without the
secretion signal) followed by the yeast
alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned
into this vector that are fused in
frame with amylase sequence will lead to the secretion of amylase from
appropriately transfected yeast colonies.
3. Transformation and Detection
DNA from the library described in paragraph 2 above was chilled on ice to
which was added
electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and
vector mixture was then
electroporated as recommended by the manufactwer. Subsequently, SOC media
(Life Technologies, 1 ml) was added
and the mixture was incubated at 37°C for 30 minutes. The transfotmants
were then plated onto 20 standard 150
mm LB plates containing atnpicillin and incubated for 16 hours (37°C).
Positive colonies were scraped off the plates
180
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
and the DNA was isolated from the bacterial pellet using standard protocols,
e.g. CsCI-gradient. The purified DNA
was then carried on to the yeast protocols below.
The yeast methods were divided into three categories: (1) Transformation of
yeast with the plasmidlcDNA
combined vector; (2) Detection and isolation of yeast clones secreting
amylase; and (3) PCR amplification of the
insert directly from the yeast colony and purification of the DNA for
sequencing and further analysis.
The yeast strain used was HD56-SA (ATCC-90785). This strain has the following
genotype: MAT alpha,
tua3-52, leu2-3, leu2-112, his3-l 1, his3-15, MAL+, SUC', GAL'. Preferably,
yeast mutants can be employed that
have deficient post-translational pathways. Such mutants may have
translocation deficient alleles in sec7l, sec72,
sec62, with truncated sec71 being most preferred. Alternatively, antagonists
(including antisense nucleotides and/or
ligands) which interfere with the normal operation of these genes, other
proteins implicated in this post translation
pathway (e.g., SEC6lp, SEC72p, SEC62p, SEC63p, TD)Ip or SSAlp~p) or the
complex formation of these proteins
may also be preferably employed in combination with the amylase-expressing
yeast.
Transformation was performed based on the protocol outlined by Gietz et al.,
Nucl. Acid. Res., 2,1:1425
(1992). Transformed cells were then inoculated from agar into YEPD complex
media broth (100 ml) and grown
overnight at 30°C. The YEPD broth was prepared as described in Kaiser
et al., Methods in Yeast Genetics, Cold
Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight
culture was then diluted to about 2
x 106 cells/ml (approx. ODD=0.1) into fresh YEPD broth (500 ml) and regrown to
1 x' 10 cells/ml (approx.
ODD=0.4-0.5).
The cells were then harvested and prepared for transformation by uansfer into
GS3 rotor bottles in a Sotval
GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then
resuspended into sterile water, and
centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR
centrifuge. The supernatant was
discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM
Tris-HCI, 1 mM EDTA pH 7.5,
100 mM Li200CCH~), and resuspended into LiAcITE (2.5 ml).
Transformation took place by mixing the prepared cells (100 ~I) with freshly
denatured single stranded
salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1
fig, vol. < 10 ~l) in microfuge
tubes. The mixture was mixed briefly by vonexing, then 40% PEG/TE (600 ~1, 40%
polyethylene glycol-4000, 10
mM Tris-HCI, 1 mM EDTA, 100 mM LizOOCCH3, pH 7.5) was added. This mixture was
gently mixed and
incubated at 30°C while agitating for 30 minutes. The cells were then
heat shocked at 42°C for 15 minutes, and the
reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds,
decanted and resuspended into TE (500
~d, 10 mM Tris-I-ICI, 1 mM EDTA pH 7.5) followed by recentrifugation. The
cells were then diluted into TE (1 ml)
and aliquots (200 ~d) were spread onto the selective media previously prepared
in 150 mm growth plates (VWR).
Alternatively, instead of multiple small reactions, the transformation was
performed using a single, large
scale reaction, wherein reagent amounts were scaled up accordingly.
The selective media used was a synthetic complete dextrose agar lacking wacil
(SCD-Ura) prepared as
described in Kaiser et al., ~yiethods in Yeast Genetics, Cold Spring Harbor
Press, Cold Spring Harbor, NY, p. 208-
210 (1994). Transforrnattts were grown at 30°C for 2-3 days.
The detection of colonies secreting amylase was performed by including red
starch in the selective growth
media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the
procedure described by Biely et al.,
Anal. Biochem., 1:176-179 (1988). The coupled starch was incorporated into the
SCD-Ura agar plates at a final
concentration of 0.15 % (w/v), and was buffered with potassium phosphate to a
pH of 7.0 (50-100 mM final
181
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
concentration).
The positive colonies were picked and streaked across fresh selective media
(onto 150 mm plates) in order
to obtain well isolated and identifiable single colonies. Well isolated single
colonies positive for amylase secretion
were detected by direct incorporation of red starch into buffered SCD-Ura
agar. Positive colonies were determined
by their ability to break down starch resulting in a clear halo around the
positive colony visualized directly.
4. Isolation of DNA by PCR Ampl-ification
When a positive colony was isolated, a portion of it was picked by a toothpick
and diluted into sterile water
(30 ~l) in a 96 well plate. At this time, the positive colonies were either
frozen and stored for subsequent analysis
or immediately amplified. An aliquot of cells (5 u1) was used as a template
for the PCR reaction in a 25 ~I volume
containing: 0.5 ~l Klencaq (Clontech, Palo Alto, CA); 4.0 ~l 10 mM dNTP's
(Perkin Elmer-Cetus); 2.5 ~1 Kentaq
buffer (Clontech); 0.25 ~1 forward oligo 1; 0.25 u1 reverse oligo 2; 12.5 ~1
distilled water. The sequence of the
forward oligonucleotide 1 was:
5'-TGTAAAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID N0:324)
The sequence of reverse oligonucleotide 2 was:
5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID N0:325)
PCR was then performed as follows:
a. Denature 92°C, 5 minutes
b. 3 cycles of: Denature 92°C, 30 seconds
Anneal 59°C, 30 seconds
Extend 72°C, 60 seconds
c. 3 cycles of: Denature 92°C, 30 seconds
Anneal 57 ° C, 30 seconds
Extend 72°C, 60 seconds
d. 25 cycles of: Denature 92°C, 30 seconds
Anneal 55°C, 30 seconds
Extend 72°C, 60 seconds
e. Hold 4°C
The underlined regions of the oligonucleotides annealed to the ADH promoter
region and the amylase
region, respectively, and amplified a 307 by region from vector pSST-AMY.O
when no insert was present. Typically,
the first 18 nucleotides of the 5' end of these oligonucleotides contained
annealing sites for the sequencing primcrs.
Thus, the total product of the PCR reaction from an empty vector was 343 bp.
However, signal sequence-fused
cDNA resulted in considerably longer nucleotide sequences.
Following the PCR, an aliquot of the reaction (5 p1) was examined by agarose
gel electrophoresis in a 1 %
agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by
Sambrook et al., suTra. Clones
resulting in a single svong PCR product larger than 400 by were further
analyzed by DNA sequencing after
purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth,
CA).
182
CA 02421372 2003-03-25
WO 99/46281 PCTlUS99/05028
EXAMPLE 3: Isolation of cDNA Clones Encoding Human PR0213
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA2873S. Based
on the DNA2873S consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0213.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer S'-TGGAGCAGCAATATGCCAGCC-3' (SEQ ID N0:3)
reverse PCRprimer S'-TTTTCCACTCCTGTCGGGTTGG-3' (SEQ ID N0:4)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA28735
sequence which had the following nucleotide sequence
hybridizationpr2be
5'-GGTGACACTTGCCAGTCAGATGTGGATGAATGCAGTGCTAGGAGGG-3' (SEQ ID NO:S)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0213 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal lung tissue.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0213
[herein designated as UNQ187 (DNA30943-1163)] (SEQ ID NO:1) and the derived
protein sequence for PR0213.
The entire nucleotide sequence of UNQ187 (DNA30943-1163) is shown in Figure 1
(SEQ ID NO:1). Clone
UNQ187 (DNA30943-1163) contains a single open reading frame with an apparent
translational initiation site at
nucleotide positions 336-338 and ending at the stop codon at nucleotide
positions 1221-1223 (Figure 1). The
predicted polypeptide precursor is 295 amino acids long (Figure 2). Clone
UNQ187 (DNA30943-1163) has been
deposited with ATCC.
Analysis of the amino acid sequence of the full-length PR0213 polypeptide
suggests that a portion of it
possesses significant homology to the human growth arrest-specific gene 6
protein. More specifically, an analysis
of the Dayhoff database (version 35.45 SwissProt 35) evidenced significant
homology between the PR0213 amino
acid sequence and the following Dayhoff sequences, HSMHC3WSA 6 and B48089.
EXAMPLE 4: Isolation of cDNA Clones Encoding Human PR0274
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA36469. Based
on the DNA36469 consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0274. ESTs proprietary
to Genentech were employed in the consensus assembly. The ESTs are shown in
Figures S-7 and are herein
designated DNA17873, DNA361S7 and DNA28929, respectively.
3S Pairs of PCR primers (forward and reverse) were synthesized:
forward PCR primer l s,36469.f1) S'-CTGATCCGGTTCTTGGTGCCCCTG-3' (SEQ ID NO:11)
fot-ward PCR primer 2 ,36469.f2) S'-GCTCTGTCACTCACGCTC-3' (SEQ ID N0:12)
forward PCR primer 536469. f3) S'-TCATCTCTTCCCTCTCCC-3' (SEQ ID N0:13)
forward PCR primer 4 (36469.f4) S'-CCTTCCGCCACGGAGTTC-3' (SEQ ID N0:14)
183
CA 02421372 2003-03-25
WO 99/46281 PCTlUS99/05028
reverse PCR primer 1 (36469.r1) 5'-GGCAAAGTCCACTCCGATGATGTC-3' (SEQ ID NO:15)
reverse PCR primer 2 136469.r21 5'-GCCTGCTGTGGTCACAGGTCTCCG-3' (SEQ ID N0:16)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA36469
sequence which had the following nucleotide sequence
~tybridization probe (36469.1
5'-TCGGGGAGCAGGCCTTGAACCGGGGCATTGCTGCTGTCAAGGAGG-3' (SEQ ID N0:17)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0274 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB229),
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0274
[herein designated as UNQ241 (DNA39987-1184)] (SEQ ID NO:1) and the derived
protein sequence for PR0274.
The entire nucleotide sequence of UNQ241 (DNA39987-1184) is shown in Figure 3
(SEQ ID N0:6). Clone
UNQ241 (DNA39987-1184) contains a single open reading frame with an apparent
translational initiation site at
nucleotide positions 83-85 and ending at the stop codon at nucleotide
positions 1559-1561 (Figure 3). The predicted
polypepride precursor is 492 amino acids long (Figure 4), has an estimated
molecular weight of about 54,241 daltons
and an estimated pI of about 8.21. Clone UNQ241 (DNA39987-1184) has been
deposited with ATCC and is assigned
ATCC deposit no. 209786.
Analysis of the amino acid sequence of the full-length PR0274 polypepiide
suggests that it possesses
significant homology to the Fn54 protein. More specifically, an analysis of
the Dayhoff database (version 35.45
SwissProt 35) evidenced significant homology between the PR0274 amino acid
sequence and the following Dayhoff
sequences, MMFN54S2_l, MMFN54S1_l, CELF48C1 8, CEF38B7 6, PRP3 RAT, INL3_PIG,
MTCY07A7_13,
YNAX KLEAE, A47234 and HME2 MOUSE.
EXAMPLE 5: Isolation of cDNA Clones Encoding Human PR0300
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA35930. Based
on the DNA35930 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0300.
Forward and reverse PCR primers were synthesized:
forward PCR primer 1 (35930 fl( 5'-GCCGCCTCATCTTCACGTTCTTCC-3' (SEQ ID N0:20)
forward primer 30 5'-TCATCCAGCTGGTGCTGCTC-3' (SEQ ID
PCR 2 (359 f21N0:21)
forward primer 30 5'-CTTCTTCCACTTCTGCCTGG-3' (SEQ ID
PCR 3 (359 f31N0:22)
~'grward primer 30 5'-CCTGGGCAAAAATGCAAC-3' (SEQ ID
PCR 4 (359 f41N0:23)
reverse rimer 0 5'-CAGGAATGTAGAAGGCACCCACGG-3' (SEQ
PCRp 1 (3593 r()ID N0:24)
reverse primer 0 5'-TGGCACAGATCTTCACCCACACGG-3' (SEQ
PCR 2 (3593 r2)ID N0:25)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA35930
sequence which had the following nucleotide sequence
hybridization probe (35930.01)
5'-TGTCCATCATTATGCTGAGCCCGGGCGTGGAGAGTCAGCTCTACAAGCTG-3' (SEQ ID N0:26)
184
CA 02421372 2003-03-25
WO 99!46281 PCT/US99/05028
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0300 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0300
[herein designated as UNQ263 (DNA40625-I 189)) (SEQ ID N0:18) and the derived
protein sequence for PR0300.
The entire nucleotide sequence of UNQ263 (DNA40625-1189) is shown in Figure 8
(SEQ ID N0:18).
Clone UNQ263 (DNA40625-1189) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 45-47 and ending at the stop codon at nucleotide
positions 1416-1418 (Figure 8). The
predicted polypeptide precursor is 457 amino acids long (Figure 9). Clone
UNQ263 (DNA40625-I 189) has been
deposited with ATCC and is assigned ATCC deposit no. 209788.
Analysis of the amino acid sequence of the full-length PR0300 polypeptide
suggests 'that portions of it
possess significant homology to the Diff 33 protein. More specifically, an
analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced significant homology between the PR0300 amino
acid sequence and the following
Dayhoff sequence, HSU49188_1.
EXAMPLE 6: Isolation of cDNA Clones Encoding Human PR0284
Two cDNA sequences were isolated in the amylase screen described in Example 2
and those cDNA
sequences are herein designated DNA12982 (see Figure I2; human placenta-
derived) and DNA15886 (see Figure
13; human salivary gland-derived). The DNA12982 and DNA15886 sequences were
then clustered and aligned,
giving rise to a consensus nucleotide sequence herein designated DNA18832.
Based on the DNA18832 consensus sequence, oligonucleotide probes were
generated and used to screen
a human placenta library (LIB89) prepared as described in paragraph 1 of
Example 2 above. The cloning vector was
pRKSB (pRKSB is a precursor of pRKSD that does not contain the SfiI site; see,
Holmes et al., Science, 2~:1278-
1280 (1991)), and the cDNA size cut was less than 2800 bp.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 1 (18832.est.fl 5'-TCGTACAGTTACGCTCTCCC-3' (SEQ ID N0:31)
forward PCR primer 2 518832.f15'-CTTGAGGAGCGTCAGAAGCG-3' (SEQ ID N0:32)
reverse PCR primer (18832.r) 5'-ATAACGAATGAAGCCTCGTG-3' (SEQ ID N0:33)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA18832 sequence which
had the following nucleotide sequence
hybridization probe (18832.n1
5'-GCTAATATCTGTAAGACGGCAGCTACAGCAGGCATCATTG-3' (SEQ ID N0:34)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pairs identified above. A positive
library was then used to isolate clones
encoding the PR0284 gene using the probe oligonucleotide and one of the PCR
primers.
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 16?-169 and ending at the stop codon
found at nucleotide positions 1022-1024
(Figure 10; SEQ ID N0:27). The predicted polypeptide precursor is 285 amino
acids long, has a calculated
molecular weight of approximately 32,190 daltons and an estimated p! of
approximately 9.03. Analysis of the full-
185
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
length PR0284 sequence shown in Figure 11 (SEQ ID N0:28) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 24, transmembrane domains
from about amino acid 76 to about
amino acid 96 and from about amino acid 171 to about amino acid 195 and a
potential N-glycosylation site from about
amino acid 153 to about amino acid 156. Clone UNQ247 (DNA23318-121 I ) has
been deposited with ATCC on April
21, 1998 and is assigned ATCC deposit no. 209787.
Analysis of the amino acid sequence of the full-length PR0284 polypeptide
suggests that it possesses no
significant sequence similarity to any lrnown protein. However, an analysis of
the Dayhoff database (version 35.45
SwissProt 35) evidenced some degree of homology between the PR0284 amino acid
sequence and the following
Dayhoff sequences, JQ0124, CELE04A4 5, AB006451-1, AF030162_1, IM23 YEAST,
S71194, NIA_CUCMA,
IM17 YEAST, I50479 and HUMZFHP 1.
EXAMPLE 7: Isolation gf cDNA Clones EncodingHuman PR0296
A cDNA sequence isolated in the amylase screen as described in Example 2 above
was found, by BLAST
and FasLA sequence alignment, to have sequence homology to a nucleotide
sequence encoding sarcoma-associated
protein SAS. This cDNA sequence is herein designated DNA23020 (see Figure 16).
The DNA23020 sequence was
1S then compared to a variety of expressed sequence tag (EST) databases which
included pubiic EST databases (e.g.,
GenBank) and a proprietary EST DNA database (LIFESEQT"', Incyte
Pharmaceuticals, Palo Alto, CA) to identify
existing homologies. The homology search was performed using the computer
program BLAST or BLAST2 (Altshul
et al., Methods in Enzvmologv X66:460-480 (1996)). Those comparisons resulting
in a BLAST score of 70 (or in
some cases 90) or greater that did not encode lQtown proteins were clustered
and assembled into a consensus DNA
sequence with the program "phrap" (Phil Green, University of Washington,
Seattle, Washington;
http://bozeman.mbt.Washington.edu/phrap.docs/phrap.html). The consensus
sequence obtained therefrom is herein
designated DNA35858. Two proprietary Genentech ESTs were employed in the
assembly wherein those EST
sequences are herein identified as DNA21971 (Figure 17; SEQ ID N0:38) and
DNA29037 (Figure 18; SEQ ID
N0:39).
2S Based on the DNA35858 consensus sequence, oligonucleotide probes were
generated and used to screen
a human kidney library (LIB228) library prepared as described in paragraph 1
of Example 2 above. The cloning
vector was pRKSB (pRKSB is a precursor of pRKSD that does not contain the SfiI
site; see, Hohnes et al., Science,
ZS~:1278-1280 (1991)), and the cDNA size cut was less than 2800 bp.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 1 135858.f1) S'-ACCCACGTCTGCGTTGCTGCC-3' (SEQ 1D N0:40)
forward PCR primer 2 135858.f2) S'-GAGAATATGCTGGAGAGG-3' (SEQ ID N0:41)
reverse PCR primer 1358S8.r1) S'-AGGAATGCACTAGGATTCGCGCGG-3' (SEQ ID N0:42)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA35858
sequence which had the following nucleotide sequence
hybridization probe (35858jpIl
5'-GGCCCCAAAGGCAAGGACAAAGCAGCTGTCAGGGAACCTCCGCCG-3' (SEQ ID N0:43)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0296 gene using the probe oligonucleotide and one of the PCR
primers.
186
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 174-176 and ending at the stop codon
found at nucleotide positions 786-788
(Figure 14; SEQ ID N0:35). The predicted polypeptide precursor is 204 amino
acids long, has a calculated
molecular weight of approximately 22,147 daltons and an estimated pI of
approximately 8.37. Analysis of the full-
length PR0296 sequence shown in Figure 15 (SEQ ID N0:36) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 34 and transmembrane
domains from about amino acid 47 to
about amino acid 63, from about amino acid 72 to about amino acid 95 and from
about amino acid 162 to about amino
acid 182. Clone UNQ260 (DNA39979-1213) has been deposited with ATCC on April
21, 1998 and is assigned
ATCC deposit no. 209789.
Analysis of the amino acid sequence of the full-length PR0296 polypeptide
suggests that it possesses
significant sequence similarity to the sarcoma-amplified SAS protein, thereby
indicating that PR0296 may be a novel
SAS homolog. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced
significant homology between the PR0296 amino acid sequence and the following
Dayhoff sequences, I58391,
GEN11061, SSC2B04-1, HSU81031 2, CD63 RAT, CD63 MOUSE, CD63 HUMAN, AF022813_1,
CD63 RABIT and C002 HUMAN.
EXAMPLE 8: Isolation of cDNA Clones EncodingHuman PR0329
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA35612. Based
on the DNA35612 consensus
sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0329.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 1 (35612.f1) 5'-TGGGCTGTGTCCTCATGG-3' (SEQ ID N0:46)
forward PCR primer 2 135612.f2) 5'-TTTCCAGCGCCAATTCTC-3' (SEQ ID N0:47)
reverse PCR 1?rimer 1 (35612.r1) 5'-AGTTCTTGGACTGTGATAGCCAC-3' (SEQ ID N0:48)
reverse PCR prim ~ 2 (35(~Z.r21 5'-AAACTTGGTTGTCCTCAGTGGCTG-3' (SEQ ID N0:49)
Additionally, a synthetic oligonucleotide hybridization probe was conswcted
from the consensus DNA35612
sequence which had the following nucleotide sequence
hybridization probe (35612.P1)
5'-GTGAGGGACCTGTCTGCACTGAGGAGAGCAGCTGCCACACGGAGG-3' (SEQ ID NO:50)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pairs identified above. A positive
library was then used to isolate clones
encoding the PR0329 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB6).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0329
[herein designated as UNQ291 (DNA40594-1233)] (SEQ ID N0:44) and the derived
protein sequence for PR0329.
The entire nucleotide sequence of UNQ291 (DNA40594-1233) is shown in Figure 19
(SEQ ID N0:44).
Clone UNQ291 (DNA40594-1233) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 9-11 and ending at the stop codon at nucleotide
positions 1086-1088 (Figure 19). The
predicted polypeptide precursor is 359 amino acids long (Figure 20). The full-
length PR0329 protein shown in
187
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Figure 20 has an estimated molecular weight of about 38,899 daltons and a p1
of about 5.21. Clone UNQ291
(DNA40594-1233) has been deposited with ATCC on Febtvary 5, 1998 and is
assigned ATCC deposit no. 209617.
Analysis of the amino acid sequence of the full-length PR0329 polypeptide
suggests that it possesses
significant sequence similarity to a high affinity immunoglobulin F~ receptor
protein. More specifically, an analysis
of the Dayhoff database (version 35.45 SwissProt 35) evidenced significant
homology between the PR0329 amino
acid sequence and the following Dayhoff sequences, FCGI_HUMAN, FCGO HUMAN, P
891439, P 822549,
P 891438, P W00859, P 820811, P 822550, HUMCD6406 1 and FCGI MOUSE.
EXAMPLE 9: Isolation of cDNA Clones Encoding Huma~t PR0362
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42257. Based
on the DNA42257 consensus
sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contaitled the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0362.
PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 1 (42257.f1) 5'-TATCCCTCCAATTGAGCACCCTGG-3' (SEQ ID N0:53)
forward PCR primer 2 (42257.12) 5'-GTCGGAAGACATCCCAACAAG-3' (SEQ ID N0:54)
reverse PCR primer 1 (42257.r1) 5'-CTTCACAATGTCGCTGTGCTGCTC-3' (SEQ ID N0:55)
reverse PCR~rimer 2 (42257.r2) 5'-AGCCAAATCCAGCAGCTGGCTTAC-3' (SEQ ID N0:56)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA42257
sequence which had the following nucleotide sequence
hvbridization probe (42257.E1
5'-TGGATGACCGGAGCCACTACACGTGTGAAGTCACCTGGCAGACTCCTGAT-3' (SEQ ID N0:57)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened-
by PCR amplification with the PCR primer pairs identified above. A positive
library was then used to isolate clones
encoding the PR0362 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal brain tissue (LIB153).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0362
[herein designated as UNQ317 (DNA454I6-1251)] (SEQ 1D N0:51) and the derived
protein sequence for PR0362.
The entire nucleotide sequence of UNQ317 (DNA45416-1251) is shown in Figure 21
(SEQ ID N0:51).
Clone UNQ317 (DNA45416-1251) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 119-121 and ending at the stop codon at nucleotide
positions 1082-1084 (Figure 21). The
predicted polypeptide precursor is 321 amino acids long (Figure 22). The full-
length PR0362 protein shown in
Figure 2 has an estimated molecular weight of about 35,544 dahons and a p1 of
about 8.51. Analysis of the full-length
PR0362 polypeptide as shown in Figure 22 evidences the presence of a
glycosaminoglycan attachment site at about
amino acid 149 to about amino acid 152 and a transmembrane domain from about
amino acid 276 to about amino acid
306. Clone UNQ317 (DNA45416-1251) has been deposited with ATCC on February 5,
1998 and is assigned ATCC
deposit no. 209620.
Analysis of the amino acid sequence of the full-length PR0362 polypeptide
suggests that it possesses
significant sequence similarity to the A33 antigen protein and the HCAR
protein. More specifically, an analysis of
the Dayhoff database (version 35.45 SwissProt 35) evidenced significant
homology between the PR0362 amino acid
188
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
sequence and the following Dayhoff sequences, AB002341_1, HSU55258_1,
HSC7NRCAM'1, RNU81037_1,
A33 HUMAN, P W14158, NMNCAMRI_1, HSTITINN2_l, 571824_1 and HSU63041-1.
EXAMPLE 1~: Isolation of cDNA Clones E~ncodine Human P1R0363
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42828. Based
on the DNA42828 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0363.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer f42828.f1~ 5'-CCAGTGCACAGCAGGCAACGAAGC-3' (SEQ ID N0:60)
revert PCR primer (42828.r1) 5'-ACTAGGCTGTATGCCTGGGTGGGC-3' (SEQ ID N0:61)
Additionally, a synthetic oligonucleotide hybridization probe was constructcd
from the consensus DNA42828
sequence which had the following nucleotide sequence
hybridization probe (42828.p11
5'-GTATGTACAAAGCATCGGCATGGTTGCAGGAGCAGTGACAGGC-3' (SEQ ID N0:62)
IS In order to screen several libraries for a source of a full-length clone,
DNA from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
er~odirtg the PR0363 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clor~s isolated as described above gave the full-length
DNA sequence for PR0363
[herein designated as UNQ318 (DNA45419-1252)] (SEQ ID N0:58) and the derived
protein sequence for PR0363.
The entire nucleotide sequence of UNQ318 (DNA4S419-1252) is shown in Figure 23
(SEQ ID N0:58).
Clone UNQ318 (DNA45419-1252) contains a single open reading frame with an
apparent uanslational initiation site
at nucleotide positions 190-192 and ending at the stop codon at nucleotide
positions 1309-1311 (Figure 23). The
predicted polypeptide precursor is 373 amino acids long (Figure 24). The full-
length PR0363 protein shown in
Figure 24 has an estimated molecular weight of about 41,281 daltons and a p1
of about 8.33. A transmembrane
domain exists at atnino acids 221 to 254 of the amino acid sequence shown in
Figure 24 (SEQ ID N0:59). The
PR0363 polypeptide also possesses at least two myelin PO protein domains from
about amino acids 15 to 56 and from
about amino acids 87 to 116. Clone UNQ318 (DNA45419-1252) has been deposited
with ATCC on February 5,
1998 and is assigned ATCC deposit no. 209616.
Analysis of the amino acid sequence of the full-length PR0363 poiypeptide
suggests that it possesses
significant sequence similarity to the cell swface protein HCAR, thereby
indicating that PR0363 may be a novel
HCAR homolog. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced
significant homology between the PR0363 amino acid sequence and the following
Dayhoff sequences, HS46KDA 1,
HSU90716_l. MMCARH_I, MMCARHOM_1, MMU90715_1, A33 HUMAN, P W14146, P W14I58,
A42632
and B42632.
EXAMPLE 11: Isolation of cDNA Clones Encodine Human PR0868
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA38133. Based
on the DNA38133 consensus
189
CA 02421372 2003-03-25
WO 99146281 PCT/IJS99/05028
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0868.
A pair of PCR primers (forward and reverse) were synthesized:
forward PC>~rimer 138133.f11 5'-GTAGCAGTGCACATGGGGTGTTGG-3' (SEQ ID N0:65)
reverse PCR primer (38133.r1) 5'-ACCGCACATCCTCAGTCTCTGTCC-3' (SEQ ID N0:66)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA38133
sequence which had the following nucleotide sequence
hvbridization probe (38133.011
5'-ACGATGATCGCGGGCTCCCTTCTCCTGCTTGGATTCCTTAGCACCACCAC-3' (SEQ ID N0:67)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0868 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the fall-length
DNA sequence for PR0868
[herein designated as UNQ437 (DNA52594-1270)) (SEQ ID N0:63) and the derived
protein sequence for PR0868.
The entire nucleotide sequence of UNQ437 (DNA52594-1270) is shown in Figure 25
(SEQ 1D N0:63).
Clone UNQ437 (DNA52594-1270) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 325-327 and ending at the stop codon at nucleotide
positions 2290-2292 (Figure 25). The
predicted polypeptide precursor is 655 amino acids long (Figure 26). The full-
length PR0868 protein shown in
Figure 26 has an estimated molecular weight of about 71,845 daltons and a pI
of about 8.22. Analysis of the full-
length PR0868 polypeptide sequence demonstrates the presence of conserved
cysteine-containing domains from about
amino acid 66 to about amino acid 78 and from about amino acid 123 to about
amino acid 134 of the sequence shown
in Figure 26 (SEQ ID N0:3), a TNFR death domain from about amino acid 85 to
about amino acid 110, a
FASA mouse death domain block from about amino acid 159 to about amino acid
175 and a uansmembrane domain
from about amino acid 347 to about amino acid 375. Clone UNQ437 (DNA52594-
1270) has been deposited with
ATCC on March 17, 1998 and is assigned ATCC deposit no. 209679
Analysis of the amino acid sequence of the full-length PR0868 polypeptide
suggests that it possesses
significant sequence similarity to the tumor necrosis factor receptor protein,
thereby indicating that PR0868 may be
a novel member of the tumor necrosis factor receptor family. More
specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced significant homology between the PR0868
amino acid sequence and the
following Dayhoff sequences, RNU94330_1, P 899933, P 899945, P_R99950,
HSU94332_1, CD40 HUMAN,
S63368 1, TNR2 HUMAN, MVU87844 1 AND CVU87837 1.
E~PLE 12: Isolation o~ cDNA Clones Encoding Human PR0382
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA30892. Based
on the DNA30892 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0382.
A pair of PCR primers (forward and reverse) were synthesized:
~rward PCR primer 5'-TGACATCGCCCTTATGAAGCTGGC-3' (SEQ ID NO:?0)
190
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
reverse PCR primer 5'-TACACGTCCCTGTGGTTGCAGATC-3' (SEQ ID N0:71)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA30892
sequence which had the following nucleotide sequence
hybridization probe
5'-CGTTCAATGCAGAAATGATCCAGCCTGTGTGCCTGCCCAACTCTGAAGAG-3' (SEQ ID N0:72)
In order to screen several libraries for a source of a full-length clone; DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0382 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0382
[herein designated as UNQ323 (DNA45234-1277)] (SEQ ID N0:68) and the derived
protein sequence for PR0382.
The entire nucleotide sequence of UNQ323 (DNA45234-1277) is shown in Figure 27
(SEQ ID N0:68).
Clone UNQ323 (DNA45234-1277) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 126-128 and ending at the stop codon at nucleotide
positions 1485-1487 (Figure 27). The
predicted polypeptide precursor is 453 amino acids long (Figure 28). The full-
length PR0382 protein shown in
Figure 28 has an estimated molecular weight of about 49,334 daltons and a pI
of about 6.32. Analysis of the native
PR0382 amino acid sequence shown in Figure 28 (SEQ ID N0:69) indicates the
presence of a putative
transmembrane domain from about amino acid 240 to about amino acid 284, a
putative signal peptide at about amino
acid 1 to about amino acid 20, a putative apple domain at about amino acid 386
to about amino acid 419, a putative
Kringle domain at about amino acid 394 to about amino acid 406 and a histidine-
containing protease active site at
about amino acid 253 to about amino acid 258. Clone UNQ323 (DNA45234-1277) has
been deposited with ATCC
on March 5, 1998 and is assigned ATCC deposit no. 209654.
Analysis of the amino acid sequence of the full-length PR0382 polypeptide
suggests that it possess
significant homology to serine protease proteins, thereby indicating that
PR0382 may be a novel serine protease.
Specifically, an analysis of the Dayhoff database (version 35.45 SwissProt 35)
evidenced significant homology
between the PR0382 amino acid sequence and the following Dayhoff sequences,
HSU75329-1, EN'TK_MOUSE,
HEPS HUMAN, AF030065 1, HEPS RAT, PLMN PIG, P 889430, P 889435, PLMN HORSE,
PLMN BOVIN
and P 883959.
EXAMPLE 13: Isolation of cDNA Clones Encoding Human PR0545
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA44706. An EST
proprietary to Genentech was
employed in the consensus assembly and is herein designated DNA13217 (Figure
31; SEQ ID N0:75). Based on
the DNA44706 consensus sequence, oligonucleotides were synthesized: 1) to
identify by PCR a cDNA library that
contained the sequence of interest, and 2) for use as probes to isolate a
clone of the full-length coding sequence for
PR0545.
Forward and reverse PCR primers were synthesized:
forward PCR primer 1 5'-GTCTCAGCACGTGTTCTGGTCTCAGGG-3' (SEQ ID N0:76)
forward PCR pLlIfleT 2 5'-CATGAGCATGTGCACGGC-3' (SEQ ID N0:77)
forward PCR primer 3 5'-TACCTGCACGATGGGCAC-3' (SEQ ID N0:78)
191
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
forward PCR primer 4 5'-CACTGGGCACCTCCCTTC-3' (SEQ ID N0:79)
reverse PCR primer 1 5'-CTCCAGGCTGGTCTCCAAGTCCTTCC-3' (SEQ ID N0:80)
reverse PCR primer 2 5'-TCCCTGTTGGACTCTGCAGCTTCC-3' (SEQ ID N0:81)
reverse PCR primer 3 5'-CTTCGCTGGGAAGAGTTTG-3' (SEQ ID N0:82)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA44?06
sequence which had the following nucleotide sequence
hybridization probe
5'-GTGCAACCAACAGATACAAACTCTTCCCAGCGAAGAAGCTGAAAAGCGTC-3'
(SEQ ID N0:83)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PROS45 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human placenta tissue
(L1B90).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0545
[herein designated as UNQ346 (DNA49624-1279)] (SEQ ID N0:73) and the derived
protein sequence for PR0545.
The entire nucleotide sequence of UNQ346 (DNA49624-1279) is shown in Figure 29
(SEQ ID N0:73).
Clone UNQ346 (DNA49624-1279) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 311-313 and ending at the stop codon at nucleotide
positions 2516-2518 (Figure 29). The
predicted polypeptide precursor is 735 amino acids long (Figure 30). The full-
length PR0545 protein shown in
Figure 30 has an estimated molecular weight of about 80,177 daltons and a pI
of about 7.08. Important regions of
the PR0545 amino acid sequence include the signal peptide, corresponding to
amino acids 1-28, five potential
N-glycosylation sites, from about amino acid 111-114, amino acids 146-149,
amino acids 348-351, amino acids 449-
452, and amino acids 648-651, and a neutral zinc metallopeptidase, zinc-
binding region signature sequence, from
about amino acids 344-353. Clone UNQ346 (DNA49624-1279) has been deposited
with ATCC and is assigned
ATCC deposit no. 209655.
EXAMPLE 14: elation of cDNA Clones Encoding Human PR06I7
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42798. Based
on the DNA42798 sequence,
oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and
2) for use as probes to isolate a clone of the full-length coding sequence for
PR0617.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 5'-ACGGGCACACTGGATCCCAAATG-3' (SEQ ID N0:86)
reverse PCR~rimer 5'-GGTAGAGATGTAGAAGGGCAAGCAAGACC-3' (SEQ ID N0:87)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA42798
sequence which had the following nucleotide sequence
hybridization probe
5'-GCTCCCTACCCGTGCAGGTTTCTTCATTTGTTCCTTTAACCAGTATGCCG-3' (SEQ ID N0:88)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
192
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
encoding the PR0617 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0617
(herein designated as UNQ353 (DNA48309-1280)] (SEQ ID NO:1) and the derived
protein sequence for PR0617.
The entire nucleotide sequence of UNQ353 (DNA48309-1280) is shown in Figure 32
(SEQ ID N0:84).
Clone UNQ353 (DNA48309-1280) contains a single open reading frame with an
apparent uanslational initiation site
at nucleotide positions 723-725 and ending at the stop codon at nucleotide
positions 924-926 (Figure 32). The
predicted polypeptide precursor is 67 amino acids long (Figure 33). The full-
length PR0617 protein shown in Figure
33 has an estimated molecular weight of about 6,981 daltons and a p1 of about
7.47. Analygjs of the PR0617 amino
acid sequence also evidences the existence of a putative signal peptide from
about amino acid 15 to about amino acid
27 and a putative protein kinase C phosphorylation site from about amino acid
41 to about amino acid 43. Clone
UNQ353 (DNA48309-1280) has been deposited on March 5, 1998 with ATCC and is
assigned ATCC deposit no.
209656.
Analysis of the amino acid sequence of the full-length PR0617 polypeptide
suggests that it possesses
significant homology to the CD24 protein, thereby indicating that PR0617 rnay
be a novel CD24 homolog, More
specifically, an analysis of the Dayhoff database (version 35.45 SwissProt 35)
evidenced significant homology
between the PR0617 amino acid sequence and the following Dayhoff sequences,
CD24 HUMAN, CD24 MOUSE,
S15785, CD24 RAT, VGE BPG4, MSES_HUMAN, HSMHC3W36A 2. MLU15184_8, P 885075,
SEPL HUMAN
and MTCY63 13.
EXAMPLE 15: Isolation of cDNA Clones Encoding Human PR0700
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA30837. Based
on the DNA30837 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0700.
Forward and reverse PCR primers were synthesized:
forward PCR plim~~l_ 5'-ATGTTCTTCGCGCCCTGGTG-3' (SEQ ID N0:91)
forward PCR nt7me~~ 5'-CCAAGCCAACACACTCTACAG-3' (SEQ ID N0:92)
reverse PCR,~rimer 1 5'-AAGTGGTCGCCTTGTGCAACGTGC-3' (SEQ ID N0:93)
reverse PCI;'",primer 2 5'-GGTCAAAGGGGATATATCGCCAC-3' (SEQ ID N0:94)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA30837
sequence which had the following nucleotide sequence
hybridization probe
5'-GCATGGAAGATGCCAAAGTCTATGTGGCTAAAGTGGACTGCACGGCCCA-3'
(SEQ ID N0:95)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0700 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(LIB227).
193
CA 02421372 2003-03-25
I
WO 99146281 PCT/US99/05028
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0700
[herein designated as UNQ364 (DNA46776-1284)] (SEQ ID N0:89) and the derived
protein sequence for PR0700.
The entire nucleotide sequence of UNQ364 (DNA46776-1284) is shown in Figure 34
(SEQ ID N0:89).
Clone UNQ364 (DNA46776-1284) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 33-35 and ending at the stop codon at nucleotide
positions 1329-1331 (Figure 34). The
predicted polypeptide precursor is 432 amino acids long (Figure 35). The full-
length PR0700 protein shown in
Figure 35 has an estimated molecular weight of about 47,629 daltons and a p1
of about 5.90. Important regions of
the amino acid sequence of PR0700 include the signal peptide, corresponding to
amino acids from about 1 to 33,
regions homologous to disulfide isomerase, corresponding to amino acids from
about 82-99. 210-255, and 345-360,
a tyrosine kinase phosphorylation site, corresponding to amino acids from
about 143-151, and an endoplasmic
reticulum targeting sequence, corresponding to amino acids from about 429-432.
Clone UNQ364 (DNA46776-1284)
has been deposited with ATCC and is assigned ATCC Deposit No. 209721.
EXAMgLE 16: Isolation of cDNA Clones Encoding Human PR0702
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA36623. Based
on the DNA36623 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0702.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer (36623.f1) 5'-CGCTGACTATGTTGCCAAGAGTGG-3' (SEQ ID N0:98)
reverse PCR primer (36623.r1) 5'-GATGATGGAGGCTCCATACCTCAG-3' (SEQ ID N0:99)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA36623
sequence which had the following nucleotide sequence
)ybridizatior>-probe 1366231)
5'-GTGTTCATTGGCGTGAATGACCTTGAAAGGGAGGGACAGTACATGTTCAC-3' (SEQ ID N0:100)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0702 gene using the probe oligonucleotide and one of the PCR
primers. RNA for conswction of
the cDNA libraries was isolated from human fetal liver tissue (LIB229).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0702
[herein designated as UNQ366 (DNA50980-1286)] (SEQ 1D N0:96) and the derived
protein sequence for PR0702.
The entire nucleotide sequence of UNQ366 (DNA50980-1286) is shown in Figure 36
(SEQ ID N0:96).
Clone UNQ366 (DNA50980-1286) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 22-24 and ending at the stop codon at nucleotide
positions 853-855 (Figure 36). The predicted
polypeptide precursor is 277 amino acids long (Figure 37). The full-length
PR0702 protein shown in Figtue 37 has
an estimated molecular weight of about 30,645 daltons and a p1 of about 7.47.
Analysis of the full-length native
PR0702 amino acid sequence evidences the presence of a putative signal peptide
from about amino acid 1 to about
amino acid 25, potential N-glycosylation sites from about amino acid 230 to
about amino acid 233 and from about
amino acid 258 to about amino acid 261 and a C-type lectin domain signature
sequence from about amino acid 248
to about amino acid 270. Clone UNQ366 (DNA50980-1286) has been deposited with
ATCC on March 31, 1998 and
194
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
is assigned ATCC deposit no. 209717.
Analysis of the amino acid sequence of the full-length PR0702 polypeptidc
suggests that it possesses
significant sequence similarity to the conglutinin protein, thereby indicating
that PR0702 may be a novel conglutinin
homolog. More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant
homology between the PR0702 amino acid sequence and the following Dayhoff
sequences, S32436, P 875642, P
W18780, P W18781, A53330, AC002528_1, HSPPA21C0_1, CA21 HUMAN, CA14_HUMAN and
A61262.
EXAMPLE 17: Isolation of cDNA Clones Encoding Human PR0703
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43047. Based
on the DNA43047 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0703.
Forward and reverse PCR primers were synthesized:
forward PCR primer 5'-GAGAGCCATGGGGCTCCACCTG-3' (SEQ ID N0:103)
reverse PCR primer 1 5'-GGAGAATGTGGCCACAAC-3' (SEQ ID N0:104)
reverse PCR primgL 5'-GCCCTGGCACAGTGACTCCATAGACG-3' (SEQ ID NO:105)
reverse PCR primer 3 5'-ATCCACTTCAGCGGACAC-3' (SEQ ID N0:106)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40654
sequence which had the following nucleotide sequence
Hybridization probe
5'-CCAGTGCCAGGATACCTCTCTTCCCCCCAGAGCATAACAGACACG-3'
(SEQ ID N0:107)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0703 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0703
[herein designated as UNQ367 (DNA50913-1287)] (SEQ ID NO:101) and the derived
protein sequence for PR0703.
The entire nucleotide sequence of UNQ367 (DNAS0913-1287) is shown in Figure 38
(SEQ ID NO:101).
Clone UNQ367 (DNA50913-1287) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 115-117 and ending at the stop codon at nucleotide
positions 2305-2307 (Figure 38). The
predicted polypeptide precursor is 730 amino acids long (Figure 39). The full-
length PR0703 protein shown in
Figure 39 has an estimated molecular weight of about 78,644 daltons, and a p1
of about: 7.65. Important regions of
the PR0703 amino acid sequence include the signal peptide, a CAMP- and cGMP-
dependent protein kinase
phosphorylation site, a CUB domain protein motif, N-glycosylation sites and a
putative AMP-binding domain
signature. Clone UNQ367 (DNA50913-1287) has been deposited with ATCC and is
assigned ATCC deposit no.
209716.
195
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
EXAMPLE 18: Isolation of eDNA Clones Encoding Human PR0705
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43437. Based
on the DNA43437 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0705.
S A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-AAGCGTGACAGCGGGCACGTC-3' (SEQ ID NO:110)
reverse PCR grimer 5'-TGCACAGTCTCTGCAGTGCCCAGG-3' (SEQ ID NO:111)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA43437
sequence which had the following nucleotide sequence
hybridization globe 143437.p1)
5'-GAATGCTGGAACGGGCACAGCAAAGCCAGATACTTGCCTG-3' (SEQ 1D N0:112)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0705 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0705
(herein designated as UNQ369 (DNA50914-1289)] (SEQ ID N0:108) and the derived
protein sequence for PR0705.
The emire nucleotide sequence of UNQ369 (DNA50914-1289) is shown in Figure 40
(SEQ ID N0:108).
Clone UNQ369 (DNA50914-1289) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 566-568 and ending at the stop codon at nucleotide
positions 2231-2233 (Figure 40). The
predicted polypeplide precursor is 555 amino acids long (Figure 41). The full-
length PR0705 protein shown in
Figure 41 has an estimated molecular weight of about 62,736 daltons and a pI
of about 5.36. Analysis of the full-
length PR0705 sequence as shown in Figure 41 evidences the presence of the
following: a signal peptide from about
amino acid 1 to about amino acid 23, a eukaryotic DNA topoisomerase I active
site from about amino acid 418 to
about amino acid 436, and various regions that show homology to various
glypican proteins from about amino acid
237 to about amitw acid 279, about amino acid 421 to about amino acid 458,
about amino acid 53 to about amino acid
74, about amino acid 466 to about amino acid 504, about amino acid 308 to
about amino acid 355, about amino acid
104 to about amino acid 156 and about amino acid 379 to about amino acid 410.
Clone UNQ369 (DNA50914-1289)
has been deposited with ATCC on March 31, 1998 and is assigned ATCC deposit
no.209722.
Analysis of the amino acid sequence of the full-length PR0705 polypeptide
suggests that it possesses
significant sequence similarity to the K-glypican protein, thereby indicating
that PR0705 may be a novel glypican
protein family member. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35)
evidenced significant homology between the PRO?OS amino acid sequence and the
following Dayhoff sequences,
GPCK MOUSE. GLYP CHICK, GLYP RAT, GLYP HUMAN, GPC2'RAT, GPCSlHUMAN, GPC3
HUMAN,
GPC3 RAT, P 830168 and CEC03H12 2.
EXAMPLE 19: Isolation of cDNA Clones Encoding Human PR0708
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA34024. Based
on the DNA34024 consensus
196
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
sequence, oligonucleotides were synthesized: I ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0708.
A pair of PCR primers (forward and reverse) were synthesized:
forward P~R~rimer 5'-CCCAACCCAACTGTTTACCTCTGG-3' (SEQ ID NO:115)
reverse PCR p,~imer 5'-CTCTCTGAGTGTACATCTGTGTGG-3' (SEQ ID NO:I 16)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA34024
sequence which had the following nucleotide sequence
hybridization probe
5'-GCCACCCTACCTCAGAAACTGAAGGAGGTTGGNTATTCAACGCATATGGTCGG-3' (SEQ ID N0:117)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0708 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow tissue (LIB255).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0708
[herein designated as UNQ372 (DNA48296-1292)] (SEQ ID N0:113) and the derived
protein sequence for PR0708.
The entire nucleotide sequence of UNQ372 (DNA48296-1292) is shown in Figures
42A-B (SEQ ID
N0:113). Clone UNQ372 (DNA48296-1292) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 891-893 and ending at the stop codon
at nucleotide positions 2436-2438 (Figures
42A-B). The predicted polypeptide precursor is 515 amino acids long (Figure
43). The full-length PR0708 protein
shown in Figure 43 has an estimated molecular weight of about 56,885 daltons
and a p1 of about 6.49. Analysis of
the PR0708 amino acid sequence shown in Figure 43 (SEQ ID NO:I 14) evidences
the existence of a putative signal
peptide at about amino acid 1 to about amino acid 37, putative sulfatase
signature sequences at about amino acid 120
to about amino acid 132 and about amino acid 168 to about amino acid 177, a
putative tyrosine kinase phosphorylation
site from about amino acid 163 to about amino acid 169 and potential N-
glycosylation sites from about amino acid
157 to about amino acid 160, about amino acid 306 to about amino acid 309 and
about amino acid 318 to about amino
acid 321. Clone UNQ372 (DNA48296-1292) has been deposited with ATCC on March
11, 1998 and is assigned
ATCC deposit no. 209668.
Analysis of the amino acid sequence of the full-length PR0708 polypeptide
suggests that it possesses
significant homology to the aryl sulfatase proteins, thereby indicating that
PR0708 may be a novel aryl sulfatase
homolog. More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant
homology between the PR0708 amino acid sequence and the following Dayhoff
sequences, ARSB_HUMAN,
CELC54D2 2, 602857, STS HUMAN, 137186. I37187, GEN12648, CELD1014 ?, GA6S
HUMAN and
SPHM HUMAN.
EXAMPLE 20: Isolation of cDNA Clones EncQdine Human PR0320
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA28739. Based
on the DNA28739 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0320.
197
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR grimer S'-CCTCAGTGGCCACATGCTCATG-3' (SEQ ID N0:120)
reverse PCR primer 5'-GGCTGCACGTATGGCTATCCATAG-3' (SEQ ID N0:121)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA28739
sequence which had the following nucleotide sequence
hybridization Qrobe
S'-GATAAACTGTCAGTACAGCTGTGAAGACACAGAAGAAGGGCCACAGTGCC-3' (SEQ ID N0:122)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0320 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal lung tissue (LIB25).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0320
[herein designated as UNQ281 (DNA32284-1307)] (SEQ ID NO:I 18) and the derived
protein sequence for PR0320.
The entire nucleotide sequence of UNQ281 (DNA32284-1307) is shown in Figure 44
(SEQ ID N0:118).
Clone UNQ281 (DNA32284-1307) contains a single open reading frame with an
apparent translational initiation site
1S at nucleotide positions 135-137 and ending at the stop codon at nucleotide
positions 1149-1151 (Figure 44). The
predicted polypeptide precursor is 338 amino acids long (Figure 4S). The full-
length PR0320 protein shown in
Figure 4S has an estimated molecular weight of about 37,143 daltons and a p/
of about 8.92. Important regions of
the PR0320 amino acid sequence include the signal peptide, corresponding to
amino acids 1-21, an EGF-like domain
cysteine pattern signature, corresponding to amino acids 80-91, and three
calcium-binding EGF-like domains,
corresponding to amino acids 103-124, 230-1S1 and 185-206, respectively. Clone
UNQ281 (DNA32284-1307) has
been deposited with ATCC and is assigned ATCC deposit no. 209670.
EXAMPLE 21: Isolation of cDNA Clones Encodine Human PR0324
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
2S wherein the consensus sequence obtained is herein designated DNA34347.
Based on the DNA34347 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0324.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 1 S'-GCAATGAACTGGGAGCTGC-3' (SEQ ID N0:12S)
forward PCR primer 2 S'-CTGTGAATAGCATCCTGGG-3' (SEQ ID N0:126)
forward PCR primer 3 S'-CTTTTCAAGCCACTGGAGGG-3' (SEQ ID N0:127)
reverse PCR primer 1 S'-CTGTAGACATCCAAGCTGGTATCC-3' (SEQ ID N0:128)
reverse PCR primer 2 S'-AAGAGTCTGCATCCACACCACTC-3' (SEQ ID N0:129)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA34347
3S sequence which had the following nucleotide sequence
hybridization probe
S'-ACCTGACGCTACTATGGGCCGAGTGGCAGGGACGACGCCCAGAATG-3' (SEQ ID N0:130)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
198
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
clones encoding the PR0324 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal liver tissue
(I,IB6).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0324
(herein designated as UNQ285 t'DNA36343-1310)] (SEQ ID N0:123) and the derived
protein sequence for PR0324.
The entire nucleotide sequence of UNQ285 (DNA36343-1310) is shown in Figure 46
(SEQ ID N0:123).
Clone UNQ285 (DNA36343-1310) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 144-146 and ending at the stop codon at nucleotide
positions 1011-1013 (Figure 46). The
predicted polypeptide precursor is 289 amino acids long (Figure 47). The full-
length PR0324 protein shown in
Figure 47 has an estimated molecular weight of about 32,268 daltons and a pI
of about 9.21. Analysis of the PR0324
polypeptide sequence shown in Figure 47 (SEQ ID N0: 324) evidence the presence
of the following: a signal peptide
from about amino acid 1 to about amino acid 31, a transmembrane domain from
about amino acid 136 to about amino
acid 157, tyrosine ianase phosphorylation sites from about amino acid 106 or
about amino acid 107 to about amino
acid 113 and regions that are homologous to short-chain alcohol dehydrogenase
regions from about amino acid 80
to about amino acid 90, from about amino acid 131 to about amino acid 168,
from about amino acid 1 to about amino
acid 13 and from about amino acid 176 to about amino acid 185. Clone UNQ285
(DNA36343-1310) has been
deposited with ATCC on March 30, 1998 and is assigned ATCC deposit no. 209718.
Analysis of the amino acid sequence of the full-length PR0324 polypeptide
suggests that it possesses
significant sequence similarity to oxidoreductases, thereby indicating that
PR0324 may be a novel oxidoreductase
homolog. More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant
homology between the PR0324 amino acid sequence and the following Dayhoff
sequences, B61209, A69965,
YQJQ BACSU, D69930, S76124, FABG ECOLI, C70023, S77280, FABG VIBHA and MTV013
6.
EXAMPLE 22: Isolation of cDNA Clones Encoding Human PR0351
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA35950. Based
on the DNA35950 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0351.
Forward and reverse PCR primers were synthesized:
forward PCR~rimer 5'-CCTGTGCTGTGCCTCGAGCCTGAC-3' (SEQ ID N0:133)
reverse PCR rrimer 5'-GTGGGCAGCAGTTAGCACCGCCTC-3' (SEQ ID N0:134)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA35950
sequence which had the following nucleotide sequence
hybridization ppobe
5'-GGCTGGCATCATCAGCTTTGCATCAAGCTGTGCCCAGGAGGACGC-3'
(SEQ 1D N0:135)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0351 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal liver tissue
(LIB230).
199
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0351
(herein designated as UNQ308 (DNA40571-1315)) (SEQ ID N0:131) and the derived
protein sequence for PR0351.
The entire nucleotide sequence of UNQ308 (DNA40571-1315) is shown in Figure 48
(SEQ ID N0:131).
Clone UNQ308 (DNA40571-1315) contains two open reading frames with an apparent
translational initiation site at
nucleotide positions 189-191 and a second open reading frame beginning at
nucleotide 470, with the two open reading
frames ending at the stop codons at nucleotide positions 363-365 and 2009-
2011, respectively (Figure 48). The
predicted polypeptide precursor is 571 amino acids long (Figure 49). Important
regions of the amino acid sequence
of PR0351 include the signal peptide, regions having sequence similarity to
serine proteases of the trypsin family,
two N-glycosylation sites, and three Kringle domains. Clone UNQ308 (DNA40571-
1315) has been deposited with
ATCC and is assigned ATCC deposit no. 209784.
EXAMPLE 23: 1_~olation of cDNA Clones Encoding Human PR0352
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA36950. Based
on the DNA36950 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0352.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 1 5'-CTGGCACAGCTCAACCTCATCTGG-3' (SEQ ID . :138)
forward PCRprimer 2 5'-GCTGTCTGTCTGTCTCATTG-3' (SEQ ID N0:139)
forward PCRprimer 3 S'-GGACACAGTATACTGACCAC-3' (SEQ ID N0:140)
reverse PCR primer 1 5'-TGCGAACCAGGCAGCTGTAAGTGC-3' (SEQ ID N0:141)
reverse PCR nriraer 2 5'-TGGAAGAAGAGGGTGGTGATGTGG-3' (SEQ ID N0:142)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA36950
sequence which had the following nucleotide sequence
hybridization probe
5'-CAGCTGACAGACACCAAACAGCTGGTGCACAGTI-I'CACCGAAGGC-3' (SEQ ID N0:143)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0352 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0352
(herein designated as UNQ309 (DNA4138tr1316)] (SEQ ID N0:136) and the derived
protein sequence for PR0352.
The entire nucleotide sequence of UNQ309 (DNA41386-1316) is shown in Figure 50
(SEQ ID N0:136).
Clone UNQ309 (DNA41386-1316) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 152-154 and ending at the stop codon at nucleotide
positions 1100-1102 (Figure 50). The
predicted polypeptide precursor is 316 amino acids long (Figure 51). The full-
length PR0352 protein shown in
Figure 2 has an estimated p1 of about 4.62. Analysis of the full-length PR0352
sequence evidences the presence of
a signal peptide from about amino acid I to about amino acid 28, a
transmembrane domain from about amino acid
251 to about amino acid 270, potential N-glycosylation sites from about amino
acid 91 to about amino acid 94, about
amino acid 104 to about amino acid 107, about amino acid 189 to about amino
acid 192 and about amino acid 215
200
CA 02421372 2003-03-25
WO 99146281 PCT/US99/05028
to about amino acid 218 and a region having homology to immunoglobulins and
MHC from about amino acid 217
to about amino acid 234. Clone UNQ309 (DNA41386-1316) has been deposited with
ATCC on March 26, 1998 and
is assigned ATCC deposit no. 209703.
Analysis of the amino acid sequence of the full-length PR0352 polypeptide
suggests that it possesses
significant sequence similarity to the buryrophilin protein, thereby
indicating that PR0352 is a novel butyrophilin
S homolog. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced significant
homology between the PR0352 amino acid sequence and the following Dayhoff
sequences, BUTY HUMAN,
HSB73 1, GGCD80 1, 146690, A33 HUMAN, P 867988, CD86 MOUSE, P 871360, B39371
and D50558 1.
EXAMPLE 24: Isolation of cDNA Clones Encoding_Human PR03~j
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA39651. Based
on the DNA39651 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0381.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CTTTCCTTGCTTCAGCAACATGAGGC-3' (SEQ ID N0:146)
revgJse PCR primer 5'-GCCCAGAGCAGGAGGAATGATGAGC-3' (SEQ ID N0:147)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA39651
sequence which had the following nucleotide sequence
hvbridization,probe
5'-GTGGAACGCGGTCTTGACTCTGTTCGTCACTTCTTTGATTGGGGCTTTG-3' (SEQ ID N0:148)
In order to screen several libraries for a source of a full-length clone, Dh'A
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0381 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0381
[herein designated as UNQ322 (DNA44194-1317)) (SEQ ID N0:144) and the derived
protein sequence for PR0381.
The entire nucleotide sequence of UNQ322 (DNA44194-1317) is shown in Figure 52
(SEQ ID N0:144).
Clone UNQ322 (DNA44194-1317) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 174-176 and ending at the stop codon at nucleotide
positions 807-809 (Figure 52). The
predicted polypeptide precursor is 211 amino acids long (Figure 53). The full-
length PR0381 protein shown in
Figure 53 has an estimated molecular weight of about 24,172 daltons and a pI
of about 5.99. Analysis of the full-
length PR0381 polypeptide shown in Figure 53 (SEQ 1D N0:145) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 20, a potential N-
glycosylation site from about amino acid 176
to about amino acid 179, potential casein kinase II phosphorylation sites from
about amino acid 143 to about amino
acid 146, from about amino acid 156 to about amino acid 159, from about amino
acid 178 to about amino acid 181,
and from about amino acid 200 to about amino acid 203, an endoplasmic
reticulum targeting sequence from about
amino acid 208 to about amino acid 21 I, FKBP-type peptidyl-prolyl cis-traps
isomerase sites from about amino acid
~8 to about amino acid 114 and from about amino acid 118 to about amino acid
131, EF-hand calcium binding
'vine from about amino acid 191 to about amino acid 203, from about amino acid
184 to about amino acid 203
201
CA 02421372 2003-03-25
PCTlUS99/05028
WO 99/46281
and from about amino acid 140 to about amino acid 159, and an S-100/ICaBP type
calcium binding domain from
about amino acid 183 to about amino acid 203. Clone UNQ322 (DNA44194-1317) has
been deposited with ATCC
on April 28, 1998 and is assigned ATCC deposit no. 209808.
Analysis of the amino acid sequence of the full-length PR0381 polypeptide
suggests that it possesses
significant sequence similarity to FKBP immunophilin proteins, thereby
indicating that PR0381 may be a novel FKBP
immunophilin homolog. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35)
evidenced significant homology between the PR0381 amino acid sequence and the
following Dayhoff sequences,
AF040252_l, 149669, P 893551, 571238, CELCOSC8_1, CEU27353-l, MIP TRYCR,
CEZC455_3,
FKB4 HUMAN and 140718.
EXAMPLE 25: Isolation of cDNA Clones Encodin>' Human PR0~86
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA40674. Two
proprietary Genentech EST
sequences were employed in the consensus sequence assembly, wherein those EST
sequences are herein designated
DNA23350 (Figure 56; SEQ 1D N0:151) and DNA23536 (Figure 57; SEQ ID N0:152).
Based on the DNA40674
consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a
cDNA library that contained the
sequence of interest, and 2) for use as probes to isolate a clone of the full-
length coding sequence for PR0386.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-ACGGAGCATGGAGGTCCACAGTAC-3' (SEQ ID N0:153)
reverse PCR primer 5'-GCACGTTTCTCAGCATCACCGAC-3' (SEQ ID N0:154)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40674
sequence which had the following nucleotide sequence
hvbridization,~robe
5'-CGCCTGCCCTGCACCTTCAACTCCTGCTACACAGTGAACCACAAACAGTT-3' (SEQ ID N0:155)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR arrtplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0386 gene using the probe oIigonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal brain tissue (LIB153).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0386
[herein designated as UNQ326 (DNA45415-1318)] (SEQ ID N0:149) and the derived
protein sequence for PR0386.
The entire nucleotide sequence of UNQ326 (DNA45415-1318) is shown in Figure 54
(SEQ ID N0:149).
Clone UNQ326 (DNA45415-1318) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 146-148 and ending at the stop codon at nucleotide
positions 791-793 (Figure 54). The
predicted polypeptide precursor is 215 amino acids long (Figure 55). The full-
length PR0386 protein shown in
Figtue 55 has an estimated molecular weight of about 24,326 dattons and a p1
of about 6.32. Analysis of the full-
length PR0386 sequence shown in Figure 55 (SEQ ID N0:150) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 20, a transmembrane domain
from about amino acid 161 to
about amino acid 179, an immunoglobulin-like fold from about amino acid 83 to
about amino acid 127 and potential
N-glycosylation sites from about amino acid 42 to about amino acid 45, from
about amino acid 66 to about amino
acid 69 and from about amino acid 74 to about amino acid 77. Clone UNQ326
(DNA45415-1318) has been deposited
202
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
with ATCC on April 28, 1998 and is assigned ATCC deposit no. 209810.
Analysis of the amino acid sequence of the full-length PR0386 polypeptide
suggests that it possesses
significant sequence similarity to the sodium channel beta-2 subunit, thereby
indicating that PR0386 is a novel
homolog thereof. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced
significant homology between the PR0386 amino acid sequence and the following
Dayhoff sequences, A57843,
MYPO HUMAN, GEN14531, JC4024, HS46KDA l, HSU90716 1, D86996 2, MUSIGLVD 1,
DMU42768 1
and S19247.
EXAMPLE 26: Isolation of cDNA Clones Encoding Human PR0540
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA39631. Based
on the DNA39631 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0540.
Forward and reverse PCR primers were synthesized:
forward PCR~rimer S'-CTGGGGCTACACACGGGGTGAGG-3' (SEQ ID N0:158)
reverse PCR primer 5'-GGTGCCGCTGCAGAAAGTAGAGCG-3' (SEQ ID N0:159)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40654
sequence which had the following nucleotide sequence
hyblidization gJrobe
5'-GCCCCAAATGAAAACGGGCCCTACTTCCTGGCCCTCCGCGAGATG-3'
(SEQ ID N0:160)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0540 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0540
[herein designated as UNQ341 (DNA44189-1322)] (SEQ ID N0:156) and the derived
protein sequence for PR0540.
The entire nucleotide sequence of UNQ341 (DNA44189-1322) is shown in Figure 58
(SEQ ID N0:156).
Clone UNQ341 (DNA44189-1322) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 21-23 and ending at the stop codon at nucleotide
positions 1257-1259 (Figure 58). The
predicted polypeptide precursor is 412 amino acids long (Figure 59). The full-
length PR0540 protein shown in
Figure 59 has an estimated molecular weight of about 46,658 daltons and a pI
of about 6.65. hnportant regions of
the amino acid sequence of PR0540 include the signal peptide, potential N-
glycosylation sites, a potential lipid
substrate binding site, a sequence typical of lipases and serine proteins, and
a beta-uansducin family Trp-Asp repeat.
Clone UNQ341 (DNA44189-1322) has been deposited with ATCC and is assigned ATCC
deposit no. 209699.
EXAMPLE 27: Illation of cDNA Clones EncodinE Human PR061G_5
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42240. Based
on the DNA42240 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
203
CA 02421372 2003-03-25
r!
WO 99/46281 PCT/US99/05028
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0615.
Forward and reverse PCR primers were synthesized:
forward PCR primer 5'-TGGTCTTCGCCTTGATCGTGTTCT-3' (SEQ ID N0:163)
forward PCR primer 5'-GTGTACTGAGCGGCGGTTAG-3' (SEQ ID N0:164)
reverse PCR primer 5'-CTGAAGGTGATGGCTGCCCTCAC-3' (SEQ ID N0:165)
reverse PCR primer 5'-CCAGGAGGCTCATGGGAAAGTCC-3' (SEQ ID N0:166)
Additionally, a synthetic oligonucleotide hybridization probe was constntcted
from the consensus DNA42240
sequence which had the following nucleotide sequence:
hybridization probe
5'-CCACGAGTCTAAGCAGATGTACTGCGTGTTCAACCGCAACGAGGATGCCT-3'
(SEQ ID N0:167)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0615 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human bone marrow tissue
(LIB255).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0615
[herein designated as UNQ352 (DNA48304-1323)] (SEQ 1D N0:161) and the derived
protein sequence for PR0615.
The entire nucleotide sequence of UNQ352 (DNA48304-1323) is shown in Figure 60
(SEQ ID N0:161).
Clone UNQ352 (DNA48304-1323) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 51-53 and ending at the stop codon at nucleotide
positions 723-725 (Figure 60). The predicted
polypeptide precursor is 224 amino acids long (Figure 61). The full-length
PR0615 protein shown in Figure 61 has
an estimated molecular weight of about 24,810 daltons and a p/ of about 4.75.
Important regions of the amino acid
sequence of PR0615 include a type II transmembrane domain, corresponding to
about amino acids 24-43, other
transmembrane domains, corresponding to about amino acids 74-90, 108-126, and
145-161, respectively, and a
potential N-glycosylation site, corresponding to about amino acids 97-100.
Clone UNQ352 (DNA48304-1323) has
been deposited with ATCC and is assigned ATCC deposit no. 209811.
EXAMPLE 28: Isolation of cDNA Clones Encoding_Human PR0618
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA30900. Based
on the DNA30900 consensus
sequence, oligonucleotides were synthesized: I ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0618.
Forward and reverse PCR primers were synthesized:
forward PCR primer 5'-TAACAGCTGCCCACTGCTTCCAGG-3' (SEQ ID N0:171)
reverse PCR~rimer 5'-TAATCCAGCAGTGCAGGCCGGG-3' (SEQ ID N0:172)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA30900
sequence which had the following nucleotide sequence
hybridization probe
S'-ATGGCCTCCACGGTGCTGTGGACCGTGTTCCTGGGCAAGGTGTGGCAGAA-3'
(SEQ ID N0:173)
204
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Screening of the above described library gave rise to the partial cDNA clone
designated herein DNA35597
(SEQ ID N0:170). Extension of this sequence using repeated cycles of BLAST and
phrap gave rise to a nucleotide
sequence designated herein as DNA43335. Primers based upon the DNA43335
consensus sequence were then
prepared as follows.
forward PCR primer 5'-TGCCTATGCACTGAGGAGGCAGAAG-3' (SEQ ID N0:174)
reverse PCRprimer 5'-AGGCAGGGACACAGAGTCCATTCAC-3' {SEQ ID N0:175)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA43335
sequence which had the following nucleotide sequence
hybridization probe
5'-AGTATGATTTGCCGTGCACCCAGGGCCAGTGGACGATCCAGAACAGGAGG-3'
(SEQ ID N0:176)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
full length clones encoding the PR0618 gene using the second probe
oligonucleotide and one of the second set of PCR
primers. RNA for construction of the cDNA libraries was isolated from human
fetal liver tissue (LIB229).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0618
(herein designated as UNQ354 (DNA49152-1324)] (SEQ ID N0:168) and the derived
protein sequence for PR0618.
The entire nucleotide sequence of UNQ354 (DNA49152-1324) is shown in Figure 62
(SEQ ID N0:168).
Clone UNQ354 (DNA49152-1324) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 73-75 and ending at the stop codon at nucleotide
positions 2479-2481 (Figure 62). The
predicted polypeptide precursor is 802 amino acids long (Figure 63). The full-
length PR0618 protein shown in
Figure 63 has an estimated molecular weight of about 88,846 daltons and a pI
of about 6.41. Important regions of
the amino acid sequence of PR0618 include type II transmembrane domain, a
sequence typical of a protease, trypsin
family, histidine active site, multiple N-glycosylation sites, two sequences
typical of a Kringle domain, two regions
having sequence similarity to KalIiIGein light chain, and a region having
sequence similarity to low-density lipoprotein
receptor. Clone UNQ354 (DNA49152-1324) has been deposited with ATCC and is
assigned ATCC deposit no.
209813.
EXAbPLE 29: Isolation of cDNA Clones Encodine Human PR0719
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA44851. Based
on the DNA44851 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
intcrest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0719.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 5'-GTGAGCATGAGCGAGCCGTCCAC-3' (SEQ ID N0:179)
reverse PCR primer 5'-GCTATTACAACGGTTCTTGCGGCAGC-3' (SEQ ID N0:180)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA44851
sequence which had the following nucleotide sequence
hybridization rrobe
5'-TTGACTCTCTGGTGAATCAGGACAAGCCGAGTTTTGCCTTCCAG-3' (SEQ ID N0:181)
205
CA 02421372 2003-03-25
v
WO 99/46281 PCT/US99/05028
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0719 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human placenta tissue (LIB90).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0719
[herein designated as UNQ387 (DNA49646-1327)) (SEQ ID N0:177) and the derived
protein sequence for PR0719.
The entire nucleotide sequence of UNQ387 (DNA49646-1327) is shown in Figure 65
(SEQ ID N0:177).
Clone UNQ387 (DNA49646-1327) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 223-225 and ending at the stop codon at nucleotide
positions 1285-1287 (Figure 65). The
predicted polypeptide precursor is 354 amino acids long (Figure 66). The full-
length PR0719 protein shown in
Figure 66 has an estimated molecular weight of about 39,362 daltons and a p1
of about 8.35. Analysis of the full
length PR0719 sequence evidences the presence of a signal peptide from about
amino acid 1 to about amino acid 16
as shown in Figure 66 (SEQ ID N0:178), a lipase-associated serine-containing
active site at about amino acid 163
to about amino acid 172, and two potential N-glycosylation sites from about
amino acid 80 to about amino acid 83
and about amino acid 136 to about amino acid 139. Clone UNQ387 (DNA49646-1327)
has been deposited with
ATCC on March 26, 1998 and is assigned ATCC deposit no. 209705.
Analysis of the amino acid sequence of the full-length PR0719 polypeptide
suggests that it possesses
significant sequence similarity to the lipoprotein lipase H protein, thereby
indicating that PR0719 may be a nove3
lipoprotein lipase homolog. More specifically, an analysis of the Dayhoff
database (version 35.45 SwissProt 35)
evidenced significant homology between the PR0719 amino acid sequence and the
following Dayhoff sequences,
LIPL HUMAN, LIPH HUMAN, D83548 1. A24059 1, P 830740, D88666 1, A43357,
A46696, B43357 and
A49488.
EXAMPLE 30: isolation of cDNA Clones Encoding Human PR0724
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA35603. Based
on the DNA35603 consensus
sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0724.
Pairs of PCR primers (forward and reverse) were synthesized:
forward PCRrprimer 1 5'-GGCTGTCACTGTGGAGACAC-3' (SEQ 1D N0:184)
forward PCR primer 2 5'-GCAAGGTCATTACAGCTG-3' (SEQ ID N0:185)
reverse PCR~~r_ 1 5'-AGAACATAGGAGCAGTCCCACTC-3' (SEQ ID N0:186)
reverse PCR primer 2 5'-TGCCTGCTGCTGCACAATCTCAG-3' (SEQ ID N0:187)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA35603
sequence which had the following nucleotide sequence
It bri ' ation~robe
5'-GGCTATTGCTTGCCTTGGGACAGACCCTGTGGCTTAGGCTCTGGC-3' (SEQ ID N0:188)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pairs identified above. A positive
library was then used to isolate clones
encoding the PR0724 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
206
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
the cDNA libraries was isolated from human fetal lung tissue (LIB26).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0724
[herein designated as UNQ389 (DNA49631-1328)] (SEQ ID N0:182) and the derived
protein sequence for PR0724.
The entire nucleotide sequence of UNQ389 (DNA49631-1328) is shown in Figure 67
(SEQ ID N0:182).
Clone UNQ389 (DNA4963I-1328) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 546-548 and ending at the stop colon at nucleotide
positions 2685-2687 (Figure 67). The
predicted polypeptide precursor is 713 amino acids long (Figure 68). The full-
length PR0724 protein shown in
Figure 68 has an estimated molecular weight of about 76,193 daltons and a p/
of about 5.42. Analysis of the full-
length PR0724 amino acid sequence shown in Figure 68 (SEQ ID N0:183) evidences
the presence of the following:
a signal peptide from about amino acid 1 to about amino acid 16, a
transmembrane domain from about amino acid
442 to about amino acid 462 and LDL receptor class A domain regions from about
amino acid 152 to about amino
acid 171, about amino acid 331 to about amino acid 350, about amino acid 374
to about amino acid 393 and about
amino acid 411 to about amino acid 430. Clone UNQ389 (DNA49631-1328) has been
deposited with ATCC on April
28, 1998 and is assigned ATCC deposit no. 209806
Analysis of the amino acid sequence of the full-length PR0724 polypeptide
suggests that it possesses
significant sequence similarity to the human LDL receptor protein, thereby
indicating that PR0724 may be a novel
LDL receptor homolog. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35)
evidenced significant homology between the PR0724 amino acid sequence and the
following Dayhoff sequences,
P 848547, MMAM2R 1, LRP2 RAT, P 860517, P 847861, P 805533, A44513 1, A30363,
P 874692 and
LMLIPOPHO 1.
EXAMPLE 31: Isolation of cDNA Clones Encoding Human PR0772
One cDNA sequence was isolated in the amylase screen described in Example 2,
wherein that cDNA
sequence is herein designated DNA43509 (see Figure 71). Based on the DNA43509
sequence, oligonucleotide probes
were generated and used to screen a human fetal lung library (LIB25) prepared
as described in paragraph 1 of
Example 2 above. The cloning vector was pRKSB (pRKSB is a precursor of pRKSD
that does not contain the Sfil
site; see, Holmes et al., c'e ce, 25:1278-1280 (1991)), and the cDNA size cut
was less than 2800 bp.
A pair of PCR primers (forward and reverse) were synthesized based on the
DNA43509 sequence:
forward PCR primer 5'-CGTTTTGCAGAACCTACTCAGGCAG-3' (SEQ ID N0:192)
reverse PCR primer 5'-CCTCCACCAACTGTCAATGTTGTGG-3' (SEQ ID N0:193)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA43509
sequence which had the following nucleotide sequence
Itvbridization~ro,~e
5'-AAAGTGCTGCTGCTGGGTCTGCAGACGCGATGGATAACGT-3' (SEQ ID N0:194)
Using the above described primers and library, a full length clone was
identified that contained a single open
reading frame with an apparent translational initiation site at nucleotide
positions 131-133 and ending at the stop
colon found at nucleotide positions 587-589 (Figwe 69; SEQ ID N0:189). The
predicted polypeptide precursor is
152 amino acids long, has a calculated molecular weight of approximately
17,170 daltons and an estimated p1 of
approximately 9.62. Analysis of the full-length PR0772 sequence shown in
Figure 70 (SEQ ID N0:190) evidences
the presence of the following: a potential type II transmembrane domain from
about amino acid 26 to about amino
207
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
acid 42, other potential transmembrane domains from about amino acid 44 to
about amino acid 65, from about amino
acid 81 to about amino acid 101 and from about amino acid 109 to about amino
acid 129, leucine zipper pattern
sequences from about amino acid 78 to about amino acid 99 and from about amino
acid 85 to about amino acid 106.
Clone UNQ410 (DNA49645-1347) has been deposited with ATCC on April 28, 1998
and is assigned ATCC deposit
no. 209809.
Analysis of the amino acid sequence of the full-length PR0772 polypeptide
suggests that it possesses
significant sequence similarity to the human A4 protein, thereby indicating
that PR0772 may be a novel A4 protein
homolog. More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant
homology between the PR0772 amino acid sequence and the following Dayhoff
sequences, HSU93305_1,
A4P HUMAN, CELB0454 2, VPU JSRV, CELC12D12 2, OCCM AGRTI, LBPH1GIE 50,
YIGK_ECOLI,
576245 and P 850807.
EXAMPLE 32: Isolation of cDNA Clones Encoding Human PR0852
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA34364. Based
on the DNA34364 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0852.
PCR primers (forward and reverse) were synthesized:
)'onward PCR~rimer 1 5'-CGCAGAAGCTACAGATTCTCG-3' (SEQ 1D N0:197)
forward PCR primer 2 5'-GGAAATTGGAGGCCAAAGC-3' (SEQ ID N0:198)
forward PCR primer 3 5'-GGATGTAGCCAGCAACTGTG-3' (SEQ ID N0:199)
forward PCR primer 4 5'-GCCTTGGCTCGTTCTCTTC-3' (SEQ ID N0:200)
forward PCR~rimer 5 5'-GGTCCTGTGCCTGGATGG-3' (SEQ 1D N0:201)
reverse PCR primer I 5'-GACAAGACTACCTCCGTTGGTC-3' (SEQ ID N0:202)
reverse PCR primer 2 5'-TGATGCACAGTTCAGCACCTGTTG-3' (SEQ 1D N0:203)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA34364
sequence which had the following nucleotide sequence
~bridization probe
5'-CGCTCCAAGGGCTTTGACGTCACAGTGAAGTACACACAAGGAAGCTG-3' (SEQ ID N0:204)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0852 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB228).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0852
[herein designated as UNQ418 (DNA45493-1349)) (SEQ ID N0:195) and the derived
protein sequence for PR0852.
The entire nucleotide sequence of UNQ418 (DNA45493-1349) is shown in Figure 72
(SEQ ID N0:195).
Clone UNQ418 (DNA45493-1349) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 94-96 and ending at the stop codon at nucleotide
positions 16748-1650 (Figure 72). The
predicted polypeptide precursor is 518 amino acids long (Figure 73). The full-
length PR0852 protein shown in
Figure 73 has an estimated molecular weight of about 56,180 daltons and a pI
of about 5.08. Analysis of the full-
208
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
length PR0852 sequence shown in Figure 73 (SEQ ID N0:196) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 20, a transmembrane domain
from about amino acid 466 to
about amino acid 494, potential N-glycosylation sites from about amino acid
170 to about amino acid 173 and about
amino acid 366 to about amino acid 369, leucine zipper sequence pattern blocks
from about amino acid 10 to about
amino acid 31 and from about amino acid 197 to about amino acid 218 and blocks
of amino acids having sequence
homology to eukaryotic and viral asparryl proteases from about amino acid 109
to about amino acid 118, from about
amino acid 252 to about amino acid 261 and from about amino acid 298 to about
amino acid 310. Clone UNQ418
(DNA45493-1349) has been deposited with ATCC on April 28, 1998 and is assigned
ATCC deposit no. 209805.
Analysis of the amino acid sequence of the full-length PR0852 polypeptide
suggests that it possesses
significant sequence similarity to various protease proteins, thereby
indicating that PR0852 may be a novel protease
protein or homolog thereof. More specifically, an analysis of the Dayhoff
database (version 35.45 SwissProt 35)
evidenced significant homology between the PR0852 amino acid sequence and the
following Dayhoff sequences,
PEPC HUMAN, 566516, S66517, PEPS CHICK, CATD HUMAN, P 874207, CARP YEAST, PEP2
RABIT,
CATE HUMAN and RENI MOUSE.
EXAMPLE 33: Isolation of cDNA Clones Encoding Human PR0853
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43050. Based
on the DNA43050 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) fot use as probes to isolate a clone of the full-length
coding sequence for PR0853.
Forward and reverse PCR primers were synthesized:
forward PCR primer 5'-CTTCATGGCCTTGGACTTGGCCAG-3' (SEQ ID N0:207)
reverse PCR primer 5'-ACGCCAGTGGCCTCAAGCTGGTTG-3' (SEQ ID N0:208)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA43050
sequence which had the following nucleotide sequence
h b~zation grobe
5'-CTTTCTGAGCTCTGAGCCACGGTTGGACATCCTCATCCACAATGC-3' (SEQ ID N0:209)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0853 gene using the probe oligonucleotide and one of the
PCR primers. RNA for construction
of the cDNA libraries was isolated from human fetal kidney tissue (LIB228).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0853
(herein designated as UNQ4l9 (DNA48227-1350)] (SEQ ID N0:205) and the derived
protein sequence for PR0853.
The entire nucleotide sequence of UNQ419 (DNA48227-1350) is shown in Figure 74
(SEQ ID N0:205).
Clone UNQ419 (DNA48227-1350) contains a single open reading frame with an
apparent uanslatiottal initiation site
at nucleotide positions 128-130 and ending at the stop codon at nucleotide
positions 1259-1261 (Figure 74). The
predicted polypeptide precursor is 377 amino acids long (Figure 75). The full-
length PR0853 protein shown in
Figure 75 has an estimated molecular weight of about 40,849 daltons and a pI
of about 7.98. Important regions of
the amino acid sequence of PR0853 include the signal peptide, corresponding to
amino acids from about 1 to about
16 of SEQ ID N0:206, the glycosaminoglycan attachment site, corresponding to
amino acids from about 46 to about
209
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
49 of SEQ ID N0:206, and two sequences typical of the short-chain alcohol
dehydrogenase family, corresponding
to amino acids from about 37 to about 49 and about 114 to about 124 of SEQ ID
N0:206, respectively. Clone
UNQ419 (DNA48227-1350) has been deposited with ATCC and is assigned ATCC
deposit no. 209812.
EXAMPLE 34: Isolation of cDNA Clones Encodine Human PR0860
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA38137. Based
on the DNA38137 consensu
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0860.
Forward and reverse PCR primers were synthesized:
forward PCRprimer 5'-GAAGGGACCTACATGTGTGTGGCC-3' (SEQ ID N0:212)
reverse PCR primer 5'-ACTGACCTTCCAGCTGAGCCACAC-3' (SEQ ID N0:213)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40654
sequence which had the following nucleotide sequence
hybridization probe
5'-AGGACTACACGGAGCCTGTGGAGCTTCTGGCTGTGCGAATTCAGCTGGAA-3'
(SEQ ID N0:214)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0860 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal lung tissue
(LIB26).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0860
[herein designated as UNQ421 (DNA41404-1352)] (SEQ 1D N0:210) and the derived
protein sequence for PR0860.
The entire nucleotide sequence of UNQ421 (DNA41404-1352) is shown in Figures
76A-B (SEQ ID
N0:210). Clone UNQ421 (DNA41404-1352) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 58-60 and ending at the stop codon at
nucleotide positions 3013-3015 (Figures
76A-B). The predicted polypeptide precursor is 985 amino acids long (Figure
?7). The full-length PR0860 protein
shown in Figure 77 has an estimated molecular weight of about 105,336 daltons
and a p1 of about 6.55. Important
regions of the amino acid sequence of PR0860 include the transmembrane region
corresponding to about amino acids
448-467, the extracelluiar domain, corresponding to amino acids about 1-447,
several N-glycosylation sites, numerous
N-myristoylation sites and a sequence typical of phosphoryrosine interaction
domain proteins.. Clone UNQ421
(DNA41404-1352) has been deposited with ATCC and is assigned ATCC deposit no.
209844.
EXAMPLE 35: Isolation of cDNA Clones Encodine Human p~t0846
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA39949. Based
on the DNA39949 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0846.
Forward and reverse PCR primers were synthesized:
forward PCR primer 5'-CCCTGCAGTGCACCTACAGGGAAG-3' (SEQ ID N0:217)
210
CA 02421372 2003-03-25
WO 99/d6281 PCT/US99/05028
~versc PCR primer 5'-C'TGTCTTCCCCTGCTTGGCTGTGG-3' (SEQ 1D N0:218)
Additionally, a synthetic oGgonucleotide hybridization probe was constructed
from the consensus DNA39949
sequence which had the following nucleotide sequence
hybridization probe
5'-GGTGCAGGAAGGGTGGGATCCTCTTCTCTCGCTGCTCTGGCCACATC-3'
(SEQ ID N0:219)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0846 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal ladney tissue
(LIB227)_
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PRO846
(herein designated as UNQ422 (DNA44196-1353)] (SEQ ID N0:215) and the derived
protein scqtience for PR0846.
The entire nucleotide sequence of UNQ422 (DNA44196-1353) is shown in Figure 78
(SEQ ID N0:215).
Clone UNQ422 (DNA44196-1353) contains a single open reading frame with an
apparent trarulational initiation site
at nucleotide positions 25-27 and ending at the stop codon at nucleotide
positions 1021-1023 (Figure 78). The
predicted poiypeptide precursor is 332 amino acids long (Figure 79). The full-
length PR0846 protein shown in
Frgure 79 has an estimated molecular weight of about 36,143 daltons and a p1
of about 5.89. Important regions of
the amino acid sequence of PR084b include the signal peptide, the
transmcmbrane domain, an N-glycosylation site,
a sad typical of bbrirtoge~ beta and gamma chair>_s C-terminal domain, and a
sequence typical of Ig like V-type
domain as shown in Fgure 79. Clone UNQ422 (DNA4419ti-1353) has been deposited
with ATCC and is assigned
ATCC deposit no. 209847.
EXAMPLE 36: Isolation of eDNA Clones Encoding Numan PR0862
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus scque~rrce obtained is herein designated DNA47370. Based
on the DNA47370 consensus
sequence, oligonucleotides wue synthesized: l) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0862.
Forurard and reverx PCR primers were synthesized:
forward P~~Qatr 5'GGGATCATGTTGT1'GGCCCTGGTC-3' (SEQ ID N0:222)
reverse PCR primer 5'-GCAAGGCAGACCCAGTCAGCCAG-3' (SEQ ID NO:?23)
Additionally, a synthetic oligonucleotide hybridization probe was corutructed
from the consensus DNA47370
sequence which had the fofiowing nucleotide sequence
h~rbridi~ation probe
5'-CTGCCTGC~'ACCCTCCAAGTGAGGCCAAGCTCTACGGTCGTTGTG-3'
(SEQ ID N0224)
In order to semen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0862 gene using the probe oligonuckotidc and ortc of the
PCR primers. RNA for
consutraion of the cDNA libraries was isolated from htrrnart pancreas tissue
(LdBSS).
211
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0862
[herein designated as UNQ424 (DNA52187-1354)] (SEQ ID N0:220) and the derived
protein sequence for PR0862.
The entire nucleotide sequence of UNQ424 (DNA52187-1354) is shown in Figure 80
(SEQ ID N0:220).
Clone UNQ424 (DNA52187-1354) contairu a single open reading frame with an
apparent translational initiation site
at nucleotide positions 410-412 and ending at the stop codon at nucleotide
positions 848-850 (Figure 80). The
predicted polypeptide precursor is 146 amino acids long (Figure 81). The full-
length PR0862 protein shown in
Figure 81 has an estimated molecular weight of about 16,430 dahons and a pI of
about 5.05. Important regions of
the amino acid sequence of PR0862 include the signal peptide, an N-
myristoylation site, and sequences having
similarity to region to Alpha-lactalbumin/lysoryme C proteins as shown in
Figure 81. Clone UNQ424 (DNA52I87-
1354) has been deposited with the ATCC and is assigned ATCC deposit no.
209845.
EXAMPLE 37: Isolation of cDNA Clones Encoding,j-luman PR0864
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA40666. Based
on the DNA40666 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0864.
Forward and reverse PCR primers were synthesized:
forward PCR~rimer 5'-GCTGCAGCTGCAAATTCCACTGG-3' (SEQ ID N0:227)
rgverse PCR~rimer 5'-TGGTGGGAGACTGTTTAAATTATCGGCC-3' (SEQ ID N0:228)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40666
sequence which had the following nucleotide sequence
~tybridization probe
5'-TGCTTCGTCAAGTGCCGGCAGTGCCAGCGGCTCGTGGAGTT-3'
(SEQ ID N0:229)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0864 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal brain tissue
(LIB153).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0864
[herein designated as UNQ426 (DNA48328-1355)] (SEQ ID N0:225) and the derived
protein sequence for PR0864.
The entire nucleotide sequence of UNQ426 (DNA48328-1355) is shown in Figure 82
(SEQ ID N0:225).
Clone UNQ426 (DNA48328-1355) contains a single open reading frame with an
apparent translatiortal initiation site
at nucleotide positions 37-39 and ending at the stop codon at nucleotide
positions 1090-1092 (Figure 82). The .
predicted polypeptide precursor is 351 amino acids long (Figure 83). The full-
length PR0864 protein shown in
Figure 83 has an estimated molecular weight of about 39,052 and a pI of about
8.97. Important regions of the amino
acid sequence of PR0864 include the signal peptide, two N-glycosylation sites,
a Wnt-1 family signature sequence,
and sequence regions homologous to Wnt-I family proteins as shown in Figure
83. Clone UNQ426 (DNA48328-
1355) has been deposited with ATCC and is assigned ATCC deposit no. 209843.
212
CA 02421372 2003-03-25
.r
WO 99/46281 PCTfUS99J05028
EXAMPLE 38: Isolation of cDNA Clones Encoding Human PR0792
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA38106. Based
on the DNA38106 consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0792.
A pair of PCR primers (forward and reverse) were synthesized:
forwar PCR primp 5'-GCGAGAACTGTGTCATGATGCTGC-3' (SEQ ID N0:232)
reverse PCR primer 5'-GTTTCTGAGACTCAGCAGCGGTGG-3' (SEQ ID N0:233)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA38106
sequence which had the following nucleotide sequence
hybridization pro,~e
5'-CACCGTGTGACAGCGAGAAGGACGGCTGGATCTGTGAGAAAAGGCACAAC-3' (SEQ ID N0:234)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0792 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow tissue (LIB255).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0792
jherein designated as UNQ431 (DNA56352-1358)] (SEQ ID N0:230) and the derived
protein sequence for PR0792.
The entire nucleotide sequence of UNQ431 (DNA56352-1358) is shown in Figure 84
(SEQ ID N0:230).
Clone UNQ431 (DNA56352-1358) contains a single open reading frame with an
apparent uanslational initiation site
at nucleotide positions 67-69 and ending at the stop codon at nucleotide
positions 946-948 (Figure 84). The predicted
polypeptide precursor is 293 amino acids long (Figure 85). The full-length
PR0792 protein shown in Figure 85 has
an estimated molecular weight of about 32,562 daltons and a pI of about 6.53.
Analysis of the full-length PR0792
sequence shown in Figure 85 (SEQ ID N0:231) evidences the presence of the
following: a type II transmembrane
domain from about amino acid 31 to about amino acid 54, potential N-
glycosylation sites from about amino acid 73
to about amino acid 76 and from about amino acid 159 to about amino acid 162,
a leucine zipper amino acid sequence
pattern from about amino acid 102 to about amino acid 123> potential N-
myristolation sites from about amino acid
18 to about amino acid 23, from about amino acid 133 to about amino acid 138
and from about amino acid 242 to
about amino acid 247 and a C-type lectin domain signature block from about
amino acid 264 to about amino acid 287.
Clone UNQ431 (DNA56352-1358) has been deposited with ATCC on May 6, 1998 and
is assigned ATCC deposit
no. 209846.
Analysis of the amino acid sequence of the full-length PR0792 polypeptide
suggests that it possesses
significant sequence similarity to the CD23 protein, thereby indicating that
PR0792 may be a novel CD23 homolog.
More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant homology
between the PR0792 amino acid sequence and the following Dayhoff sequences,
S34198, A07100_l, A05303_I,
P 841689, P P82839, A108?1_1, P 812796, P 847199, A46274 and P 832188.
EXAMPLE 39: j,~olation of cDNA Clones Encoding Human PR0866
213
CA 02421372 2003-03-25
WO 99/46281 PCT1US99/05028
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA44708. Based
on the DNA44708 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0866.
PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 1 S'-CAGCACTGCCAGGGGAAGAGGG-3' (SEQ ID N0:237)
forward PCR primer 2 5'-CAGGACTCGCTACGTCCG-3' (SEQ ID N0:238)
forward PCR primer 3 5'-CAGCCCCTTCTCCTCCTTTCTCCC-3' (SEQ 1D N0:239)
reverse PCR~rimer 1 5'-GCAGTTATCAGGGACGCACTCAGCC-3' (SEQ ID N0:240)
reverse PCR primer 2 5'-CCAGCGAGAGGCAGATAG-3' (SEQ 1D N0:241)
reverse PCR p3imer 3 S'-CGGTCACCGTGTCCTGCGGGATG-3' (SEQ ID N0:242)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA44708
sequence which had the following nucleotide sequence
)~bridization grobe
5'-CAGCCCCTTCTCCTCCTTTCTCCCACGTCCTATCTGCCTCTC-3' (SEQ ID N0:243)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0866 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(L1B228).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0866
[herein designated as UNQ435 (DNA539?1-1359)] (SEQ ID N0:235) and the derived
protein sequence for PR0866.
The entire nucleotide sequence of UNQ435 (DNA53971-1359) is shown in Figure 86
(SEQ ID N0:235).
Clone UNQ435 (DNA53971-1359) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 275-277 and ending at the stop codon at nucleotide
positions 1268-1270 (Figure 86). The
predicted polypeptide precursor is 331 amino acids long (Figure 87). The full-
length PR0866 protein shown in
Figure 87 has an estimated molecular weight of about 35,844 daltons and a pI
of about 5.45. Analysis of the full-
length PR0866 sequence shown in Figure 87 (SEQ ID N0:236) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 26. Clone UNQ435 (DNA53971-
1359) has been deposited with
ATCC on April 7, 1998 and is assigned ATCC deposit no. 209750.
Analysis of the amino acid sequence of the full-length PR0866 polypeptide
suggests that it possesses
significant sequence similarity to the mindin/spondin family of proteins,
thereby indicating that PR0866 may be a
novel mindin homolog. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35)
evidenced significant homology between the PR0866 amino acid sequence and the
following Dayhoff
sequences,AB006085_1. AB006084_1, AB006086_1, AF017267_1, CWU422I3-1,
AC004160_1, CPM1CRP_l,
S49108, A48569 andI46687.
EXAMPLE 40: elation of cDNA Clones EncodinE Human PR0871
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA40324. Based
on the DNA40324 consensus
sequence, oligonueleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
214
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0871.
PCR primers (forward and reverse) were synthesized:
forward PCR primer I 5'-TGCGGAGATCCTACTGGCACAGGG-3' (SEQ ID N0:246)
forward PCR primer 2 S'-CGAGTTAGTCAGAGCATG-3' (SEQ ID N0:247)
forward PCR primer 3 5'-CAGATGGTGCTGTTGCCG-3' (SEQ ID N0:248)
reverse PCR~rimer 1 5'-CAACTGGAACAGGAACTGAGATGTGGATC-3' (SEQ ID N0:249)
reverse PCR primer 2 5'-CTGGTTCAGCAGTGCAAGGGTCTG-3' (SEQ ID N0:250)
reverse PCR primer 3 5'-CCTCTCCGATTAAAACGC-3' (SEQ ID N0:251)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40324
sequence which had the following nucleotide sequence
hybridization probe
5'-GAGAGGACTGGTTGCCATGGCAAATGCTGGTTCTCATGATAATGG-3' (SEQ ID N0:252)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0871 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0871
[herein designated as UNQ438 (DNA50919-1361)] (SEQ ID N0:244) and the derived
protein sequence for PR0871.
The entire nucleotide sequence of UNQ438 (DNA50919-1361) is shown in Figure 88
(SEQ ID N0:244).
Clone UNQ438 (DNA50919-1361) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 191-193 and ending at the stop codon at nucleotide
positions 1607-1609 (Figure 88). The
predicted polypeptide precursor is 472 amino acids long (Figure 89). The full-
length PR0871 protein shown in
Figure 89 has an estimated molecular weight of about 53,847 daltons and a p1
of about 5.75. Analysis of the full
length PR0871 sequence shown in Figure 89 (SEQ ID N0:245) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 21, potential N-
glycosylation sites from about amino acid 109
to about amino acid 112 and from about atnirto acid 201 to about amino acid
204, a cyclophilin-type peptidy-prolyl
cis-traps isomerase signature sequence from about amino acid 49 to about amino
acid 66 and regions that are
homologous to cyclophilin-type peptidy-prolyl cis-traps isomerases from about
amino acid 96 to about amino acid 140,
from about amino acid 49 to about amino acid 89 and from about amino acid 22
to about amino acid 51. Clone
UNQ438 (DNA50919-1361) has been deposited with ATCC on May 6, 1998 and is
assigned ATCC deposit no.
209848.
Analysis of the amino acid sequence of the full-length PR0871 polypeptide
suggests that it possesses
significant sequence similarity to the cyclophilin family of proteins, thereby
indicating that PR0871 may be a novel
cyclophilin protein family member. More specifically, an analysis of the
Dayhoff database (version 35.45 SwissProt
35) evidenced significant homology between the PR0871 amino acid sequence and
the following Dayhoff sequences,
SPBC16H5 5, S64705, YALS SCHPO, CYP4 CAEEL, CELC34D4 7, CYPA CAEEL, HUMORF006
1,
CYPI MYCTU. AF043642 1 and HSSRCYP 1.
EXAMPLE 41: Jsolation of cDNA Clones Encoding! Human PR0873
215
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA39621. Based
on the DNA39621 consensus
sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0873.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-AGGTGCCTGCAGGAGTCCTGGGG-3' (SEQ ID N0:255)
reverse PCR primer 5'- CCACCTCAGGAAGCCGAAGATGCC-3' (SEQ ID N0:256)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA39621
sequence which had the following nucleotide sequence:
~tvbridization probe
5'-GAACGGTACAAGTGGCTGCGCTTCAGCGAGGACTGTCTGTACCTG-3' (SEQ ID N0:257)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0873 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB229).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0873
[herein designated as UNQ440 (DNA4dl79-1362)] (SEQ ID N0:253) and the derived
protein sequence for PR0873.
The entire nucleotide sequence of UNQ440 (DNA44179-1362) is shown in Figure 90
(SEQ ID N0:253).
Clone UNQ440 (DNA44179-1362) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 139-141 and ending at the stop codon at nucleotide
positions 1774-1776 (Figure 90). The
predicted polypeptide precursor is 545 amino acids long (Figure 91). The full-
length PR0873 protein shown in
Figure 91 has an estimated molecular weight of about 58,934 daltons and a pI
of about 9.45. Analysis of the full-
length PR0873 sequence shown in Figure 91 (SEQ 1D N0:254) evidences the
presence of the following features:
a signal peptide from about amino acid 1 to about amino acid 29; a
carboxylesterase type-B serine active site at about
amino acid 312 to about amino acid 327; a carboxylesterase type-B signature 2
motif at about amino acid 218 to about
amino acid 228; and three potential N-glycosylation sites at about amino acid
318 to about amino acid 321, about
amino acid 380 to about amino acid 383, and about amino acid 46S to about
amino acid 468. Clone UNQ440
(DNA44179-1362) has been deposited with ATCC on May 6, 1998 and is assigned
ATCC deposit no. 209851.
Analysis of the amino acid sequence of the full-length PR0873 polypeptide
suggests that it possesses
significant sequence similarity to a human liver carboxylesterase, thereby
indicating that PR0873 may be a novel
carboxylesterase. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced
significant homology between the PR0873 amino acid sequence and the following
Dayhoff sequences: ES10 RAT,
GEN12405, AB010633_1, EST4 RAT, A48809, SASB~ANAPL, RNU41662-1, RNU22952-1,
BAL RAT,
GEN 13522.
EXAMPLE 42: Isolation of cDNA Clones Encodine Human PR0940
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA47442. Based
on the DNA47442 consensus
sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0940.
216
CA 02421372 2003-03-25
WO 99/4b281 PCT/US99l05028
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CAAAGCCTGCGCCTGGTCTGTG-3' (SEQ 1D N0:260)
Leverse PCR vrimcr 5'-TTCTGGAGCCCAGAGGGTGCTGAG-3' (SEQ ID N0:2b1)
Additionally, a synthetic oligonueleotide hybridization probe was constructed
from the consensus DNA47442
sequence which had the following nucleotide sequence
hybridization probe
5'-GGAGCTGCCACCCATTCAAATGGAGCACGAAGGAGAGTTCACCTG-3' (SEQ ID N0:262)
In order to scroert several fbraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encAdirtg the PR0940 gene using the probe oligonuclcotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB229).
DNA sequeTtcittg of the clones isolated as described above gave the full-
length DNA sequence for PR0940
(herein designated as UNQ477 (DNA54002-1367)j (SEQ ID N0:258) and the derived
protein sequence for PR0940.
The entire nucleotide sequence of UNQ477 (DNA54002-13b7) is shown in Figure 92
(SEQ ID N0:258).
Clone UNQ477 (DNA54002-1367) contains a single open reading frame with an
apparent translational initiation site
at nucleotide posiaorls 468 and ending at the stop codon at nucleotide
positioru 1678-1680 (Figure 92). The
predicted polypeptide precw-sor is S44 amino acids long (Figure 93). The full-
length PR0940 protein shown in
Figure 93 has an estimated moluular weight of about 60,268 daltons and a p1 of
about 9.53. Analysis of the full-
length PR0940 sequence shown in Figure 93 (SEQ ID N0:259) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 15, potential N-
glycosylation sites from about amino acid 100
to about amino acid 103, from about amino add 297 to about amino acid 300 and
from about amino acid 306 to about
amino acid 309 and an ittuttunoglobulin and major histocompatibility complez
signature sequence block from about
amino acid 365 to about amino acid 371. Clone UNQ4?7 (DNA54002-1367) has been
deposited wiUt ATCC on April
7, 1998 and is assigned ATCC deposit no. 209754.
Analysis of the amino acid sequence of the full-length PR0940 polypeptide
suggests that it possesses
significant sequence similarity w CD33 and the OB binding protein-2. More
specifically, an analysis of the Dayhoft
database (version 35.45 SwissProt 3S~ evidenced significant homology between
the PR094t1 amino acid sequence and
the following Dayhoff xqucncts, CD33 NUMAN, HSU71382-l, HSU71383_I, D86359_l,
PGBM HUMAN,
MAGS MOUSE, D86983_l, C22B HUMAN, P W01002 and HW24116_l.
EXP~] PLE 43: Isolation of cDNA Clones~.rtcodine Human PR0941
A conscmus sequemc was obtai~d rtrlativc to a variety of EST xquettees as
described in Example I above,
wherein the consensus seqt~nce obtained is herein designated DNA35941. An EST
scqttcnce proprietary to
Ge~ntech was employed in the assembly and is herein designated DNA6415 (Figure
96; SEQ ID N0:265). Based
on the DNA35941 consensus xquence, oligonucleotides were synthesized: 1) to
identify by PCR a cDNA library
that contait>td the sequence of interest, and 2) for ttse as probes to isolate
a clone of the full-Icngdt coding sequence
for PR0941.
A pair of PCR primcxs (forward and reverse) were synthesized:
forward PCR nrimcr 5'-C'I'TGACTGTCTCTGAATCTGCACCC-3' (SEQ ID N0:2.66)
reverse PCR nrin?er 5'-AAGTtGGTGGAAGCCTCCAGTGTGG-3' (SEQ ID N0:2b7)
217
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Additionally, a synthetic oligonucleoade hybridization probe was constructed
from the consensus DNA35941
sequence which had the following nucleotide sequence
~tybridization~robe
5'-CCACTACGGTATTAGAGCAAAAGTTAAAAACCATCATGGTTCCTGGAGCAGC-3' (SEQ ID N0:268)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0941 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0941
[herein designated as UNQ478 (DNA53906-1368)] (SEQ ID N0:263) and the derived
protein sequence for PR0941.
The entire nucleotide sequence of UNQ478 (DNA53906-1368) is shown in Figure 94
(SEQ ID N0:263).
Clone UNQ478 (DNAS3906-1368) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 37-39 and ending at the stop codon at nucleotide
positions 2353-2355 (Figure 94). The
predicted polypeptide precursor is 772 amino acids long (Figure 95). The full-
length PR0941 protein shown in
Figure 9S has an estimated molecular weight of about 87,002 daltons and a p1
of about 4.64, Analysis of the full-
length PR0941 sequence shown in Figure 95 (SEQ ID N0:264) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 21, potential N-
glycosylation sites from about amino acid 57
to about amino acid 60, from about amino acid 74 to about amino acid 77, from
about amino acid 419 to about amino
acid 422, from about amino acid 437 to about amino acid 440, from about amino
acid 508 to about amino acid 511,
from about amino acid 515 to about amino acid 518, from about amino acid 516
to about amino acid S19 and from
about amino acid 534 to about amino acid 537, and cadherin extracellular
repeated domain signature sequences from
about amino acid 136 to about amino acid 146 and from about amino acid 244 to
about amino acid 254. Clone
UNQ478 (DNA53906-1368) has been deposited with ATCC on April 7, 1998 and is
assigned ATCC deposit no.
209747.
Analysis of the amino acid sequence of the full-length PR0941 polypeptide
suggests that it possesses
significant sequence similarity to a cadherin protein, thereby indicating that
PR0941 may be a novel cadherin protein
family member. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced
significant homology between the PR0941 amino acid sequence and the following
Dayhoff sequences, IS0180,
CADA CHICK, 1501?8, GEN12782, CADC_HUMAN, P W25637, A38992, P_R49731, D38992
and 602678.
EXAMPLE 44: isolation of cDNA Clones Encodingl-1 tman PR0944
A consetutts sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequettct obtained is herein designated DNA47374. A
variety of proprietary Genentech EST
sequences were employed in the assembly and are shown in Figures 99-107. Based
on the DNA47374 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding seguence for PR0944.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCRSri~er S'-CGAGCGAGTCATGGCCAACGC-3' (SEQ ID N0:280)
reverse PCR primer 5'-GTGTCACACGTAGTCTTTCCCGCTGG-3' (SEQ ID N0:281)
218
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA47374
sequence which had the following nucleotide sequence
hybridization probe
5'-CTGCAGCTGTTGGGCTTCATTCTCGCCTTCCTGGGATGGATCG-3' (SEQ ID N0:282)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0944 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0944
(herein designated as UNQ481 (DNA52185-1370) (SEQ ID N0:269) and the derived
protein sequence for PR0944.
The entire nucleotide sequence of UNQ481 (DNA52185-1370) is shown in Figure 97
(SEQ ID N0:269).
Clone UNQ481 (DNA52185-1370) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 219-221 and ending at the stop codon at nucleotide
positions 852-854 (Figure 97). The
predicted polypeptide precursor is 211 amino acids long (Figure 98). The full-
length PR0944 protein shown in
Figure 98 has an estimated molecular weight of about 22,744 daltons and a pI
of about 8.51. Analysis of the full-
length PR0944 sequence shown in Figure 98 (SEQ ID N0:2?0) evidences the
presence of the following: a signal
peptide from about amino acid I to about amino acid 21, transmembrane domains
from about amino acid 82 to about
amino acid 102, from about amino acid 118 to about amino acid 142 and from
about amino acid 161 to about amino
acid 187, a potential N-glycosylation site from about amino acid 72 to about
amino acid 75, a sequence block having
homology to PMP-22/EMP/MP20 family of proteins from about amino acid 70 to
about amino acid 111 and a
sequence block having homology to ABC-2 type transport system integral
membrane protein from about amino acid
119 to about amino acid 133. Clone UNQ481 (DNA52185-1370) has been deposited
with ATCC on May 14, 1998
and is assigned ATCC deposit no. 209861.
Analysis of the amino acid sequence of the full-length PR0944 polypeptide
suggests that it possesses
significant sequence similarity to the CPE-R protein, thereby indicating that
PR0944 may be a novel CPE-R
homolog. More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant
homology between the PR0944 amino acid sequence and the following Dayhoff
sequences, AB000713_1,
AB000714 1, AF035814 1, AF000959 1, HSU89916 1, EMP2 HUMAN, JC5732, CELF53B3
6, PM22 MOUSE
and CGU49797 1.
EXAMPLE 45: Isolation of cDNA Clones Encoding, Human PR0983
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA47473. Various
proprietary Genentech EST
sequences were employed in the assembly, wherein those EST sequences are shown
in Figures 110-116. Based on
the DNA47473 consensus sequence, oligonucleotides were synthesized: 1 ) to
identify by PCR a cDNA library that
contained the sequence of interest, and 2) for use as probes to isolate a
clone of the full-length coding sequence for
PR0983.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR n~'t,~er 5'-GCACCACCGTAGGTACTTGTGTGAGGC-3' (SEQ ID N0:292)
reverse PCR printer 5'-AACCACCAGAGCCAAGAGCCGGG -3' (SEQ ID N0:293)
219
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA47473
sequence which had the following nucleotide sequence
hybridization probe
5'-CAGCGGAATCATCGATGCAGGGGCCTCAATTAATGTATCTGTGATGTTAC-3' (SEQ ID N0:294)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0983 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow (LIB256).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0983
[herein designated as UNQ484 (DNA53977-1371)) (SEQ ID N0:283) and the derived
protein sequence for PR0983.
The entire nucleotide sequence of UNQ484 (DNA53977-1371) is shown in Figure
108 (SEQ ID N0:283).
Clone UNQ484 (DNA53977-1371) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 234-236 and ending at the stop codon at nucleotide
positions 963-965 (Figure 108). The
predicted polypeptide precursor is 243 amino acids long (Figure 109). The full-
length PR0983 protein shown in
Figure 109 has an estimated molecular weight of about 27,228 daltons and a p1
of about 7.43. Analysis of the full-
length PR0983 sequence shown in Figure 109 (SEQ ID N0:284) evidences the
presence of the following features:
a putative transmembrane domain from about amino acid 224 to about amino acid
239; a potentia) N-glycosylation
site from about amino acid 68 to about amino acid 71; and three potential N-
myristoylation sites from about amino
acid 59 to about amino acid 64, from about amino acid 64 to about amino acid
69, and from about amino acid 235
to about amino acid 240. Clone UNQ484 (DNA53977-1371) has been deposited with
ATCC on May 14, 1998 and
is assigned ATCC deposit no. 209862.
Analysis of the amino acid sequence of the full-length PR0983 polypeptide
suggests that it possesses
significant sequence similarity to the vesicle-associated protein, VAP-33,
thereby indicating that PR0983 may be a
novel vesicle associated membrane protein. More specifically, an analysis of
the Dayhoff database (version 35.45
SwissProt 35) evidenced significant homology between the PR0983 amino acid
sequence and the following Dayhoff
sequences: VP33 APLCA, CELF33D11_12, CELF42G2 2, S50623, YDFC SCHPO, CELF54H5
2, CELZC196-8,
CEF57A10_3, MSP3 GLORO, CEC15H11,1.
EXAMPLE 46: Isolation of eDNA Clones Encoding Human PR01057
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA49808. Based
on the DNA49808 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a eDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR01057.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-GCATCTGCAGGAGAGAGCGAAGGG-3' (SEQ ID N0:297)
reverse PCR primer 5'-CATCGTTCCCGTGAATCCAGAGGC-3' (SEQ ID N0:298)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA49808
sequence which had the following nucleotide sequence
hybridization vrobe
5'-GAAGGGAGGCCTTCCTTTCAGTGGACCCGGGTCAAGAATACCCAC-3' (SEQ ID N0:299)
220
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR01057 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR01057
[herein designated as UNQ522 (DNA57253-1382)] {SEQ ID N0:295) and the derived
protein sequence for PR01057.
The entire nucleotide sequence of UNQ522 (DNA57253-1382) is shown in Figure
117 (SEQ ID N0:295).
Clone UNQ522 (DNA57253-1382) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 275-277 and ending at the stop codon at nucleotide
positions 1514-1516 (Figure 117). The
predicted polypeptide precursor is 413 amino acids long (Figure 118). The full-
length PR01057 protein shown in
Figure 118 has an estimated molecular weight of about 47,070 daltons and a p1
of about 9.92. Analysis of the full-
length PR01057 sequence shown in Figure 118 (SEQ ID N0:296) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 16, potential N-
glycosylation sites from about amino acid 90
to about amino acid 93, from about amino acid 110 to about amino acid I 13 and
from about amino acid 193 to about
amino acid 196, a glycosaminoglycan attachment site from about amino acid 236
to about amino acid 239 and a serine
protease histidine-containing active site from about amino acid 165 to about
amino acid 170. Clone UNQ522
(DNA57253-1382) has been deposited with ATCC on May 14, 1998 and is assigned
ATCC deposit no. 209867.
Analysis of the amino acid sequence of the full-length PR01057 polypeptide
suggests that it possesses
significant sequence similarity to various protease proteins, thereby
indicating that PR01057 may be a novel protease.
More specifically, an analysis of the Dayhoff database (version 35.45
SwissProt 35) evidenced significant homology
between the PR01057 amino acid sequence and the following Dayhoff
sequences,TRYE DROER, P 814159,
A69660, EBNI EBV, 565494, GEN12688, A51084 1, P 899571, A57514 and AF003200 1.
EXAMPLE 47: Isolation of cDNA Clones Encoding Human PR01071
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA53035. Based
on the DNA53035 consensus
sequetxe, it was determined that that consensus sequence shared significant
sequence identity with Incyte EST clone
no. 2872569, a clone that upon review appeared to encode a full length
protein. As such, lncyte EST clone no.
2872569 was purchased and its insert was obtained and sequenced so as to
confirm the proper sequence. This
sequence is herein designated UNQ528 or DNA58847-1383.
DNA sequencing of the clone isolated as described above gave the full-length
DNA sequence for PR01071
[herein designated as UNQ528 (DNA58847-1383)) (SEQ ID N0:300) and the derived
protein sequence for PR01071.
The entire nucleotide sequence of UNQ528 (DNA58847-1383) is shown in Figure
119 (SEQ ID N0:300).
Clone UNQ528 (DNA58848-1383) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 133-135 and ending at the stop codon at nucleotide
positions 1708-1710 (Figure 119). The
predicted polypeptide precursor is 525 amino acids long (Figure 120). The full-
length PR01071 protein shown in
Figure 120 has an estimated molecular weight of about 58,416 daltons and a pI
of about 6.62. Analysis of the fitll-
length PR01071 sequence shown in Figure 120 (SEQ ID N0:301) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 25, a potential N-
glycosylation site from about amino acid 251
to about amino acid 254, a thrombospondin-1 homology block from about amino
acid 385 to about amino acid 399
221
CA 02421372 2003-03-25
WO 99/46281 PCT/US99105028
and von Willibrands factor type C homology blocks from about amino acid 38S to
about amino acid 399, from about
amino acid 445 to about amino acid 459 and from about amino acid 42 to about
amino acid 56. Clone UNQ528
(DNAS8847-1383) has been deposited with ATCC on May 20, 1998 and is assigned
ATCC deposit no. 209879.
Analysis of the amino acid sequence of the full-length PR01071 polypeptide
suggests that it possesses
significant sequence similarity to the thrombospondin protein, thereby
indicating that PR01071 may be a novel
thrombospondin homolog. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35)
evidenced significant homology between the PR01071 amino acid sequence and the
following Dayhoff sequences,
AB002364 1, D67076 I , BTPCINPGN 1, CET13H 10 1, CEF25H8 5, CEFS3B6 2, CEC26C6
6, HSSEMG -1 >
CET21B6 4 and BTY08S61 1.
EXAMPLE 48: Isolation of cDNA Clones Encoding Human PR01072
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNAS312S. Based
on the DNA5312S consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for FR01072.
PCR primers (forward and reverse) were synthesized:
forward PCRprimer S'-CCAGGAAATGCTCCAGGAAGAGCC-3' (SEQ ID N0:30S)
rev_grse PCRpyimer 5'-GCCCATGACACCAAATTGAAGAGTGG-3' (SEQ ID N0:306)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA53125
sequence which had the following nucleotide sequence
hybridization probe
5'-AACGCAGGGATCTTCCAGTGCCCTTACATGAAGACTGAAGATGGG-3' (SEQ ID N0:307)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR ampliFcation with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR01072 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
2S the cDNA libraries was isolated from human fetal lung tissue (LIB26).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR01072
[herein designated as UNQ529 (DNA58747-1384)) (SEQ ID N0:302) and the derived
protein sequence for PR01072.
The entire nucleotide sequence of UNQ529 (DNA58747-1384) is shown in Figure
121 (SEQ ID N0:302).
Clone UNQ529 (DNA58747-1384) contains a single open reading frame with an
apparent uanslational initiation site
at nucleotide positions 65-67 and ending at the stop codon at nucleotide
positions 1073-1075 (Figure 121). The
predicted polypeptide precursor is 336 amino acids long (Figure 122). The full-
length PR01072 protein shown in
Figure 122 has an estimated molecular weight of about 36,865 dahons and a p1
of about 9.15. Analysis of the full
length PR01072 sequence shown in Figure 122 (SEQ ID N0:303) evidences the
presence of the following: a signal
peptide from about amino acid I to about amino acid 21, shoe-chain alcohol
dehydrogenase protein homology blocks
from about amino acid 134 to about amino acid 144, from about amino acid 44 to
about amino acid S6 and from about
amino acid 239 to about amino acid 248 and potential N-glycosylation sites
from about amino acid 212 to about amino
acid 21S and from about amino acid 239 to about amino acid 242. Clone UNQ529
(DNAS8747-1384) has been
deposited with ATCC on May 14, 1998 and is assigned ATCC deposit no. 209868.
222
CA 02421372 2003-03-25
' a
WO 99/46281 PCT1US99/05028
Analysis of the amino acid sequence of the full-length PR01072 polypeptide
suggests that it possesses
significant sequence similarity to the reductase family of proteins, thereby
indicating that PR01072 may be a novel
reductase. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced significant
homology between the PR01072 amino acid sequence and the following Dayhoff
sequences, P W03198, P W15759,
P 860800, MTV037 3, CEC15H11 6, ATAC00234314, MTV022 13, SCU43704 1, OXIR
STRAT AND
CELCO1G8 3.
EXAMPLE 49: Isolation of cDNA Clones Encoding Human PR01075
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA34363. Based
on the DNA34363 sequence,
oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and
2) for use as probes to isolate a clone of the full-length coding sequence for
PR01075.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-TGAGAGGCCTCTCTGGAAGTTG-3' (SEQ ID N0:312)
forward PCR primer 5'-GTCAGCGATCAGTGAAAGC-3' (SEQ ID N0:313)
forward PCR primer 5'-CCAGAATGAAGTAGCTCGGC-3' (SEQ ID N0:314)
forward PCR primer 5'-CCGACTCAAAATGCATTGTC-3' (SEQ ID N0:315)
forward PCR primer 5'-CATTTGGCAGGAATTGTCC-3' (SEQ ID N0:316)
forward PCR primer 5'-GGTGCTATAGGCCAAGGG-3' (SEQ ID N0:317)
reverse PCR~rimer 5'-CTGTATCTCTGGGCTATGTCAGAG-3' (SEQ ID N0:318)
reverse PCR,primer 5'-CTACATATAATGGCACATGTCAGCC-3' (SEQ ID N0:319)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA34363
sequence which had the following nucleotide sequence
h~rbridization probe
5'-CGTCTTCCTATCCTTACCCGACCTCAGATGCTCCCTTCTGCTCCTG-3' (SEQ ID N0:320)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR01075 gene using the probe oligonucieotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human skin tumor tissue (L1B324).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR01075
[herein designated as UNQ532 (DNA57689-1385)] (SEQ ID N0:308) and the derived
protein sequence for PR01075.
The entire nucleotide sequence of UNQ532 (DNA57689-1385) is shown in Figure
124 (SEQ ID N0:308).
Clone UNQ532 (DNA57689-1385) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 137-139 and ending at the stop codon at nucleotide
positions 1355-1357 (Figure 124). The
predicted polypeptide precursor is 406 amino acids long (Figure 125). The full-
length PR01075 protein shown in
Figure 125 has an estimated molecular weight of about 46,927 daltons and a p1
of about 5.21. Analysis of the full-
length PR01075 sequence shown in Figure 125 (SEQ ID N0:309) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 29, an endoplasmic
reticulum targeting sequence from about
amino acid 403 to about amino acid 406, a tyrosine kinase phosphorylation site
from about amino acid 203 to about
amino acid 211 and a sequence block having homology to the thioredoxin family
of proteins from about amino acid
223
CA 02421372 2003-03-25
WO 99/46281 PCTlUS99/05028
50 to about amino acid 66. Clone UNQ532 (DNA57689-1385) has been deposited
with ATCC on May I4, 1998 and
is assigned ATCC deposit no. 209869.
Analysis of the amino acid sequence of the full-length PR01075 polypeptide
suggests that it possesses
significant sequence similarity to protein disulfide isomerase, thereby
indicating that PR01075 may be a novel protein
disulfide isomerase. More specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced
significant homology between the PR01075 amino acid sequence and the following
Dayhoff sequences,
CELC30H7 2, CELC06A6 3, CELF42G8 3, S57942, ER72 CAEEL, CELC07A12 3, CEH06O01
4 and
P 851696.
EXAMPLE 50: Isolation of cDNA Clones Encoding Human PR0181
A cDNA sequence isolated in the amylase screen described in Example 2 above
was found, by BLAST and
FastA sequence alignment, to have sequence homology to a nucleotide sequence
encoding the cornichon protein. This
cDNA sequence is herein designated DNA13242 (Figure 130; SEQ ID N0:323). Based
on the sequence homology,
oligonucleotide probes were generated from the sequence of the DNA13242
molecule and used to screen a human
placenta (LIB89) library prepared as described in paragraph 1 of Example 2
above. The cloning vector was pRKSB
(pRKSB is a precursor of pRKSD that does not contain the SfiI site; see,
Holmes et al., Scie e, 253:1278-1280
(1991)), and the cDNA size cut was less than 2800 bp.
The oligonucleotide probes employed included:
forward~CR~rimer 5'-GTGCAGCAGAGTGGCTTACA-3' (SEQ ID N0:326)
reverse PCR~rimer 5'-ACTGGACCAATTCTTCTGTG-3' (SEQ ID N0:327)
hvbridization probe
5'-GATATTCTAGCATATTGTCAGAAGGAAGGATGGTGCAAATTAGCT-3' (SEQ 1D N0:328)
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 14-16 and ending at the stop codon
found at nucleotide positions 446-448 (Figure
128; SEQ ID N0:321). The predicted polypeptide precursor is 144 amino acids
long, has a calculated molecular
weight of approximately 16,699 daltons and an estimated pl of approximately
5.6. Analysis of the full-length PR0181
sequence shown in Figtue 129 (SEQ )D N0:322) evidences the presence of the
following: a signal peptide from about
amino acid 1 to about amino acid 20, a putative type II transmembrane domain
from about amino acid 11 to about
amino acid 31 and other transmembrane domains from about amino acid 57 to
about amino acid 77 and from about
amino acid 123 to about amino acid 143. Clone UNQ155 (DNA23330-1390) has been
deposited with ATCC on April
14, 1998 and is assigned ATCC deposit no. 209775.
Analysis of the amino acid sequence of the full-length PR0181 polypeptide
suggests that it possesses
significant sequence similarity to the cornichon protein, thereby indicating
that PR0181 may be a novel cornichon
hotnolog. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced significant
homology between the PR0181 amino acid sequence and the following Dayhoff
sequences, AF022811-1,
CET09E8 3, S64058, YGF4 YEAST, YB60_YEAST, EBU89455-I , SIU36383 3 and PH1371.
EXwIPLE 51: Isolation of cDNA Clones Encoding Human PR0195
A cDNA sequence was isolated in the amylase screen described in Example 2
above and is herein
designated DNA13199 (Figure 134; SEQ ID N0:332). The DNA13199 sequence was
then compared to a variety
224
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
of expressed sequence tag (FST) databases which included public EST databases
(e.g., GenBank) to identify existing
homologies. The homology search was performed using the computer program BLAST
or BLASTZ (Altshul et al.,
Methods in Ettz~mology x:460-480 (1996)). Those comparisons resulting in a
BLAST score of 70 (or in some
cases 90) or greater that did not encode lrnown proteins were clustered and
assembled into consensus DNA sequences
with the program "phrap" (Phil Green, University of Washington, Seattle,
Washington;
http://bozeman.mbt.washington.edu/phrap.docs/phrap.hunl). The consensus
sequence obtained therefrom is herein
designated as DNA22778.
Based on the DNA22778 sequence, oligonucleotide probes were generated and used
to screen a human
placenta library (LIB89) prepared as described in paragraph 1 of Example 2
above. The cloning vector was pRKSB
(pRKSB is a precursor of pRKSD that does not contain the SfiI site; see,
Holmes et al., cie ce, X53:1278-1280
(1991)), and the cDNA size cut was less than 2800 bp.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-ACAAGCTGAGCTGCTGTGACAG-3' (SEQ ID N0:333)
reverse PCR primer 5'-TGATTCTGGCAACCAAGATGGC-3' (SEQ ID N0:334)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA22778 sequence which
had the following nucleotide sequence
hybridization r
5'-ATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGCTGAAG-3' (SEQ ID N0:335)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0195 gene using the probe oligonucleotide and one of the PCR
primers.
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 70-72 and ending at the stop codon
found at nucleotide positions 1039-1041
(Figure 132; SEQ ID N0:330). The predicted polypeptide precursor is 323 amino
acids long, has a calculated
molecular weight of approximately 36,223 daltons and an estimated pI of
approximately 5.06. Analysis of the full-
length PR0195 sequence shown in Figure 132 (SEQ ID N0:330) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 31, a transmembrane domain
from about amino acid 241 to
about amino acid 260 and a potential N-glycosylation site from about amino
acid 90 to about amino acid 93. Clone
UNQ169 (DNA26847-1395) has been deposited with ATCC on April 14, 1998 and is
assigned ATCC deposit no.
209772.
Analysis of the amino acid sequence of the full-length PR0195 polypeptide
suggests that it possesses no
significant sequence similarity to any latown protein. However, an analysis of
the Dayhoff database (version 35.45
SwissProt 35) evidenced some degree of homology between the PR0195 amino acid
sequence and the following
Dayhoff sequences, P P91380, AF035118_1, HUMTROPCS-1, NUOD SALTY and E70002.
EXAMPL~52: Isolation of cD, ?~ Clones Encoding Human PR0865
A cDNA sequence isolated in the amylase screen described in Example 2 above
was herein designated
DNA37642 (Figure 137, SEQ m N0:338). The DNA37642 sequence was then compared
to a variety of expressed
sequence tag (EST) databases which included public EST databases (e.g.,
GenBank) and a proprietary EST DNA
database (1~ESEQ'~"', Incyte Pharmaceuticals, Palo Alto, CA) to identify
homologies therebetween. The homology
225
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
search was performed using the computer program BLAST or BLAST2 (Altshul et
al., Methods in Enzvmology
266:46080 (1996)). Those comparisons resulting in a BLAST score of 70 (or in
some cases 90) or greater that did
not encode known proteins were clustered and assembled into consensus DNA
sequences with the program "phrap"
( Ph s 1 Green, University of Washington, Seattle, Washington;
http:l/bozeman.mbt.washington.edulphrap.docs/phrap.html). The consensus
sequence obtained is herein designated
DNA48615.
Based on the DNA48615 consensus sequence, probes were generated and used to
screen a human fetal
kidney (LIB227) library prepared as described in paragraph 1 of Example 2
above. The cloning vector was pRKSB
(pRKSB is a precursor of pRKSD that does not contain the Sfil site; see,
Holmes et al., Scienc , 2_~3-:1278-1280
(1991)), and the cDNA size cut was less than 2800 bp.
PCR primers (forward and reverse) were synthesized:
forward PCR primer s 5'-AAGCTGCCGGAGCTGCAATG-3' (SEQ ID N0:339)
forward PCR primes 2 5'-TTGCTTCTTAATCCTGAGCGC-3' (SEQ ID N0:340)
forward PCR primer 3 5'-AAAGGAGGACTTTCGACTGC-3' (SEQ ID N0:341)
reverse PCR primer 1 5'-AGAGATTCATCCACTGCTCCAAGTCG-3' (SEQ ID N0:342)
reverse PCR primer 2 5'-TGTCCAGAAACAGGCACATATCAGC-3' (SEQ ID N0:343)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA48615
sequence which had the following nucleotide sequence
hybridization probe
5'-AGACAGCGGCACAGAGGTGCTTCTGCCAGGTTAGTGGTTACTTGGATGAT-3' (SEQ ID N0:344)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pairs identified above. A positive
library was then used to isolate clones
encoding the PR0865 gene using the probe oligonucleotide and one of the PCR
primers.
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 173-175 and ending at the stop codon
found at nucleotide positions 1577-1579
(Figure 135; SBQ ID N0:336). The predicted polypeptide precursor is 468 amino
acids long, has a calculated
molecular weight of approximately 54,393 daltons and an estimated p1 of
approximately 5.63. Analysis of the full-
length PR0865 sequence shown in Figure 136 (SEQ ID N0:337) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 23, potential N-
glycosylation sites from about amino acid 280
to about amino acid 283 and from about amino acid 384 to about amino acid 387,
a potential amidation site from
about amino acid 94 to about amino acid 97, glycosaminoglycan attachment sites
from about amino acid 20 to about
amino acid 23 and from about amino acid 223 to about amino acid 226, an
aminotransferase class-V pyridoxyl-
phosphate amino acid sequence block from about amino acid 216 to about amino
acid 222 and an amino acid sequence
block similar to that found in the imerleukin-7 protein from about amino acid
338 to about amino acid 343. Clone
UNQ434 (DNA53974-1401 ) has been deposited with ATCC on April 14, 1998 and is
assigned ATCC deposit no.
209774.
Analysis of the amino acid sequence of the full-length PR0865 polypeptide
suggests that it possesses no
significant sequence similarity to any known protein. However, an analysis of
the Dayhoff database (version 35.45
SwissProt 35) evidenced some degree of homology between the PR0865 amino acid
sequence and the following
Dayhoff sequences, YMNO YEAST, AT'FCA4 43, S44168, P W 14549 and RABTCRG4,1.
226
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
EXAMPLE 53: Isolation of cDNA Clones Encodin~Human PR0827
A cDNA sequence isolated in the amylase screen described in Example 2 above
was found, by BLAST and
FastA sequence alignment, to have sequence homology to nucleotide sequences
encoding various integrin proteins.
This cDNA sequence is herein designated DNA47751 (see Figure 140; SEQ ID
N0:347). Based on the sequence
homology, probes were generated from the sequence of the DNA47751 molecule and
used to screen a human fetal
pigment epithelium library (LIB113) prepared as described in paragraph 1 of
Example 2 above. The cloning vector
was pRKSB (pRKSB is a precursor of pRKSD that does not contain the Sfi1 site;
see, Holmes et al., Science,
2:1278-1280 (1991)), and the cDNA size cut was less than 2800 bp.
PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 5'-AGGGACAGAGGCCAGAGGACTTC-3' (SEQ ID N0:348)
reverse PCR primer 5'-CAGGTGCATATTCACAGCAGGATG-3' (SEQ ID N0:349)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA47751
sequence which had the following nucleotide sequence
hybridization probe
5'-GGAACTCCCCTTCGTCACTCACCTGTTCTTGCCCCTGGTGTTCCT-3' (SEQ ID
N0:350)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0827 gene using the probe oligonucleotide and one of the PCR
primers.
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 134-136 and ending at the stop codon
found at nucleotide positions 506-508
(Figure 138; SEQ ID N0:345). The predicted polypeptide precursor is 124 amino
acids long, has a calculated
molecular weight of approximately 13,352 daltons and an estimated p1 of
approximately 5.99. Analysis of the full-
length PR0827 sequence shown in Figure 139 (SEQ ID N0:346) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 22, a cell attachment
sequence from about amino acid 70 to
about amino acid 72, a potential N-glycosylation site from about amino acid 98
to about amino acid 101 and an
integrin alpha chain protein homology sequence from about amino acid 67 to
about amino acid 81. Clone UNQ468
(DNA57039-1402) has been deposited with ATCC on April 14, 1998 and is assigned
ATCC deposit no. 209777.
Analysis of the amino acid sequence of the full-length PR0827 polypeptide
suggests that it possesses
significant sequence similarity to the VLA-2 integrin protein and various
other integrin proteins, thereby indicating
that PR0827 may be a novel integrin or splice variant thereof. More
specifically, an analysis of the Dayhoff database
(version 35.45 SwissProt 35) evidenced significant homology between the PR0240
amino acid sequence and the
following Dayhoff sequences, S44142, ITA2 HUMAN, ITA1 RAT, ITAl HUMAN, ITA4
HUMAN,
ITA9 HUMAN, AF032108_l, /TAM MOUSE, ITA8 CHICK and ITA6 CHICK.
E7~AMPLE 54: Isolation of cDNA Clones Encoding Human PRO11 l4
A cDNA sequence isolated in the amylase screen described in Example 2 was
found, by the WU-BLAST2
sequence alignment computer program, to have certain sequence identity to
other lrnown interferon receptors. This
cDNA sequence is herein designated DNA48466 (Figure 143; SEQ ID N0:352). Based
on the sequence identity,
probes were generated from the sequence of the DNA48466 molecule and used to
screen a human breast carconoma
227
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
library (LIBI35) prepared as described in paragraph 1 of Example 2 above. The
cloning vector was pRKSB (pRKSB
is a precursor of pRKSD that does not contain the SfiI site; see, Holmes et
al., Science, 253:1278-1280 (1991)), and
the cDNA size cut was less than 2800 bp.
The oligonucleotide probes employed were as follows:
forward PCRprimer S'-AGGCTTCGCTGCGACTAGACCTC-3' (SEQ ID N0:354)
reverse PCR~rimer S'-CCAGGTCGGGTAAGGATGGTTGAG-3' (SEQ ID N0:355)
hybridization~robe
S'-TTTCTACGCATTGATTCCATGTTTGCTCACAGATGAAGTGGCCATTCTGC-3' (SEQ ID N0:356)
A full length clone was identified that contained a single open reading frame
with an apparent translational
initiation site at nucleotide positions 2S0-252, and a stop signal at
nucleotide positions 1183-1185 (Figure 141, SEQ
ID N0:351). The predicted polypeptide precursor is 311 amino acids long, has a
calculated molecular weight of
approximately 35,076 daltons and an estimated pi of approximately 5.04.
Analysis of the full-length PR01114
interferon receptor sequence shown in Figure 142 (SEQ 1D N0:352) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 29, a transmembrane domain
from about amino acid 230 to
about amino acid 255, potential N-glycosylation sites from about amino acid 40
to about amino acid 43 and from
about amino acid 134 to about amino acid 137, an amino acid sequence block
having homology to tissue factor
proteins from about amino acid 92 to about amino acid 119 and an amino acid
sequence block having homology to
integrin alpha chain proteins from about amino acid 232 to about amino acid
262. Clone UNQ557 (DNA57033-1403)
has been deposited with ATCC on May 27, 1998 and is assigned ATCC deposit no.
209905.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-
BLAST2 sequence alignment
analysis of the full-length sequence shown in Figure I42 (SEQ ID N0:352),
evidenced significant homology between
the PR01114 interferon receptor amino acid sequence and the following Dayhoff
sequences: 601418,
INR1 MOUSE, P R7103S, INGS HUMAN, A26S95 1, A26593 l, I56215 and TF HUMAN.
EXAMPLE 55: Isolation of cDNA Clones Encodin~~Human PR0237
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA30905. Based
on the DNA30905 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0237.
PCR primers (forward and reverse) were synthesized:
forward PCR primer S'-TCTGCTGAGGTGCAGCTCATTCAC-3' (SEQ ID N0:359)
reverse PCR grimer S'-GAGGCTCTGGAAGATCTGAGATGG-3' (SEQ ID N0:360)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA30905
sequence which had the following nucleotide sequence
hybridization vrobe
S'-GCCTCTTTGTCAACGTTGCCAGTACCTCTAACCCATTCCTCAGTCGCCTC-3' (SEQ ID N0:361)
In order to screen several libraries for a sowce of a full-length clone, DNA
from the libraries was screened
by PCR ampli5cation with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0237 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal brain tissue (LIB153).
228
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0237
[herein designated as UNQ211 (DNA34353-1428)] (SEQ ID N0:357) and the derived
protein sequence for PR0237.
The entire nucleotide sequence of UNQ211 (DNA34353-1428) is shown in Figure
144 (SEQ ID N0:357).
Clone UNQ211 (DNA34353-1428) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 586-588 and ending at the stop codon at nucleotide
positions 1570-1572 (Figure 144). The
predicted polypeptide precursor is 328 amino acids long (Figure 145). The full-
length PR0237 protein shown in
Figwe 145 has an estimated molecular weight of about 36,238 daltons and a pI
of about 9.90. Analysis of the full-
length PR0237 sequence shown in Figure 145 (SEQ ID N0:358) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 23, a transmembrane domain
from about amino acid 177 to
about amino acid 199, potential N-glycosylation sites from about amino acid
118 to about amino acid 121, from about
amino acid 170 to about amino acid 173 and from about amino acid 260 to about
amino acid 263 and eukaryotic-type
carbonic anhydrase sequence homology blocks from about amino acid 222 to about
amino acid 270, from about amino
acid 128 to about amino acid l64 and from about amino acid 45 to about amino
acid 92. Clone UNQ211
(DNA34353-1428) has been deposited with ATCC on May 12, 1998 and is assigned
ATCC deposit no. 209855.
Analysis of the amino acid sequence of the full-length PR0237 polypeptide
suggests that it possesses
significant sequence similarity to the carbonic anhydrase protein. More
specifically, an analysis of the Dayhoff
database (version 35.45 SwissProt 35) evidenced significant homology between
the PR0237 amino acid sequence and
the following Dayhoff sequences, AF050106-1, OACALP_l, CELD1022_8, CAH2 HUMAN,
1CAC,
CAHS HUMAN, CARP HUMAN, CAH3 HUMAN, CAH1 HUMAN and 2CAB.
EXAMPLE 56: Isolation of cDNA Clones Encoding Human PR0541
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42259. Based
on the DNA42259 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0541.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-GGACAGAATTTGGGAGCACACTGG-3' (SEQ ID N0:364)
forward PCR primer 5'-CCAAGAGTATACTGTCCTCG-3' (SEQ ID N0:365)
reverse PCR primer 5'-AGCACAGATTTTCTCTACAGCCCCC-3' (SEQ ID N0:366)
reverse PCR primer 5'-AACCACTCCAGCATGTACTGCTGC-3' (SEQ ID N0:367)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA42259
sequence which had the following nucleotide sequence
hvbridization,probe
5'-CCATTCAGGTGTTCTGGCCCTGTATGTACACATTATACACAGGTCGTGTG-3' (SEQ 1D N0:368)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with one of the PCR primer pairs identified above. A
positive library was then used to isolate
clones encoding the PR0541 gene using the probe oligonucleotide and one of the
PCR primers. RNA for
construction of the cDNA libraries was isolated from human fetal kidney tissue
(LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0541
(herein designated as UNQ342 (DNA45417-1432)] (SEQ ID N0:362) and the derived
protein sequence for PR0541.
229
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The entire nucleotide sequence of UNQ342 (DNA45417-1432) is shown in Figure
146 (SEQ ID N0:362).
Clone UNQ342 (DNA45417-1432) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 469~7I and ending at the stop codon at nucleotide
positions 1969-1971 (Figure 146). The
predicted polypeptide precursor is 500 amino acids long (Figure 147). The full-
length PR0541 protein shown in
Figure 147 has an estimated molecular weight of about 56.888 daltons and a p1
of about 8.53. Analysis of the full-
length PR0541 sequence shown in Figure 147 (SEQ 1D N0:363) evidences the
presence of the following: a signal
peptide from about amino acid 1 to about amino acid 20, amino acid sequence
blocks having homology to
extracellular proteins SCP/Tpx-1/Ag5/PR-1/Sc7 from about amino acid 165 to
about amino acid 186, from about
amino acid 196 to about amino acid 218, from about amino acid 134 to about
amino acid 146, from about amino acid
96 to about amino acid 108 and from about amino acid 58 to about amino acid 77
and a potential N-glycosylation site
from about amino acid 28 to about amino acid 31. Clone UNQ342 (DNA45417-1432)
has been deposited with ATCC
on May 27, 1998 and is assigned ATCC deposit no. 209910.
Analysis of the amino acid sequence of the full-length PR0541 polypeptide
suggests that it possesses
significant sequence similarity to a trypsin inhibitor protein, thereby
indicating that PR0541 may be a novel trypsin
inhibitor. More specifically, an analysis of the Dayhoff database (version
35.45 SwissProt 35) evidenced significant
homology between the PR0541 amino acid sequence and the following Dayhoff
sequences, D45027-1, AB009609_I,
JC5308, CRS3 HORSE, TPX1 HUMAN, HELO HELHO, GEN14351, A28112 I, CET05A10 4 and
P W11485.
EXAMPLE 57: Isolation of cDNA Clones Encoding Human ,~R0273
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA36465. Based
on the DNA36465 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0273.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR~rir,~er 5'-CAGCGCCCTCCCCATGTCCCTG-3' (SEQ ID N0:371)
reverse PCR primer 5'-TCCCAACTGGTTTGGAGTTTTCCC-3' (SEQ ID N0:372)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA36465
sequence which had the following nucleotide sequence
hybridizationprol?g
5'-CTCCGGTCAGCATGAGGCTCCTGGCGGCCGCTGCTCCTGCTGCTG-3' (SEQ ID N0:373)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0273 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0273
[herein designated as UNQ240 (DNA39523-1192)] (SEQ ID N0:369) and the derived
protein sequence for PR0273.
The entire nucleotide sequence of UNQ240 (DNA39523-1192) is shown in Figure
148 (SEQ ID N0:369).
Clone UNQ240 (DNA39523-1192) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 167-169 and ending at the stop codon at nucleotide
positions 500-502 (Figure 148). The
predicted polypeptide precursor is 111 amino acids long (Figure 149). Clone
UNQ240 (DNA39523-1192) has been
230
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
deposited with the ATCC. It is understood that the deposited clone contains
the actual sequence and that the
sequences provided herein are merely representative based on current
sequencing techniques. Moreover, given the
sequences provided herein and knowledge of the universal genetic code, the
corresponding nucleotides for any given
amino acid can be routinely identified and vice versa.
Analysis of the amino acid sequence of the full-length PRO273 polypeptide
suggests that ponions of it
possess sequence identity with human macrophage inflammatory protein-2,
cytokine-induced neutrophil
chemoattractant 2, and neutrophil chemotactic factor 2-beta, thereby
indicating that PR0273 is a novel chemokine.
As discussed further below, the cDNA was subcloned into a baculovirus vector
and expressed in insect cells
as a C-terminally tagged 1gG fusion protein. N-terminal sequencing of the
resultant protein identified the signal
sequence cleavage site, yielding a mature polypeptide of 77 amino acids. The
mature sequence, showing 31-40%
identity to other human CXC chemokines, includes the four canonical cysteine
residues but lacks the ELR motif.
Northern analysis demonstrates expression at least in the small intestine,
colon, spleen, lymph node and kidney. By
in situ hybridization, also described in detail below, mRNA is localized to
the lamina propria of intestinal villi and
to renal tubules.
EXAMPLE 58: Isolation of cDNA Clones Encoding Human PR0701
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA39848. Based
on the DNA39848 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0701.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-GGCAAGCTACGGAAACGTCATCGTG-3' (SEQ ID N0:376)
reverse PCR primer 5'-AACCCCCGAGCCAAAAGATGGTCAC-3' (SEQ ID N0:377)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA39848
sequence which had the following nucleotide sequence:
hybridization probe
5'-GTACCGGTGACCAGGCAGCAAAAGGCAACTATGGGCTCCTGGATCAG-3' (SEQ ID N0:378).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0701 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0701
[herein designated as UNQ365 (DNA44205-1285)] (SEQ ID N0:374) and the derived
protein sequence for PR0701.
The entire nucleotide sequence of UNQ365 (DNA44205-1285) is shown in Figure
150 (SEQ ID N0:374).
Clone UNQ365 (DNA44205-1285) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 50-52 and ending at the stop codon at nucleotide
positions 2498-3000 (Figure 150). The
predicted polypeptide precursor is 816 amino acids long (Figure 151). The full-
length PR0701 protein shown in
Figure 151 has an estimated molecular weight of about 91,794 daltons, a pl of
about 5.88 and NX(SlT) being 4.
Clone UNQ365 (DNA44205-1285) has been deposited with the ATCC on March 31,
1998. It is understood that the
clone was the correct and actual sequence, wherein the sequences provided
herein are representative based on
231
CA 02421372 2003-03-25
WO 99/46281 PCT1US99/05028
sequencing techniques.
Still regarding the amino acid sequence shown in Figure I51, there is a
potential signal peptide cleavage site
at about amino acid 25. There are potential N-glycosylation sites at about
amino acid positions 83, 511, 716 and 803.
The carboxylesterases type-B signature 2 sequence is at about residues 125 to
135. Regions homologous with
carboxylesterase type-B are also at about residues 54-74, 197-212 and 221-261.
A potential transmembrane region
corresponds approximately to amino acids 671 through about 700. The
corresponding nucleic acids can be routinely
determined from the sequences provided herein.
Analysis of the amino acid sequence of the full-length PR0701 polypeptide
suggests that it possess
significant homology to the neuroligins from rattus norvegicus indicating that
PR0701 may be a novel human
neuroligin.
EXAMPLE 59: 1s91ation of cDNA Clones Encoding Human PR0704
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43033. Based
on the DNA43033 consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0704.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CCTTGGGTCGTGGCAGCAGTGG-3' (SEQ ID N0:381);
reverse PCR primer 5'-CACTCTCCAGGCTGCATGCTCAGG-3' (SEQ ID N0:382).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA43033 consensus
sequence which had the following nucleotide sequence:
hybridization probe
5'-GTCAAACGTTCGAGTACTTGAAACGGGAGCACTCGCTGTCGAAGC-3' (SEQ ID N0:383).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0704 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0704
[herein designated as UNQ368 (DNA50911-1288)] (SEQ 1D N0:379) and the derived
protein sequence for PR0704.
The entire nucleotide sequence of UNQ368 (DNA5091 I-1288) is shown in Figure
152 (SEQ ID N0:379).
Clone UNQ368 (DNA50911-1288) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 8-10 and ending at the stop codon at nucleotide
positions 1052-1054 (Figure 152). The
predicted polypeptide precursor is 348 amino acids long (Figure 153). The full-
length PR0704 protein shown in
Figure 153 has an estimated molecular weight of about 39,711 and a pI of about
8.7. Clone UNQ368 (DNA50911-
1288) has been deposited with the ATCC on March 31, 1998. Regarding the
sequence, it is understood that the
deposited clone contains the correct sequence, and the sequences provided
herein are based on known sequencing
techniques.
Analysis of the amino acid sequence of the full-length PR0704 polypeptide
suggests that portions of it
possess significant homology to the vesicular integral membrane protein 36,
thereby indicating that PR0704 tray be
a novel vesicular integral membrane protein.
232
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Still analyzing the amino acid sequence of SEQ ID N0:380, the putative signal
peptide is at about amino
acids 1-39 of SEQ ID N0:380. The transmembrane domain is at amino acids 310-
335 of SEQ ID N0:380. A
potential N-glycosylation site is at about amino acids 180-l83 of SEQ ID
N0:380. The corresponding nucleotides
can be routinely determined given the sequences provided herein.
EXAMPLE 60: Isolation of cDNA Clones Encoding Human PR0706
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA40669. Based
on the DNA40669 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0706.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CCAAGCAGCTTAGAGCTCCAGACC-3' (SEQ ID N0:386)
reverse PCR-primer 5'-TTCCCTATGCTCTGTATTGGCATGG-3' (SEQ 1D N0:387)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA40669
sequence which had the following nucleotide sequence
hybridization probe
5'-GCCACTTCTGCCACAATGTCAGCTTTCCCTGTACCAGAAATGGCTGTGTT-3' (SEQ ID N0:388)
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0706 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal brain tissue (LIB153).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0706
[herein designated as UNQ370 (DNA48329-1290)] (SEQ ID N0:384) and the derived
protein sequence for PR0706.
It is understood that the deposited clone contains the actual sequence, and
that the sequences provided herein are
representative based on current sequencing techniques.
The entire nucleotide sequence of UNQ370 (DNA48329-1290) is shown in Figure
154 (SEQ ID N0:384).
Clone UNQ370 (DNA48329-1290) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 279-281 and ending at the stop codon at nucleotide
positions 1719-1721 (Figure 154). The
predicted polypeptide precursor is 480 amino acids long (Figure 155). The full-
length PR0706 protein shown in
Figure 155 has an estimated molecular weight of about 55,239 daltons and a p1
of about 9.30. Clone UNQ370
(DNA48329-1290) has been deposited with the ATCC on April 21, 1998.
Still regarding the amino acid sequence shown in Figure 155, there is a
potential signal peptide cleavage site
at about amino acid 19. There are potential N-glycosylation sites at about
amino acid positions 305 and 354. There
is a potential tyrosine Idnase phosphorylation site at about amino acid
position 333. A region homologous with
histidine acid phosphatase is at about residues 87-102. The corresponding
nucleic acid regions can be routinely
determined given the provided sequences, i.e., the codons can be determined
from the specifically named amino acids
given.
Analysis of the amino acid sequence of the full-length PR0706 polypeptide
suggests that portions of it
possess significant homology to the htunan prostatic acid phosphatase
precursor thereby indicating that PR0706 may
233
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
be a novel human prostatic acid phosphatase.
EXAMPLE 61: Isolation of cDNA Clones Encoding Human PR0707
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42775. Based
on DNA42775, olieonucleotides
were synthesized: 1) to identify by PCR a cDNA library that contained the
sequence of interest, and 2) far use as
probes to isolate a clone of the full-length coding sequence for PR0707.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 5'-TCCGTCTCTGTGAACCGCCCCAC-3' (SEQ ID N0:391);
reverse PCR primer 5'-CTCGGGCGCATTGTCGTTCTGGTC-3' (SEQ ID N0:392).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA42775 sequence which
had the following nucleotide sequence:
h~rbridizationprobe
5'-CCGACTGTGAAAGAGAACGCCCCAGATCCACTTATTCCCC-3' (SEQ ID N0:393).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0707 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0707
[herein designated as UNQ3?1 (DNA48306-1291)] (SEQ ID N0:389) and the derived
protein sequence for PR0707.
The entire nucleotide sequence of UNQ371 (DNA48306-1291) is shown in Figure
156 (SEQ ID N0:389),
Clone UNQ371 (DNA48306-1291) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 371-373 and ending at the stop codon at nucleotide
positions 3119-3121 of SEQ ID N0:389.
The predicted polypeptide precursor is 916 amino acids long (Figure 157). The
full-length PR070? protein shown
in Figure 157 has an estimated molecular weight of about 100,204 daltons and a
p1 of about 4.92. Clone UNQ371
(DNA48306-1291) has been deposited with ATCC on May 27, 1998. It is understood
that the clone UNQ371 which
is deposited is that which encodes PR0707, and that the sequences herein are
merely representations based on known
sequencing techniques which may be subject to minor errors.
Regarding analysis of the amino acid sequence, the signal sequence appears to
be at about 1 through 30 of
SEQ ID N0:390. Cadhetins extracellular repeated domain signature sequence is
at about amino acids 121-131, 230-
240, 335-345, 4401150, and 550-560 of SEQ ID N0:390. Tyrosine kinase
phosphorylation sites are at about amino
acids 124-132 and 580-586 of SEQ 1D N0:390. A potential transmembrane domain
is at about amino acids 682-715
t 5. The nucleic acid positions can be derived by referring to the
corresponding codon for the named amino acid.
Analysis of the amino acid sequence of the full-length PR0707 polypeptide
suggests that portions of it
possess significant homology to the cadherin FIB3 protein, expressed in human
fibroblasts, thereby indicating that
PR070? may be a novel cadherin.
234
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
EXA PLE 62: Isolation of cDNA Clone Encodine Human PR0322
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA48336. Based
on the DNA48336 consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0322.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CAGCCTACAGAATAAAGATGGCCC-3' (SEQ ID N0:396)
reverse PCR primer 5'-GGTGCAATGATCTGCCAGGCTGAT-3' (SEQ ID N0:397)
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA48336 consensus
sequence which had the following nucleotide sequence:
hybridization~robe
5'-AGAAATACCTGTGGTTCAGTCCATCCCAAACCCCTGCTACAACAGCAG-3' (SEQ ID N0:398).
In order to screen several libraries for a source of a full-length clone. DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0322 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0322
[herein designated as UNQ283 tDNA48336-1309)J (SEQ ID N0:394) and the derived
protein sequence for PR0322.
It is understood that UNQ283 (DNA48336-1309) in fact encodes PR0322, and that
SEQ ID N0:394 is a
representation of the sequence based on sequencing techniques known in the
art.
Tlte entire nucleotide sequence of UNQ283 (DNA48336-1309) is shown in Figure
158 (SEQ ID N0:394).
Clone UNQ283 (DNA4833Cr1309) contains a single open reading frame with an
apparent uanslational initiation site
at nucleotide positions 166-168 and ending at the stop codon at nucleotide
positions 946-948 (Figure 158). The
predicted polypeptide precursor is 260 amino acids long (Figure 159). The full-
length PR0322 protein shown in
Figure 159 has an estimated molecular weight of about 28,028 daltons and a p1
of about 7.87. Clone UNQ283
(DNA48336-1309) has been deposited with ATCC and is assigned ATCC deposit no.
209669.
Regarding the amino acid sequence of Figure 159, a potential N-glycosylation
site is at amino acid 110 of
SEQ ID N0:395. The serine proteases, trypsin family and histidine active site
is identified at amino acids 69 through
74 of SEQ )~ N0:395 and the consensus sequence is identified at amino acids
207 through 217 of SEQ ID N0:395.
The kringle domain proteins motif is identified at amino acids 205 through 217
of SEQ ID N0:395. The putative
signal peptide is encoded at about amino acids 1-23.
Analysis of the amino acid sequence of the full-length PR0322 polypeptide
suggests that portions of it
possess significant homology to neuropsin and other serine proteases, thereby
indicating that PR0322 is a novel
serine protease related to neuropsin.
EXAMPLE 63: Isolation of cDNA Clones Encoding Nutnan PRQ526
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example l above,
wherein the consensus sequence obtained is herein designated DNA39626. Based
on the DNA39626 consensus
sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0526.
235
CA 02421372 2003-03-25
WO 99!46281 PCT/US99/05028
A pair of PCR primers (forward and reverse) were synthesized:
forward PCRprimer 5'-TGGCTGCCCTGCAGTACCTCTACC-3' (SEQ ID N0:401);
Ieverse PCR primer 5'-CCCTGCAGGTCATTGGCAGCTAGG-3' (SEQ ID N0:402).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA39626 consensus
sequence which had the following nucleotide sequence:
~bridization probe
5'-AGGCACTGCCTGATGACACCTTCCGCGACCTGGGCAACCTCACAC-3' (SEQ ID N0:403).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0526 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB228).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0526
[herein designated as UNQ330 (DNA44184-1319)J (SEQ ID N0:399) and the derived
protein sequence for PR0526.
The entire nucleotide sequence of UNQ330 (DNA44184-1319) is shown in Figure
160 (SEQ ID N0:399).
Clone UNQ330 (DNA44184-1319) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 514-S 16 and ending at the stop codon at nucleotide
positions 1933-1935 (Figure 160). The
predicted polypeptide precursor is 473 amino acids long (Figure 161 ). The
full-length PR0526 protein shown in
Figure 161 has an estimated molecular weight of about 50,708 daltons and a pI
of about 9.28. Clone UNQ330
(DNA44184-1319) has been deposited with the ATCC on March 26, 1998. It is
understood that the clone contains
the actual sequence, whereas the sequences presented herein are representative
based an current sequencing
techniques.
Analysis of the amino acid sequence of the full-length PR0526 polypeptide
suggests that portions of it
possess significant homology to the leucine repeat rich proteins including
ALS, SLIT, carboxypeptidase and platelet
glycoprotein V thereby indicating that PR0526 is a novel protein which is
involved in protein-protein interactions.
Still analyzing SEQ ID N0:400, the signal peptide sequence is at about amino
acids 1-26. A leucine zipper
pattern is at about amino acids 135-156. A glycosaminoglycan attachment is at
about amino acids 436-439. N-
glycasylation sites are at about amino acids 82-85, 1?9-182, 237-240 and 423-
426. A von Willebrand factor (VWF)
type C domains) is found at about amino acids 411-425. The skilled artisan can
understand which nucleotides
correspond to these amino acids based on the sequences provided herein.
EXAMPLE 64: Isolation of cDNA Clones Encoding Human PR0531
An ECD database was searched and an expressed sequence tag (EST) from
LIFESEQT"", Incyte
Pharmaceuticals, Palo Alto, CA was identified which showed homology to
protocadherin 3. Based on this sequence,
a search was performed using the computer program BLAST or BLAST2 (Altshul et
al., Methods in Enzvmology
~:460~80 (1996)} as a comparison of the ECD protein sequences to a 6 frame
translation of the EST sequence.
Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or
greater that did not encode known
proteins were clustered and assembled into consensus DNA sequences with the
program "phrap" (Phil Green,
University of Washington, Seattle, Washington;
http://bozeman.mbt.Washington.edu/phrap.docs/phrap.html).
A consensus DNA sequence was assembled relative to other EST sequences using
phrap. Based on the
consensus sequence obtained, oligonucleotides were synthesized: 1) to identify
by PCR a cDNA library that contained
236
CA 02421372 2003-03-25
A
WO 99/46281 PCT/US99/05028
the sequence of interest, and 2) for use as probes to isolate a clone of the
full-length coding sequence for PR0531.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR,primer 5'-CTGAGAACGCGCCTGAAACTGTG-3' (SEQ ID N0:406);
reverse PCR prime3 5'-AGCGTTGTCATTGACATCGGCG-3' (SEQ ID N0:407).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA sequence
which had the following nucleotide sequence:
hybridization Drobe
5'-TTAGTTGCTCCATTCAGGAGGATCTACCCTTCCTCCTGAAATCCGCGGAA-3' (SEQ ID N0:408).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0531 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal brain tissue (LIB153). The
cDNA libraries used to isolate the
cDNA clones were constntcted by standard methods using commercially available
reagents such as those from
Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI
site, linked with blunt to Salt
hemikinased adaptors, cleaved with Notl, sized appropriately by gel
electrophoresis, and cloned in a defined
IS orientation into a suitable cloning vector (such as pRKB or pRKD; pRKSB is
a precursor of pRKSD that does not
contain the SfiI site; see, Holmes et al., c' nee, 29,x:1278-1280 (1991)) in
the unique Xhol and Notl sites.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0531
[herein designated as UNQ332 (DNA48314-1320)] (SEQ ID N0:404) and the derived
protein sequence for PR0531.
Tlie entire representative nucleotide sequence of UNQ332 (DNA48314-1320) is
shown in Figure 162 (SEQ
ID N0:404). It is understood that the actual sequence is that within the clone
deposited with the ATCC as
DNA48314-1320. Clone UNQ332 (DNA48314-1320) contains a single open reading
frame with an apparent
translational initiation site at nucleotide positions 171-173 and ending at
the stop codon at nucleotide positions 2565
2567 (Figure 162). The predicted polypeptide precursor is 789 amino acids long
(Figure 163). The full-length
PR0531 protein shown in Figure 163 has an estimated molecular weight of about
87,552 daltons and a pI of about
4.84. Clone UNQ332 (DNA48314-1320) has been deposited with the ATCC on March
26, 1998.
Analysis of the amino acid sequence of the full-length PR0531 polypeptide
suggests that portions of it
possess sigttificatu homology to protocadherin 3. Moreover, PR0531 is found in
the brain, like other protocadherins,
thereby indicating that PR0531 is a novel member of the cadherin
superfatttily.
Still analyzing the amino acid sequence of SEQ ID N0:405, the cadherin
extracellular repeated domain
signature is found at about amino acids 122-132, 231-241, 336-346, 439-449 and
549-559 of SEQ ID N0:405. An
ATP/GTP-binding site motif A tP-loop) is found at about amino acids 285-292 of
SEQ 1D N0:405. N-glycosylation
sites are found at least at about amino acids 567-570, 786-790, 418-421 and
336-339 of SEQ ID N0:405. The signal
peptide is at about amino acids 1-26, and the uansmembrane domain is at about
amino acids 685-712 of SEQ ID
N0:405.
EXAMPLE 65: Isolation of cDNA Clones Encodir~,Human PR0534
A consensus sequence was obtained relative to a variety of EST sequences as
described in Exatttple 1 above,
wherein the consensus sequence obtained is herein designated DNA43038. Based
on the 43048 consensus sequence,
oiigonucleotides were synthesized; 1) to identify by PCR a cDNA library that
contained the sequence of interest, and
237
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
2) for use as probes to isolate a clone of the full-length coding sequence for
PR0534_
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CACAGAGCCAGAAGTGGCGGAATC-3' (SEQ ID N0:411);
reverse PCR primer 5'-CCACATGTTCCTGCTCTTGTCCTGG-3' (SEQ ID N0:412).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA43038
sequence which had the following nucleotide sequence:
hybridization probe
5'-CGGTAGTGACTGTACTCTAGTCCTGTTTTACACCCCGTGGTGCCG-3' (SEQ ID N0:413).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0534 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal lung tissue (LIB26).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0534
[herein designated as UNQ335 (DNA48333-1321)) (SEQ ID N0:409) and the derived
protein sequence for PR0534.
The entire nucleotide sequence of UNQ335 (DNA48333-1321) is shown in Figure
164 (SEQ 1D N0:409).
Clone UNQ335 (DNA48333-1321) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 87-89 and ending at the stop codon at nucleotide
positions 1167-1169 (Figure 164). The
predicted polypeptide precursor is 360 amino acids long (Figure 165). The full-
length PR0534 protein shown in
Figure 165 has an estimated molecular weight of about 39,885 daltons and a pI
of about 4.79. Clone UNQ335
(DNA48333-1321) has been deposited with ATCC on March 26, 1998. It is
understood that the deposited clone
contains the actual sequence, and that the sequences provided herein are
representative based on current sequencing
techniques.
Analysis of the amino acid sequence of the full-length PR0534 polypeptide
suggests that portions of it
possess significant sequence identity with the protein disulfide isomerase,
thereby indicating that PR0534 may be a
novel disulfide isomerase.
Still analyzing the amino acid sequence of PR0534, the signal peptides is at
about amino acids 1-25 of SEQ
ID N0:410. The transmembrane domain is at about amino acids 321-340 of SEQ ID
N0:410. The disulfide
isomerase corresponding region is at amino acids 212-302 of SEQ ID N0:410. The
thioredoxin domain is at amino
acids 211-227 of SEQ )D N0:410. N-glycosylation sites are at: 165-168, 181-
184, 187-190, 194-197, 206-209, 278-
281, and 293-296 of SEQ ID N0:410. The corresponding nucleotides can routinely
be determined from the
sequences provided herein. PR0534 has a transmembrane domain rather than an ER
retention peptide like other
protein disulfide isomerases. Additionally, PR0534 may have an intron at the 5
prime end.
EXAMPLE 66: Isolation of cDNA Clones Encoding Human PR0697
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43052. Based
on this consensus sequence,
oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and
2) for use as probes to isolate a clone of the full-length coding sequence for
PR0697.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-CCTGGCTCGCTGCTGCTGCTC-3' (SEQ ID N0:416);
238
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
reverse PCR primer 5'-CCTCACAGGTGCACTGCAAGCTGTC-3' (SEQ ID N0:417).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA43052 consensus
sequence which had the following nucleotide sequence:
hybridization probe
S'-CTCTTCCTCTTTGGCCAGCCCGACTTCTCCTACAAGCGCAGAATTGC-3' (SEQ ID N0:418).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0697 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0697
[herein designated as UNQ361 (DNA50920-1325)] (SEQ 1D N0:414) and the derived
protein sequence for PR0697.
The entire nucleotide sequence of UNQ361 (DNA50920-1325) is shown in Figure
166 (SEQ ID N0:414).
Clone UNQ361 (DNA50920-1325) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 44-46 and ending at the stop codon at nucleotide
positions 929-931 (Figure 166). The
predicted polypeptide precursor is 295 amino acids long (Figure 167). The full-
length PR0697 protein shown in
1S Figure 167 has an estimated molecular weight of about 33,518 daltons and a
pI of about 7.74. Clone UNQ361
(DNA50920-1325) was deposited with the ATCC on March 26, 1998. It is
understood that the deposited clone
contains the actual sequence, and that the sequences provided herein are
representative based on current sequencing
techniques.
Analysis of the amino acid sequence of the full-length PR0697 polypeptide
suggests that portions of it
possess significant sequence identity with sFRPs, thereby indicating that
PR0697 may be a novel sFRP family
member.
Still analyzing the amino acid sequence of PR0697, the signal peptides is at
about amino acids 1-20 of SEQ
ID N0:41S. The cystein rich domain, having identity with the frizzled N-
terminus, is at about amino acids 6-153
of SEQ ID N0:415. The corresponding nucleotides can routinely be determined
from the sequences provided herein.
2S
EXAMPLE 67: Isolation of cDNA Clones Encoding Human PR0717
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA42829. Based
on the DNA42829 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0717.
A pair of PCR primers (forward and reverse) were synthesized:
Forward PCRprimer S'-AGCTTCTCAGCCCTCCTGGAGCAG-3' (SEQ ID N0:421);
Fe_verse PCR primer 5'-CGGGTCAATAAACCTGGACGCTTGG-3' (SEQ ID N0:422).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA42829 consensus
sequence which had the following nucleotide sequence:
~,vbridization,probe
S'-TATGTGGACCGGACCAAGCACTTCACTGAGGCCACCAAGATTG-3' (SEQ ID N0:423).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
239
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
encoding the PR0717 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal liver tissue (LIB229).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0717
[herein designated as UNQ385 (DNA50988-1326)) (SEQ 1D N0:419) and the derived
protein sequence for PR0717.
The entire nucleotide sequence of UNQ385 (DNA50988-1326) is shown in Figure
168 (SEQ ID N0:419).
Clone UNQ385 (DNA50988-1326) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 17-19 and ending at the stop codon at nucleotide
positions 1697-1699 (Figure 168). The
predicted polypeptide precursor is 560 amino acids long (Figure 169). The full-
length PR0717 protein shown in
Figure 169 has an estimated molecular weight of about 58,427 dahons and a p1
of about 6.86. Clone UNQ385
(DNA50988-1326) has been deposited with the ATCC on April 28, 1998. Regarding
the sequence, it is understood
that the deposited clone contains the correct sequence, and the sequences
provided herein are based on known
sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0717 polypeptide
suggests that PR0717 may be
a novel 12 transmembrane receptor. The reverse complement strand of DNA50988
has a stretch that matches
identically with human regulatory myosin light strand.
Still analyzing the amino acid sequence of SEQ ID N0:420, transmembrane
domains are at about amino
acids 30-50, 61-79, 98-112, 12fr146, 169-182, 201-215, 248-268, 280-300, 318-
337, 341-357, 375-387, and 420-.44I
of SEQ ID N0:420. N-glycosylation sites are at about amino acids 40-43 and 43-
46 of SEQ ID N0:420. A
glycosaminoglycan anachment site is at about amino acids 468-471 of SEQ ID
N0:420. The corresponding
nucleotides can be routinely determined given the sequences provided herein.
EXAMPLE 68: Isolation of cDNA Clones Encoding, Human PR0731
A database was used to search expressed sequence tag (EST) databases. The EST
database used herein was
the proprietary EST DNA database LIFESEQT"", of Incyte Pharmaceuticals, Palo
Alto, CA. Incyte clone 2581326
was herein identified and termed DNA42801. Based on the DNA42801 sequence,
oligonucleotides were synthesized:
1) to identify by PCR a cDNA library that contained the sequence of interest,
and 2) for use as probes to isolate a
clone of the full-length coding sequence for PR0731.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR~rimer 5'-GTAAGCACATGCCTCCAGAGGTGC-3' (SEQ ID N0:426);
reverse PCR primer 5'-GTGACGTGGATGCTTGGGATGTTG-3' (SEQ ID N0:427).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA42801 sequence which
had the following nucleotide sequence:
hybridization probe
5'-TGGACACCTTCAGTATTGATGCCAAGACAGGCCAGGTCATTCTGCGTCGA-3' (SEQ ID N0:428).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0731 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow tissue (LIB255). The
cDNA libraries used to isolate the
cDNA clones were constructed by standard methods using commercially available
reagents such as those from
Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a Notl
site, linked with blunt to Sal1
240
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
hemiltinased adaptors, cleaved with NotI, sized appropriately by gel
electrophoresis, and cloned in a defined
orientation into a suitable cloning vector (such as pRICB or pRKD; pRKSB is a
precursor of pRKSD that does not
contain the SfiI site; see, Holmes et al., cie c , x:1278-1280 (1991)) in the
unique Xhol and NotI sites.
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0731
[herein designated as UNQ395 (DNA48331-1329)] (SEQ ID N0:424) and the derived
protein sequence for PR0731.
The entire nucleotide sequence of UNQ395 (DNA48331-1329) is shown in Figures
170A-B (SEQ ID
N0:424). Clone UNQ395 (DNA48331-1329) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 329-331 and ending at the stop codon
at nucleotide positions 3881-3883 (Figures
170A-B). The predicted polypeptide precursor is 1184 amino acids long (Figure
171). The full-length PR0731
protein shown in Figure 171 has an estimated molecular weight of about 129,022
daltons and a p1 of about 5.2. Clone
UNQ395 (DNA48331-1329) was deposited with the ATCC on March 31, 1998.
Regarding the sequence, it is
understood that the deposited clone contains the correct sequence, and the
sequences provided herein are based on
lmown sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0731 polypeptide
suggests that portions of it
possess significant identity and similarity to members of the protocadherin
family, thereby indicating that PR0731
may be a novel protocadherin.
Still analyzing the amino acid sequence of SEQ ID N0:425, the putative signal
peptide is at about amino
acids 1-13 of SEQ ID N0:425. The transmembrane domain is at amino acids 719-
739 of SEQ 1D N0:425. The N-
glycosylation of SEQ ID N0:425 are as follows: 415118, 582-586, 659-662, 662-
665, and 857-860. The cadhezin
extracelhtlar repeated domain signatures are at about amino acids (of SEQ ID
N0:425): 123-133, 232-242, 340-350,
448-458, and 553-563. The corresponding nucleotides can be routinely
determined given the sequences provided
herein.
EXAMPLE 69: 1_~lation of cDNA Clones Encoding Hum~;rt PR0218
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA17411. Two
proprietary Genentech EST
sequences were employed in the consensus assembly and are shown in Figure 174
and 175. Based on the DNA17411
consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a
cDNA library that contained the
sequence of interest, and 2) for use as probes to isolate a clone of the full-
length coding sequence for PR0218.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-AAGTGGAGCCGGAGCCTTCC-3' (SEQ 1D N0:433);
reverse PCR primer 5'-TCGTTGTTTATGCAGTAGTCGG-3' (SEQ ID N0:434).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the consensus DNA17411
sequence which had the following nucleotide sequence:
hybridization probe
5'-ATTGTTTAAAGACTATGAGATACGTCAGTATGTTGTACAGG-3' (SEQ ID N0:435).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0218 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
241
CA 02421372 2003-03-25
WO 99/46281 PCTlUS99/05028
the cDNA libraries was isolated from human fetal kidney tissue (LIB28).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0218
[herein designated as UNQ192 (DNA30867-1335)] (SEQ ID N0:429) and the derived
protein sequence for PR0218.
The entire nucleotide sequence of UNQ192 (DNA30867-1335) is shown in Figure
172 (SEQ ID N0:429).
Clone UNQ192 (DNA30867-1335) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 150-152 and ending at the stop colon at nucleotide
positions 1515-1517 (Figure 172). The
predicted polypeptide precursor is 455 amino acids long (Figure 173). The full-
length PR0218 protein shown in
Figure 173 has an estimated molecular weight of about 52,917 daltons and a p1
of about 9.5. Clone UNQ192
(DNA30867-1335) has been deposited with the ATCC on April 28, 1998. Regarding
the sequence, it is understood
that the deposited clone contains the correct sequence, and the sequences
provided herein are based on known
sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0218 polypeptide
suggests that PR0218 may be
a novel transmembrane protein.
Still analyzing the amino acid sequence of SEQ ID N0:430, the putative signal
peptide is at about amino
acids 1 through 23 of SEQ ID N0:430. Transmembrarte domains are potentially at
about amino acids 37-55, 81-102,
IS 150-168, 288-311, 338-356, 375-398, and 425-444 of SEQ ID N0:430. N-
glycosylation sites are at about amino
acids 67, 180, and 243 of SEQ 1D N0:430. Eukaryotic cobalamin-binding protein
is at about amino acids 151-160
of SEQ ID N0:430. The corresponding nucleotides can be routinely determined
given the sequences provided herein.
EXAMPLE 70: Isolation of cDNA Clones Encodine Human PR0768
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43448. Based
on the DNA43448 consensus
sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0768.
A pair of PCR primers (forward and reverse) were synthesized:
~otvvard PCR primer 5'-GGCTGACACCGCAGTGCTCTTCAG-3' (SEQ ID N0:438);
reverse PCR primer 5'-GCTGCTGGGGACTGCAATGTAGCTG-3' (SEQ ID N0:439).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA43448 consensus
sequence which had the following nucleotide sequence:
~vbridization probe
5'-CATCCTCCATGTCTCCCATGAGGTCTCTATTGCTCCACGAAGCATC-3' (SEQ ID N0:440).
1n order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0768 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow tissue (LIB255).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0768
[herein designated as UNQ406 (DNA55737-1345)) (SEQ ID N0:436) and the derived
protein sequence for PR0768.
The entirc nucleotide sequence of UNQ406 (DNA55737-1345) is shown in Figures
1?6A-B (SEQ ID
N0:436). Clone UNQ406 (DNA55737-1345) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 20-22 and ending at the stop colon at
nucleotide positions 3443-3445 (Figures
242
CA 02421372 2003-03-25
WO 99/46281 PCT/US99J05028
176A-B). The predicted polypeptide precursor is 1141 amino acids long (Figure
177). The full-length PR0768
protein shown in Figure 177 has an estimated molecular weight of about 124,671
daltons and a pI of about 5.82.
Clone UNQ406 (DNA55737-1345) has been deposited with the ATCC on April 6,
1998. Regarding the sequence,
it is understood that the deposited clone contains the correct sequence, and
the sequences provided herein are based
on lQtown sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0768 polypeptide
suggests that portions of it
possess significant sequence identity and similarity with integrin 7.
Still analyzing the amino acid sequence of SEQ ID N0:437, the putative signal
peptide is at about amino
acids I-33 of SEQ ID N0:437. The transmembrane domain is at amino acids 1039-
1064 of SEQ ID N0:437. N-
glycosylation sites are at amino acids: 8b-89, 746-749, 949-952, 985-988 and
1005-1008 of SEQ ID N0:437.
Integrin alpha chain protein domains are identified at about amino acids: 1064-
1071, 384-409, 1041-1071, 317-346,
443-465, 3851107, 215-224, 634-647, 85-99, 322-346, 470-479, 442-466, 379-408
and 1031-1047 of SEQ ID
N0:437. The corresponding nucleotides can be routinely determined given the
sequences provided herein.
13XAMPLE 71: Isolation of cDNA Clones Encodine Human PR0771
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA43330. Based
on the DNA43330 sequence,
oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and
2) for use as probes to isolate a clone of the full-length coding sequence for
PR0771.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR-pn-mer 5'-CAGCAATATTCAGAAGCGGCAAGGG-3' (SEQ ID N0:443);
reverse PCR primer 5'-CATCATGGTCATCACCACCATCATCATC-3' (SEQ ID N0:444).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA43330 consensus
sequence which had the following nucleotide sequence:
hybridization probe
5'-GGTTACTACAAGCCAACACAATGTCATGGCAGTGTTGGACAGTGCTGG-3' (SEQ ID N0:445).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0771 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal Iddney tissue (LIB28).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0771
[herein designated as UNQ409 (DNA49829-1346)] (SEQ ID N0:441) and the derived
protein sequence for PR0771.
The entire nucleotide sequence of UNQ409 (DNA49829-1346) is shown in Figure
178 (SEQ ID N0:441).
Clone UNQ409 (DNA49829-1346) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 134-136 and ending at the stop codon at nucleotide
positions 1442-1444 (Figure 1?8). The
predicted polypeptide precursor is 436 amino acids long (Figure 179). The full-
length PR0771 protein shown in
Figure I79 has an estimated molecular weight of about 49,429 daltons and a p1
of about 4.8. Clone UNQ409
(DNA49829-1346) has been deposited with the ATCC on April 7, 1998. Regarding
the sequence, it is understood
that the deposited clone contains the correct sequence, and the sequences
provided herein are based on latown
sequencing techniques.
243
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
Analysis of the amino acid sequence of the full-length PR0771 polypeptide
suggests that portions of it
possess significant homology to the testican protein, thereby indicating that
PR0771 may be a novel testican
homologue.
Still analyzing the amino acid sequence of SEQ ID N0:442, the putative signal
peptide, leucine zipper
pattern, N-myristoylation sites, and thyroglobulin type-1 repeats are also
shown in Figure 179. The corresponding
nucleotides can be routinely determined given the sequences provided herein.
EXAMPLE 72: Isolation of cDNA Clones Encoding Human PRQ733
A consensus sequence was obtained relative to a variety of EST sequences as
described in Example 1 above,
wherein the consensus sequence obtained is herein designated DNA45600. Based
on the DNA45600 consensus
sequence, oligonucleotides were synthesized: I ) to identify by PCR a cDNA
library that contained the sequence of
interest, and 2) for use as probes to isolate a clone of the full-length
coding sequence for PR0733.
A pair of PCR primers (forward and reverse) were synthesized:
forty ra d PCRprimer 5'-CCCAGCAGGGATGGGCGACAAGA-3' (SEQ ID N0:448);
reverse PCR primer 5'-GTCTTCCAGTTTCATATCCAATA-3' (SEQ ID N0:449).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA45600 consensus
sequence which had the following nucleotide sequence:
hybridization probe
5'-CCAGAAGGAGCACGGGGAAGGGCAGCCAGATCTTGTCGCCCAT-3' (SEQ ID N0:450).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
encoding the PR0733 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human bone marrow tissue (LIB255).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR0733
[herein designated as UNQ411 (DNA52196-1348)] (SEQ ID N0:446) and the derived
protein sequence for PR0733.
The entire nucleotide sequence of UNQ411 (DNA52196-1348) is shown in Figures
180A-B (SEQ ID
N0:446). Clone UNQ411 (DNA52196-1348) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 106-108 and ending at the stop codon
at nucleotide positions 793-795 (Figures
180A-B). The predicted polypeptide precursor is 229 amino acids long (Figure
181). The full-length PR0733 protein
shown in Figure 181 has an estimated molecular weight of about 26,017 daltons
and a pI of about 4.73. Clone
UNQ411 (DNA52196-1348) has been deposited with the ATCC on April 7, 1998.
Regarding the sequence, it is
understood that the deposited clone contains the correct sequence, and the
sequences provided herein are based on
la~town sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0733 polypeptide
suggests that portions of it
possess significant sequence identity and similarity to the Tl/ST2 receptor
binding protein precursor and therefore
may have a similar function in cell signaling. If it is a cytolcine, it may be
useful in the treatment of inflammation
and cancer.
Still analyzing the amino acid sequence of SEQ 1D N0:447, the putative signal
peptide, uansmembrane
domain, N-myristoylation site, and tyrosine ldnase site are also shown in
Figure 181. The corresponding nucleotides
can be routinely determined given the sequences provided herein.
244
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
EXAMPL~73: Isolation of cDNA Clones Encoding Human PR016~
An expressed sequence tag (EST) DNA database (Merclc/Washington University)
was searched and an EST
AA397543 was identified which showed homology to human pancreatitis-associated
protein. The EST AA397543
cole was purchased and its insert obtained and sequenced and the sequence
obtained is shown in Figure 182 (SEQ
ID N0:4S1).
The entire nucleotide sequence of PR0162 is shown in Figure 182 (SEQ ID
N0:451). DNA sequencing
of the clone gave the full-length DNA sequence for PR0162 [herein designated
as UNQ429 (DNA56965-1356)] (SEQ
ID N0:451) and the derived protein sequence for PR0162. Clone UNQ429 (DNA5696S-
1356) contains a single open
reading frame with an apparent translational initiation site at nucleotide
positions 86-88 and ending at the stop colon
at nucleotide positions 611-613 (Figure 182). The predicted polypeptide
precursor is 175 amino acids long (Figure
183). The full-length PR0162 protein shown in Figure 183 has an estimated
molecular weight of about 19,330
daltons and a pI of about 7.25. Clone UNQ429 (DNA56965-1356) has been
deposited with the ATCC. Regarding
the sequence, it is understood that the deposited clone contains the correct
sequence, and the sequences provided
herein are based on lrnown sequencing techniques.
Analysis of the amino acid sequence of the full-length PR0162 polypeptide
suggests that portions of it
possess significant homology to the human pancreatitis-associated protein,
thereby indicating that PR01b2 may be
a novel pancreatitis-associated protein.
Still analyzing the amino acid sequence of SEQ ID N0:4S2, the putative signal
peptide is at about amino
acids 1-26 of SEQ ID N0:4S2. A C-type lectin domain signatwe is at about amino
acids 146-171 of SEQ 1D
N0:452. The corresponding nucleotides can be routinely determined given the
sequences provided herein.
EXAMPLE 74: Isolation of cDNA Clones Encodine Hu aq. PROZ~B
A consensus DNA sequence (designated herein as DNA49308) was assembled
relative to other EST
sequetxxs using phrap as described in Example 1 above. Based upon an observed
homology between the DNA49308
consensus sequence and the Incyte EST clo0ne no. 2777282, the Incyte EST clone
no. 2777282 was purchased and
its insert obtained and sequenced, which gave the full-length DNA sequence for
PR0788 [herein designated as
UNQ430 (DNAS640S-I357)] (SEQ ID N0:4S3) and the derived protein sequence for
PR0788.
Clone UNQ430 (DNA56405-1357) contains a single open reading frame with an
apparent translational
initiation site at rnucleotide positions 84-86 and ending at the stop colon at
nucleotide positions 459-461 (Figure 184).
The predicted polypeptide precursor is 12S amino acids long (Figure 185). The
full-length PR0788 protein shown
in Figure 185 has an estimated molecular weight of about 13,115 daltons and a
pl of about 5.90. Clone UNQ430
(DNAS640S-1357) has been deposited with the ATCC. Regarding the sequence, it
is understood that the deposited
clone contains the coaect sequence, and the sequences provided herein are
based on lawwn sequencing techniques.
Still analyzing Figure 185, a signal peptide is shown at about amino acids 1-
17 of SEQ ID N0:454. An N-
glycosylation site is at about amino acids 46-d9 of SEQ ID N0:4S4.
3S
E3i,,A. PLE 75: Isolation of cDNA~l~,ones ncoding Human hRQ~,008
A consensus DNA sequence was assembled relative to other EST sequences using
phrap as described in
Example 1 above. This consensus sequence is herein designated as DNA49804. An
EST proprietary to Genentech
was employed in the consensus assembly and is herein designated as DNA16S08
(Figure 188; SEQ ID N0:4S7).
245
CA 02421372 2003-03-25
WO 99/46281 PCTIUS99l05028
Based upon an observed homology between the DNA49804 sequence and Merck EST
clone no. AA143670, the
Merck EST clone no. AA143670 was purchased and its insert obtained and
sequenced. That sequence is shown
herein in Figure 186 (SEQ ID N0:455).
Sequencing gave the full length sequence for PR01008 [herein designated as
UNQ492 (DNA57530-1375))
(SEQ ID N0:455) and the derived protein sequence for PR01008 were identified.
The entire nucleotide sequence of UNQ492 (DNA57530-1375) is shown in Figure
186 (SEQ ID N0:455).
Clone UNQ492 (DNA57530-1375) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 138-140 and ending at the stop codon at nucleotide
positions 936-938 (Figure 186). The
predicted polypeptide precursor is 266 amino acids long (Figure 187). The full-
length PR01008 protein shown in
Figure 187 has an estimated molecular weight of about 28,672 daltons and a pI
of about 8.85. Clone UNQ492
(DNA57530-1375) has been deposited with the ATCC on May 20, 1998. Regarding
the sequence, it is understood
that the deposited clone contains the correct sequence, and the sequences
provided herein are based on known
sequencing techniques.
Analysis of the amino acid sequence of the full-length PR01008 polypeptide
suggests that portions of it
possess significant sequence identity and/or similarity with mdkk-1, thereby
indicating that PR01008 may be a novel
member of this family and have head inducing activity.
Still analyzing the amino acid sequence of SEQ ID N0:456, the putative signal
peptide is at about amino
acids 1-23 of SEQ ID N0:456. The N-glycosylation site is at about amino acids
256-259 of SEQ ID N0:456, and
the fungal zn-(2)-cys(6) binuclear cluster domain is at about amino acids 110-
126 of SEQ ID N0:456. The
corresponding nucleotides can of all the amino acids can be routinely
determined given the sequences provided herein.
EXAMPLE 76: Isolation of cDNA Clones Encoding Human PR01012
A consensus DNA sequence was assembled relative to other EST sequences using
phrap as described in
Example 1 above, wherein the consensus sequence is herein designated DNA49313.
Based on the DNA49313
consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a
cDNA library that contained the
sequence of interest, and 2) for use as probes to isolate a clone of the full-
length coding sequence for PR01012.
A pair of PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-ACTCCCCAGGCTGTTCACACTGCC-3' (SEQ ID N0:460);
reverse PCR primer 5'-GATCAGCCAGCCAATACCAGCAGC-3' (SEQ 1D N0:461).
Additionally, a synthetic oligonucleotide hybridization probe was constructed
from the DNA49313 consensus
sequence which had the following nucleotide sequence:
hybridizatio~t probe
5'-GTGGTGATGATAGAATGCTTTGCCGAATGAAAGGAGTCAACAGCTATCCC-3' (SEQ ID N0:462).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened
by PCR amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones
eocodittg the PR01012 gene using the probe oligonucleotide and one of the PCR
primers. RNA for construction of
the cDNA libraries was isolated from human fetal kidney tissue (LIB227).
DNA sequencing of the clones isolated as described above gave the full-length
DNA sequence for PR01012
[herein designated as UNQ495 (DNA56439-1376)] (SEQ ID N0:458) and the derived
protein sequence for PR01012.
246
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
The entire nucleotide sequence of UNQ495 (DNA56439-1376) is shown in Figures
189A-B (SEQ ID
N0:458). Clone UNQ495 (DNA56439-1376) contains a single open reading frame
with an apparent translational
initiation site at nucleotide positions 404-406 and ending at the stop codon
at nucleotide positions 2645-2647 (Figures
189A-B). The predicted polypeptide precursor is 747 amino acids long (Figure
190). The full-length PR01012
protein shown in Figure 190 has an estimated molecular weight of about 86,127
daltons and a pI of about 7.46. Clone
UNQ495 (DNA56439-1376) has been deposited with ATCC on May 14, 1998. Regarding
the sequence, it is
understood that the deposited clone contains the correct sequence, and the
sequences provided herein are based on
latown sequencing techniques.
Analysis of the amino acid sequence of the full-length PR01012 polypeptide
suggests that portions of it
possess sequence identity with disulfide isomerase thereby indicating that
PR01012 may be a novel disulfide
isomerase related protein.
Still analyzing the amino acid sequence of SEQ ID N0:459, the cytochrome C
family heme-binding site
signature is at about amino acids 158-163 of SEQ ID N0:459. The Nt-DNAI domain
signature is at about amino
acids 77-96 of SEQ ID N0:459. An N-glycosylation site is at about amino acids
484-487 of SEQ ID N0:459. The
ER targeting sequence is at about amino acids 744-747 of SEQ 1D N0:459. It is
understood that the polypeptide and
nucleic acids disclosed can be routinely formed with or without, these
portions as desired, in alternative embodiments.
For example, it may be desirable to produce PR01012 without the ER targeting
sequence. The corresponding
nucleotides can be routinely determined given the sequences provided herein.
EXAMPLE 77: Isolation of cDNA Clones Encoding Human PR01014
A consensus DNA sequence was assembled relative to other EST sequences using
phrap as described in
Example 1 abobe, wherein the consensus sequence obtained is herein designated
DNA49811. Based upon an
observed homology between the DNA49811 sequence and Incyte EST clone no.
2612207, Incyte EST clone no:
2612207 was purchased and its insert was obtained and sequenced, wherein the
sequence obrained is shown in Figure
191 (SEQ OD N0:463).
DNA sequencing gave the full-length DNA sequence for PR01014 [herein
designated as UNQ497
(DNA56409-1377)] (SEQ ID N0:463) and the derived protein sequence for PR01014.
The entire nucleotide sequence of UNQ497 (DNA56409-1377) is shown in Figure
I91 (SEQ ID N0:463).
Clone UNQ497 (DNA56409-1377) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 66-68 and ending at the stop codon at nucleotide
positions 966-968 (Figure 191). The
predicted polypeptide precursor is 300 amino acids long (Figure 192). The full-
length PR01014 protein shown in
Figure 192 has an estimated molecular weight of about 33,655 daltons and a p1
of about 9.31. Clone UNQ497
(DNA56409-1377) has been deposited with the ATCC on May 20, 1998. Regarding
the sequence, it is understood
that the deposited clone contains the correct sequence, and the sequences
provided herein are based on latown
sequencing techniques.
Analysis of the amino acid sequence of the full-length PR01014 polypeptide
suggests that portions of it
possess sequence identity with reductase, thereby indicating that PR01014 may
be a novel member of the reductase
family.
Still analyzing the amino acid sequence of SEQ 1D N0:464, the putative signal
peptide is at about amino
acids 1-19 of SEQ ID N0:464. The CAMP and cGMP dependent protein lcinase
phosphorylation sites are at about
247
CA 02421372 2003-03-25
WO 99/46281 PCT/US99/05028
amino acids 30-33 and 58-61 of SEQ ID N0:464. Short chain alcohol
dehydrogenase family proteins are at about
amino acids 165-202, 37-49, 112-122 and 210-219 of SEQ ID N0:464. The
corresponding nucleotides of these
domains and any other amino acids provided herein can be routinely determined
given the sequences provided herein.
EXAMPLE 78: Isolation of cDNA Clones Encoding Human PR01017
A consensus DNA sequence was assembled relative to other EST sequences using
phrap as described in
Example 1 above, wherein that consensus DNA sequence is herein designated
DNA53235. Based upon an observed
homology between the DNA53235 consensus sequence and the Merck EST clone no.
AA243086, the Merck EST
clone no. AA243086 was purchased and its insert obtained and sequenced,
wherein the sequence obtained is shown
in Figure 193 (SEQ ID N0:465). DNA sequencing gave the full-length DNA
sequence for PR01017 [herein
designated as UNQ500 (DNA561 I2-1379)] (SEQ ID N0:465) and the derived protein
sequence for PR01017.
The entire nucleotide sequence of UNQ500 (DNA56112-1379) is shown in Figure
193 (SEQ ID N0:465).
Clone UNQ500 (DNA56112-1379) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 128-130 and ending at the stop codon at nucleotide
positions 1370-1372 (Figure 193). The
predicted polypeptide precursor is 414 amino acids long (Figure 194). The full-
length PR01017 protein shown in
Figure 194 has an estimated molecular weight of about 48,414 daltons and a p1
of about 9.54. Clone UNQ500
(DNA56112-1379) has been deposited with the ATCC. Regarding the sequence, it
is understood that the deposited
clone contains the correct sequence, and the sequences provided herein are
based on known sequencing techniques.
Analysis of the amino acid sequence of the full-length PR01017 polypeptide
suggests that portions of it
possess sequence identity with HNK-1 sulfotransferase, thereby indicating that
PR01017 may be a novel
sulfotransferase.
Still analyzing the amino acid sequence of SEQ ID N0:466, the putative signal
peptide is at about amino
acids 1-31 of SEQ ID N0:466. N-glycosylation sites are at about amino acids
134-137, 209-212, 280-283 and 370-
273 of SEQ ID N0:466. The TNFR/NGFR family cystein-rich region protein is at
about amino acids 329-332 of
SEQ )D N0:466. The corresponding nucleotides can be routinely determined given
the sequences provided herein.
The protein can be secreted.
EXAMPLE 79: Isolation of cDNA Clones Encodine Human PR0474
A consensus DNA sequence was assembled relative to other EST sequences using
phrap as described in
Example 1 above, wherein the consensus sequence obtained is herein designated
DNA49818. Based upon an
observed homology between the DNA49818 consensus sequence and the Merck EST
clone no. H77889, the Merck
FST clone no. H77889 was purchased and its insert obtained and sequenced,
wherein the sequence obtained is herein
shown in Figure 195 (SEQ 1D N0:467). DNA sequencing gave the full-length DNA
sequence for PR0474 (herein
designated as UNQ502 (DNA56045-1380)] (SEQ ID N0:467) and the derived protein
sequence for PR0474.
The entire nucleotide sequence of UNQ502 (DNA56045-1380) is shown in Figure
195 (SEQ 1D N0:467).
Clone UNQ502 (DNA56045-1380) contains a single open reading frame with an
apparent translational initiation site
at nucleotide positions 106-108 and ending at the stop codon at nucleotide
positions 916-918 (Figure 195). The
predicted polypeptide precursor is 270 amino acids long (Figure 196). The full-
length PR0474 protein shown in
Figure 196 has an estimated molecular weight of about 28,317 daltons and a pI
of about 6Ø Clone UNQ502
248
CA 02421372 2003-03-25
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOM
CECI EST LE TOME ~ DE
NOTE: Pour les tomes additionels, veillez contacter 1e Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTLON OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME ~ OF
NOTE: For additional volumes please contact the Canadian Patent Office.
